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ABSTRACT 
The DNA mismatch repair (MMR) pathway is responsible for correction of 
replicative errors, hence is a key factor in maintenance of genomic stability. 
Paradoxically, functional DNA MMR also mediates the cytotoxicity of certain 
chemotherapeutic DNA damaging agents. Poor treatment response in therapy-related 
acute myeloid leukaemia (t-AML) is influenced by a number of factors, one of which 
might be chemoresistance due to acquired defects in DNA MMR.  
Using a range of paired MMR proficient and deficient cell lines, investigations 
herein demonstrate that DNA MMR status mediates response to nucleoside analogues 
such as cytarabine (Ara-C) used in t-AML chemotherapy. Interestingly, defects of 
specific MMR components had different and opposing effects on the cytotoxicity of 
these agents. These findings implicate defects of MMR components as potential 
prognostic factors in t-AML and suggest assessment of DNA MMR status may be 
warranted in individual patients when selecting treatment. 
Cytarabine was mutagenic to DNA at the TK and HPRT loci. Furthermore, the 
frequency of Ara-C-induced mutation was increased in an MMR-deficient cell line, 
supporting a role for MMR components in the cellular response to nucleoside 
analogues, and also suggesting that use of these agents themselves could contribute to 
the risk of t-AML development. 
Defective DNA MMR might also contribute to development of relapsed AML, 
given that genomic instability is demonstrated in some patients at relapse. Genome-
wide analysis of DNA copy number aberrations and loss of heterozygosity in a small 
cohort of matched presentation and relapsed AML samples demonstrated a potential 
MMR defect in one patient, and also provided some important insights into the clonal 
origins of relapsed AML.   
The findings of these investigations together highlight several important 
considerations for the use of nucleoside analogues in the treatment of t-AML, as well 
as in other cancers in which dysfunction of the DNA MMR system is implicated. 
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1.1. The DNA Mismatch Repair Pathway 
The DNA mismatch repair (MMR) pathway is one of a number of cellular 
mechanisms responsible for maintaining the stability of the genome, by ensuring DNA 
replication errors are corrected before they can result in mutation. There are two main 
types of error for which MMR is able to elicit repair. Simple base:base mismatches, 
which occur when a DNA polymerase enzyme inserts an incorrect base in the daughter 
strand which is subsequently missed by its proofreading activity. Secondly, 
insertion/deletion loops (IDLs) which are extrahelical loops of DNA arising either when 
DNA polymerase inserts an extra base during replication (single base IDLs) or when the 
template and primer strands in a repetitive sequence (microsatellite) misalign, 
resulting in a larger IDL. Dysfunction of the DNA MMR pathway gives rise to genomic 
instability and predisposition to the acquisition of mutations throughout the genome. 
This is referred to as a ‘mutator phenotype’ (Branch et al., 1993) which can contribute 
to the development of cancer (see Section 1.4.1.1), and exemplifies the importance of 
DNA MMR in maintaining replication fidelity.  
In addition to repair of replication errors, DNA MMR components have been 
implicated in other cellular processes including regulation of recombination (see 
Section 1.1.2), and also play an important role in mediating cell cycle arrest and/or 
apoptosis in response to certain DNA damaging agents (described in Section 1.2).  
1.1.1. Overview of the DNA MMR pathway 
1.1.1.1. MMR in Escherichia coli 
The Escherichia coli MMR pathway has been extensively studied and is well 
characterised both biochemically and genetically. The pathway is highly conserved 
from prokaryotes to eukaryotes, hence E. coli MMR has provided a useful framework 
for understanding DNA MMR in other organisms. Furthermore, a large number of 
proteins involved in MMR in humans, and in other species, have been identified based 
on their homology to E. coli MMR proteins.  
Reconstitution of the E. coli DNA MMR pathway in a purified system 
demonstrated the biochemistry of the reactions involved in mismatch correction 
(Lahue et al., 1989). The initial step in the process involves recognition of replication 
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damage, which is mediated in E. coli by the homodimeric protein MutS. Upon 
recognition of damage, MutS physically interacts with a second homodimeric protein, 
MutL, forming a complex in an ATP-dependent manner (Spampinato and Modrich, 
2000), which in turn activates a third protein, MutH. MutH is responsible for 
distinguishing the newly replicated daughter strand (which it does by recognition of a 
hemimethylated dGATC sequence either 5’ or 3’ to the mismatch), whereupon it 
generates a single strand nick. MutS and MutL then activate UvrD helicase, the role of 
which is to unwind the DNA duplex, generating single-strand DNA. This is rapidly 
bound by single-strand DNA binding protein (SSB) in order to protect it from nuclease 
attack and to allow one of several exonucleases to digest the mismatch-containing 
strand from the nicked site to the mismatched base. The resulting gap is refilled by the 
DNA polymerase III holoenzyme, which is probably recruited to the damage 
intermediate by physical interaction with MutL (Li et al., 2008a). Finally, DNA ligase 
functions to seal the remaining nick in the daughter strand. 
1.1.1.2. MMR in Humans 
A basic representation of the processes involved in DNA MMR in humans is 
shown in Figure 1.1. Detection of replication-related DNA damage is mediated by two 
MutS complexes, each with specific substrate specificities (Figure 1.1, top inset). 
Whereas E. coli MutS is a homodimer, the human MutS homologues form 
heterodimers in order to mediate damage recognition. MutSα is a heterodimer of the 
proteins MHS2 and MSH6 (Drummond et al., 1995; Acharya et al., 1996). It 
preferentially recognises base:base mispairs, and also has some activity towards small 
IDLs of 1 or 2 nucleotides (Genschel et al., 1998). MutSβ on the other hand, consisting 
of MSH2 heterodimerised with MSH3 (Acharya et al., 1996) recognises both small and 
large IDLs but cannot mediate recognition of mispairs (Palombo et al., 1996; Genschel 
et al., 1998). 
MSH2   MSH6 MSH2   
MSH3 
MutSα MutSβ
Base:base mispair           Single base insertion Extrahelical 
loop 
5’ 3’
5’ 3’
5’ 3’
5’ 3’
5’ 3’
DAMAGE RECOGNITION 
MutSα, MutSβ
TERNARY COMPLEX FORMATION 
MutLα (MLH1+PMS2) 
EXCISION OF DAMAGE 
EXO1 
DNA RESYNTHESIS AND LIGATION
RPA, DNA Pol δ, DNA ligase I
Figure 1.1. The human DNA MMR pathway.
See text for description of pathway. Top inset illustrates substrate specificities of MutSα and MutSβ. Lower inset displays three alternative models by
which MMR components might facilitate communication between the damage site (red) and the single strand nick from which excision is initiated
(described in text).
‘stationary’                 ‘sliding clamp’ ‘translocation’ 
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Like E. coli MMR, MutSα and MutSβ are ATPases which are activated following 
damage detection, and recruit MutL homologues to the damaged site (Blackwell et al., 
1998). Recent investigations have shown that MutS complexes function as transient 
clamps that scan duplex DNA for mismatched nucleotides (Jeong et al., 2011). 
Mismatch identification provokes ATP binding, transforming MutS scanning clamps 
into highly stable signalling clamps which are speculated to be capable of chromatin 
remodelling, enabling interaction with MutL homologues, as well as other MMR 
components (Jeong et al., 2011). 
At least four human MutL homologues (MLH1, MLH3, PMS1 and PMS2) have 
been identified. MutLα, a heterodimer of MLH1 and PMS2, is the major complex 
involved in replication-related MMR (Li and Modrich, 1995). Recruitment of MutLα to 
the damaged site results in formation of a ternary complex which promotes 
intracellular signalling to initiate excision and repair of the damage (Kadyrov et al., 
2006). Alternative MutL complexes may have roles in other cellular processes, for 
example MutLγ (a heterodimer of MLH1 and MLH3) has been implicated in meiosis (Li, 
2008). 
As in E. coli MMR, excision of the damage-containing region appears to originate 
from a single strand nick in the daughter strand which can be either 3’ or 5’ to the 
damage (Li, 2008). A number of fundamental problems however remain to be resolved 
regarding the mechanisms associated with strand excision. Firstly, it is not clear in 
humans, how the daughter DNA strand is distinguished from the parental strand 
following DNA replication. In the case of lagging strand DNA replication, the presence 
of Okazaki fragments may serve to identify the daughter DNA strand, and the gaps 
between fragments could provide the origin for excision of the damaged region. 
Replication of the leading strand however, proceeds in a continuous manner and it 
remains undetermined how the daughter strand is identified and which protein is 
responsible for generating the single strand nick.  
Whereas damaged strand excision in E. coli can be mediated by at least four 
exonucleases, in humans, only one DNA MMR-related exonuclease has as yet been 
identified. This exonuclease, exonuclease I (EXO1), is a 5’→3’ exonuclease, yet has 
been shown to be involved in excision originating either 5’ or 3’ of the damaged site 
(Genschel et al., 2002). Hence another unsolved problem is how an exonuclease with 
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only 5’→3’ activity can mediate excision in both directions. It was originally suggested 
that EXO1 may possess a cryptic 3’→5’ exonuclease activity (Genschel et al., 2002), 
however this is not supported by current data. Recent investigations suggest that, 
following recognition of a nick 3’ to the damage site, MutLα makes an incision 5’ to the 
damage, via its endonuclease activity, allowing EXO1 to perform 5’→3’ excision 
through the damage site to the 3’ nick (Kadyrov et al., 2006).  
A further unsolved problem in human DNA MMR, which also applies to MMR in 
E. coli and other organisms, is the key question of how MMR components facilitate 
communication between the site of the mismatch and the physically distant single 
strand nick, be it either 5’ or 3’ to the site of damage. A number of alternative models 
have been proposed for this process (Figure 1.1, lower inset). The ‘stationary’ model 
proposes that MutSα (or MutSβ) is bound at the site of the mismatch, whereas MutLα 
and other MMR components are located at the nicked site. Activation of MutSα 
promotes physical interaction with MutLα, bringing the two distant sites together by 
bending or ‘looping out’ of the intervening DNA (Guarne et al., 2004). The ‘moving’ 
model, sometimes referred to as the ‘sliding clamp’ model, proposes that the MutSα-
MutLα (or MutSβ-MutLα) ternary complex forms at the site of the mismatch and 
undergoes an ATP-dependent conformational change which allows it to slide along the 
DNA in either direction. This leaves the damage site empty for formation of further 
MutSα-MutLα sliding clamps. Excision is initiated when one of the clamps encounters a 
nicked site (Gradia et al., 1997; Gradia et al., 1999). A variation of this model, referred 
to as the ‘translocation’ model, suggests that sliding clamps move in a unidirectional 
manner, scanning bidirectionally from the mispair (hence forming a looped DNA 
structure containing the mismatch) until a nicked site in either orientation is reached 
(Allen et al., 1997). Although a number of studies have attempted to elucidate which 
model is most likely to occur, the available evidence has not allowed firm conclusions 
to be made. For instance, recent studies demonstrated that a double strand break 
(DSB) or protein ‘blockage’ between the mismatch site and the nick inhibits MMR in 
vitro (Pluciennik and Modrich, 2007), arguing in favour of the ‘moving’ models. This 
however is at odds with a similar previous investigation supporting the ‘stationary’ 
model, in which mismatch-provoked excision could still occur despite the placement of 
a biotin-streptavidin blockade between the mismatch and nick (Wang and Hays, 2004). 
 7 
 
Following excision, the single strand DNA-binding protein, replication protein A 
(RPA) is required to protect the nascent single stranded regions and recruit DNA 
polymerase δ and DNA ligase I to re-synthesise DNA (Longley et al., 1997; Ramilo et al., 
2002). Other proteins which are essential in human DNA MMR, but have no identified 
homologue in E. coli, include proliferating cell nuclear antigen (PCNA) (Umar et al., 
1996) and replication factor C (RFC) (Dzantiev et al., 2004). PCNA in particular has roles 
in almost every step of the pathway. It can interact with MSH2, MSH3 and MSH6 (Gu 
et al., 1998; Clark et al., 2000) and may help localise MutSα and MutSβ to damage sites 
in newly replicated DNA (Kleczkowska et al., 2001; Lau and Kolodner, 2003). It can also 
interact with MLH1 and is essential, in combination with RFC, for the endonuclease 
function of MutLα (Kadyrov et al., 2006).  
1.1.2. MMR and Recombination 
In general terms, recombination provides a mechanism by which genetic 
information can be exchanged or transferred between homologous DNA sequences. In 
mammals, this occurs largely during meiosis and also forms the basis of the 
homologous recombination repair (HRR) pathway, a key mechanism for the repair of 
DSBs, as described below. To maintain genomic integrity, perfect homology is 
required, hence a system must exist to regulate recombination events. A significant 
body of evidence points to DNA MMR as a likely regulator of recombination. 
It was initially demonstrated in prokaryotes that DNA MMR was able to provide a 
barrier against recombination between unrelated species, whose DNA differs 
significantly in sequence, by aborting or destabilising mismatched heteroduplex 
recombination intermediates (Rayssiguier et al., 1989). Subsequently, using gene 
targeting experiments in yeast (Selva et al., 1995), mouse (de Wind et al., 1995; Abuin 
et al., 2000) and human cells (Ciotta et al., 1998), it was found that the frequency of 
recombination events between imperfectly matched (homeologous) sequences was 
significantly elevated in MMR-defective cells. These studies demonstrated a role for 
MMR in suppression of recombination between diverged or homeologous sequences. 
Studies in mice and yeast reveal an essential role for DNA MMR components in 
meiotic recombination processes. Notably, homozygous Mlh1 or Pms2 knockout mice 
are sterile (Baker et al., 1995; Baker et al., 1996; Edelmann et al., 1996). Specific details 
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regarding the involvement of MMR components in meiosis are beyond the scope of 
this project, however Kolas and Cohen (2004) provide a comprehensive review on this 
subject. (Kolas and Cohen, 2004) 
1.1.2.1. MMR and HRR 
HRR is one of two major DNA repair pathways responsible for repair of DSBs, a 
particularly genotoxic form of DNA damage occurring as a result of exogenous agents 
(e.g. ionising radiation (IR)), endogenous processes (e.g. collapsed replication forks) or 
during specialised recombination events (e.g. immunoglobulin class switching). HRR 
ensures accurate repair of DSBs because homologous sequences in the form of 
undamaged sister chromatids are used as repair templates, it is therefore only 
operational during late S and G2 phases of the cell cycle when these are available 
(Hoeijmakers, 2001). The HRR pathway and the major components involved in DSB 
repair are shown in Figure 1.2A.  
MSH2 and MSH6 have both been shown to co-localise with key HRR proteins in 
mammalian cells, including BRCA1 (Wang et al., 2000) and RAD51 (Rajesh et al., 2009), 
suggesting a role for MMR components in the HRR pathway. The specific involvement 
of MMR components in HRR remains unclear, however several lines of evidence 
suggest a role in ensuring that recombination intermediates formed as a result of 
strand exchange are true homologues, and in mediating abortion of recombination if 
this is not the case. In the yeast Saccharomyces cerevisiae, MSH2 interacts directly with 
recombination intermediates (Alani et al., 1997; Evans et al., 2000) and a model was 
proposed in which it interacts with a helicase enzyme to unwind heteroduplex regions 
containing mismatches (referred to as heteroduplex rejection) (Sugawara et al., 2004; 
Goldfarb and Alani, 2005). Similarly, in human cell lines, MSH2 and MSH6 have been 
shown to regulate the activity of the BLM helicase (Yang et al., 2004b), which is 
localised to recombination intermediates (Wu et al., 2001), also suggesting a role in 
mediating heteroduplex unwinding.  
5’3’
5’ END RESECTION                 
(MRN)
5’3’
STRAND INVASION           
(RAD52, RAD54)
HOMOLOGY SEARCH
(RAD51) 
HOLLIDAY
JUNCTION
RESOLUTION
(Resolvases) 
DNA SYNTHESIS AND LIGATION
(DNA pol δ, DNA ligase I)
COATING OF SINGLE STRAND REGIONS
(RAD51, RPA, RAD52 ?BRCA1, ?BRCA2)
5’3’
5’3’
5’3’
5’3’
5’3’
5’3’
5’3’
5’3’
NON-CROSSOVER (rare)
CROSSOVER (common)
A
Figure 1.2. Homologous recombination repair (continued on next page).
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5’3’
5’3’
3’ TAIL REMOVAL
Msh2          Msh3
Rad1-Rad10
Figure 1.2. Homologous recombination repair (continued from previous page).
A. Following DSB formation, activation of ATM mediates cell cycle arrest via p53
(Morrison et al., 2000), as well as phosphorylation of the histone, H2AX, in the
vicinity of the DSB, which may provide a local chromatin state necessary for repair
(Paull et al., 2000) (not shown in figure). ATM also activates a complex consisting of
MRE11, RAD50 and NBS1 (MRN) which exposes 3’ DNA ends at the break via its 5’-3’
exonuclease activity (Petrini, 2000). RAD51 polymerises onto the single-stranded
DNA, assisted by RPA and RAD52, to form a nucleoprotein filament (Symington,
2002). In addition, BRCA1 and BRCA2 are also implicated in mediating a proper
RAD51 response although their roles are not well understood (Gudmundsdottir and
Ashworth, 2006). The RAD51 nucleoprotein filament searches for the homologous
duplex DNA and, once located, DNA strand exchange generates a recombinant
heteroduplex between the damaged molecule and its undamaged homologue
(Baumann and West, 1998), a process stimulated by RAD52 and RAD54 (Symington,
2002). DNA synthesis by polymerase fills in the single stranded gaps using the intact
homologue as a template, after which DNA ligase seals the nicks. Finally, the
junctions between the DNA strands (termed Holliday junctions) are resolved. This can
occur in either a horizontal or vertical fashion, giving rise to non-crossover or
crossover events respectively.
B. Homologous recombination intermediates in S. cerevisiae require additional
processing to remove 3’ non-homologous ends resulting from heteroduplex
formation. The DNA MMR proteins Msh2 and Msh3 are involved in this processing
step to recruit the Rad1-Rad10 endonuclease (see text).
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Cells deficient in MSH2 demonstrate aberrant RAD51 (and MRE11) foci formation 
and a higher level of chromosomal damage following exposure to low dose-rate IR 
(Franchitto et al., 2003; Barwell et al., 2007). Similarly, RAD51 levels decrease in 
response to low dose-rate IR, but only in cells with functional MLH1 protein (Yan et al., 
2009). Loss of MLH1 also results in an increase in IR-induced mitotic recombination 
(Wang et al., 2006) and chromosome translocations (Zhang et al., 2008). Together 
these data indicate that MSH2 and MLH1 may regulate RAD51 to suppress HRR.  
Inactivation of DNA MMR can result in deregulation of HRR by permitting the 
completion of imperfect recombinational exchanges. Repair of DSBs by HRR is 
deregulated in murine embryonic stem (ES) cells deficient in Msh2 (Msh2-/-) (Elliott and 
Jasin, 2001). Although Msh2-/- mutants can efficiently repair DSBs, they cannot repair 
mismatches in the heteroduplex DNA formed adjacent to the DSB, resulting in gene 
conversion. Similar results have also been observed in human cell lines deficient in 
MSH2 (Villemure et al., 2003; Smith et al., 2007) and MLH1 (Siehler et al., 2009).  
MMR proteins in S. cerevisiae are known to have an additional function in HRR 
which involves removal of non-homologous 3’ ends which result following 
heteroduplex formation (Figure 1.2B). Both Msh2 and Msh3 are required to recruit the 
Rad1/Rad10 endonuclease to the sites of recombination (Sugawara et al., 1997), 
although Msh2 and Msh3 only appear to be required if the 3’ ends are at least 30 
nucleotides in length (Paques and Haber, 1997). More recent evidence suggests that 
binding of an Msh2/Msh3 complex alters the conformation of the junction between 
the heteroduplex and the 3’ ends which may facilitate recognition by Rad1/Rad10 
(Surtees and Alani, 2006; Lyndaker and Alani, 2009). A similar function of MSH2/MSH3 
has yet to be demonstrated in mammalian cells.  
 
1.2. Mismatch Repair and Response to DNA Damaging Agents 
The finding that MMR-defective cells were more resistant to certain DNA 
damaging agents than MMR-proficient counterparts implicated DNA MMR as a 
mediator of drug cytotoxicity and furthermore highlighted defective MMR as a 
potential drug resistance mechanism. This was considered a somewhat paradoxical 
finding given that DNA MMR is a repair pathway. Careful molecular investigation has 
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since revealed that DNA MMR components have an important role in induction of cell 
cycle arrest and apoptosis in response to certain DNA damaging agents, as is described 
in this section. 
1.2.1. Methylating Agents and 6-Thioguanine 
Early studies showed that MMR-deficient cells demonstrated a high level of 
resistance to methylating agents, as well as cross-resistance to the base analogue 6-
thioguanine (6-TG) (Goldmacher et al., 1986; Aquilina et al., 1989; Aquilina et al., 1990; 
Kat et al., 1993; Hawn et al., 1995; Shin et al., 1998; Humbert et al., 1999). Despite the 
apparent diversity of these agents, they were subsequently found to exert their 
cytotoxicity by a common mechanism, which is absolutely dependent on functional 
DNA MMR. 
1.2.1.1. DNA Damage Induced by Methylating Agents and 6-TG 
Methylating agents are a class of DNA damaging agents which can add a methyl 
group to nucleophilic sites on DNA bases. N-methyl-N-nitrosourea (MNU) and N-
methyl-N’-nitro-N-nitrosoguanidine (MNNG) are examples of model unimolecular 
nucleophilic substitution-type methylating agents. Those in clinical use include 
procarbazine, dacarbazine, streptozocin and temozolomide. Of the numerous adducts 
produced in DNA by methylating agents, methylation at the O6 position of guanine (O6-
meG) is the most cytotoxic, despite accounting for only 7% of the total adduct burden 
produced (Beranek, 1990). In mammals, O6-meG lesions can be directly repaired, both 
prior to and post DNA replication, by the protein O6-methylguanine DNA 
methyltransferase (MGMT) in a reaction which involves transfer of the methyl group 
from the base to a cysteine residue in the catalytic pocket of the protein (Margison and 
Santibanez-Koref, 2002) (see Figure 1.4). Cells deficient in MGMT are unable to repair 
O6-meG lesions (Goth-Goldstein, 1980) and demonstrate hypersensitivity to the 
cytotoxic effects of methylating agents compared to MGMT-proficient counterparts 
(Yarosh et al., 1983; Kaina et al., 1991; Kaina et al., 1997; Tominaga et al., 1997; 
Meikrantz et al., 1998). Studies demonstrating that loss of MMR activity counteracted 
the hypersensitivity to MNU observed in MGMT-deficient cells provided the initial 
suggestion that DNA MMR was responsible for the cytotoxicity of O6-meG in the 
absence of MGMT (Branch et al., 1993). 
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6-thioguanine (6-TG), as well as azathioprine and 6-mercaptopurine, belongs to a 
class of compounds known as thiopurine antimetabolites, which have widespread use 
as immunosuppressive, anti-cancer and anti-inflammatory agents. 6-TG is an analogue 
of the purine nucleobase, guanine. It is distinguished from guanine solely by the 
substitution of the oxygen atom with a thiol group at position 6 of the purine ring 
(Figure 1.3A). Following administration, 6-TG is readily transported into cells and 
metabolised via the purine salvage pathway, resulting in the active DNA precursor, 
deoxythioguanine triphosphate (thio-dGTP) (Figure 1.3B). Given its similarity to 
deoxyguanosine triphosphate, thio-dGTP is a good substrate for replicative DNA 
polymerases and is readily incorporated within DNA (Ling et al., 1991). The thiol group 
of 6-TG is highly reactive however, and renders the incorporated nucleotide 
susceptible to methylation in situ by S-adenosylmethionine (SAM), a cellular methyl 
donor (Swann et al., 1996). Unlike O6-meG, there have been no mechanisms 
discovered which can reverse methylation of 6-TG. 
1.2.1.2. O6-meG and me6-TG Cytotoxicity Mediated by DNA MMR 
In vitro, unrepaired O6-meG within DNA impedes the function of replicative 
polymerases, although the lesion can be replicated by low-fidelity translesion 
polymerases (Perrino et al., 2003; Choi et al., 2006). Under physiological conditions 
however, approximately one third of O6-meG lesions become mispaired by incorrect 
insertion of thymine opposite the lesion (Abbott and Saffhill, 1979; Toorchen and 
Topal, 1983; Snow et al., 1984). Replication of methylated 6-TG (me6-TG) lesions on 
the other hand occurs readily, as demonstrated by in vitro primer extension assays 
(Ling et al., 1991), however like O6-meG, mispairing with T often occurs (Swann et al., 
1996). The subsequent mispairs can escape proofreading by polymerases due to the 
structural similarity to canonical base pairs (Warren et al., 2006). Functional MutSα 
and MutLα are essential for cell cycle arrest and subsequent cytotoxicity induced by 
O6-meG and me6-TG (Koi et al., 1994; Umar et al., 1997; Shin et al., 1998; Hickman and 
Samson, 1999; Cejka et al., 2003), however the exact mechanisms by which DNA MMR 
mediates these responses remain ill defined. 
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Figure 1.3. 6-thioguanine and its intracellular metabolism.
A. Structures of the normal nucleobase, guanine, and its analogue, 6-thioguanine
(6-TG; 2-amino-6-mercaptopurine). The thiol group of 6-TG is shown in red. B.
Metabolism of 6-TG occurs via purine salvage. Hypoxanthine-guanine
phosphoribosyltransferase (HPRT) converts 6-TG to thioguanine monophosphate
(TGMP) which is subsequently converted to the active DNA precursor,
deoxythioguanine triphosphate (thio-dGTP) by deoxynucleoside kinases and
reductase. Both 6-TG and TGMP are also substrates for thiopurine S-
methyltransferase (TPMT), an enzyme which methylates the thiol groups resulting in
the inactive metabolites, me6-TG and meTGMP. For a recent review, see Karran and
Attard (2008).
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Following treatment with methylating agents or 6-TG, MMR-proficient cell lines 
undergo cell cycle arrest in G2 phase but this is delayed until the second cell cycle 
following treatment (Zhukovskaya et al., 1994; Hawn et al., 1995; Carethers et al., 
1996; Cejka et al., 2003; Stojic et al., 2004a). Furthermore, only replicating cells 
undergo significant levels of cell death (Roos et al., 2004). These data suggest that 
replication of O6-meG and me6-TG must be a requirement for cell cycle arrest and cell 
death (Figure 1.4). Consistently, MutSα can recognise and bind to O6-meG or me6-TG 
mispaired with thymine with high efficiency, but not when paired with the canonical 
partner cytosine (Duckett et al., 1996; Swann et al., 1996; Waters and Swann, 1997; 
Berardini et al., 2000). What remains unclear is how detection of these mispairs by 
MutSα is linked to G2 cell cycle arrest and what causes subsequent cell death.  
Two models have been proposed to explain how DNA MMR might mediate cell 
cycle arrest in response to methylating agents and 6-TG (Figure 1.5A). In the model 
initially proposed, referred to as the ‘futile repair’ model, O6-meG:T or me6-TG:T 
mispairs detected by MutSα are subject to attempted MMR-mediated repair however, 
given that the methylated lesion would be in the template DNA strand and MMR can 
only be directed to the daughter strand, insertion of the incorrect base (thymine) 
opposite the lesion is predicted to recur. Repeated futile repair attempts are proposed 
to result in formation of aberrant repair intermediates which activate DNA damage 
signalling pathways to induce cell cycle arrest. Following unsuccessful resolution of 
these complex intermediates, attempted presumably by other repair pathways, cells 
die by apoptosis. The demonstration that O6-meG:T mispairs cannot be successfully 
repaired by MMR provided biochemical evidence for this model (York and Modrich, 
2006). Furthermore, reports of persistent single strand DNA regions in cells treated 
with these agents (Yan et al., 2003; Mojas et al., 2007) also supports a futile processing 
model. Additional recent evidence that murine embryonic fibroblasts (MEFs) deficient 
in EXO1 demonstrate resistance to methylating agents also suggests that MMR-
mediated excision and resynthesis is required for the cytotoxic effects of methylating 
agents, although EXO1 may have other functions in the induction of DNA damage 
responses that could also explain this observation (Klapacz et al., 2009). 
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Figure 1.4. DNA mispair formation following exposure to methylating agents or 6-
thioguanine.
Methylated guanine nucleotides are formed during the first cell cycle by the action of
methylating agents (left). This can be directly reversed prior to DNA replication, but
only in cells expressing MGMT. In the case of 6-TG (right), following intracellular
metabolism, 6-TG nucleotides become incorporated into DNA by replicative
polymerases. Incorporated 6-TG becomes rapidly methylated in situ by the methyl
donor, S-adenosyl methionine (SAM). In both cases, during the following round of
DNA replication, polymerase can incorrectly insert a thymine opposite the
methylated lesions, resulting in O6-meG:T and me6-TG:T mispairs respectively, which
are a substrate for MutSα binding. Subsequent processing requires functional DNA
MMR, resulting in G2 cell cycle arrest and apoptosis.
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The alternative model, referred to as the ‘direct signalling’ model, suggests that 
MMR components are general DNA damage sensors and have the ability to signal cell 
cycle arrest and/or apoptosis without the requirement for futile lesion processing. In 
support of this model are studies which demonstrate rapid induction of damage 
signalling pathways following drug exposure, which are described below, as well as 
physical interaction between MMR components and mediators of cell cycle arrest, 
particularly between MSH2 and ATR (Carethers et al., 1996; Yoshioka et al., 2006; 
Pabla et al., 2011). Intriguing findings also in support of a direct damage signalling 
function of MMR components come from reports of separation of function mutations 
in Msh2 and Msh6 in murine models (Lin et al., 2004; Yang et al., 2004a). These 
mutations disable the mismatch repair function of the Msh2 and Msh6 proteins, 
however the mice remain sensitive to methylating agents, demonstrating that the 
ability to mediate cell death remains unaffected.  
Multiple redundant pathways can signal G2 cell cycle arrest and cell death 
following DNA damage; evidence suggests a number of these pathways may be 
activated in an MMR-dependent manner (Figure 1.6). Arrest at the G2 checkpoint 
following methylating agent or 6-TG exposure is accompanied by activation of ATR 
(Caporali et al., 2004; Stojic et al., 2004a; Yamane et al., 2004; Yan et al., 2004; 
Yoshioka et al., 2006). ATR is primarily responsible for cell cycle arrest as a result of 
stalled replication forks (Kastan and Bartek, 2004), hence its activation in response to 
these agents argues in favour of the generation of aberrant repair intermediates which 
block replication. Concomitant with ATR activation is the appearance of nuclear foci, 
containing phosphorylated H2AX, RPA and other DNA repair proteins, which may 
represent sites of DNA damage (Stojic et al., 2004a). ATM, primarily activated in 
response to DSBs (Shiloh, 2006), is also activated in response to methylating agents 
and 6-TG (Caporali et al., 2004; Stojic et al., 2004a; Yan et al., 2004; Adamson et al., 
2005). In the case of methylating agents, this has been shown to occur later than ATR 
activation (Caporali et al., 2004), suggesting that some repair intermediates resulting 
from processing of O6-meG:T mispairs might be converted to DSBs. Reports that MMR-
proficient cell lines display a higher frequency of chromosomal aberrations and sister 
chromatid exchange than MMR-deficient subclones also provides evidence for the 
formation of DSBs (Armstrong and Galloway, 1997; Vernole et al., 2003). 
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Figure 1.6. Pathways which may mediate MMR-dependent G2 cell cycle arrest and
apoptosis in response to methylating agents or 6-thioguanine.
The serine-threonine protein kinases ATR and ATM mediate the major checkpoint
signalling pathway in response to DNA damage (red). Upon activation, ATR and ATM
phosphorylate and activate their respective substrates Chk1 and Chk2. The activated
complexes signal cell cycle arrest through phosphorylation of the Cdc25C phosphatase,
leading to its inhibition via sequestration in the cytoplasm. This prevents Cdc25C from
dephosphorylating Cdc2, which is required to permit progression to mitosis. ATR/Chk1
and ATM/Chk2 can also phosphorylate p53 which contributes to cell cycle arrest by
transcriptional activation of p21, a direct inhibitor of Cdc2 activity (yellow). In addition,
p53 can act as a transcription factor for several pro-apoptotic genes. It is unclear however,
whether either of these responses occur following treatment with methylating agents or
6-TG (indicated by dashed lines) (Li et al., 2008). A pathway involving MAPK signalling
could also link damage detection with apoptosis (blue). Genotoxic insult results in ATM-
dependent activation of the non-receptor tyrosine kinase c-Abl, causing a MAPK signalling
cascade leading to activation of Jun-N-terminal kinase (JNK), which in turn directly
phosphorylates c-Jun, a transcription factor with roles in promoting apoptosis. Other
investigations have demonstrated c-Abl-mediated activation of GADD45α in response to
methylation damage (green) (Li et al., 2008; Wagner et al., 2008). p38α, also a member of
the MAPK family, is activated in an MMR-dependent manner following methylating agent
exposure and promotes cell cycle arrest through phosphorylation of Cdc25C (Hirose et al.,
2003). It is not clear how p38α is activated, although evidence suggests it may occur
downstream of GADD45α activation (Wagner et al., 2008). GADD45α can also directly de-
phosphorylate Cdc2 to contribute to cell cycle arrest and is implicated in pro-apoptotic
signalling (Li et al., 2008). p73α (pink), also activated by c-Abl (Yuan et al., 1999), has been
implicated in direct promotion of apoptosis, which is independent of G2 arrest, following
exposure to methylating agents or 6-TG (Li et al., 2008). The DNA repair protein and
transcription factor, BRCA1 (purple) has recently been identified as a potential candidate
in activation of c-Abl-mediated responses, through DNA MMR and ATM-dependent
phosphorylation (Yamane et al., 2007).
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ATR/Chk1 and ATM/Chk2 can phosphorylate and activate p53, a key 
transcription factor capable of promoting both cell cycle arrest and apoptosis. 
Although methylating agent-induced cell death occurs primarily via apoptosis (Kaina et 
al., 1997; Meikrantz et al., 1998), and p53 is phosphorylated and stabilised in an MMR-
dependent manner (Davis et al., 1998; Duckett et al., 1999), it has been shown that 
p53 does not play a key role in G2 arrest responses or apoptosis after methylating 
agent exposure (Li et al., 2008b). 
Mitogen activated protein kinase (MAPK) signalling is another prominent 
pathway activated in response to cellular stress (see Figure 1.6), including exposure to 
methylating agents (Kim et al., 2007). Furthermore, activation in response to 
methylating agents appears dependent on functional MMR (Kim et al., 2007), 
suggesting a potential signalling pathway linking detection of O6-meG:T mispairs with 
induction of apoptosis. In addition, a direct interaction between MLH1, PMS2 and c-
Abl was identified which argues in favour of a direct signalling role for the MutLα 
complex (Kim et al., 2007).  
Recent studies have shown that a mutation in the BRCA1 gene can almost 
completely abolish G2 cell cycle arrest in response to 6-TG, causing BRCA1 mutant cells 
to be more resistant than isogenic wild-type counterparts (Yamane et al., 2007). 
BRCA1 can be phosphorylated by ATM, disrupting its interaction from a dormant 
complex with c-Abl, allowing both proteins to become active (Foray et al., 2002). 
Furthermore, BRCA1 can directly interact with MSH2 and ATM (Wang et al., 2000). 
Taken together, this identifies BRCA1 as a potential candidate that could bridge the 
gap between DNA MMR and c-Abl signalling responses. 
p73α and GADD45α, also downstream targets of c-Abl (see Figure 1.6), are 
rapidly activated in an MMR-dependent manner following methylating agent exposure 
(Li et al., 2008b; Wagner et al., 2008). Down-regulation of GADD45α blocked both G2 
arrest and apoptosis in response to methylating agents (Li et al., 2008b), possibly 
through activation of p38α MAPK (Hirose et al., 2003), demonstrating a key role in 
these processes. Interestingly, down-regulation of p73α only affected apoptosis, 
providing the first evidence that MMR may be able to signal an apoptotic response 
independently of cell cycle arrest (Li et al., 2008b). It should be noted that these same 
studies also report observation of single strand regions and DSBs following methylating 
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agent exposure (Wagner et al., 2008), hence evidence which apparently supports the 
direct signalling model for MMR-dependent arrest and apoptosis does not rule out 
MMR-mediated futile cycling, merely that it is not the trigger required to initiate 
damage signalling. 
Taking all of the available evidence into account, it appears that a number of 
cellular MMR-dependent processes can signal cell cycle arrest and/or apoptosis 
following methylating agent or 6-TG exposure. It still remains uncertain however, 
exactly how detection of DNA damage results in their initiation, and ongoing studies 
are required to delineate this. 
One of the purposes of G2 cell cycle arrest is to allow DNA repair pathways an 
opportunity to repair DNA damage sustained during DNA replication, prior to the onset 
of mitosis (Kastan and Bartek, 2004). Given that at least some O6-meG:T and me6-TG:T 
mispairs appear to be converted into DSBs as a result of MMR-mediated processing, a 
likely candidate repair pathway is HRR. Consistent with this model, HRR is activated in 
response to methylating agents (Zhang et al., 1996) through a mechanism that is 
dependent on functional DNA MMR (Zhang et al., 2000). Rajesh and colleagues (2011) 
provided direct evidence that HRR is required in the cellular response to 6-TG-induced, 
and by extension methylating agent-induced DNA damage downstream of DNA MMR. 
Specifically, MEFs deficient in Rad51 were found to be hypersensitive to 6-TG, show an 
enhanced G2 arrest and a substantial increase in chromosomal aberrations following 
exposure (Rajesh et al., 2011). Furthermore, this phenotype was almost completely 
rescued by deletion of Mlh1, strongly suggesting that HRR is involved in the repair of 6-
TG-induced DSBs generated by DNA MMR. This is also consistent with previous 
findings that cells and tumours deficient in the HRR genes BRCA1, BRCA2 or XRCC3 are 
hypersensitive to 6-TG (Issaeva et al., 2010). 
1.2.1.3.   Methylation Tolerance in MMR-defective Cells 
Concomitant resistance to methylating agents and 6-TG occurs in cells in which 
components of the DNA MMR pathway are defective (Aquilina et al., 1989; Aquilina et 
al., 1990; Hawn et al., 1995; Shin et al., 1998; Humbert et al., 1999). In MMR-deficient 
cells, O6-meG:T or me6-TG:T mispairs accumulate in DNA but do not trigger G2 cell 
cycle arrest or apoptosis (Karran and Bignami, 1994). This phenomenon, referred to as 
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methylation ‘tolerance’, is a hallmark of MMR-defective cells and represents a 
mechanism by which DNA damage can be uncoupled from cell death, thus conferring a 
cellular survival advantage (Karran, 2001). Tolerance to DNA damage however, comes 
at the cost of significantly increased mutability due to uncorrected mispairs (Branch et 
al., 1993; Branch et al., 1995) (Figure 1.5B). This has been referred to as a ‘super 
mutator phenotype’, and is also considered a hallmark of MMR-defective cells (Karran 
et al., 2003). These phenotypes have clear implications for both the aetiology and 
treatment of DNA MMR-defective cancer, and these are discussed in the context of 
therapy-related leukaemia in Section 1.4.1.1. 
1.2.2. 5-Fluorouracil 
5-fluorouracil (5-FU) is an analogue of the nucleobase, uracil, which has a 
fluorine atom substituted in place of hydrogen at the 5-position of the pyrimidine ring. 
It is widely employed in the treatment of solid cancers, most notably colorectal cancer, 
as it exhibits tumour-selective toxicity (Longley et al., 2003). A number of cellular DNA 
repair processes have been implicated as mediators of response to 5-FU, including 
DNA MMR, although the extent of MMR contribution and the mechanistic details of 
this response remain largely unclear.  
1.2.2.1. MMR and 5-FU Cytotoxicity 
Because 5-FU is a structural analogue of uracil, once it has been transported into 
cells, it can readily participate in uracil metabolism, culminating in the generation of 
fraudulent DNA and RNA precursors (Longley et al., 2003), similar to 6-TG described 
above. Cellular metabolism of 5-FU also results in inhibition of thymidylate synthetase, 
causing nucleotide pool imbalances which can favour nucleotide misincorporation 
during replication (Longley et al., 2003). 
The triphosphate of 5-FU is a good substrate for some replicative polymerases, 
leading to incorporation into genomic DNA (Tanaka et al., 1981). Biochemical evidence 
demonstrates incorporation most frequently opposite adenine (Tanaka et al., 1981), 
although nucleotide pool imbalance has been shown to cause misinsertion opposite 
guanine (Meyers et al., 2005). A number of studies have reported that cells deficient in 
MMR components, particularly MSH2 and MLH1, demonstrate decreased cell cycle 
arrest and apoptosis in response to 5-FU (Carethers et al., 1999; Tokunaga et al., 2000; 
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Meyers et al., 2001; Meyers et al., 2005). Furthermore, 5-FU:G mispairing is higher in 
MMR-defective cells, implying that loss of MMR leads to cellular tolerance of this 
lesion (Meyers et al., 2005). These findings are consistent with a model in which MMR-
dependent recognition of 5-FU lesions is required to initiate cytotoxicity.  
Unlike methylating agents and 6-TG, in which arrest occurs in the second cell 
cycle, MMR-dependent cell cycle arrest in response to 5-FU takes place in the first cell 
cycle (Meyers et al., 2005; Liu et al., 2008). This suggests MMR components detect 5-
FU inserted in the daughter strand during the first round of DNA replication following 
treatment. Consistently, biochemical assays have demonstrated that MutSα can 
recognise 5-FU mispaired opposite guanine but not when paired opposite adenine 
(Tajima et al., 2004; Meyers et al., 2005; Fischer et al., 2007). How this affects cell cycle 
arrest and apoptosis however, is unclear. 
Cell-free assays demonstrate that 5-FU:G mispairs can be efficiently corrected by 
MMR components, although it is unlikely repair would be successful in vitro or in vivo 
given that nucleotide pool imbalance would favour re-insertion of 5-FU (Fischer et al., 
2007). Futile repair cycling leading to generation of pro-apoptotic replication 
intermediates and/or DSBs is therefore a possibility. Consistent with this model, DSBs 
(Meyers et al., 2001) and ATR activation (Liu et al., 2008) have been reported in MMR-
proficient cells following 5-FU treatment. Other evidence suggests that direct signalling 
by MMR components to the c-Abl/p73α/GADD45α arrest/apoptosis pathway occurs in 
response to 5-FU:G mispairs, and this does not involve either ATR or ATM (Meyers et 
al., 2001). It is clear, as in the case of methylating agents and 6-TG, that multiple 
models could account for MMR-mediated cell death following 5-FU treatment, and 
further studies are required to delineate exact mechanisms. 
As stated above, 5-FU is used in the treatment of colorectal cancer, including 
hereditary non-polyposis colorectal cancer (HNPCC), a condition characterised by 
defective DNA MMR (see Section 1.4.1.1). Similar to in vitro studies described above, 
clinical studies examining 5-FU responses in these patients do not provide a clear 
picture of the specific involvement of MMR. Early reports suggested that patients with 
defective MMR might selectively benefit from 5-FU treatment (Hemminki et al., 2000). 
Subsequent studies however report either no difference in response between MMR-
proficient and deficient patients (Popat et al., 2005; Lamberti et al., 2007), or in some 
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cases, an unfavourable response in MMR-deficient patients (Ribic et al., 2003; 
Carethers et al., 2004; Jover et al., 2006). Prolonged exposure to 5-FU, such as would 
occur clinically, has been reported to result in MMR-independent cytotoxic responses 
involving other DNA repair pathways (Liu et al., 2008). The apparent discrepancies in 
the response of patients with MMR defects to 5-FU may therefore reflect the fact that 
the status of other DNA repair pathways were not assessed. 
1.2.3. Crosslinking Agents 
Crosslinking agents damage DNA by forming numerous intra and interstrand 
crosslinks (ICLs) between bases. These bulky lesions block DNA polymerases resulting 
in replication fork stalling, sustained G2 cell cycle arrest and apoptosis. The nucleotide 
excision repair (NER) pathway, as well as the HRR pathway, are the primary 
mechanisms which respond to ICls (Vasquez, 2010). Early studies demonstrating that 
MMR-defective cell lines display a low level of cisplatin resistance compared to 
isogenic MMR-proficient counterparts (Aebi et al., 1996; Fink et al., 1996) suggested 
DNA MMR was also involved. 
1.2.3.1. MMR and Cisplatin Cytotoxicity 
Cisplatin is one of the most effective chemotherapeutics for the treatment of 
testicular and ovarian cancers. This platinating agent modifies predominantly the N7-
position of purine bases, giving rise to monoadducts as well as crosslinks when two 
purines are in close proximity. Of the numerous bulky adducts formed, 1,2-ICLs 
occurring between the N7 atoms of two adjacent guanine bases can be bound by 
MutSα with high affinity (Duckett et al., 1996; Yamada et al., 1997). Unlike 5-FU, 
methylating agents and 6-TG, there is no evidence to suggest that this results in 
subsequent MutLα recruitment and further processing (Karran, 2001). Instead, 
resistance to cisplatin in DNA MMR-defective cells appears to be linked to the failure 
of these cells to directly activate damage signalling pathways that trigger apoptosis. 
Activation of c-Abl and downstream JNK kinase following cisplatin exposure is 
completely absent in MMR-defective cells (Nehme et al., 1997; Nehme et al., 1999). 
Additionally, cellular p73α protein is increased in response to cisplatin, but only in cells 
which have a functional DNA MMR system (Gong et al., 1999). A direct interaction 
between PMS2 and p73α has also been demonstrated following cisplatin exposure, 
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abrogation of which resulted in a diminished apoptotic response (Shimodaira et al., 
2003). Taken together, these findings revealed the existence of an MMR-dependent 
apoptosis pathway which contributes to cisplatin-induced cytotoxicity. It has been 
suggested that this may well be the same c-Abl mediated MMR-dependent pathway 
reported to occur following exposure to methylating agents (Li et al., 2008b) (see 
Section 1.2.1.2), in which case this would support the theory that MMR components 
can act as general DNA damage sensors with essential roles in signalling cell cycle 
arrest and/or apoptosis responses, and which does not necessarily depend on lesion 
processing.  
Whereas tolerance to methylating agents and 6-TG is accompanied by 
acquisition of a supermutator phenotype with implications for genomic stability, this is 
not observed in MMR-defective cells displaying low-level cisplatin resistance, 
presumably because other DNA repair pathways can efficiently process cisplatin 
damage (Stojic et al., 2004b). Nevertheless, cisplatin treatment can lead to the 
emergence/selection of MMR-deficient cell clones (Fink et al., 1998); the clinical 
significance of this is described in Section 1.4.1.1. 
1.2.3.2. MMR and Repair of ICLs 
As stated above, NER and HRR are the primary mechanisms which respond to 
ICLs, and both pathways cooperate in the repair of these lesions (Vasquez, 2010). Early 
observations that MMR-defective human cell lines demonstrated hypersensitivity to 
the ICL-inducing agents N-(2-chloroethyl)-N’-cyclohexyl-N-nitrosourea (CCNU) and 
mitomycin C (MMC) suggested that DNA MMR might also contribute to the repair of 
certain ICLs (Aquilina et al., 1998; Aquilina et al., 2000; Fiumicino et al., 2000). A 
possible mechanism has been explored in the case of CCNU. 
CCNU, like many other ICL-inducing agents, induces DSBs in proliferating cells 
through processing involving NER proteins (De Silva et al., 2000). Studies using a PMS2-
deficient cell line demonstrated that γ-H2AX foci (a sensitive indicator of DSB 
formation) persist in cells lacking a functional MutLα complex, and that these cells 
demonstrate a higher frequency of CCNU-induced chromosomal damage (Casorelli et 
al., 2008). This implicates active MMR in repair of CCNU-induced DSBs by HRR, possibly 
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through stabilisation of RAD51-containing repair intermediates, given that this protein 
was also inefficiently localised in PMS2-deficient cells (Casorelli et al., 2008). 
Further evidence implicating MMR components in the repair of ICLs comes from 
the response of MMR-defective cells to psoralens, photoactivatable ICL-inducing 
agents (Cimino et al., 1985) which can be used to target ICLs to particular genomic 
sites (Liu et al., 2009). The MutSβ complex plays a role in initial processing of psoralen-
induced ICLs via interaction with NER proteins, leading to removal or uncoupling of 
these lesions (Zhang et al., 2002; Lan et al., 2004; Zhao et al., 2009). Additionally, 
deficiency of MSH2 renders cells hypersensitive and hypermutable in response to 
psoralen-induced ICLs, suggesting a role in error-free repair of these lesions (Wu et al., 
2005). A mechanism has been speculated in which processing involving MutSβ and 
NER proteins gives rise to DSBs which are channelled into HRR for efficient 
recombination-mediated repair (Zhang et al., 2007). Surprisingly, whereas MSH2-
deficient cells are hypersensitive to psoralen, MLH1 deficiency confers resistance and 
inefficient induction of apoptosis by psoralen ICLs, through lack of G2 checkpoint 
activation (Wu and Vasquez, 2008). It appears therefore, that DNA MMR components 
have distinct and unique functions in the repair of and response to psoralen and 
CCNU-induced ICLs, which lie outside of their defined roles in DNA MMR. 
1.2.4. Ionising Radiation 
Available evidence is conflicting regarding the influence of cellular MMR status 
on radiosensitivity. Initial studies aimed at elucidating a role for DNA MMR in response 
to IR demonstrated that MEFs deficient in either MSH2, MLH1 or PMS2 showed 
increased survival following exposure to IR compared to MMR-proficient counterparts 
(Fritzell et al., 1997; DeWeese et al., 1998). Subsequent studies using strictly isogenic 
cell lines however, show no differences in cytotoxicity, arguing against an involvement 
of DNA MMR in cell death induced by IR (Papouli et al., 2004).  
1.2.4.1. MMR and IR-Induced Cell Cycle Checkpoint Activation 
IR induces a spectrum of lesions that can cause structural damage to DNA, 
including single strand nicks, DSBs, cross-links, oxidative base modifications and 
clustered base damage. Of these, unrepaired DSBs are thought to be the main lesion 
associated with cell killing following exposure to IR (Martin et al., 2010). Unlike all of 
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the agents previously described, it has not been established whether DNA MMR 
components can recognise IR-induced DNA damage directly (with the possible 
exception of oxidative base modifications as described below). IR-induced 
accumulation of cells in G2 phase of the cell cycle however, is reported to be 
diminished in MMR-deficient cells (described below), suggesting MMR components 
may have roles in cell cycle regulation following IR exposure.  
Two distinct G2 checkpoints are activated following exposure to IR (Xu et al., 
2002). The first occurs early after IR (referred to as the early G2 checkpoint), is very 
transient and appears to be dependent on ATM (Xu et al., 2002). Its function is to 
prevent cells which were in G2 phase at the time of irradiation from progressing to 
mitosis. Loss of MSH2 has been reported to result in inefficient activation of this 
checkpoint following IR exposure (Franchitto et al., 2003). Furthermore, this 
checkpoint is also reported to be absent following cisplatin exposure in MMR-defective 
cells (Marquez et al., 2003), hence MutSα has been proposed as a trigger of early 
checkpoint activation in response to DNA damage.  
The second checkpoint occurs several hours after irradiation and represents the 
accumulation of cells that had been in earlier phases of the cell cycle at the time of 
exposure. This checkpoint is ATM independent, and likely to be primarily activated by 
the ATR kinase which phosphorylates Chk1 (Xu et al., 2002). Both the early and late 
checkpoints involve inhibition of Cdc25C, which provides a block to progression into 
mitosis through failure to activate Cdc2 (see Figure 1.6). 
The role of MMR proteins in the late G2 arrest is uncertain. In one study, cell lines 
deficient in MLH1 demonstrated reduced late G2 arrest compared to MMR-proficient 
counterparts, which resulted in hypersensitivity to IR (Davis et al., 1998). A further 
study by the same investigators demonstrated a similar reduced late G2 arrest in 
MSH2-deficient cells, although this had no effect on cell survival (Yan et al., 2001b). 
Conversely, other investigations demonstrated a prolonged G2 arrest in response to IR 
in MutSα-deficient cells, which had no apparent effect on cytotoxicity (Aquilina et al., 
1999). The differing effects of MMR deficiency observed between studies may reflect 
an inability to clearly distinguish between the two G2 checkpoints using particular 
experimental systems, a caveat reported for certain cell cycle checkpoint assays (Xu et 
al., 2002).  
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In addition to arrest in G2 phase, an intra-S phase checkpoint is also activated in 
response to IR, but only in MMR-proficient cell lines (Brown et al., 2003). This 
checkpoint is also mediated by ATM activation and phosphorylation of Chk2, resulting 
in targeting of the Cdc25A phosphatase for degradation, meaning it can no longer 
dephosphorylate its substrate Cdk2, hence blocking replicating cells in S phase (Falck et 
al., 2001) (see Figure 1.12). MLH1 and MSH2 have been shown to interact with ATM 
and Chk2 respectively, and assembly of the MMR complex at damage sites has been 
suggested to provide a molecular scaffold that allows ATM to phosphorylate and 
activate Chk2, hence initiating S phase arrest (Brown et al., 2003). This, however, is 
contended by studies using strictly isogenic cell lines, in which no differences in 
phosphorylation of Chk2 (or other checkpoint kinases) are observed as a result of 
MMR deficiency, suggesting they may in fact be MMR-independent events (Cejka et 
al., 2004). 
1.2.4.2. MMR and Removal of 8-Oxoguanine 
Reactive oxygen species (ROS) are generated by exposure to IR as well as a 
variety of exogenous genotoxic agents, but also by endogenous metabolic functions 
such as mitochondrial respiration (Cooke et al., 2003). Intracellular ROS are highly 
damaging and oxidise bases in DNA and RNA as well as in the cellular dNTP pool 
(Cooke et al., 2003). Among several base lesions which have been identified, oxidation 
of guanine appears to occur most readily (Cooke et al., 2003). The resulting oxidised 
base, 8-oxoguanine (8-oxoG), is highly mutagenic and miscoding during DNA 
replication (Shibutani et al., 1991). Given this major threat to genomic stability, cells 
possess a number of mechanisms which prevent the accumulation of 8-oxoG in DNA, 
most notably the base excision repair (BER) pathway mediated by the OGG1 and MYH 
DNA glycosylases (Slupska et al., 1999; Boiteux and Radicella, 2000). Both in vitro and 
in vivo studies demonstrate that loss of MMR components results in accumulation of 
8-oxoG (and other oxidative lesions) in DNA (DeWeese et al., 1998; Colussi et al., 2002; 
Russo et al., 2007), illustrating that DNA MMR also contributes to the control of DNA 
oxidation.  
During DNA replication, 8-oxoG in the parental DNA strand most often directs 
incorporation of adenine or cytosine opposite the lesion, although guanine and 
thymine misincorporation can also occur (Shibutani et al., 1991). Of the possible 
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resulting mispairs, MutSα has been shown to bind to 8-oxoG:T and 8-oxoG:G with high 
affinity, but not to the 8-oxoG:C and 8-oxoG:A mispairs most likely to arise (Mazurek et 
al., 2002; Larson et al., 2003). Given that 8-oxoG:C and 8-oxoG:A mispairs can be 
efficiently repaired by BER proteins (Slupska et al., 1999; Boiteux and Radicella, 2000), 
a mechanism was proposed in which resynthesis following MMR-mediated excision of 
guanine or thymine would allow another chance for insertion of adenine or cytosine, 
thus generating substrates which could be addressed by BER (Larson et al., 2003).  
The cellular dNTP pool also provides a source of 8-oxoG, in the form of 8-
oxodGTP, which can be incorporated into daughter DNA strands by replicative 
polymerases (Colussi et al., 2002). The enzyme MTH1 provides protection against this 
by hydrolysis of 8-oxodGTP, preventing its incorporation during replication (Mo et al., 
1992). Loss of either MSH2 or MLH1 results in increased levels of incorporated 8-
oxodGTP in vitro (Colussi et al., 2002; Macpherson et al., 2005), suggesting another 
role of MMR may be in excision of this lesion, hence providing supplementary 
protection against 8-oxodGTP incorporation. 
Expression of transfected hMTH1 into Msh2-/- MEFs, as well as reducing the level 
of DNA 8-oxodGTP, decreases their mutator phenotype to almost wild-type levels 
(Russo et al., 2004). This finding implicates oxidised bases in the mutator phenotype 
and genomic instability of MMR-defective cells, and furthermore suggests that they 
could significantly contribute to carcinogenesis associated with loss of DNA MMR 
(described in Section 1.4.1.1).  
 
1.3. Acute Myeloid Leukaemia 
Acute myeloid leukaemia (AML) is a malignant disorder of the blood and bone 
marrow which arises as a result of de-regulation of haematopoiesis, the process by 
which the cellular components of blood are formed (Figure 1.7). It is a relatively rare 
cancer, with an incidence of approximately 2,300 cases annually in the UK 
[www.hmrn.org]. The median age of patients at diagnosis is 68 years [www.hmrn.org], 
hence AML is considered mainly a disease of adults, although it can present at any age. 
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Figure 1.7. Simplified representation of human haematopoiesis.
Haematopoietic stem cells differentiate into lineage committed common myeloid and lymphoid precursors which give rise to all myeloid and lymphoid
lineages respectively. In the bone marrow, precursors differentiate into immature lineage-restricted blast cells which rapidly develop into mature cells,
each possessing the ability to perform specialised functions. Haematopoiesis is regulated by numerous inter- and intra-cellular signalling factors (green
text) such as growth factors, cytokines and cell cycle regulatory proteins. Active genes associated with cell growth, signal transduction and
transcriptional regulation during early stages of differentiation are also shown (blue text). Specific cell types express characteristic surface markers (red
text) which are functional to the cell, but also allow identification and isolation of specific cell populations.
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AML manifests as a differentiation block of one or more myeloid cell lineages, 
leading to the accumulation of immature myeloblast cells in the bone marrow and 
diminished production of normal circulating erythrocytes and/or leukocytes. This is the 
cause of the characteristic clinical symptoms of AML which include fatigue and 
shortness of breath, accompanied by inability to fight infection and in some cases, 
haemorrhaging. It is unclear within the haematopoietic cell hierarchy, which cell 
constitutes the target for leukaemic transformation leading to AML. Evidence suggests 
the multipotent haematopoietic stem cell (HSC) as the likely target, as only HSCs 
isolated from AML patients were able to transfer AML to immunocompromised mice, 
whereas more committed progenitor cells could not, despite demonstrating a 
leukaemic blast phenotype (Bonnet and Dick, 1997).  
AML can occur de novo, described in this section, or as a secondary malignancy 
following cytotoxic therapy, termed therapy-related AML (t-AML; see Section 1.4). In 
rare cases, a predisposition to AML may be inherited as part of a more complex illness 
or syndrome.  
AML has historically been classified into 8 subtypes depending on the specific cell 
lineage(s) affected, which is determined by morphological appearance of the 
myeloblasts populating the leukaemic bone marrow (Table 1.1). In addition to 
morphological classification, detection of certain genetic mutations (cytogenetic and 
molecular genetic) can also delineate specific AML subtypes. Furthermore, many 
commonly detected genetic mutations are prognostically relevant and, in some cases, 
can direct therapeutic choice. 
 
FAB
Subtype
% of AML 
cases Description Morphology
M0 <5 Acute myeloblastic 
leukaemia, minimally 
differentiated
Immature myeloblasts without 
definite myeloid differentiation
M1 20 Acute myeloblastic leukaemia 
without maturation
Immature myeloblasts, Auer rods 
may be present
M2 30 Acute myeloblastic leukaemia 
with maturation
Immature myeloblasts (more 
mature than M1), Auer rods often 
present
M3 10 Acute promyelocytic
leukaemia
Hypergranular promyelocytes, 
bundles of Auer rods
M4
M4eo
25 Acute myelomonocytic
leukaemia
Mixture of abnormal monocytes
and myeloblasts/promyelocytes
(eosinophil precursors in M4eo)
M5a
M5b
10 Acute monocytic leukaemia M5a 80% immature monoblasts
M5b 20% differentiated monocytes
M6 <5 Acute erythroleukaemia Abnormal multinucleated 
erythroblasts, characterised by 
ringed sideroblasts
M7 <5 Acute megakaryoblastic
leukaemia
Megakaryoblasts, often 
myelofibrils, increased bone 
marrow reticulin
Table 1.1. Overview of the French-American-British (FAB) classification system of
AML (Bennett et al., 1976)
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1.3.1. Genetic Mutations in AML Leukaemogenesis 
Cytogenetically-detectable abnormalities are present in approximately 55% of de 
novo AML cases (Sanderson et al., 2006). Those most commonly observed are 
balanced translocations, which do not involve gain or loss of genetic material but cause 
aberrant localisation of a gene or part of a gene, usually resulting in either its de-
regulated expression or generation of a novel fusion protein with oncogenic 
properties. The remaining 45% of AML diagnoses demonstrate a cytogenetically 
normal karyotype (Sanderson et al., 2006). Such patients were previously poorly 
characterised with respect to genetic changes, however recent improvements in 
molecular diagnostic techniques have lead to the identification of a number of 
molecular genetic mutations. In both cases, affected genes are often involved directly 
or indirectly in haematopoiesis, aberrant (or lost) expression of which can de-regulate 
proliferation, differentiation and/or apoptosis of various immature myeloid cells. 
The cytogenetic and molecular genetic mutations commonly detected in AML 
can be grouped into at least two broad classes: Class I mutations which confer a 
proliferative and/or survival advantage to cells, and class II mutations which primarily 
impair haematopoietic differentiation. It is hypothesised that AML likely follows a 
‘two-hit’ model of leukaemogenesis, with leukaemic transformation being the 
consequence of collaboration between members of both classes of mutation (Deguchi 
and Gilliland, 2002; Kelly and Gilliland, 2002). Thus far, it has not been firmly 
established which mutations are primary events, and which occur later in AML 
development, if such an order indeed exists (Pedersen-Bjergaard et al., 2008).  
The incidences of the most common class I and II mutations observed in de novo 
AML (as well as t-AML; see Section 1.4.1.2) are summarised in Table 1.2. Probable roles 
in leukaemogenesis are described below. 
Gene Mutation
Incidence (%)a
de novo AML t-AML
Class I mutations
FLT3
Internal tandem duplication 22b 12b
Point mutations 6b 2b
N-RAS, K-RAS Point mutations 10 10
Class II mutations
AML1
t(8;21)(q22;q22) 7-10 5-7
Point mutations 10c 16d
CBFβ inv(16)(p13q22) 5-8 2-3
EVI1 inv(3)(q21q26) 2-3 2-3
MLL
Balanced rearrangements 
affecting 11q23
2-3e 9-10e
Partial tandem duplication 6b 3b
RARα t(15;17)(q22;q21) 5-10 2-3
NPM1 Point mutations 40-50 15
C/EBPα Point mutations 15-20 rare
Class III mutations?
TP53 Point mutations 10-15 20-25
Table 1.2. Summary of genetic mutations observed in de novo and therapy-related 
AML.
a Incidences obtained from Pedersen-Bjergaard et al., (2007) unless otherwise stated.
b Incidences obtained from Bacher et al., (2007).
c Incidence obtained from Harada and Harada (2009).
d Incidence obtained from Christiansen et al., (2004).
e Incidences obtained from Schoch et al., (2003).
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1.3.1.1. Class I Mutations 
FLT3 
The fms-related tyrosine kinase 3 (FLT3) gene on chromosome 13q12 encodes a 
membrane-bound receptor involved in the regulation of proliferation, differentiation 
and apoptosis of haematopoietic cell progenitors (Stirewalt and Radich, 2003). Internal 
tandem duplications (ITDs) which affect the juxtamembrane domain of the receptor 
are among the most prevalent mutations in de novo AML, being detected in around 
22% of cases (Bacher et al., 2007). An additional 5-6% of cases demonstrate missense 
point mutations within the tyrosine kinase domain of the gene (Bacher et al., 2008). 
Both mutations result in a protein that is constitutively activated, promoting 
proliferation and decreasing apoptosis of leukaemic blasts (Gilliland and Griffin, 2002). 
Due to the relatively high frequency of FLT3 mutations in AML, much concentration 
focuses on the development of FLT3 inhibitors for treatment of this AML subgroup (see 
Section 1.3.2.3). 
RAS 
Mutations of RAS genes (N-RAS, K-RAS and H-RAS) are frequent observations in 
several cancer types. In AML, point mutations in N-RAS and K-RAS collectively are 
found in approximately 10% of patients (Pedersen-Bjergaard et al., 2007), with N-RAS 
codon 12 mutations being the most common (Renneville et al., 2008). These genes 
encode a family of guanine-nucleotide binding proteins that regulate intracellular 
signal transduction. Mutations abrogate intrinsic GTPase activity and thus confer 
constitutive activation of RAS proteins and their downstream effectors, which play an 
important role in proliferation, differentiation and apoptotic processes (Beaupre and 
Kurzrock, 1999).   
1.3.1.2. Class II Mutations 
AML1 
A balanced translocation between chromosomes 8 and 21, which fuses the 
RUNX1 (AML1) gene at 21q22 with the RUNX1T1 (ETO) gene at 8q22, represents the 
most common chromosomal abnormality in AML. The resulting fusion oncoprotein 
consists of the N-terminal DNA-binding domain of AML1, a subunit of the core binding 
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factor (CBF) transcription activator essential for haematopoiesis (Okuda et al., 1996), 
and almost all of ETO, a protein thought to function as a co-repressor for a variety of 
transcription factors (Davis et al., 2003). AML1/ETO promiscuously targets a number of 
haematopoietic transcription factors including PU.1, GATA-1 and C/EBPα; the 
consequence being de-regulated haematopoietic differentiation (Petrie and Zelent, 
2007). AML1/ETO can be detected in HSCs from AML patients, meaning the 
translocation probably occurs at the stem cell level and hence represents an early 
event in AML leukaemogenesis (Miyamoto et al., 2000). Despite this, it is not sufficient 
alone to cause leukaemic transformation and subsequent mutations are required 
(Yuan et al., 2001). 
Point mutations of the AML1 gene are detected in approximately 10% of AML 
patients, with an even higher frequency detected in t-AML (see Section 1.4.1.2) 
(Harada and Harada, 2009). Surprisingly, numerous mutations are observed in AML1 
and are distributed throughout the full length of the gene (Harada and Harada, 2009). 
Despite this diversity, they can roughly be grouped into two subtypes: those affecting 
the N-terminal runt homology domain of the protein, and those affecting the C-
terminal ‘activation’ domain (Harada and Harada, 2009). Investigations of the effects 
of forced expression of AML1 mutants in human CD34+ cells demonstrate a pivotal 
role in early AML leukaemogenesis. Mutations affecting the C-terminal domain result 
in a block in cell differentiation and increased proliferation and self-renewal capacity, 
suggesting these mutations alone may be sufficient to drive AML development (Harada 
and Harada, 2009). N-terminal mutations on the other hand, block differentiation and 
slightly increase self-renewal capacity but block proliferation, hence additional 
mutations that induce proliferation activity appear necessary for transformation to 
AML (Harada and Harada, 2009). Consistently, cytogenetic abnormalities and 
mutations of other genes are more frequently detected in patients with N-terminal 
AML1 mutations compared to patients with C-terminal mutations (Harada and Harada, 
2009). 
CBFβ 
An inversion within chromosome 16 represents another commonly reported 
chromosomal aberration in AML, particularly in subtype M4 (Le Beau et al., 1983). The 
breakpoints of the inversion lie within the MYH11 gene at 16p13 and the CBFβ gene at 
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16q22, which encodes the β unit of CBF (Liu et al., 1993). The resulting CBFβ/MYH11 
fusion product, like AML1/ETO causes impaired haematopoietic differentiation (Reilly, 
2005). Accordingly, AMLs with t(8;21) or inv(16) are often grouped together and 
referred to as CBF leukaemias, given that they seem to share a common pathogenic 
mechanism. 
EVI1 
Another chromosomal inversion, which is observed in a small number of AML 
cases, affects the 3q26 locus, harbouring the EVI1 gene (Testoni et al., 1999). Although 
the exact pathogenic mechanism of the rearrangement remains unclear, it appears 
that over-expression of EVI1 as a result of the inversion also interferes with 
differentiation of immature progenitor cells, particularly of the erythroid and 
granulocytic lineages (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003). 
MLL 
Balanced rearrangements, the majority of which are reciprocal translocations, 
involving band 11q23 occur in approximately 2% of cases of AML (Schoch et al., 2003). 
The 11q23 locus contains the mixed lineage leukaemia (MLL) gene, encoding a 
transcription factor with a role in regulation of haematopoietic development (Hess et 
al., 1997). Translocations affecting this locus result in fusion of the 5’ component of 
MLL with one of a number of partner genes, creating a fusion protein with 
transforming properties (Ayton and Cleary, 2001). Unlike AML1/ETO described above, 
it has been demonstrated using murine models that certain MLL fusion proteins are 
sufficient to cause leukaemic transformation without the requirement for co-operating 
mutations (Forster et al., 2003).  
In addition to cytogenetic rearrangements, the MLL gene can also undergo 
partial tandem duplication (PTD) spanning multiple exons, which occurs in 
approximately 6% of AML patients (Bacher et al., 2007). The leukaemogenic 
mechanism of the MLL-PTD is thought to be distinct from that of MLL fusion proteins, 
and may involve suppression of the remaining wild-type MLL allele by the mutant 
allele, resulting in a lack of normal MLL protein (Whitman et al., 2005). 
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RARα 
AML of subtype M3, or acute promyelocytic leukaemia (APL), is characterised by 
the occurrence of a specific translocation between chromosomes 15 and 17, fusing the 
promyelocyte gene (PML; 15q22) with the retinoic acid receptor alpha gene (RARα; 
17q12) (de The et al., 1990; Kakizuka et al., 1991). The hybrid protein created by the 
fusion targets and represses transcription of a number of genes containing retinoic 
acid response elements, ultimately resulting in a block in myeloid differentiation, as 
well as conferring a survival and proliferative advantage and genetic instability on the 
expressing cells (Pandolfi, 2001). Like t(8;21) however, the translocation alone is not 
sufficient for transformation to overt leukaemia and co-operating mutations are 
required (Pandolfi, 2001). 
NPM1 
Point mutations in the nucleophosmin 1 (NPM1) gene have been identified in a 
number of haematological disorders, and are thought to occur in as many as 50% of de 
novo AML diagnoses (Pedersen-Bjergaard et al., 2007). NPM is a multi-functional 
shuttling protein, one role of which is regulation of p53 activity (Grisendi et al., 2006). 
Mutation of NPM1 results in improper localisation of the protein (Mariano et al., 
2006), and is probably an early event in AML leukaemogenesis (Thiede et al., 2006). 
The pathogenic mechanism however remains unclear, despite it being such a common 
observation in haematological malignancy (Baldus et al., 2007). 
C/EBPα 
The CCAAT/enhancer binding protein alpha (C/EBPα) gene encodes a member of 
a family of transcription regulators with an essential role in granulocyte differentiation 
(Zhang et al., 1997). Mutations of C/EBPα occur in 15-20% of cytogenetically normal 
AML patients (Pedersen-Bjergaard et al., 2007) and are usually associated with AML of 
FAB subtype M1 or M2 (Pabst and Mueller, 2009). Two types of mutation are 
predominantly observed: N-terminal frameshift mutations which result in a truncated 
form of the protein, and C-terminal insertions or deletions which affect DNA binding 
(Pabst et al., 2001). Interestingly, the majority of patients have more than one 
mutation, most commonly a combination of an N-terminal frameshift and a C-terminal 
insertion or deletion, usually located on different alleles (Pabst and Mueller, 2007). 
The role of C/EBPα mutation in leukaemogenesis remains to be clarified, however 
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microarray analysis demonstrates upregulation of genes involved in erythroid 
differentiation (such as GATA-1), as well as downregulation of genes involved in 
myeloid differentiation (such as AML1 and PU.1) and proliferation signalling pathways 
(such as FLT3) in C/EBPα-mutated AML patients (Marcucci et al., 2008b). 
1.3.1.3. Class III Mutations 
Inactivating mutations of genes involved in regulation of cell cycle and/or 
apoptosis, such as the TP53 tumour suppressor gene, possibly constitute a third class 
of mutation in AML leukaemogenesis (Pedersen-Bjergaard et al., 2007). Point 
mutations of TP53 are detected in 10-15% of de novo AML patients (Pedersen-
Bjergaard et al., 2007), but appear to be significantly more frequent in t-AML (see 
Section 1.4.1.2). Patients with TP53 mutation are generally resistant to chemotherapy 
and have very short survival (Wattel et al., 1994). 
1.3.1.4. Other Genetic Abnormalities 
In addition to balanced chromosome rearrangements, certain deletions affecting 
either whole chromosomes or specific regions are often observed in AML, and also 
may be associated with leukaemic transformation and/or prognosis. Deletions of the 
long arms of chromosomes 5 and 7 (del(5q) and del(7q) respectively), or entire loss of 
these chromosomes are observed most frequently. As these deletions are significantly 
associated with t-AML, they are described below (Section 1.4.1.2). Loss of 
chromosomes in AML generally predicts for an adverse prognosis, especially combined 
loss of more than one chromosome (termed a monosomal karyotype) which is 
detected in approximately 10% of cases (Breems et al., 2008). 
A limited number of recurrent chromosomal trisomies are also reported in AML. 
Although rare as sole abnormalities, these are usually observed in conjunction with 
other abnormalities. The most common is trisomy 8, accounting for around 10% of de 
novo AML cases (4% as a sole abnormality) (Mrozek et al., 2004). Trisomy 8 has been 
reported to confer a proliferative advantage to leukaemic cells, hence it may be 
involved in promoting clonal expansion (Yan et al., 2001a). Other recurrent trisomies 
reported in AML are +11, +13, +21 and +22 (Mrozek et al., 2004). 
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Non-coding microRNAs (miRNAs) have also recently been found to be involved in 
myeloid leukaemogenesis, as well as in transformation of several other human 
malignancies (Marcucci et al., 2009). miRNAs are 19-25 nucleotide RNA molecules 
which can hybridise to imprecisely complementary mRNA targets, thereby inhibiting 
translation of the corresponding proteins (Ambros, 2004). They are present in all cell 
types and, by affecting gene regulation, are likely to be involved in most biological 
processes (Ambros, 2004). Genome-wide miRNA-expression profiling has 
demonstrated that specific subtypes of AML have unique miRNA expression 
signatures, capable of distinguishing them from other AML subtypes (Dixon-McIver et 
al., 2008; Jongen-Lavrencic et al., 2008; Li et al., 2008c). Furthermore, a growing body 
of evidence suggests that miRNA expression can influence clinical outcome in AML 
(Dixon-McIver et al., 2008; Garzon et al., 2008; Marcucci et al., 2008a). Functional 
studies of miRNA expression are currently in their infancy but will likely provide 
important insights into AML leukaemogenesis and pathogenesis. 
1.3.2. Treatment Strategies for Acute Myeloid Leukaemia 
1.3.2.1. Standard Chemotherapeutic Approaches in AML 
Treatment of patients with AML typically consists of at least one course of 
intensive myelosuppressive induction chemotherapy, followed by a consolidation 
phase usually involving higher drug doses, and subsequently an extended period of 
lower intensity maintenance therapy. Historically, the nucleoside analogue cytarabine 
(Ara-C; Section 1.5) has formed the backbone of all phases of AML treatment, and 
remains a mainstay in current AML therapeutic regimes. Ara-C is usually administered 
in combination with the anthracycline daunorubicin (or in some cases idarubicin), a 
DNA intercalating agent. Other agents sometimes used in combination with Ara-C and 
daunorubicin include the base analogue 6-TG and topoisomerase inhibitors (such as 
etoposide or topotecan).  
Overall, with standard chemotherapy, approximately 60-80% of adult AML 
patients will achieve complete remission (CR), however many will relapse within 2 
years, often with chemoresistant disease (Shipley and Butera, 2009). The treatment of 
relapsed and refractory AML remains a major challenge, as does the treatment of t-
AML, in which the CR rate has been reported to be as low as 28% (Larson, 2007). 
 41 
 
Relapsed, refractory and t-AML patients are also treated with Ara-C, although the low 
CR rate demonstrates the poor success of this approach. Novel regimens which include 
the use of fludarabine, mitoxantrone and G-CSF with high dose Ara-C are currently 
being trialled and are showing favourable early results (Robak and Wierzbowska, 
2009). 
Treatment of elderly AML patients (those aged 60 years and over) also currently 
poses a significant challenge which is due, in large part, to an inability to tolerate 
aggressive therapeutic regimes. Strategies such as liposomal encapsulation of Ara-C 
and daunorubicin, which can reduce drug-associated toxicity and decrease dosage, 
have showed promise in elderly de novo AML patients (Feldman et al., 2011). 
1.3.2.2. Alternative Nucleoside Analogues for AML Treatment 
Clofarabine (Section 1.5.4), a next generation nucleoside analogue which is 
licensed for the treatment of acute lymphoblastic leukaemia (ALL), is currently being 
trialled in patients with AML, particularly elderly patients who are unsuitable for 
conventional chemotherapy, and those with relapsed or refractory AML who do not 
typically respond well. Indications suggest that using clofarabine in combination with 
high dose Ara-C in relapsed/refractory AML patients (Faderl et al., 2005), or with low 
dose Ara-C in elderly patients (Faderl et al., 2008) is capable of achieving an improved 
CR rate as well as demonstrating a favourable toxicity profile.  
Fludarabine (Section 1.5.4), an adenosine nucleoside analogue commonly used 
to treat chronic lymphocytic leukaemia (CLL), is currently being trialled for the 
treatment of relapsed/refractory AML (in combination with high dose Ara-C), with 
favourable early results being demonstrated in small scale studies (Jackson, 2004). 
Other nucleoside analogues also being investigated include troxacitabine and 
sapacitabine, both of which are similar in structure and function to Ara-C (Robak and 
Wierzbowska, 2009). 
Certain nucleoside analogues which can act as hypomethylating agents also 
demonstrate efficacy in the treatment of AML. Endogenous DNA methylation occurs 
when a methyl group is attached to a cytosine base in a CpG dinucleotide by a DNA 
methyltransferase (DNMT) enzyme. This leads to remodelling of the chromatin 
structure thus preventing access by DNA binding proteins. DNA methylation of 
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promoter regions occurs often in cells and provides a mechanism by which genes can 
be epigenetically silenced when their expression is not required. Aberrant DNA 
methylation has been reported in AML and several other malignancies (Ellis et al., 
2009). Azacytidine (AZA) and decitabine (DEC), like Ara-C, are nucleoside analogues of 
cytidine which are readily incorporated into DNA and RNA and are able to inhibit 
DNMTs, hence providing a block to DNA methylation. Both agents have been used in 
the past to treat relapsed/refractory AML, although the treatment-related toxicity was 
considerable (Robak and Wierzbowska, 2009). However, more recent small-scale trials 
have demonstrated that lower doses of AZA and DEC may be just as effective as higher 
doses, and furthermore are well tolerated in elderly patients (Sudan et al., 2006; Blum 
et al., 2007). It has been suggested that AML patients with the t(8;21) translocation 
may particularly benefit from the use of these agents given that one of the 
mechanisms by which the AML1/ETO fusion protein blocks gene expression is through 
aberrant recruitment of DNMTs (Petrie and Zelent, 2007). This however remains to be 
formally tested. 
1.3.2.3. Targeted Therapies for Treatment of AML 
Recent years have seen the advent of so called ‘targeted therapies’ which 
interfere with specific molecules unique to leukaemic cells, rather than targeting all 
dividing cells in the way traditional chemotherapeutic agents do. All-trans retinoic acid 
(ATRA) was the first example of targeted therapy, which revolutionised treatment of 
patients with APL. ATRA is a vitamin A derivative which specifically affects the function 
of the fusion protein encoded by the characteristic t(15;17) translocation. Disruption of 
the fusion protein abrogates the differentiation block and enables cells to mature 
along the granulocyte lineage (Raelson et al., 1996). Using ATRA in combination with 
standard chemotherapy can induce CR in over 90% of APL patients, with 95% of 
patients remaining in remission at 5 years (Hu et al., 2009). 
The immunotoxin gemtuzumab ozogamycin (GO) is another example of a 
targeted therapy which is being trialled in the treatment of AML. GO consists of an 
anti-CD33 antibody conjugated to calichemycin, a potent cytotoxic antibiotic. It binds 
to the CD33 antigen, which is expressed on the surface of AML cells in 80-90% of 
patients, following which the antibiotic is internalised and causes cytotoxic DNA DSBs 
(Stasi et al., 2008). GO monotherapy is approved for treatment of relapse in elderly 
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AML patients who are unfit for standard cytotoxic chemotherapy, and can induce CR in 
26% of cases (Larson et al., 2005). GO has also shown remarkable activity in APL 
patients, probably owing to the high expression of CD33 on APL blasts (Estey et al., 
2002; Lo-Coco et al., 2004). Combinations of GO with standard chemotherapy are still 
under investigation in other AML patient subgroups (Stasi et al., 2008). 
Other examples of targeted therapies which are currently under trial for efficacy 
in AML treatment include FLT3 inhibitors which may be effective in patients with FLT3 
mutations, and farnesyl-transferase inhibitors which can block constitutively activated 
Ras signalling in RAS-mutated AML patients. In both cases, small scale trials have 
showed encouraging results and larger multicentre trials are underway (Robak and 
Wierzbowska, 2009).  
 
1.4. Therapy-Related Acute Myeloid Leukaemia 
Therapy-related acute myeloid leukaemia (t-AML) is recognised as a specific form 
of AML which arises as a direct consequence of therapy (chemotherapy or 
radiotherapy) for a primary malignancy, or non-malignant condition in some cases. 
Primary disorders commonly preceding t-AML include Hodgkin lymphoma (HL), non-
Hodgkin lymphoma (NHL), multiple myeloma, breast cancer, ovarian cancer and 
prostate cancer (Smith et al., 2003). A number of distinct subtypes of t-AML are 
recognised and these are associated with the nature of the therapy received for the 
preceding malignancy. Unlike the majority of other cancers, t-AML is considered 
unique in the respect that its aetiology, and the genetic events involved in disease 
progression, are well defined. This is especially true in the case of methylating agent-
related t-AML, as described below.   
Currently, t-AML is estimated to account for around 2% of AML diagnoses in the 
UK [www.hmrn.org], although the incidence is predicted to rise due to the increasing 
number of cancer survivors (Travis et al., 2006). Survival times of t-AML patients are 
often short, and the CR rate is as low as 28% (Larson, 2007). This is attributed to t-AML 
being less responsive to current forms of therapy than de novo AML, a complication 
which may be due to the underlying genetics of the condition, but may also reflect 
other factors, such as patient age (as t-AML patients are often elderly and hence 
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expected to demonstrate decreased tolerance to intensive therapy) or 
immunosuppression persisting following the primary disorder (Godley and Larson, 
2008).  
1.4.1. Methylating Agent-Related Acute Myeloid Leukaemia 
The most common subtype of t-AML, accounting for 75% of cases (Yin et al., 
2010), arises in patients who have been treated with chemotherapeutic regimes 
involving the use of DNA methylating agents. Patients who develop methylating agent-
related t-AML generally show a long latency period of 3-7 years (median 5 years) from 
initial methylating agent exposure, often present with a preceding myelodysplastic 
phase and usually demonstrate a complex karyotype with loss of genetic material 
(Allan and Travis, 2005). Typically, multiple haematopoietic cell lineages are affected 
which suggests the disease may arise in a multipotent HSC or progenitor cell (Qian et 
al., 2010). Prognosis for methylating agent-related t-AML is particularly poor and 
median survival following disease presentation is typically less than 9 months (Smith et 
al., 2003).  
1.4.1.1. DNA MMR Dysfunction and t-AML Carcinogenesis – The ‘Genomic Instability’ 
Model 
The aetiology of methylating agent-related t-AML is particularly well defined and 
involves a complex series of events leading to leukaemic transformation (Figure 1.8A). 
Accumulating evidence suggests that, because of its interaction with 
chemotherapeutic methylating agents, DNA MMR may play a role in the early stages of 
this process.  
Primary Malignancy
11q23 (MLL) 
Rearrangement  
t-AML
Genetic abnormalities 
(chromosome aberrations, 
mutation)
t-AML
Genetic Instability 
(MMR dysfunction)
-5/del(5q)
-7/del(7q)
Genetic abnormalities 
(chromosome aberrations, 
mutation)
t-AML
METHYLATING 
AGENTS
TOPOISOMERASE 
INHIBITORS
A
B
i
ii
Figure 1.8. Genetic pathways in t-AML pathogenesis.
A. Exposure to chemotherapeutic methylating agents may give rise to genetic instability through dysfunction of the DNA MMR system (see Section
1.4.1.1). Downstream events include loss of all or part of chromosomes 5 and/or 7 as well as acquisition of other chromosomal and molecular
genetic abnormalities, leading to eventual leukaemic transformation. Note that the exact order in which these events occur remains unclear.
B. Chemotherapy involving topoisomerase inhibitors results in balanced chromosomal rearrangements, commonly affecting the MLL locus at 11q23.
Abnormal proteins resulting from these rearrangements may themselves be sufficient for leukaemic transformation (i). However, subsequent
genetic aberrations may also be required for transformation to t-AML (ii). These events occur over a shorter timescale (2 - 3 years) compared to
those occurring as a result of methylating agent exposure (3 – 7 years).
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The main evidence for an association between DNA MMR and t-AML comes from 
several studies which have demonstrated high-grade microsatellite instability (MSI) in 
patients with t-AML following exposure to methylating agent chemotherapy. MSI 
refers to alterations in the length of short repetitive DNA sequences dispersed 
throughout the genome (termed microsatellites) that arises due to slippage of DNA 
polymerase during DNA replication. DNA MMR can repair polymerase slippage events, 
and biochemical evidence has directly linked the development of MSI to defective DNA 
MMR (Umar et al., 1994; Boyer et al., 1995). Detection of MSI is therefore considered a 
marker of MMR dysfunction. Figure 1.9 summarises key studies which have assessed 
MSI in t-AML and de novo AML. Consistent observation of high levels of MSI in t-AML 
strongly implicates loss of normal DNA MMR function in the pathogenesis of this 
disease. Further support is provided by the direct identification of defects affecting 
MSH2 or MLH1 expression, preferentially in t-AML patients (Horiike et al., 1999; Zhu et 
al., 1999; Casorelli et al., 2003). In addition, a small number of studies have 
investigated MSI status in relapsed and secondary AML (also included in Figure 1.9). 
The finding of MSI in these AML subtypes suggests they could share similarities in 
disease pathogenesis with t-AML (discussed further in Chapter 7). By contrast, MSI is 
relatively rare in de novo AML, suggesting MMR defects have little involvement in the 
aetiology of AML arising as a primary malignancy, except perhaps in the elderly (Das-
Gupta et al., 2001).  
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Figure 1.9. Frequency of microsatellite instability in AML.
The bar chart summarises studies reporting microsatellite instability (MSI) frequency
in de novo AML, relapsed AML, secondary AML (defined as AML transformed from
prior myelodysplastic syndrome) and t-AML. Data is presented as the percentage of
study patients defined as positive for MSI according to criteria specified in each study.
Where possible, data is separated according to patients demonstrating MSI-high (MSI
observed at 30% or more of loci examined) and those demonstrating MSI-low (MSI at
less than 30% of loci examined). Note that this data could be somewhat confounded
due to the use of different microsatellite loci among the studies cited. References:
Ben-Yehuda et al., 1996; Boyer et al., 1998; Casorelli et al., 2003; Das Gupta et al.,
2001; Herzog et al., 2005; Indraccolo et al., 1999; Nomdedeu et al., 2005; Ohyashiki
et al., 1996; Olipitz et al., 2002; Pabst et al., 1996; Rimza et al., 2000; Rund et al.,
2005; Serrano et al., 2008; Sheikhha et al., 2002; Sill et al., 1996; Tasaka et al., 1997;
Worrillow et al., 2003.
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Predicted models for the role of DNA MMR in methylating agent-related t-AML 
development are shown in Figure 1.10. As described in Section 1.2.1.3, dysfunction of 
DNA MMR represents a mechanism by which malignant cells could evade the cytotoxic 
effects of methylating agent chemotherapy. One possibility therefore, is that 
chemotherapeutic agents themselves cause abrogation of DNA MMR function, giving 
rise to a cell clone that can survive treatment. This has been demonstrated to occur in 
response to cisplatin chemotherapy for ovarian cancer (Fink et al., 1998; Samimi et al., 
2000). Alternatively, a pre-existing MMR-defective myeloid cell clone could be 
enriched during chemotherapy. In either case, positive selection during further rounds 
of chemotherapy would promote the emergence of an MMR-deficient population 
(Allan and Travis, 2005). This has been shown to occur following exposure to the 
chemotherapeutic methylating agent temozolomide using a murine model of t-AML 
(Reese et al., 2003) and has also been demonstrated in vivo in ovarian cancer patients 
treated with cisplatin (Fink et al., 1997; Samimi et al., 2000). 
MMR deficiency itself is not sufficient for leukaemic transformation (Reese et al., 
2003). One consequence of DNA MMR dysfunction however, is acquisition of a 
mutator phenotype as described in Section 1.2.1.3. A mutator phenotype is presumed 
to have genome-wide consequences, increasing the likelihood of additional 
transforming mutations which contribute to leukaemic transformation (hence the 
model of t-AML carcinogenesis as a result of DNA MMR loss is often referred to as the 
‘genomic instability’ model (Allan and Travis, 2005)). Furthermore, as well as 
demonstrating genomic instability and a mutator phenotype, the survival advantage 
also afforded to MMR-defective cells may allow avoidance of apoptosis, leading to an 
expanded cell clone susceptible to tumourigenic mutation (Fishel, 2001). 
Dysfunction of DNA MMR is not unique to t-AML and has been identified in a 
number of other malignancies such as HNPCC, in which heritable germline mutations 
in MMR genes (most commonly MSH2 and MLH1 (Peltomaki, 2003)) constitute a pre-
disposing factor for development of cancer, often at a young age. Sporadic cancers in 
which somatic MMR dysfunction is observed include breast, skin, lung, prostate and 
bladder cancers, although its role is not well understood in many cases (Peltomaki, 
2003). 
Figure 1.10. DNA MMR loss in methylating agent-related t-AML carcinogenesis.
Treatment of a primary malignancy with methylating agents (or other
chemotherapeutic agents known to interact with DNA MMR) may promote
generation of (top pathway), or emergence of a pre-existing (bottom pathway) MMR-
defective cell clone. Loss of MMR may also confer tolerance to the cytotoxic effect of
methylating agents and allow avoidance of apoptosis, leading to clonal enrichment
(middle pathway). In each case, MMR loss results in genetic instability and a mutator
phenotype, increasing the possibility of subsequent genetic aberrations leading to
eventual leukaemic transformation. Note that only one mutational event is depicted
prior to leukaemic transformation, however multiple events are likely required.
Adapted from Allan and Travis (2005).
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1.4.1.2. Cooperating Genetic Aberrations in t-AML Aetiology 
A number of mutational events are probably required for eventual 
transformation to t-AML, consistent with the long latency period associated with this 
disease. Of particular significance are -5/del(5q) and -7/del(7q). Such abnormalities, 
when grouped together, are observed in more than 80% of methylating agent-related 
t-AML cases (Smith et al., 2003). Del(5q) is the most common abnormality, and it is 
believed that the commonly deleted region (5q31-33) contains at least one leukaemia-
specific tumour suppressor gene (TSG) (Qian et al., 2010). Attempts to elucidate the 
identity of TSGs on 5q has proved challenging, although some candidates include the 
transcriptional regulator early growth response 1 (EGR1) (Joslin et al., 2007), the 
adenomatous polyposis coli (APC) gene (Qian et al., 2008) and the gene encoding 
alpha-catenin (CTNNA1) (Liu et al., 2007). Similarly, it is likely that the commonly 
deleted region on chromosome 7 (7q22-31) harbours a TSG (Le Beau et al., 1996), 
although candidates have so far remained elusive. 
As in de novo AML, a growing body of evidence suggests that point mutations in 
genes responsible for regulation of haematopoiesis may be involved in the progression 
and pathogenesis of methylating agent-related t-AML. Interestingly, although the 
spectrum of observed molecular mutations is similar, many of the mutations common 
in de novo AML, such as mutations within FLT3, NPM1 and C/EBPα, are rare 
observations in methylating agent-related t-AML (see Table 1.2) (Side et al., 2004; 
Christiansen et al., 2005; Kayser et al., 2011). Conversely, mutations affecting AML1 or 
TP53 appear to be more common in therapy-related disease than de novo AML and are 
reported to be significantly associated with -7/del(7q) and -5/del(5q) respectively 
(Horiike et al., 1999; Christiansen et al., 2001; Harada et al., 2003; Christiansen et al., 
2004; Side et al., 2004; Pedersen-Bjergaard et al., 2008).  
1.4.1.3. Deregulation of Other DNA Repair Pathways 
Accumulating evidence suggests that MSI-related abrogation of other key DNA 
repair genes, in particular those involved in the HRR pathway, may contribute to t-AML 
leukaemogenesis. MSI occurring within the coding region of the MRE11 gene (a 
component of the MRE11/RAD50/NBS1 (MRN) complex), resulting in aberrant splicing, 
has been reported in MMR-defective cell lines (Ham et al., 2006) and in a small subset 
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of t-AML patients (Casorelli et al., 2003), as well as in other cancers displaying MSI, 
including colorectal, gastric, and endometrial cancer (Giannini et al., 2002; Giannini et 
al., 2004; Ottini et al., 2004). Furthermore, Worrillow and Allan (2006) demonstrated 
de-regulation of the expression of Mre11 (with concurrent deregulation of a number of 
other HRR genes) in Msh2-deficient murine ES cells. These findings suggest a model 
whereby de-regulation of HRR occurs as a consequence of DNA MMR loss, and this is 
predicted to contribute to genomic instability and t-AML carcinogenesis (Worrillow 
and Allan, 2006). These observations are consistent with DNA MMR as a negative 
regulator of HRR, as described in Section 1.1.2.1. 
Similarly, MSI affecting a coding microsatellite within the FANCD2 gene has 
recently been reported in t-AML patients and in leukaemic cell lines displaying MSI 
(Offman et al., 2005). The FANCD2 gene product is a member of the Fanconi Anaemia 
complementation group of proteins, and has a probable role in HRR (Taniguchi et al., 
2002; Thompson and Hinz, 2009), providing further evidence that this pathway is a 
target for de-regulation following DNA MMR loss.  
1.4.2. DNA Topoisomerase Inhibitor-Related Acute Myeloid Leukaemia 
The second major subtype of t-AML (accounting for 20-30% of t-AML cases 
(Rowley and Olney, 2002)) arises following treatment with chemotherapeutic 
inhibitors of DNA topoisomerase enzymes; such inhibitors include etoposide and 
mitoxantrone. Compared to methylating agent-related t-AML, patients who develop 
topoisomerase inhibitor-related t-AML are generally younger, have a shorter latency 
period (2-3 years) and rarely present with MDS (Allan and Travis, 2005). Prognosis is 
also generally more favourable, with response rates similar to patients with de novo 
AML (Godley and Larson, 2008). 
Almost all cases of topoisomerase inhibitor-related t-AML present with balanced 
translocations, most commonly involving 11q23 (affecting MLL) (Rowley and Olney, 
2002). Other abnormalities include t(8;21) (affecting AML1), t(15;17) (affecting RARα) 
and inv(16) (affecting CBFβ) (Rowley and Olney, 2002). The mechanism of formation of 
these abnormalities has been directly linked to the action of DNA topoisomerase 
inhibitors (Libura et al., 2005). Topoisomerase enzymes uncoil DNA, via generation of 
transient DSBs, to enable DNA replication or transcription (Wang, 2002). 
 52 
 
Topoisomerase inhibitors trap the enzymes before re-ligation, thus generating DSBs 
which have the potential to participate in translocations (Richardson and Jasin, 2000).  
It is thought that translocations are an early event in topoisomerase inhibitor-
related t-AML carcinogenesis (Figure 1.8B), and some may even be sufficient alone to 
cause leukaemic transformation (Allan and Travis, 2005). For example, in the case of 
11q23 rearrangements, some of the resulting MLL fusion proteins are sufficient to 
cause leukaemia in mouse models (Forster et al., 2003). In other cases, however, it is 
likely that the acquisition of additional genetic alterations is required for complete 
transformation to t-AML (Yuan et al., 2001).  
1.4.3. Therapy-Related Acute Myeloid Leukaemia Following Radiotherapy 
Certain investigations have identified radiotherapy as a risk factor for 
development of t-AML, particularly when used as a pre-conditioning treatment for 
autologous stem cell transplant (Krishnan et al., 2000; Pedersen-Bjergaard et al., 
2000). It is difficult to determine however, to what extent t-AML development can be 
attributed to radiation alone given that it is often administered in combination with 
chemotherapeutic regimes involving methylating agents or topoisomerase inhibitors 
(Smith et al., 2003). Furthermore, in the case of stem cell transplant, chemotherapy for 
the malignancy necessitating transplant may also influence outcome (Hake et al., 
2007).  
Radiotherapy (ionising radiation) causes DNA damage in the form of DSBs (as 
well as other less cytotoxic forms of DNA damage), hence it is conceivable that 
exposure would increase the likelihood of genetic aberrations (for example, 
chromosomal deletions or translocations) which could contribute to leukaemic 
transformation. Consistently, t-AML has been observed in patients who received 
radiotherapy alone (Kantarjian et al., 1986; Krishnan et al., 2000; Smith et al., 2003; 
Christiansen et al., 2005).  
Overall, no specific clinical or cytogenetic differences appear to separate t-AML 
following radiotherapy from chemotherapy-related t-AML (Smith et al., 2003). 
Similarly, no specific molecular genetic abnormalities have been significantly 
associated with t-AML following radiotherapy, with the potential exception of FLT3 
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mutations, reported by a single study, although the clinical significance remains 
unknown (Christiansen et al., 2005). 
1.4.4. Therapy-Related Acute Myeloid Leukaemia Following Organ Transplantation 
In addition to cancer patients, t-AML has been observed in patients who have 
received solid organ transplants, with an aetiology associated with the use of 
immunosuppressive therapies administered to minimise organ rejection, such as 
azathioprine (Arnold et al., 1999; Offman et al., 2004). 
Azathioprine is a thiopurine prodrug, related to 6-TG. As described in Section 
1.2.1.2, the DNA MMR system plays an important role in mediating the cytotoxicity of 
these drugs, via interaction with thiopurine nucleotides incorporated into DNA (Waters 
and Swann, 1997). Given this similarity between azathioprine and methylating agents 
with regards to interactions with DNA MMR, it is probable that t-AML following organ 
transplantation is closely related, if not identical, to methylating agent-related t-AML.  
Frequent observation of loss of all or part of chromosomes 5 and 7 in transplant-
related t-AML (Offman et al., 2004) is also consistent with this notion. 
1.4.5. Atypical Therapy-Related Acute Myeloid Leukaemia 
Although the vast majority of t-AML cases can be classified into one of the 
subtypes described above, a small number of clinically atypical cases are reported 
which do not appear to associate with any specific type of previous therapy (Pedersen-
Bjergaard et al., 2007). Little is known about the molecular biology of these 
leukaemias, however a normal karyotype is commonly observed, as are mutations 
affecting the RTK/RAS-BRAF signalling pathway (Christiansen et al., 2005). It has been 
suggested that these leukaemias may be considered identical to de novo AML with a 
normal karyotype (Pedersen-Bjergaard et al., 2007). It is therefore possible that AML 
observed in these patients is in fact a de novo disease representing a second primary 
cancer, rather than a therapy-induced secondary disorder. 
1.4.6. Genetic Predisposition to Therapy-Related Acute Myeloid Leukaemia 
The major risk factor for t-AML is high-dose chemotherapy (or radiotherapy), 
however risk is variable and not all patients exposed to leukaemogenic therapy will 
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develop t-AML. Inherent differences in drug response exist between individuals due to 
genetic variability in enzymes that metabolise chemotherapeutic agents and those that 
repair drug-induced DNA damage, some of which have been identified as potential 
modifiers of t-AML susceptibility (summarised in Table 1.3). 
Metabolism of chemotherapeutic agents in humans is mediated by two groups of 
enzymes. Phase I enzymes, including the cytochrome p450 (CYP) enzymes, activate 
substrates into electrophilic intermediates, whereas phase II enzymes, including 
glutathione S-transferase (GST) and NAD(P)H:quinone oxoreductase 1 (NQO1), 
function to inactivate genotoxic substrates.   
A large number of single nucleotide polymorphisms (SNPs) have been identified 
in genes encoding CYP enzymes, several of which have been studied in t-AML, 
although the majority do not appear to be significantly associated with development of 
the disease (Seedhouse and Russell, 2007). Of potential interest is an A>G 
polymorphism in the promoter region of the CYP3A4 gene (located 293bp upstream of 
the transcription start site (Rebbeck et al., 1998)) which has been proposed to protect 
against t-AML development, particularly following treatment with topoisomerase II 
inhibitors (Rund et al., 2005). It is postulated that the variant (G) allele may modify the 
rate of metabolism and reduce the risk of DNA damage associated with these agents 
(Felix et al., 1998), however larger studies are required to confirm this hypothesis.  
Homozygous deletion polymorphisms have been identified in the genes encoding 
phase II GST enzymes (Seidegard et al., 1988; Pemble et al., 1994). These constitutional 
deletions result in absence of functional protein, with the apparent consequence being 
a higher level of DNA damage (Wiencke et al., 1995). As in the case of the CYP 
enzymes, the majority do not demonstrate a significant association with t-AML, 
however one study did report a significant increase in the likelihood of developing t-
AML in GSTT1-null Caucasians (Sasai et al., 1999). Given that approximately 30-40% of 
Caucasians are thought to be GSTT1-null (Pemble et al., 1994), this also may warrant 
further investigation. In another of the GST enzymes, GSTP1, a common G>A 
polymorphism at codon 105 affecting protein activity has also been significantly 
associated with t-AML development in a substrate-specific manner (Allan et al., 2001). 
Gene Variant /SNP Patient Cohort Odds Ratio (95% CIa) of t-AML Study
Phase I metabolising enzymes
CYP3A4 A>G 293bp upstream of transcription 
start site 
44 t-AML, 134 controls Not given. Variant allele under-
represented in t-AML (P<0.025)
Rund et al., 2005
Phase II metabolising enzymes
GSTT1 Null 18 t-AML, 43 controls 4.62 (1.48-14.4) Sasai et al., 1999
GSTP1 G>A polymorphism affecting codon
105 (Ile105Val)
89 t-AML, 1022 controls Any chemotherapy 2.66 (1.39-5.09)
Known GSTP1 substrate 4.34 (1.43-13.2)
Allan et al., 2001
NQO1 C609T (Pro187Ser) 58 t-AML, 150 controls Heterozygote 0.98 (0.28-1.68)
Homozygote 2.62 (2.16-3.08)
Naoe et al., 2000
Folate metabolism
MTHFR C677T 81 t-AML, 64 controls 15.71 (1.63-151.07) Guillem et al., 2007
A1298C 5.5 (1.06-28.42)
Table 1.3. Genetic polymorphisms reported to modify risk of t-AML (continued on next page).
a CI, confidence interval.
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Gene Variant /SNP Patient Cohort Odds Ratio (95% CIa) of t-AML Study
DNA mismatch repair
MSH2 -6 exon 13 T>C (splice acceptor site) 91 t-AML, 837 controls 4.02 (1.4-11.37) Worrillow et al., 2003
MLH1 G>A 93bp upstream of transcription 
start site
133 t-AML, 1177 controls 5.31 (1.4-20.15) Worrillow et al., 2008
Homologous recombination repair
RAD51 G135C (within 5’-UTR) 51 t-AML, 186 controls 2.66 (1.17-6.02) Seedhouse et al., 2004
Nucleotide excision repair
ERCC2 Lys751Gln 41 t-AML, 729 controls 2.22 (1.04-4.74) Allan et al., 2004
Base excision repair
XRCC1 Arg399Gln 34 t-AML, 178 controls 0.44 (0.20-0.93) Seedhouse et al., 2002
Table 1.3. Genetic polymorphisms reported to modify risk of t-AML (continued from previous page).
a CI, confidence interval.
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NQO1 is also a phase II enzyme which functions to prevent the generation of 
damaging ROS during detoxification processes (Seedhouse and Russell, 2007). A 
common polymorphism in the NQO1 gene (C609T substitution resulting in a proline to 
serine change at codon 187 (Traver et al., 1992)) which reduces protein activity has 
been significantly associated with t-AML, particularly following methylating agent 
chemotherapy (Naoe et al., 2000). It is believed that people carrying the polymorphism 
are at increased risk of telomere shortening and oxidative stress as a result of 
chemotherapeutic exposure, leading to genetic instability (Fern et al., 2004). 
Another genetic variant which has been significantly associated with 
development of t-AML exists in the gene encoding methylenetetrahydrofolate 
reductase (MTHFR), a member of the folate metabolism pathway. Two SNPs within the 
gene (C677T and A1298C) have been reported to confer increased risk of t-AML 
following treatment of primary breast cancer with the antimetabolite 5-FU, although 
the cellular mechanisms underlying this association are unclear (Guillem et al., 2007). 
Given the high rate of MSI in t-AML, particularly in methylating agent-related 
disease, there has been a lot of interest in whether variations in genes encoding 
components of DNA repair pathways could be associated with increased risk of t-AML 
development. Mutations causing loss of MMR function (commonly involving MSH2 and 
MLH1 genes) are known to be a susceptibility factor for HNPCC, although these 
mutations do not seem to be common somatic events in t-AML (Sheikhha et al., 2002). 
There are however, reports of genetic variants in certain MMR genes which may pre-
dispose individuals to t-AML. A T>C SNP has been identified in a splice acceptor site 
within the MSH2 gene (-6 exon 13) which appears to be significantly associated with t-
AML development following methylating agent chemotherapy (Worrillow et al., 2003). 
Similarly a G>A SNP within the promoter of MLH1 (93bp upstream from transcription 
start site) has been reported in a high number (75%) of patients who received 
methylating chemotherapy for HL (Worrillow et al., 2008). Although the functional 
significance of these polymorphisms is unknown, one possibility is that they result in a 
reduction in the levels of the respective protein, conferring tolerance to methylating 
agent chemotherapy and concurrent susceptibility to t-AML development. Consistent 
with this, Claij and te Riele (2002) reported that murine ES cells expressing a reduced 
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level of Msh2 protein are tolerant to the cytotoxic effects, but highly sensitive to the 
mutagenic effects of methylating agents in vitro. 
Variants within genes involved in the HRR pathway have also been associated 
with an increased risk of t-AML development in some studies. For example, a G>C 
substitution within the 5’ untranslated region of the RAD51 gene (G135C) has been 
shown to be significantly over-represented in t-AML patients compared to normal 
controls (Seedhouse et al., 2004). RAD51 is one of the central proteins in the HRR 
pathway, and is essential in the maintenance of genetic stability (Sonoda et al., 1998). 
The polymorphism significantly enhances promoter activity leading to increased levels 
of RAD51 mRNA (Hasselbach et al., 2005), and is postulated to have a dominant 
negative effect on initiation of HRR (Seedhouse and Russell, 2007). This finding, in 
combination with the reports of MSI within the MRE11 gene in t-AML patients 
(described in Section 1.4.1.3), further suggest HRR de-regulation as a likely factor in t-
AML pathogenesis. 
Polymorphic variants within other DNA repair genes, such as ERCC2 (XPD), which 
is involved in NER, and XRCC1, a component of the BER pathway, have also been 
associated with risk of t-AML (Seedhouse et al., 2002; Allan et al., 2004). The latter, 
which carries a SNP within the coding region of the gene (XRCC1-Arg399Gln), appears 
to protect against t-AML carcinogenesis, possibly because the variant allele results in 
reduced BER capacity and might drive damaged cells towards apoptosis rather than 
attempted repair (Seedhouse et al., 2002). 
 
1.5. Cytarabine (Ara-C) 
Ara-C is a mainstay of treatment for AML, as described in Section 1.3.2.1. This 
section focuses on the structure of Ara-C, the current understanding of the cytotoxic 
mechanism of the drug, and the factors thought to be associated with resistance to 
Ara-C chemotherapy. In addition, some other therapeutic nucleoside analogues which 
share mechanistic similarities with Ara-C are also described. 
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1.5.1. Structure of Ara-C 
Ara-C belongs to a class of compounds known as nucleoside analogues, so-called 
due to their structural and/or functional resemblance to normal DNA precursor 
nucleosides. Ara-C is a pyrimidine nucleoside analogue bearing structural resemblance 
to deoxycytidine, and is distinguished by the presence of a hydroxyl group in β-D-
configuration on the 2’-carbon of the deoxyribose ring of the drug (Figure 1.11). 
Crystallographic studies with free nucleoside reveal that the presence of the hydroxyl 
group does not significantly alter the conformation of Ara-C from deoxycytidine 
(Sundaralingam, 1975). 
1.5.2. Cytotoxic Mechanisms of Ara-C 
1.5.2.1. Incorporation into Replicating DNA Leading to Chain Termination 
A prerequisite for the cytotoxicity of Ara-C is penetrance of the drug into cells 
and subsequent conversion to Ara-C triphosphate (Ara-CTP) (Figure 1.11). The 
cytotoxic mechanism of Ara-CTP is multifaceted but is understood primarily to involve 
fraudulent incorporation into replicating DNA (due to its structural similarity to dCTP) 
during S phase of the cell cycle, resulting in chain termination.  
DNA replication in eukaryotic cells requires three DNA polymerases: DNA 
polymerase α (pol α), DNA polymerase δ (pol δ) and DNA polymerase ε (pol ε). 
Primase, which is tightly associated with pol α, synthesises short RNA primers at 
replication origins which are then extended by pol α. Following limited DNA synthesis 
by pol α, a switch occurs to processive DNA synthesis by pol ε (leading strand) or pol δ 
(lagging strand) (for a recent review, see (Pavlov and Shcherbakova, 2010). Molecular 
analyses demonstrate that Ara-CTP is a substrate for DNA pol α and can be 
incorporated in place of dCTP during DNA synthesis (Perrino and Mekosh, 1992; 
Gandhi et al., 1997; Richardson et al., 2004). When incorporated, the hydroxyl group 
on the 2’-carbon of the deoxyribose ring of Ara-C causes major conformational 
perturbations of DNA at the site of incorporation (Gao et al., 1991; Schweitzer et al., 
1994) which is proposed to hinder binding of pol α, hence inhibiting further chain 
elongation (Perrino and Mekosh, 1992; Gandhi et al., 1997). Ara-CTP can also inhibit 
activity of the other major replicative polymerases, pol δ (Han et al., 2000; Jiang et al., 
2000) and pol ε (Huang et al., 1991), although the effects are less pronounced. 
Figure 1.11. Uptake and intracellular metabolism of cytarabine.
Interaction of cytarabine (Ara-C; 1-β-D-ararbinofuranosylcytosine) with specialised
membrane-bound nucleoside transporters is required for penetration of Ara-C into
cells. The human equilibrative nucleoside transporter I (hENT1) is the primary
transporter responsible for cellular uptake of Ara-C (Wiley et al., 1985). Once inside
cells, the enzyme deoxycytidine kinase phosphorylates Ara-C, giving rise to Ara-C
monophosphate (Ara-CMP), after which further phosphorylation events mediated by
deoxycytidine monophosphate kinase and nucleoside diphosphate kinase result in
Ara-CTP (Matsuda and Sasaki, 2004) which can enter the nucleus and interfere with
DNA replication. Inset shows the structure of Ara-CTP, compared to the normal
deoxynucleoside triphosphate, dCTP (substituted hydroxyl group is shown in red).
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The incorporation of Ara-C at 3’-terminal positions in DNA was correlated with 
reduced clonogenic survival in early studies (Kufe et al., 1980; Major et al., 1981), 
however the exact mechanisms by which this chain termination mediates cell death 
still remain uncertain. Ara-C-induced stalled replication forks lead to activation of an 
intra-S phase checkpoint which results in S-phase cell cycle arrest (Shi et al., 2001; 
Mesa et al., 2005) (Figure 1.12A). One of the consequences of this may be to permit 
attempted removal of Ara-C lesions to allow DNA replication to continue. Studies 
generally suggest that the exonuclease activities associated with replicative DNA 
polymerases are inefficient at removal of Ara-C from 3’-termini (Huang et al., 1991; 
Perrino et al., 1999). Unassociated 3’→5’ exonucleases capable of excision of Ara-C in 
template assays however, have been identified (Perrino et al., 1994; Skalski et al., 
2000). Additionally, the human APE1 endonuclease, whose major function is excision 
of damage during BER (Wilson and Barsky, 2001), has also been shown to have 
exonuclease activity towards nucleoside analogues, however its affinity for Ara-C was 
low (Chou et al., 2000). 
It has recently been suggested that DSBs form as a result of unresolved stalled 
replication forks (Ewald et al., 2008b). Consistent with this model, the appearance of 
chromosome aberrations (Jones et al., 1976; Sekizawa et al., 2007), as well as 
phosphorylation of γ-H2AX and localisation of ATM and the MRN complex (Ewald et 
al., 2008a), also suggests the formation of DSBs in response to Ara-C. These proteins 
may recruit other repair pathways, such as HRR, providing an opportunity to rescue 
the replication fork (Figure 1.12B). 
Ara-C initiates cells to die by apoptosis (Gunji et al., 1991; Bullock et al., 1995), 
which appears to be dependent on functional c-Abl (Huang et al., 1997), a tyrosine 
kinase which mediates apoptosis through p73 (Yuan et al., 1999). Failure of repair 
pathways to recover the replication fork represents the likely apoptotic signal (Roos 
and Kaina, 2006), which could be mediated by ATM given that it can activate c-Abl 
(Baskaran et al., 1997; Shafman et al., 1997) (Figure 1.12B), as well as other cell death 
signalling proteins. 
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Figure 1.12. Replication fork stalling and S phase arrest in response to Ara-C
A. ATR is attracted to single stranded regions of DNA at stalled replication forks
through interactions with replication protein A (RPA) and ATR-interacting protein
(ATRIP) (Zou and Elledge, 2003). Following its recruitment, ATR activates Chk1 kinase
(Feijoo et al., 2001), which in turn phosphorylates and activates Cdc25A phosphatase
(Bartek and Lukas, 2003). Activation of Cdc25A prevents it from dephosphorylating
cyclin-dependent kinase 2 (Cdk2), a positive regulator of cell cycle progression, thus
cell cycle arrest is induced (Hu et al., 2001). One consequence of cell cycle arrest may
be removal of Ara-C by exonuclease enzymes. B. Collapsed replication forks could be
converted to DSBs. ATM and MRN complex localisation might recruit DNA repair
pathways to attempt to rescue the replication fork. It may also signal p73-mediated
apoptosis through interaction with c-Abl.
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1.5.2.2. Inhibition of DNA Repair 
There is a growing body of evidence demonstrating that Ara-C can interfere with 
the DNA re-synthesis step of certain DNA repair pathways, highlighting another 
potential mechanism of Ara-C-mediated cytotoxicity. In fact, it has been suggested that 
under normal conditions, the majority of Ara-C nucleotide observed in DNA is as a 
result of incorporation during DNA repair re-synthesis, and only in cases where the 
pool of available deoxynucleotides is reduced is the incorporation of Ara-C into DNA by 
replicative synthesis favoured (Iwasaki et al., 1997).  
Early studies demonstrated that stimulation of DNA repair activity by ultra violet 
(UV) irradiation enhanced the incorporation of Ara-C into DNA, which had the effect of 
inhibiting repair of UV-induced damage (Kufe et al., 1984; Mirzayans et al., 1993). 
Similarly, more recent studies demonstrated that single strand DNA gap filling during 
NER could be inhibited by treatment of cells with Ara-C (Matsumoto et al., 2007). 
Consistent with these findings, some of the polymerases associated with DNA 
repair are capable of mediating incorporation of Ara-C into DNA, including polymerase 
β (pol β) and polymerase λ (pol λ), which are specialised polymerases responsible for 
re-synthesis of DNA during the BER pathway (Shcherbakova et al., 2003). Template 
assays demonstrate that Ara-CTP is an efficient substrate for both pol β (Ohno et al., 
1988; Prakasha Gowda et al., 2010) and pol λ (Garcia-Diaz et al., 2010) suggesting that 
the BER pathway might be capable of mediating the cytotoxicity of Ara-C. 
1.5.2.3. Inhibition of Topoisomerase Enzymes 
The cytotoxicity of Ara-C may also be enhanced through effects on the action of 
DNA topoisomerases, enzymes responsible for relaxing the torsion of DNA, through 
controlled generation of strand breaks, during replication and transcription (Wang, 
2002).  Ara-C treatment can result in trapping of topoisomerase I (topo I) cleavage 
complexes on DNA in leukaemic cell lines, due to the localised structural effects of Ara-
C incorporation into DNA, causing inhibition of the DNA religation reaction catalysed 
by topo I (Chrencik et al., 2003). Similarly it has been shown that the presence of Ara-C 
at particular positions in DNA can ‘poison’ topoisomerase II (topo II) resulting in an 
increase in cytotoxic DSBs (Cline and Osheroff, 1999). Consistently, cells deficient in 
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topo I or topo II are more resistant to Ara-C than parental cells with normal levels of 
the enzymes (Goz and Bastow, 1997; Pourquier et al., 2000). 
1.5.3. Mechanisms of Resistance to Ara-C 
A number of mechanisms of cellular resistance to Ara-C have been identified in 
vitro, as well as in vivo in AML patients showing poor response to Ara-C chemotherapy. 
The majority of Ara-C resistance mechanisms are related to expression of genes 
associated with uptake and cellular metabolism of Ara-C. These include deficiency of 
hENT1 resulting in decreased cellular uptake of Ara-C (Takagaki et al., 2004; Hubeek et 
al., 2005; Kanno et al., 2007; Cai et al., 2008), reduced expression of deoxycytidine 
kinase (dCK) thus limiting the activation of Ara-C into Ara-C triphosphate (Veuger et al., 
2003; Cai et al., 2008; Rathe and Largaespada, 2010), overexpression of the gene 
encoding cytidine deaminase which is responsible for deamination of Ara-C to an 
inactive form (Neff and Blau, 1996) and increased expression of 5’-nucleotidase, 
capable of dephosphorylation of Ara-C monophosphate (Dumontet et al., 1999). 
Furthermore, correlation of these mechanisms with poor outcome in AML patients has 
been demonstrated (Galmarini et al., 2002; Cros et al., 2004), suggesting their 
potential responsibility for Ara-C resistance in vivo. 
Some proteins not associated with Ara-C metabolism have also been implicated 
in Ara-C resistance, in particular those associated with regulation of apoptosis. Insulin-
like growth factor 1 (IGF1), a potent inhibitor of apoptosis, was overexpressed in Ara-
C-resistant cell lines as well as in AML patients with refractory disease (Abe et al., 
2006). Loss of expression of Nf1, an upstream regulator of RAS signalling (Maruta and 
Burgess, 1994), has also been reported in Ara-C-resistant cell lines (Yin et al., 2006). 
Similarly, loss of p53 expression is also associated with decreased sensitivity to the 
cytotoxic effects of Ara-C in cell line models (Decker et al., 2003; Kanno et al., 2004; Yin 
et al., 2006). 
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1.5.4. Other Therapeutic Nucleoside Analogues 
Fludarabine and clofarabine are both analogues of 2’-deoxyadenosine currently 
being evaluated for the treatment of AML (see Section 1.3.2.2). Fludarabine, like Ara-C, 
is distinguished by the presence of a 2’-hydroxyl group in β-D-conformation on the 
deoxyribose sugar ring, but in addition it also has substitution of a fluorine atom in 
place of hydrogen at the 2-position of the purine ring (Figure 1.13). Clofarabine is 
distinguished from the parent nucleoside by the presence of a fluorine atom at the 2’-
position of the deoxyribose sugar, as well as substitution of chlorine at the 2-position 
of the purine ring (Figure 1.13). Clofarabine, by virtue of its structure, is more stable 
and is associated with a reduction in off-target toxic effects that compromise the use 
of other nucleoside analogues, affording it a higher degree of efficacy and a wider 
clinical spectrum (Zhenchuk et al., 2009). Cladribine is also an anti-leukaemic 2’-
deoxyadenosine analogue, modified solely on the purine ring where it has substitution 
of a chlorine at the 2-position (Figure 1.13). 
The primary mechanism of fludarabine, clofarabine and cladribine-induced 
cytotoxicity appears to be similar to Ara-C in that cell death depends primarily on 
fraudulent incorporation of the triphosphate into replicating DNA, and subsequent 
inhibition of DNA synthesis (Hentosh et al., 1990; Huang et al., 1990; Parker et al., 
1991). Unlike Ara-C however, fludarabine, cladribine and clofarabine also possess an 
additional mechanism of action which contributes to their cytotoxicity. The 
triphosphates have inhibitory actions towards ribonucleotide reductase (Parker et al., 
1988; Xie and Plunkett, 1996), a key enzyme involved in the formation of 
deoxyribonucleotides from ribonucleotides. Inhibition of ribonucleotide reductase 
results in a decrease in deoxynucleotide pools, leading to enhanced incorporation of 
the fraudulent nucleotides into DNA, an action known as self-potentiation (Heinemann 
et al., 1992). 
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Figure 1.13. Structures of the normal nucleoside, 2’-deoxyadenosine and its
analogues fludarabine, cladribine and clofarabine.
Substituted groups are shown in red.
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1.6. Aims of Project 
Failure to achieve complete remission and disease relapse are major clinical 
problems in AML, and often lead to poor outcome in patients. Numerous factors can 
contribute to poor response to therapy, including presence (or acquisition) of 
mutations which allow cancer cells to evade the cytotoxic mechanisms of drugs 
(chemoresistance) or an inability to tolerate necessary aggressive therapeutic 
approaches (particularly in elderly patients). Of the many factors affecting therapeutic 
response, chemoresistance remains the major obstacle to successful treatment of 
AML, and understanding the underlying mechanisms is an important goal for 
researchers and treating clinicians. 
It is well established that defects in the DNA MMR pathway confer cellular 
resistance to certain chemotherapeutic agents in vitro, namely methylating agents, 6-
TG and cisplatin, and may also modulate response to other agents including IR and 5-
FU. Although typically chemoresistant subtypes of AML, such as relapsed AML and t-
AML, have been reported to demonstrate MMR defects in a high percentage of cases, 
a direct link between MMR loss and chemoresistance in vivo has yet to be established. 
The primary objective of this project was to investigate the role of DNA MMR in 
mediating therapeutic response to agents used to treat AML. The strategies for 
achieving this were: 
• To determine whether defects of the DNA MMR pathway (loss or 
overexpression of MMR components) affect in vitro response to 
chemotherapeutic agents used in the treatment of AML, particularly Ara-
C and other nucleoside analogues. 
• To determine if prolonged exposure of myeloid cells to either a 
methylating agent, 6-TG or Ara-C could result in loss of functional DNA 
MMR, effectively recapitulating the postulated development of t-AML, 
and investigate the effects on chemotherapeutic response. 
• To investigate the DNA-directed mutagenicity of Ara-C, including 
characterisation of the spectrum of drug-induced mutations, in order to 
identify potential substrates for interaction with DNA MMR components. 
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• To perform genome-wide molecular analysis (via high density SNP arrays) 
of a small cohort of matched presentation and relapsed AML patients, in 
order to investigate clonal architecture of AML, and whether there was 
evidence of AML evolving as the disease progresses from presentation to 
relapse.  
 
 69 
 
Chapter 2. Materials and Methods
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2.1. Chemicals and Reagents 
All chemicals and reagents used were of Analar grade and were purchased from 
Sigma-Aldrich Co. Ltd. (Dorset, UK) unless otherwise stated. Phosphate buffered saline 
(PBS) was prepared from PBS tablets (Invitrogen Life Technologies, Paisley, UK) and 
was autoclaved prior to use for sterility. Preparation of reagents for use in specific 
investigations are described in relevant sections below. 
2.2. Cell Lines 
The lymphoblastoid TK6 cell line and its subline, MT-1 were a kind gift from Prof. 
W. Thilly (MIT, MA, USA). A second culture of TK6 and its paired subline, TK6 MTXr, as 
well as the precursor B-cell line PreB697 and its subline PreB697 MTXr, were provided 
by E. C. Matheson (Northern Institute for Cancer Research (NICR), Newcastle, UK). The 
myeloid leukaemic cell line HL-60 and its subline HL-60R were a kind gift from Prof. T. 
Shimada (Nippon Medical School, Tokyo, Japan). The myeloid leukaemic cell lines KG-1 
and EoL-1 were obtained from the American Type Culture Collection (ATCC, VA, USA). 
In addition, the cell lines HeLa and LoVo were used as controls for certain experiments, 
and were provided in the form of frozen cell pellets by E. C. Matheson. 
Specific features of cell lines are described in more detail in relevant results 
chapters. 
2.3. General Cell Culture Methods 
2.3.1. Routine Cell Culture 
All cell culture reagents were purchased from Invitrogen Life Technologies 
(Paisley, UK) unless otherwise stated. Tissue culture plasticware was from Corning-
Costar (supplied by VWR International Ltd., Leicestershire, UK). All cell culture was 
carried out in a class II microbiological safety cabinet (BIOMAT-2, Medical Air 
Technology Ltd., Oldham, UK) using aseptic technique. 
All cell lines were maintained as suspension cultures in 5ml RF10 medium 
[Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% (v/v) 
foetal bovine serum (FBS) and 50μg/ml penicillin/streptomycin] in 25cm3 sterile cell 
culture flasks. Cultures were incubated at 37°C in a humidified 5% CO2 incubator 
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(Heraeus Equipment Ltd., Essex, UK). Cell cultures were passaged as required, 
according to Table 2.1, in order to maintain cells in exponential growth phase. Cell 
lines were passaged a maximum of 25 times, after which fresh stocks were 
resuscitated from liquid nitrogen storage (see Section 2.3.4). Testing for mycoplasma 
was performed by E. C. Matheson at 2 month intervals using a MycoAlert kit (Lonza 
Biologics, Slough, UK). 
2.3.2. Cell Counting and Determination of Cell Density 
An aliquot of cell suspension was mixed with a 0.4% solution of trypan blue (Life 
Technologies, Paisley, UK) in a 1:1 ratio and 10μl of the mixture was loaded onto a 
Neubauer haemocytometer (VWR International Ltd.) and a minimum of 100 cells were 
recorded for each cell count.  
2.3.3. Cryopreservation of Cell Stocks 
Following determination of cell concentration, appropriate volume of cell 
suspension containing 5 x 106 cells was dispensed into sterile BD Falcon™ centrifuge 
tubes (BD Biosciences, Oxford, UK) and centrifuged at 230 x g for 5 min. Supernatant 
was discarded, after which cell pellets were resuspended in 1ml freezing medium [FBS 
supplemented with 10% (v/v) dimethyl sulphoxide (DMSO)] and transferred to sterile 
polypropylene cryovials (Invitrogen Life Technologies). Cells were frozen slowly 
(approximately 1oC per minute) to -80°C and transferred to liquid nitrogen for long 
term storage.  
2.3.4. Resuscitation of Frozen Cell Stocks 
Cryopreserved cell aliquots were thawed rapidly and transferred to 5ml pre-
warmed RF10 medium. Suspensions were then centrifuged at 230 x g for 5 min, after 
which supernatant was completely removed and discarded. Resulting cell pellets were 
resuspended in 5ml RF10 culture medium, transferred to 25cm3 sterile cell culture 
flasks and incubated at 37°C/5% CO2. Cell cultures were checked daily for growth and 
were not used in any experimental procedures until normal exponential cell growth 
had resumed. 
Cell Line Optimum Density (x106 cells/ml)
Approximate 
Doubling Time 
(hours)
No. of Days 
between 
Passage
Split
HL-60 0.5 - 1.0 30 3 1:5
HL-60R 0.5 - 1.0 30 3 1:5
TK6 0.2 - 1.0 18 2 1:8
MT-1 0.2 - 1.0 18 2 1:8
TK6 0.2 - 1.0 18 2 1:8
TK6 MTXR 0.2 - 1.0 18 2 1:8
PreB697 0.5 - 1.0 24 3 1:5
PreB697 MTXR 0.5 - 1.0 24 3 1:5
KG-1 0.2 - 1.0 38 4 1:4
EoL-1 1.5 - 2.0 50 6 1:4
Table 2.1. Routine passage schedule of cell lines.
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2.3.5. Preparation of Cell Pellets 
Five million cells were dispensed into sterile BD Falcon™ centrifuge tubes and 
centrifuged at 230 x g for 5 min. Supernatant was discarded and cell pellets were 
resuspended in 3ml sterile PBS. Washed cells were then centrifuged and resuspended 
in 1ml sterile PBS and centrifuged again at 230 x g for 5 min. Supernatant was 
completely removed and the resulting cell pellets were stored at -80°C until required. 
2.4. Generation of Stable DNA MMR-Defective Cell Lines using Short Hairpin RNA-
Mediated Gene Knockdown 
Stable MMR-defective subclones of the cell lines TK6 and HL-60 were generated 
using short hairpin RNA (shRNA)-mediated gene knockdown. In this process, lentiviral 
particles are used to deliver shRNA constructs into cells which become incorporated 
into the host genome. Translation by RNA polymerase III (due to the H1 promoter 
sequence included in the construct) results in continual production of shRNA 
molecules which are cleaved to produce small interfering RNA (siRNA) molecules. The 
siRNA molecules become bound to the RNA-induced silencing complex (RISC) which 
subsequently binds to and cleaves mRNA molecules which match the siRNA, hence 
permanently blocking expression of the target gene. 
2.4.1. shRNA Constructs, Controls and Reagents 
Pre-packaged lentiviral transduction particles containing verified MISSION® 
shRNA constructs targeting the coding domain sequence (CDS) of MSH2, MSH3 or 
MSH6 (in pLKO.1-puro plasmid vectors) were purchased from Sigma-Aldrich, UK. The 
sequences of the shRNA constructs were as follows: 
MSH2: CCGGGCCTTGCTGAATAAGTGTAAACTCGAGTTTACACTTATTCAGCAAGGCTTTTTG 
MSH3: CCGGGCAAGGAGTTATGGATTAAATCTCGAGATTTAATCCATAACTCCTTGCTTTTTG 
MSH6: CCGGGCCAGAAGAATACGAGTTGAACTCGAGTTCAACTCGTATTCTTCTGGCTTTTTG 
In addition, lentiviral transduction particles containing an empty pLKO.1 plasmid 
vector (MISSION® pLKO.1-puro Control Transduction Particles), as well as particles 
containing a random shRNA construct confirmed not to target any known human or 
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mouse gene (MISSION® Non-Target shRNA Control Transduction Particles), were also 
purchased to use as negative controls for transduction. 
Lentiviral transduction particles containing a pLKO.1 plasmid vector expressing a 
green fluorescent protein (GFP) gene (MISSION® TurboGFP™ Control Transduction 
Particles) were also purchased to determine the transduction efficiency of cell lines 
(Section 2.4.4). 
All purchased lentiviral particles were received as frozen stock and stored at -
80°C. Upon first use, particles were aliquoted appropriately and stored at -80°C until 
required. 
An 800μg/ml stock solution of hexadimethrine bromide was prepared by 
dissolving 800μg hexadimethrine bromide in 1ml sterile dH2O. Stock solution was filter 
sterilised using a 0.2μm filter (VWR International Ltd.), stored at 4°C and used neat as 
required.  
2.4.2. Assessment of Puromycin Sensitivity 
The pLKO.1-puro plasmid used as a vector for the shRNA constructs contains a 
puromycin resistance gene, meaning the antibiotic can be used to select cells which 
have been successfully transduced. However, many cell lines are inherently sensitive to 
the effects of puromycin, hence preliminary investigations were necessary to establish 
the minimum puromycin concentration required to kill all non-transduced cells. The 
following investigation was performed for TK6 and HL-60 cells: 
A cell suspension at a density of 7.5 x 103 cells/ml was established in RF10 
medium (20ml). For administration of puromycin, a 2ml aliquot of cell suspension was 
transferred to a sterile BD Falcon™ centrifuge tube and centrifuged at 230 x g for 5 
min. Supernatant was discarded, cells were resuspended in 2ml RF10 medium 
supplemented with appropriate volume of working puromycin solution and 
transferred to a well of a sterile 6-well culture plate. Puromycin concentrations of 0 
(control), 2, 4, 6, 8 or 10 μg/ml were tested, as recommended by the manufacturer 
(Sigma-Aldrich). Plates were incubated at 37°C/5% CO2 and assessed microscopically 
each day for cell death.  
In the case of both TK6 and HL-60 cells, after approximately 72 hours in culture 
following puromycin administration, all cells in all treated cultures were found to be 
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dead upon microscopic inspection (confirmed using trypan blue dye, see Section 2.3.2). 
Therefore for both cell lines, selection of transduced cells was performed using media 
supplemented with puromycin at a concentration of 2μg/ml.  
2.4.3. Assessment of Hexadimethrine Bromide Sensitivity 
Hexadimethrine bromide is a cationic polymer which can be used to increase the 
efficiency of transduction of mammalian cell lines. Growth of certain cell lines however 
is detrimentally affected by hexadimethrine bromide, hence it was necessary to 
determine whether TK6 or HL-60 would be affected by its inclusion in media used for 
transduction. The following investigation was performed for TK6 and HL-60 cells: 
A cell suspension at a density of 5 x 104 cells/ml was established in RF10 medium 
(5ml). For administration of hexadimethrine bromide, a 1ml aliquot of cell suspension 
was transferred to a sterile BD Falcon™ centrifuge tube and centrifuged at 230 x g for 5 
min. Supernatant was discarded, cells were resuspended in 1ml RF10 medium 
supplemented with 8μg/ml hexadimethrine bromide (the concentration routinely used 
in transduction protocols) and transferred to a well of a sterile 6-well culture plate. A 
1ml aliquot of untreated cell suspension was transferred to a second well as a control. 
Plates were incubated at 37°C/5% CO2 for 72 hours.  
After 72 hours in culture, cell density and viability of the control and 
hexadimethrine bromide-treated cultures were assessed by counting cells using a 
haemocytometer and trypan blue dye (Section 2.3.2). In the case of both TK6 and HL-
60 cells, hexadimethrine bromide had no effect on cell growth and viability compared 
to the untreated control cultures (data not shown), and 8μg/ml was deemed suitable 
for use in transduction. 
2.4.4. Assessment of Transduction Efficiency 
Prior to performing transduction with lentiviral particles containing shRNA 
constructs, it was necessary to determine the optimum multiplicity of infection (MOI) 
required for transduction of each cell line using MISSION® TurboGFP™ Control 
Transduction Particles. This also served as a control to determine whether the 
transduction process itself had any effect on cell growth, so that these could be 
separated from effects of shRNA-mediated gene knockdown. 
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Lentiviral transduction of TK6 and HL-60 cells was performed using MISSION® 
TurboGFP™ Control Transduction Particles according to Section 2.4.5 below. MOIs of 0 
(control), 0.5, 1, 2 and 5 were prepared as recommended by the manufacturer (Sigma-
Aldrich).  
2.4.4.1. Assessment of GFP Expression by Flow Cytometry 
Once cell populations transduced with MISSION® TurboGFP™ Control 
Transduction Particles had resumed normal exponential growth following puromycin 
selection (see Section 2.4.6 below), transduction efficiency was determined by 
assessment of the expression of GFP by flow cytometry (the principles of flow 
cytometry are described in Section 2.12.1). 
For each transduced cell population, a suspension containing 2 x 105 cells was 
dispensed into a BD Falcon™ capped polystyrene tube. Cells were centrifuged at 450 x 
g for 4 min, supernatant discarded and cells resuspended in 500μl PBS. Flow cytometry 
was kindly performed by V. Forster (NICR) using a FACSCalibur flow cytometer with BD 
CellQuest Pro software (BD Biosciences) using pre-optimised instrument settings for 
detection of GFP fluorescence.  A total of 10,000 cells were assessed from each 
transduced cell population. For assessment of GFP-expressing cells, cell debris and 
dead cells were first excluded from the analysis based on forward and side scatter 
signals. Percentage of GFP-expressing cells in the remaining cell population was then 
determined based on detection of GFP fluorescence. 
Figure 2.1 shows the results of flow cytometric assessment of GFP expression in 
TK6 cells transduced at an MOI of 2. Expression of GFP was similar for all MOIs tested, 
in both HL-60 and TK6 cells (data not shown). It was therefore decided, based on time 
to recover exponential cell growth (approximately 4 days for MOIs 2 and 5, 
approximately 6 days in the case of MOIs 0.5 and 1), to use an MOI of 2 for subsequent 
lentiviral transductions. 
Figure 2.1. Flow cytometric assessment of transduction efficiency of TK6 with Mission® TurboGFP™ Control Transduction Particles.
10,000 cells transduced with an MOI of 2 were assessed for expression of GFP using a FACSCalibur flow cytometer (top). Left hand dot plot shows
forward scatter and side scatter profiles which were used to determine viable cells (R1 gate). Right hand dot plot (gated to contain only viable cells)
shows GFP fluorescence. The histogram displays the numbers of cells expressing GFP at increasing intensities. Those within the M1 region are
positively expressing GFP. The same analysis was also performed on non-transduced TK6 cells for comparison (bottom).
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It was also noted at this point that the growth kinetics of transduced cells was 
not significantly different from non-transduced cells (MOI 0) (data not shown), 
demonstrating that the transduction process itself has no apparent effect on the 
growth of TK6 or HL-60 cells. 
2.4.5. Lentiviral Transduction 
A suspension of exponentially growing cells was established at a density of 5 x 
104 cells/ml using RF10 culture medium (10ml) supplemented with 8μg/ml 
hexadimethrine bromide. For addition of lentiviral particles, a 1ml aliquot of cell 
suspension was transferred to a sterile 15ml BD Falcon™ centrifuge tube and 
appropriate volume of thawed lentiviral particle suspension was added directly to the 
cell suspension. The following formula was used to calculate appropriate volume of 
lentiviral particles to give the required MOI: 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 = 𝑇𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 × 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑀𝑂𝐼
𝑣𝑖𝑟𝑎𝑙 𝑡𝑖𝑡𝑟𝑒 (𝑇𝑈/𝑚𝑙)*  
Following addition of lentiviral particles, cell suspensions were centrifuged at 800 
x g for 30 min at 32°C. After centrifugation, supernatant was carefully removed and 
discarded, cells were re-suspended in 2ml RF10 culture medium and transferred to a 
sterile 6-well cell culture plate. Plates were incubated at 37°C/5% CO2 for 72 hours. 
A normal control was prepared for each cell line/shRNA combination according 
to the same procedures, but without the addition of lentiviral particles. 
2.4.6. Puromycin Selection of Transduced Cells  
After 72 hours incubation, transduced cell populations were transferred to sterile 
BD Falcon™ centrifuge tubes and centrifuged at 230 x g for 5 min. Supernatant was 
discarded, cells were resuspended in 2ml selection media [RF10 media supplemented 
with 2μg/ml puromycin] and transferred to a fresh 6 well cell culture plate. Cultures 
were incubated at 37°C/5% CO2 and selection media was replaced according to the 
above procedure every 72 hours until normal exponential cell growth had resumed 
(assessed by counting cells using a haemocytometer and trypan blue dye). At this 
point, cell populations were deemed to consist entirely of transduced cells, given that 
                                                     
* Viral titre was supplied by manufacturer for each vial of lentiviral particles received.  
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only cells which had taken up a plasmid could survive in selection media due to 
acquired puromycin resistance. 
Control non-transduced parental cell populations were treated in the same way 
as above (in order to keep cell lines paired), except normal RF10 culture media was 
used in place of selection media. 
2.4.7. Selection of TK6 Knockdown Clones by Limiting Dilution 
Individual clones of transduced TK6 cells were selected and expanded prior to 
assessment of knockdown efficiency as follows:  
A cell suspension at a density of 1 x 104 cells/ml was established using selection 
medium and 10-fold serial dilution (using selection medium) was performed to give a 
cell suspension at a density of 1 cell/ml. This was transferred to a sterile 96-well plate 
(200μl per well) and incubated at 37°C/5% CO2.  
Following sufficient time in culture (approximately 10 days), a number of wells in 
which clonal populations had become established (assessed microscopically) were 
selected at random and each transferred to a sterile 6-well culture plate with 3ml 
selection medium. Following a further 72 hours in culture, 7ml selection medium was 
added to each culture, which was then split between two 25cm3 sterile cell culture 
flasks. These were incubated for a further 48 hours, after which each cell suspension 
was transferred to a sterile 75cm3 culture flask with 30ml selection medium. After 
another 72 hours in culture, for each knockdown cell population, the contents of one 
flask was used to prepare cell pellets, according to Section 2.3.5, for assessment of 
knockdown efficiency. The contents of the second flask was used to freeze viable cell 
aliquots, according to Section 2.3.3, for use in cytotoxicity assays.  
The same procedures were also performed with control non-transduced TK6 
cells (using normal RF10 culture medium), including preparation of cell pellets and 
cryopreservation of viable cell aliquots, in order to maintain paired cell clones as best 
as possible.  
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2.4.8. Expansion of HL-60 Knockdown Populations 
Cloning of HL-60 cells is not possible by limiting dilution due to the low cloning 
efficiency of this cell line. Populations of HL-60 knockdown cells were therefore 
expanded from a small number of cells as follows. 
Cell suspensions at a density of 2 x 103 cells/ml were established using selection 
medium (2 flasks per knockdown cell line) and were incubated at 37°C/5% CO2. After 
72 hours in culture, each cell population (5ml) was transferred to a 75cm3 cell culture 
flask and 30ml selection medium was added. After a further 72 hours in culture, the 
contents of one flask was used to prepare cell pellets, according to Section 2.3.5, for 
assessment of knockdown efficiency. The contents of the second flask was used to 
freeze viable cell aliquots, according to Section 2.3.3, for use in cytotoxicity assays. 
Populations of control non-transduced HL-60 cells were also expanded in the 
same manner (using normal RF10 medium) alongside knockdown cell populations in 
order to maintain paired cell lines as best as possible. Cell pellets and cryopreserved 
cell aliquots were also prepared as above.  
2.4.9. Assessment of Knockdown Efficiency 
Efficiency of shRNA-mediated knockdown of target genes, relative to control 
non-transduced cells, was assessed by western immunoblotting according to the 
protocols described below (Section 2.7). Effect of gene knockdown on the cellular 
levels of other DNA MMR protein components was also assessed in the same way.  
The cellular amounts of DNA MMR proteins were also assessed in cells 
transduced with the pLKO.1-puro control or the non-target shRNA control to exclude 
any effects of transduction and shRNA processing, respectively, on target gene 
expression (see Figure 3.7). 
2.4.10. Routine Culture of Knockdown Cell Lines for use in Cytotoxicity Assays 
For use in cytotoxicity assays, cryopreserved aliquots of knockdown cell lines and 
their paired control non-transduced cell lines were thawed and cultured in RF10 
medium according to Sections 2.3.4 and 2.3.1 above. In order to minimise cell stress, it 
was deemed not necessary to culture knockdown cell lines in selection media given 
 81 
 
that they were only cultured for short periods to allow use in cytotoxicity assays. 
Furthermore, plasmid DNA should be stably incorporated into the host cell genome, 
meaning shRNA expression should be stable and permanent without the requirement 
for continuous selection.  
Non-transduced control cell populations were always routinely passaged 
alongside knockdown cells in order to maintain paired cell lines for assessment of 
relative cytotoxicity.  
Once normal exponential growth had resumed (assessed by counting cells using 
a haemocytometer and trypan blue dye), cytotoxicity assays were performed 
according to Section 2.6 below. Fresh cell aliquots were used each time a subsequent 
cytotoxicity assay was performed in order to minimise culture time and hence the risk 
of mutations occurring due to the mutator phenotype of MMR-deficient cells. 
2.5. Generation of Drug Resistant Cell Lines by Escalating Dosage 
In order to model the development of t-AML in vitro (Chapter 5), myeloid cell 
lines were cultured in the presence of escalating doses of either MNU, 6-TG or Ara-C, 
in an attempt to generate drug-resistant subclones for analysis of DNA MMR status. 
The myeloid cell lines HL-60, KG-1 and EoL-1 were used (described in Chapter 5), as 
well as the B-lymphoblastoid cell line TK6. 
2.5.1. Dose Finding Assay 
In order to identify a suitable starting dose for each drug in each cell line, dose 
finding assays were performed by treating the cell lines with a range of doses of each 
drug (data not shown), and the dose which resulted in death of approximately 70-80% 
of cells was selected as a starting dose (see Table 2.2). Dose finding assays were 
performed using growth inhibition in all cases, as described in Section 2.6.3. 
Cell Line Normal Doubling Time (Hrs) Drug
Initial Dose 
(μM) Dose Increment (μM) Final Dose (μM)
HL-60 24-36
MNU 0.05 0.05 0.5a
6-TG 0.5 0.5, rising to 1, rising to 2 20
Ara-C 0.01 0.01, rising to 0.05, rising to 0.2 1
EoL-1 40-48
MNU 0.01 0.01 0.1
6-TG 0.1 0.1 No recovery from second drug dose (0.2)
Ara-C 0.02 0.02 No recovery from second drug dose (0.04)
KG-1 36-38
MNU 0.05 0.05, rising to 0.1 1
6-TG 0.1 0.1 No recovery from second drug dose (0.2)
Ara-C 0.1 0.1 0.5b
TK6 16-20
MNU 0.01 0.01, rising to 0.05 0.5
6-TG 0.5 0.5, rising to 1, rising to 2 20
Ara-C 0.04 0.04, rising to 0.1, rising to 0.5 2
Table 2.2. Dosing schedule for generation of drug-resistant sub-cultures from myeloid (HL-60, EoL-1 and KG-1) and lymphoblastoid (TK6) cell lines.
a Further dosing was attempted using a dose of 0.55μM, however cells consistently failed to recover.
b Further dosing was attempted using a dose of 0.6μM, however cells consistently failed to recover.
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2.5.2. Drug Dosing 
For each cell line and drug combination, to administer the initial drug dose, 1 x 
105 cells were centrifuged at 230 x g for 5 min, then resuspended in 5ml RF10 medium 
supplemented with the appropriate volume of drug (dosed culture) and transferred to 
a sterile 25cm3 cell culture flask. At the same time, a similar culture was setup using 
RF10 medium supplemented with appropriate solvent but no drug (parental culture). 
Cultures were incubated at 37°C/5% CO2 and assessed at regular intervals for 
resumption of normal exponential growth (by counting cells using a haemocytometer 
and trypan blue dye). Once normal growth had resumed in the dosed culture, the next 
drug dose was applied using the same procedure. The parental culture was treated in 
the same manner, using appropriate solvent but no drug. The dosing schedules which 
were used are shown in Table 2.2 for each cell line and drug combination. 
2.5.3. Assessment of Resistance 
Following recovery of exponential cell growth after the final drug dose, acquired 
resistance to the drug with which cells were dosed was assessed relative to respective 
parental cultures (data not shown). In the case of HL-60, KG-1 and EoL-1 this was 
achieved via growth inhibition assay (Section 2.6.3), and in the case of TK6, via 96-well 
clonogenic assay (Section 2.6.2).  
For TK6 sub-cultures, a single cell clone was selected via limiting dilution (see 
Section 2.4.7) and expanded in normal RF10 medium for several passages. This was not 
possible in the case of HL-60, KG-1 and EoL-1 cultures as these cells demonstrate a low 
cloning efficiency. The dosed sub-cultures were therefore passaged as normal in drug-
free RF10 medium for several passages. In all cases, parental cultures were passaged 
alongside dosed cultures according to the same schedule. 
Following several passages in drug-free RF10 medium, cytotoxicity assays were 
repeated, as described above, to confirm that acquired drug-resistance was stable. 
Subsequently, cross-resistance to other agents, was assessed relative to parental 
cultures as detailed in Chapter 5. Resistance was assessed via growth inhibition assay 
(HL-60, KG-1, EoL-1) or 96-well clonogenic assay (TK6). 
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2.6. Cytotoxicity Assays 
Cytotoxicity assays were used throughout the project (Chapters 3, 4 and 5) to 
assess drug (or radiation) response in MMR-deficient cells (or drug-resistant cells), 
relative to respective normal parental counterparts. Cell lines were assessed in pairs 
(i.e. parental cell line and relevant subclone), or sets of 5 in the case of MMR 
knockdown lines (i.e. non-transduced control (parental) cell line, MSH2, MSH3 and 
MSH6 knockdown subclones and non-target shRNA control subclone). 
2.6.1. Reagents and Exposures 
Stock solutions of chemotherapeutic agents for use in cytotoxicity assays were 
prepared according to Table 2.3 using appropriate solvents. All stock solutions were 
aliquoted and stored at -80°C. Working solutions were prepared immediately prior to 
use by dilution of stock solutions in RF10 culture medium, or sterile PBS in the case of 
MNU. 
Exposure to UV radiation was performed using a Stratalinker 2400 UV Crosslinker 
(Agilent Technologies UK Ltd., Berkshire, UK) at a wavelength of 254nm.  
Exposure to IR was performed using a D3300 X-ray system (Gulmay Medical Ltd., 
Surrey, UK) at a dose rate of 2.4Gy/min, 310kV, 10mA. 
Agent Molecular Weight (g) Solvent
Stock Solution 
(mM)
Methylnitrosourea
[N-methyl-N-nitrosourea] 103.8 PBS 100
6-thioguanine
[2-amino-2-mercaptopurine] 167.2 DMSO 15
Cytarabine
[1-β-D-ararbinofuranosylcytosine] 243.2 DMSO 50
Clofarabine
[2-chloro-2’-fluoro-arabinosyladenine] 303.7 Sterile dH2O 5
Fludarabine
[9-β-D-arabinofuranosyl-2-fluoroadenine] 285.2 DMSO 50
Cladribine
[2-chloro-deoxyadenosine] 285.7 DMSO 50
Table 2.3. Preparation of stock solutions of cytotoxic agents.
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2.6.2. 96-Well Clonogenic Assay 
Cytotoxicity of TK6 and its derivative subclones was assessed using a 96-well 
plate clonogenic assay. This technique was originally developed as a method of 
determining the mutability of suspension cell lines which are capable of growth at a 
very low density (i.e. 101 cells per ml and below) (Furth et al., 1981). The assay was 
adapted for use in assessment of cytotoxicity, with the following procedures 
performed for each cell line. 
An exponentially growing cell suspension at a density of 1 x 105 cells/ml was 
established using RF10 culture medium. From this, suspensions at densities of 103, 102 
and 101 cells/ml were prepared by 10-fold serial dilution, using RF10 medium. In the 
case of assessment of cytotoxicity in response to drug treatment, for each drug dose, a 
30ml aliquot of the appropriate density cell suspension was transferred to a sterile BD 
Falcon™ centrifuge tube and centrifuged at 230 x g for 5 min. Supernatant was 
discarded and cells were resuspended in 30ml RF10 medium supplemented with 
appropriate volume of drug to give the required dose. 200μl of dosed cell suspension 
was then transferred to each well of a 96-well plate. The lowest doses were applied to 
cell suspensions at a density of 101 cells/ml (2 cells/well), mid range doses were 
applied to cell suspensions at a density of 102 cells/ml (20 cells/well) and the highest 
doses were applied to cell suspensions at a density of 103 cells/ml (200 cells/well). A 
vehicle-only control plate was also setup, in the same way, containing cells at a density 
of 101 cells/ml treated with appropriate solvent but no drug.  
Clonogenic assays for assessment of cytotoxic response to IR or UV radiation 
exposure were setup in a similar manner. For each radiation dose, 200μl of 
appropriate density cell suspension was transferred to each well of a 96-well plate and 
the plate was exposed to radiation for the appropriate length of time to give the 
required dose. As above, the lowest doses were applied to cell suspensions at a density 
of 101 cells/ml, mid range doses were applied to cell suspensions at a density of 102 
cells/ml and the highest doses were applied to cell suspensions at a density of 103 
cells/ml. A negative control plate was also setup using cells at a density of 101 cells/ml 
(200μl per well) but not exposed to any radiation source. In all cases, plates were 
incubated at 37°C/5% CO2 for 20 days. 
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Following the 20 day growth period, cloning efficiency (CE) was calculated at 
each drug or radiation dose. For each plate, wells in which a viable colony had formed 
were determined microscopically. The number of negative wells was counted for each 
plate and CE was then calculated using the following Poisson relationship (Furth et al., 
1981):  
𝐶𝐸 = − ln𝑃0 †
𝑁𝑜. 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 
The survival fraction at each dose was then determined by calculating the mean 
CE of the dosed cells as a percentage of the mean CE of the vehicle-only or negative 
control cells.   
Survival fractions at each drug or radiation dose were plotted on an X-Y scatter 
graph (using Microsoft Excel) to generate kill curves for each cell line, thus enabling 
comparison of cytotoxicity between the paired (or 5) cell lines.  
Each individual experiment was performed in triplicate and mean survival 
fractions at each drug or radiation dose were used to generate the kill curves. Standard 
error of the mean (SEM) was also calculated for each dose to enable inclusion of error 
bars on kill curves. 
2.6.3. Growth Inhibition Assay 
Cytotoxicity of all other cell lines (which do not grow readily at very low 
densities) was assessed using a flask-based growth inhibition assay. The following 
procedures were performed for each cell line. 
An exponentially growing cell suspension at a density of 1 x 104 cells/ml was 
prepared using RF10 medium. In the case of assessment of cytotoxicity in response to 
drug treatment, for each dose, a 5ml aliquot of cell suspension was transferred to a 
sterile BD Falcon™ centrifuge tube and centrifuged at 230 x g for 5 min. Supernatant 
was discarded, cell pellet was resuspended in 5ml RF10 medium supplemented with 
appropriate volume of drug to give the required dose, then transferred to a sterile 
25cm3 cell culture flask. A vehicle-only control flask was also setup in the same way, by 
                                                     
† P0 represents the fraction of negative wells per plate (Ie. No. negative wells / 96) 
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resuspending cells in 5ml RF10 medium supplemented with appropriate solvent but no 
drug. Flasks were incubated at 37°C in a humidified 5% CO2 incubator for 4 days. 
In the case of assessment of cytotoxicity in response to IR or UV radiation, for 
each dose, a 5ml aliquot of cell suspension was transferred to one well of a sterile 6-
well cell culture plate. This was then exposed to radiation for the appropriate amount 
of time to give the required dose. A negative control plate was also prepared using 5ml 
of cell suspension but not exposed to any radiation source. Plates were incubated at 
37°C/5% CO2 for 4 days. 
Following the 4 day growth period, the number of viable cells in each culture was 
determined using a haemocytometer and trypan blue dye. The survival fraction at each 
dose was then determined by calculating the viable cell density of the dosed culture as 
a percentage of the viable cell density of the vehicle-only or negative control culture.  
Kill curves were prepared as described in Section 2.6.2. Each individual 
experiment was performed in triplicate and mean (and SEM) survival fractions at each 
drug or radiation dose were used to generate the kill curves.  
2.7. Western Immunoblotting 
To determine whether the levels of particular proteins differed in MMR-
defective cell lines and their paired parental MMR-proficient counterparts (Chapters 3 
and 4), or in drug-resistant subclones and their respective parental cells (Chapter 5), 
quantitation of protein expression was performed by western immunoblotting. This 
technique involves extraction of total cytosolic proteins, separation of proteins 
according to size followed by immobilisation onto a membrane, and subsequent 
detection of target proteins of interest using labelled antibodies. The number of 
antibody molecules which can bind to each protein (and hence the amount of label 
detected) is proportional to the amount of protein present, therefore protein 
expression levels can be compared between cell lines. 
2.7.1. Cytosol Preparation 
A frozen cell pellet containing 5 x 106 cells (see Section 2.3.5) was thawed, 
resuspended in 100μl sodium dodecyl sulphate (SDS) sample buffer [62.5M Tris-HCl pH 
6.8, 2% (w/v) SDS, 20% (v/v) glycerol] and passed through a 21 gauge needle (attached 
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to a 1ml syringe) several times to disrupt cell membranes. The homogenised sample 
was boiled at 100°C for 5 min, then centrifuged at 14,000 x g for 10 min to pellet cell 
debris. Protein concentration of the supernatant was estimated via Pierce BCA assay as 
described in Section 2.7.2. 
Following estimation of protein concentration, 250μg of protein was transferred 
to a 1.5ml Eppendorf tube and made up to 450μl using SDS sample buffer. To this was 
added 25μl β-mercaptoethanol (final concentration 20% v/v) and 25μl 0.2% 
bromophenol blue aqueous solution (final concentration 0.01% v/v), resulting in a 
cytosolic extract at a protein concentration of 0.5mg/ml (500μl volume). Extracts were 
divided into 50μl aliquots for storage at -80°C until required.   
2.7.2. Estimation of Protein Concentration by Pierce BCA Assay 
Estimation of protein concentration was performed using a Pierce® BCA Protein 
Assay Kit (Fisher Scientific UK Ltd., Leicestershire, UK). This kit combines reduction of 
copper cations (Cu+2 to Cu+1) by protein with colourimetric detection of Cu+1 using an 
agent containing bicinchoninic acid (BCA). The coloured complex produced exhibits 
strong absorbance at 562nm that increases linearly with increasing protein 
concentrations, hence intensity of the coloured complex can be used to estimate 
protein concentration. The assay was performed according to manufacturers protocols 
which are briefly described as follows: 
An aliquot of each extract was diluted 1:10 using dH2O to bring protein 
concentrations within the range of detection of the kit (0.2 – 1.2 mg/ml). For each 
diluted extract, 10μl was transferred to a 96-well optical plate (VWR International Ltd.) 
in quadruplicate. To each well, 190μl of BCA Working Reagent (Reagent A + Reagent B 
in a 50:1 ratio, according to manufacturers protocol) was added, well contents were 
mixed by gentle agitation using a plate shaker and plate was incubated at 37°C for 30 
min. 
Following incubation, absorbance at 562nm was read using a Spectromax® 250 
Microplate Spectrophotometer System (Molecular Devices Corporation, Crawley, UK). 
Protein concentration was estimated from the corrected mean absorbance values by 
the spectrophotometer software (SOFTmax Pro 3.0, Molecular Devices Corporation), 
via comparison to a bovine serum albumin (BSA) standard curve which was also 
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prepared each time the assay was performed. Values generated were multiplied by 10 
(to account for dilution factor) to give protein concentration in each extract.  
2.7.3. SDS PAGE and Electrophoretic Transfer 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate proteins in the cytosolic extracts according to size. Novex® 4-20% 
Tris-glycine gels (Invitrogen Life Technologies) were used for protein separation and 
were placed in an XCell SureLock™ Mini-Cell electrophoresis system (Invitrogen Life 
Technologies) filled with SDS electrode buffer [41.2mM Tris-HCl pH 6.8, 192 mM 
glycerol, 0.1% (w/v) SDS]. For every gel, 5μl of Benchmark Pre-stained Protein Ladder 
(Invitrogen Life Technologies) was loaded into the first lane. For each cell line, 20μl 
cytosolic extract (10μg protein) was loaded per well (aliquots of cytosolic extract were 
thawed in a heating block immediately prior to loading). Electrophoresis was 
performed using a constant voltage of 200V until the bromophenol blue dye front 
reached the bottom of the gel (approximately 1 hour). 
Following separation, proteins were transferred electrophoretically from the gels 
onto polyvinylidenefluoride (PVDF) membrane (Bio-Rad Laboratories Ltd., 
Hertfordshire, UK). Gels were removed from their casing and placed in transfer 
cassettes with PVDF membrane (permeabilised in 100% methanol immediately prior to 
use), sandwiched between 3mm Whatman® chromatography papers (supplied by VWR 
International Ltd.) and transfer sponges, all of which had been pre-soaked in transfer 
buffer [10mM CAPS-NaOH pH 11, 10% (v/v) methanol]. Cassettes were placed in a Mini 
Trans Blot Electrophoretic Transfer Cell (Bio-Rad Laboratories Ltd.) filled with transfer 
buffer and electrophoresis was performed overnight at a constant voltage of 30V using 
a magnetic stirrer to maintain ion distribution in the buffer. 
2.7.4. Antibody Detection and Visualisation of Bound Proteins 
Antibodies used for detection of DNA MMR (and other) proteins are listed in 
Table 2.4. 
PVDF membranes with bound proteins were removed from transfer cassettes 
and immersed in 5% blocking solution [TBS-Tween (see below), 5% (w/v) dried non-fat 
skimmed milk powder] with constant agitation for one hour at room temperature to 
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block non-specific antibody binding sites. Following blocking, membranes were cut into 
appropriate sections (depending on which proteins were to be detected) and 
transferred to 50ml BD Falcon™ centrifuge tubes containing 5ml primary antibody 
solution (prepared according to dilution specified in Table 2.4). Incubation in most 
cases was for 1 hour at room temperature with gentle agitation (using a roller mixer), 
however in some cases an overnight incubation at 4°C was performed (with constant 
gentle agitation).  
After incubation in primary antibody, membranes were washed in 5ml 
TBS/Tween [0.01M Tris-HCl pH 7.5, 0.1M NaCl, 0.05% (v/v) Tween-20] at room 
temperature for 10 min (with gentle agitation). This wash step was repeated twice 
more to ensure removal of any unbound primary antibody. Membranes were then 
transferred to fresh 50ml Falcon tubes containing 5ml appropriate horseradish 
peroxidase-conjugated secondary antibody (prepared according to Table 2.4) and 
incubated for a minimum of 30 min at room temperature (with gentle agitation). 
Following this, a total of 4 washes were performed, as above, to ensure any unbound 
antibody was completely removed. 
Detection of bound antibodies was performed using Visualizer™ Spray & Glow™ 
ECL Western Blotting Detection System (Upstate Pharmaceuticals, VA, USA) according 
to manufacturers protocol. Visualisation of chemiluminescence was achieved via 
exposure of membranes to Kodak BioMax Light film (VWR International Ltd.) for 
appropriate length of time (10 seconds – 5 min, depending on target protein). Films 
were developed using a Mediphot 937 X-Ray Filmprocessor (Colenta Lobortechnik, 
Austria). Membranes were then either stripped as described below (Section 2.7.5) for 
re-probing, or rinsed with TBS/Tween and stored moistened in cling film at 4°C for 
future use. 
Protein Molecular Weight (kDa) Antibody Type Clone Isotype Supplier Cat No. Dilution
Primary Antibodies
MSH2 102 Monoclonal G219-1129 Mouse IgG1 BD Biosciences 556349 1:250
MSH3 127 Monoclonal 52 Mouse IgG1 BD Biosciences 611390 1:250
MSH6 160 Monoclonal 44 Mouse IgG1 BD Biosciences 610919 1:2,000
MLH1 85 Monoclonal G168-15 Mouse IgG1 BD Biosciences 551092 1:500
PMS2 100 Monoclonal A16-4 Mouse IgG1 BD Biosciences 556415 1:500
MGMT 25 Monoclonal MT3.1 Mouse IgG1 Millipore (UK)a MAB16200 1:500
ERK-2 42 Monoclonal G263-7 Mouse IgG1 BD Biosciences 554095 1:500
pERK 42 Monoclonal 12D4 Mouse IgG1 Santa Cruz Biotechnology Inc.b sc-81492 1:1,000
TPMT 32 Monoclonal 31-J Mouse IgG1 Santa Cruz Biotechnology Inc. sc-100874 1:500
Actin (loading control) 46 Monoclonal JLA20 Mouse IgM Calbiochem®c CP01 1:20,000
Secondary Antibodies
Goat Anti-Mouse IgG, 
HRP conjugate - Polyclonal - Goat IgG Millipore (UK) 12-349 1:3,750
Goat Anti-Mouse IgM, 
HRP conjugate - Polyclonal - Goat IgM Calbiochem® JA 1200 1:1,000
Table 2.4. Antibodies used in western immunoblotting
a Watford, UK
b Heidelberg, Germany
c Supplied by Merck Chemicals Ltd., Nottingham, UK
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2.7.5. Stripping PVDF Membranes for Re-Probing 
In order to remove bound antibodies to allow re-probing with a different primary 
antibody, membranes were immersed in stripping buffer [62.5mM Tris-HCl pH6.7, 2% 
(w/v) SDS, 100mM β-mercaptoethanol] with constant agitation for 40 min at 60°C. The 
high stringency of the buffer forces antibodies to become unbound from proteins, 
however the binding of proteins to the membrane is unaffected.  
Following stripping, membranes were washed twice in 5ml TBS/Tween with 
gentle agitation at room temperature for 10 min. Membranes were then transferred to 
5% blocking solution and re-probed according to Section 2.7.4. 
2.8. Gene Expression Analysis by Quantitative Real-Time PCR 
In order to determine whether the expression of particular genes involved in 
DNA MMR was altered in MMR-defective cell lines, relative to paired parental MMR-
proficient counterparts (Chapters 3 and 4), gene expression analysis was performed by 
real-time quantitative PCR using Taqman® chemistry. This technique involves two 
stages. Firstly, mRNA is reverse transcribed to cDNA. Secondly, PCR is performed using 
primers specific for the gene of interest, during which accumulation of the PCR product 
is detected in real-time. This is achieved through the use of specially designed probes 
which bind within the target sequence and fluoresce as the sequence is amplified. The 
amount of fluorescence detected (the cycle threshold (Ct) value) is therefore 
proportional to the level of expression of the target gene. Quantitation of expression 
of the target gene can either be performed in one sample relative to another (relative 
quantitation), as in these studies, or relative to a standard expression curve 
constructed from RNA of known concentration (absolute quantitation). 
2.8.1. RNA Extraction and Quantitation 
For each cell line, a frozen cell pellet consisting of 5 x 106 cells was thawed on ice. 
Total RNA was extracted from thawed cells using an RNeasy Mini kit (Qiagen, Crawley, 
UK) according to the supplied manufacturers protocol. Briefly, cells were lysed and 
homogenised, then RNA was bound to a RNeasy® silica gel membrane in spin-column 
format, after which contaminants were removed by washing in provided buffers. RNA 
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was eluted in 50μl nuclease-free distilled water (dH2O) (Invitrogen Life Technologies). 
Quantitation of RNA was performed using a NanoDrop® ND-1000 spectrophotometer 
(Thermo Scientific, DE, USA) which measures the absorbance of UV light at 260nm 
passed through a 1μl aliquot of extracted RNA, and performs the necessary 
calculations according to the Beer Lambert Law to provide RNA concentration (in 
ng/μl). 
Following quantitation, appropriate volume of eluate containing 10μg of RNA 
was transferred to a 1.5ml Eppendorf tube and made up to 20μl using nuclease-free 
dH2O, resulting in an RNA extract at a concentration of 200ng/μl. Any remaining neat 
RNA extract were stored at -80°C. 
2.8.2. Reverse Transcription of RNA into cDNA 
Preparation of cDNA was performed using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Warrington, UK). This kit uses the random 
primer method for initiating reverse transcriptase (RT)-mediated cDNA synthesis of all 
RNA molecules present. 
Appropriate volume of RT mastermix was prepared according to manufacturer’s 
protocol and 10μl was dispensed into appropriate number of 0.2ml MicroAmp® 
Reaction Tubes (Applied Biosystems). For each sample, 10μl of 200ng/μl total RNA 
extract was added. A blank reaction was also prepared using nuclease-free dH2O in 
place of RNA, to ensure no contamination of reagents. The following single cycle was 
performed using a GeneAmp® PCR System 9700 (Applied Biosystems): 
25°C 10 min 
37°C 120 min 
85°C 5 min 
Assuming a reverse transcription efficiency of 100%, this yielded 20μl of cDNA at 
a concentration of 100ng/μl. This was subsequently adjusted to 5ng/μl by addition of 
380μl nuclease-free dH2O and stored at 4°C until required. 
Gene TaqMan® Gene Expression Assay ID
MSH2 Hs00953523_m1
MSH3 Hs00989003_m1
MSH6 Hs00264721_m1
MLH1 Hs00179866_m1
PMS2 Hs00241053_m1
MGMT Hs00172470_m1
β-actin
(endogenous control) Cat no. 4333762F
Table 2.5. TaqMan® Gene Expression Assays used in RT-PCR assessment of DNA
MMR gene expression
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2.8.3. Real-Time PCR Setup 
Inventoried and validated TaqMan® Gene Expression Assays (each containing 
forward and reverse primers and 5’-FAM (carboxyfluorescein)-labelled internal probes 
for the target gene) were purchased from Applied Biosystems (Table 2.5). Assays were 
received as 20x concentrated stocks, which were aliquoted appropriately at first use 
and stored at -20°C. 
For preparation of PCR mastermixes, appropriate volume of TaqMan® Universal 
PCR Master Mix (Applied Biosystems) was added to thawed aliquots of 20x Gene 
Expression Assay (as well as β-actin), according to the manufacturers protocol. 11μl of 
each mastermix was dispensed into appropriate number of wells of a 96-well Optical 
PCR Plate (Applied Biosystems). For each reaction, 9μl of 5ng/μl cDNA (total amount, 
45ng) was added. Controls were also prepared using either a blank reverse 
transcription reaction or nuclease free dH2O in place of cDNA, to ensure no 
contamination of reagents. Assays (and controls) were setup in quadruplicate for each 
gene in each cell line. 
The following thermal cycle was performed using a 7300 Real Time PCR System 
(Applied Biosystems): 
50°C 2 min 
95°C 10 min 
95°C 15 s 
60°C 1 min 
Following completion of thermal cycling, detected fluorescence was converted to 
a Ct value for each reaction using the supplied PCR system software (SDS version 1.4, 
Applied Biosystems) using standard parameters. The means of the quadruplicate Ct 
values generated for each gene (in each cell line) were used for quantitation of gene 
expression, as described below. 
2.8.4. Data Analysis 
Relative quantitation using the 2-ΔΔCt method (Livak and Schmittgen, 2001) was 
performed to determine the expression level of each gene of interest in MMR-
deficient cell lines, relative to paired parental MMR-proficient counterparts. Briefly, 
analysis by this method first involved normalisation of the expression of each gene of 
40 cycles 
 97 
 
interest to expression of β-actin (a constitutively expressed house-keeping gene) in all 
cell lines. Normalised expression levels of genes of interest were then compared in 
MMR-defective cell lines and parental MMR-proficient cells, generating values 
representing fold change in expression for each gene. All calculations were performed 
using Microsoft Excel. 
The entire investigation was repeated a total of three times, using new frozen 
cell pellets each time. Bar charts showing the mean (and SEM) fold-changes in gene 
expression (relative to respective parental cell lines) were generated for MMR-
defective cell lines using Microsoft Excel. 
2.9. Genomic DNA Sequencing (For N-RAS and K-RAS Mutations) 
Sequencing of commonly mutated exons of N-RAS and K-RAS was performed in 
TK6 and MT-1 to exclude potential mechanisms of Ara-C sensitivity (Chapter 3). The 
following procedures were performed for each cell line: 
2.9.1. DNA Extraction and Quantitation 
Frozen cell pellets consisting of 5 x 106 cells were thawed and resuspended in 
100μl PBS. Genomic DNA was extracted using a QIAamp DNA Mini Kit (Qiagen) 
according to the supplied manufacturers protocol. Briefly, DNA extraction was 
achieved through binding of DNA to a QIAamp® silica gel membrane (in spin-column 
format) after which contaminants were removed by washing using provided buffers. 
DNA was eluted in 200μl Buffer AE [10 mM Tris-HCl, 0.5 mM EDTA, pH 9.0]. 
Quantitation of DNA was performed using a NanoDrop® ND-1000 spectrophotometer 
which measures the absorbance of UV light at 260 nm passed through a 1μl aliquot of 
extracted DNA, and performs the necessary calculations according to the Beer Lambert 
Law to provide DNA concentration (in ng/μl). 
For each sample, a 20μl aliquot of DNA at a concentration of 100ng/μl was 
prepared using Buffer AE and stored at 4°C for use in PCR reactions. Remaining DNA 
was stored at -20°C. 
 
Gene/Exon Primer Sequences AmpliconLength (bp)
Annealing 
Temp. (°C)
N-RAS exon 1
Forward: CCAAATGGAAGGTCACACTA
276 54
Reverse: AGAGACAGGATCAGGTCAGC
N-RAS exon 2
Forward: TGCCCCCTTACCCTCCACA
272 52
Reverse: CCTCATTTCCCCATAAAGATTCAGA
K-RAS exon 1
Forward: TACTGGTGGAGTATTTGATAGT
286 55
Reverse: CATGAAAATGGTCAGAGAAACC
K-RAS exon 2
Forward: TCTTTTCAAGTCCTTTGCC
256 53
Reverse: GCAAATACACAAAGAAAGCC
Table 2.6. Sequences of oligonucleotide primers used for PCR amplification of RAS
exons for sequencing.
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2.9.2. PCR Amplification 
PCR primers for amplification of specific N-RAS and K-RAS exons were provided 
as reconstituted stocks (100pmol/μl in TE buffer [10mM Tris-HCl pH 8, 1mM EDTA]) by 
E. C. Matheson. Primer sequences are shown in Table 2.6. PCR reaction conditions 
were the same for each gene/exon and consisted of 1x ReddyMix PCR buffer (Thermo 
Scientific), 1.5mM MgCl2, 10pmol primers, 0.2mM (each) dNTPs (Invitrogen Life 
Technologies), 0.5 units ThermoPrime Taq DNA polymerase (Thermo Scientific) and 
100ng cDNA in a total volume of 20μl. For setup of reactions, appropriate volume of 
PCR mastermix was initially prepared (consisting of all reagents except DNA) and 19μl 
was dispensed into appropriate number of 0.2ml MicroAmp® Reaction Tubes on ice. 
To this, 1μl of 100ng/μl DNA was added. Controls were also prepared using nuclease 
free dH2O in place of DNA, to ensure no contamination of reagents. Thermal cycles 
were performed as follows: 
94°C 1 min 
94°C 30 s 
         54/52/55/53°C‡ 30 s  30 cycles 
72°C 60 s 
72°C 7 min 
2.9.3. Agarose Gel Electrophoresis 
In order to confirm successful PCR amplification of exons, an aliquot of each 
reaction was assessed using agarose gel electrophoresis as follows:  
2.9.3.1. Gel Preparation 
A 2% agarose gel was prepared by melting 700mg of Ultrapure™ agarose 
(Invitrogen Life Technologies) in 35ml TBE buffer [89mM Tris-HCl pH 8, 89mM boric 
acid, 2mM EDTA] in a conical flask. This was allowed to cool to ‘hand heat’ and 3.5μl of 
1mg/ml ethidium bromide solution was added (final concentration in gel, 0.1μg/ml). 
Ethidium bromide is a DNA intercalating agent which, when exposed to UV light, 
fluoresces brightly with an orange colour when incorporated in nucleic acids. Its 
inclusion in the gel therefore allows visualisation of the DNA following separation, as 
                                                     
‡ See Table 2.6 for annealing temperatures for specific primers. 
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described below (Section 2.9.3.3). Gel solution was mixed thoroughly, poured into a 
gel cassette and allowed to set at room temperature. 
2.9.3.2. Electrophoresis 
The gel cassette was placed in a Sub-Cell® GT Agarose Gel Electrophoresis System 
(Bio-Rad Laboratories Ltd.) filled with TBE buffer. To allow estimation of the size of PCR 
products, 5μl of Quick-Load® 100bp DNA Ladder (New England BioLabs (UK) Ltd., 
Hitchin, UK) was loaded in to the first well. For each reaction, 7μl of PCR products was 
loaded directly into subsequent wells (loading dye was already present in the 
ReddyMix PCR buffer). A 7μl aliquot of each control reaction was also loaded into 
remaining wells to ensure no DNA contamination of reagents. Electrophoresis was 
performed at 100V for an appropriate length of time, as indicated by the position of 
the dye front (approximately 45 minutes).  
2.9.3.3. Visualisation of DNA 
Following electrophoresis, the gel was removed from the cassette and placed in 
a Gel Doc™ XR (Bio-Rad Laboratories Ltd.) for visualisation of PCR products using a UV 
light source. The Gel Doc software (Quantity One® V4.5.0) was used to capture an 
image of the gel and the gel was discarded. Presence of DNA bands of expected size (as 
estimated using the DNA ladder) confirmed successful PCR reactions. 
2.9.4. Cleanup of PCR Products for Sequencing 
Cleanup of remaining PCR products (approximately 13μl) for DNA sequencing 
was performed using a QIAquick® PCR Purification kit (Qiagen) according to 
manufacturers supplied protocol. Briefly, reaction mixtures are applied to a silica 
membrane (in spin-column format) which binds double stranded DNA, enabling 
residual PCR buffer to be washed away using supplied buffers. PCR products were 
eluted in 20μl buffer EB [10mM Tris-HCl pH 8.5] and concentration was determined 
using a Nanodrop spectrophotometer, as described above (Section 2.9.1).  
Concentration of PCR products was adjusted to 10ng/μl using nuclease-free H2O 
and 10μl of each was sent to Source BioScience LifeSciences (Nottingham, UK) (with 
appropriate primers; see Table 2.6) for forward and reverse sequencing. 
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2.9.5. Sequence Analysis 
Sequences received in FASTA format were viewed using EditSeq (DNASTAR Inc, 
WI, USA) and compared to published human N-RAS and K-RAS exon sequences using 
nucleotide BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Both forward and reverse 
sequences were analysed to ensure accurate coverage of entire exons. In addition, 
sequence traces (chromatogram format) were viewed using FinchTV (Geospiza Inc., 
WA, USA) in order to assess quality of sequence reads. 
2.10. In Vitro Mutation Assays 
In vitro mutation assays were used to investigate the DNA mutagenic potential of 
Ara-C (and MNU as a positive control) in an MMR proficient (TK6) and an MMR 
deficient (TK6 MSH2i) cell line (Chapter 6). The principles of the thymidine kinase (TK) 
and hypoxanthine-guanine phosphoribosyltransferase (HPRT) mutation assays used 
are described in more detail in Section 6.1. The workflow for setup of the assays is 
summarised in Figure 2.2 and specific details of each step are described below. 
2.10.1. Removal of Spontaneous Mutants using CHAT Medium 
Prior to performing mutation assays, cell populations were purged of any existing 
spontaneous TK or HPRT mutants by culture in CHAT (cytidine, hypoxanthine, 
aminopterin, thymidine) medium. Components in CHAT medium (aminopterin) result 
in cellular inhibition of purine nucleotide biosynthesis, forcing cells to rely on purine 
salvage pathways (using thymidine or hypoxanthine as substrates). This is therefore 
cytotoxic to mutants because they lack key components of these pathways. 
For each cell line, 5 x 105 cells were centrifuged at 230 x g for 5 min, resuspended 
in 25ml CHAT medium [RF10 medium supplemented with 10μM 2-deoxycytidine, 
17.5μM thymidine, 200μM hypoxanthine and 0.2μM aminopterin] and transferred to a 
75cm3 cell culture flask. Cultures were incubated at 37°C/5% CO2 for 48 hours. 
Exposure to mutagenic agent
(Ara-C or MNU, 16 hours)
Resuspension of cells in normal 
growth medium
(RF10)
Assessment of 
cytotoxicity of doses 
used.
Growth in non-selective conditions 
to allow phenotypic expression of 
mutant phenotype
(TK 3 days, HPRT 7 days)
Plating at low density in 
the absence of 
selective agent for 
determination of 
cloning efficiency
Plating at high density in 
the presence of selective 
agent to observe mutant 
colonies
(TFT for TK, 6-TG for HPRT)
Calculation of mutation frequency
(following approx. 20 days growth)
Figure 2.2. General workflow of mutation assays (TK and HPRT) in TK6 cells
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Following 48 hours in culture, 5 x 105 viable cells were centrifuged at 230 x g for 
5 min and resuspended in sterile PBS to wash cells. Following a second wash in sterile 
PBS, cells were resuspended in 25ml THC medium [as CHAT medium but without 
aminopterin] and transferred to a fresh 75cm3 culture flask. Cell cultures in THC 
medium were incubated at 37°C/5% CO2 for 72 hours. 
Following this culture period, the above procedure was repeated using normal 
RF10 medium to resuspend cells, which were now ready for immediate use in 
mutation assays. 
2.10.2. Drug Exposure 
For each cell line (TK6 and TK6 MSH2i), a suspension of exponentially growing 
cells at a density of 1 x 105 cells/ml was prepared using RF10 medium. For drug dosing, 
a 50ml aliquot of cell suspension was transferred to a sterile BD Falcon™ centrifuge 
tube and centrifuged at 230 x g for 5 min. Supernatant was discarded, cells were 
resuspended in 50ml RF10 medium supplemented with appropriate volume of drug 
and transferred to 175cm3 cell culture flasks. Each drug dose was prepared in triplicate. 
In addition, a vehicle-only control (for calculation of spontaneous mutation frequency) 
was also setup in the same way (in triplicate), by resuspending cells in 50ml RF10 
medium supplemented with appropriate solvent but no drug. Cultures were incubated 
for 16 hours at 37°C/5% CO2. 
Following 16 hours incubation, cell populations were washed twice using sterile 
PBS, after which appropriate volume of each cell suspension containing 5 x 105 cells 
was transferred to a sterile Falcon tube for assessment of cytotoxicity as below. 
Remaining cell suspensions were transferred to sterile 175cm3 cell culture flasks and 
incubated at 37°C/5% CO2. Cell suspensions were counted daily and diluted to a 
density of 4.5 x 105 cells/ml (in a volume of 50ml) as required, using RF10 medium. 
2.10.3. Assessment of Cytotoxicity 
For each dosed suspension, the aliquot containing 5 x 105 cells was diluted (using 
RF10 medium) to give a cell suspension at a density of 1 x 105 cells/ml. From this, cell 
suspensions at 104, 103, 102 and 101 cells/ml were prepared by 10-fold serial dilution. 
The 101, 102 and 103 suspensions were then each transferred to a sterile 96-well cell 
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culture plate (200μl per well). Plates were incubated at 37°C/5% CO2 for approximately 
20 days. 
Following the 20 day growth period, survival fraction at each dose was 
determined according to Section 2.6.2. Kill curves were generated according to Section 
2.6.2, using the mean and SEM of the triplicate results for each dose. 
2.10.4. Selection of TK Mutants 
TK mutants were selected based on resistance to trifluorothymidine (TFT) 
following 3 days in culture, the time required for expression of the TK mutant 
phenotype (Liber and Thilly, 1982). The following procedures were performed for all 
dosed (and control) cell populations: 
A cell suspension at a density of 1 x 105 cells/ml (155ml) was established using 
RF10 culture medium (remainder was returned to the incubator for subsequent 
selection of HPRT mutants). From this suspension, a 5ml aliquot was removed and a 
10-fold serial dilution was performed (using RF10 culture medium), to result in a cell 
suspension at a density of 101 cells/ml. This was then transferred to a 96-well culture 
plate (200μl per well, average 2 cells/well). Plates prepared in this way for each dose 
were to enable calculation of CE in the absence of selection. 
To the remainder of the cell suspension (150ml), 37.5μl of a 4mg/ml TFT solution 
[prepared using sterile dH2O immediately prior to use] was added (giving a final TFT 
concentration of 1μg/ml). Cell suspension was then transferred to 6 96-well culture 
plates (200μl per well, average 20,000 cells/well). All plates were incubated at 37°C/5% 
CO2 for approximately 20 days. 
2.10.5. Selection of HPRT Mutants 
Seven days in culture following removal of drug is required for expression of the 
HPRT mutant phenotype (Liber and Thilly, 1982). After this time period, HPRT mutants 
were selected based on resistance to 6-TG according to the following procedures:  
A cell suspension at a density of 1 x 105 cells/ml (155ml) was established using 
RF10 culture medium. From this suspension, a 5ml aliquot was removed and a plate 
for calculation of CE was prepared as above. To the remainder of the cell suspension 
(150ml), 120μl of a 2.5mg/ml 6-TG solution [prepared using DMSO and filter sterilised 
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immediately prior to use] was added (giving a final 6-TG concentration of 2μg/ml). Cell 
suspension was then transferred to 6 96-well culture plates (200μl per well). All plates 
were incubated at 37°C/5% CO2 for approximately 20 days. 
2.10.6. Calculation of Mutation Frequency 
After appropriate time for proliferation of any mutant colonies (approximately 
20 days), all plates were assessed microscopically for growth and the number of wells 
in which a mutant colony had grown was scored per plate. The total number of 
mutants from the 6 plates setup for each dose was used for calculation of mutation 
frequency, according to the formula below. 
For calculation of CE in the absence of selection, the CE plate prepared for each 
dose was assessed microscopically and the number of negative wells was determined. 
CE was calculated according to the formula in Section 2.6.2. 
Mutation frequency at each dose was calculated according to Liber and Thilly, 
(1982) using the following formula: 
𝑀𝐹 = 𝑇𝑜𝑡𝑎𝑙 𝑁𝑜.𝑀𝑢𝑡𝑎𝑛𝑡 𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠
𝐶𝐸 × 𝑇𝑜𝑡𝑎𝑙 𝑁𝑜.𝐶𝑒𝑙𝑙𝑠 𝑃𝑙𝑎𝑡𝑒𝑑 
All calculations were performed using Microsoft Excel. Bar charts representing 
the mean and SEM of the triplicate results at each dose in each cell line were prepared 
using Microsoft Excel. Calculation of induced MF at each drug dose was performed by 
subtracting the spontaneous MF (i.e. the MF observed in the vehicle-only treated cell 
population). These values (mean and SEM of triplicate results) were plotted on an X-Y 
scatter graph (using Microsoft Excel). 
2.10.7. Statistical Analysis 
 One-way and two-way analysis of variance (ANOVA) testing was used as 
described in Section 6.2.1 to assess effects of drug dose and DNA MMR dysfunction on 
MF. A significance level of 0.05 was used in all cases. All statistical analyses were 
performed using Minitab 15 (Minitab Ltd., Coventry, UK) statistical software package. 
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2.11. Molecular Analysis of HPRT Mutants 
To investigate particular classes of DNA mutation that Ara-C can induce (Chapter 
6), a number of drug-induced (and spontaneous) HPRT mutant TK6 colonies from the 
above assay were selected and subjected to molecular analysis as follows. 
2.11.1. Expansion of Mutant Cell Populations 
From the HPRT mutant TK6 colonies generated with the highest dose of Ara-C 
(30nM), 40 colonies were selected at random from each of the triplicate drug 
treatments (120 total). Similarly, 20 mutant colonies generated from the vehicle-only 
treated (spontaneous) TK6 cells were also randomly selected from each of the 
triplicate populations (60 total). For each colony selected, the entire contents of the 
well (approximately 200μl) was transferred to a well of a sterile 24-well cell culture 
plate containing 1ml RF10 medium supplemented with 2μg/ml 6-TG. Plates were 
incubated at 37°C/5% CO2 and assessed daily for cell growth (indicated by a change in 
colour of culture medium and confirmed microscopically). As required, another 1ml of 
RF10 medium supplemented with 2μg/ml 6-TG was added to each well. Once sufficient 
cell numbers were generated (after approximately 7 days in culture), as estimated 
microscopically, each population was divided equally into 2 and washed cell pellets 
were prepared according to Section 2.3.5 (without performing cell counts) and stored 
at -80°C. 
2.11.2. Multiplex PCR for HPRT Exon Deletions 
2.11.2.1. DNA Extraction 
For each HPRT mutant, one of the cell pellets was used for DNA extraction, 
quantitation and dilution to 100ng/μl according to Section 2.9.1, for use in genomic 
multiplex PCR reactions. 
Exon Primer Sequences AmpliconLength (bp)
1
Forward: TGGGACGTCTGGTCCAAGGATTCA
627
Reverse: CCGAACCCGGGAAACTGGCCGCCC
2
Forward: TGGGATTACACGTGTGAACCAACC
572
Reverse: GACTCTGGCTAGAGTTCCTTCTTC
3
Forward: CCTTATGAAACATGAGGGCAAAGG
1059
Reverse: TGTGACACAGGCAGACTGTGGATC
4
Forward: TAGCTAGCTAACTTCTCAAATCTTCTAG
335
Reverse: ATTAACCTAGACTGCTTCCAAGGG
5
Forward: CAAATCCCAGCAGATGGGCCACTTG
317
Reverse: TCACTCCTTTAGAACACAAGCCCAC
6
Forward: GACAGTATTGCAGTTATACATGGGG
443
Reverse: CCAAAATCCTCTGCCATGCTATTC
7/8
Forward: GATCGCTAGAGCCCAAGAAGTCAAG
1535
Reverse: TATGAGGTGCTGGAAGGAGAAAAC
9
Forward: GAGGCAGAAGTCCCATGGATGTGT
1279
Reverse: CCGCCCAAAGGGAACTGATAGTC
Table 2.7. Sequences of oligonucloeotide primers used for multiplex PCR
amplification of HPRT exons.
a Due to the close proximity of exons 7 and 8, they are co-amplified in a single
amplicon.
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2.11.2.2. Multiplex PCR Setup 
Sequences of primers for PCR amplification of all 9 HPRT exons were obtained 
from Gibbs et al., (1990) and are shown in Table 2.7. Primers were ordered from 
Sigma-Aldrich, reconstituted to 100pmol/μl using TE buffer upon receipt and stored at 
-20°C. Working stocks of primers at a concentration of 10pmol/μl were prepared using 
nuclease-free dH20 and stored at 4°C. (Gibbs et al., 1990) 
25x concentrated multiplex PCR buffer was prepared according to Gibbs et al., 
(1990) and consisted of 1.675M Tris-HCl pH 8.8, 170μM EDTA, 125mM β-
mercaptoethanol, 415mM ammonium sulphate ((NH4)2SO4) and 167.5mM MgCl2. 
Sufficient volume for all reactions was prepared in advance and stored at 4°C. 
PCR amplification of HPRT exons was performed in 2 multiplex reactions. 
Reaction 1 contained primers for exons 1, 3, 4, 7/8 and 9. Reaction conditions were 1x 
multiplex PCR buffer (67mM Tris-HCl pH 8.8, 6.8μM EDTA, 5mM β-mercaptoethanol, 
16.6mM (NH4)2SO4, 6.7mM MgCl2), 10% (v/v) DMSO, 10pmol exon 1 primers, 16pmol 
exon 3 primers, 25pmol exon 4 primers, 18pmol exon 7/8 primers, 16pmol exon 9 
primers, 1.5mM (each) dNTPs, 4 units ThermoPrime Taq DNA polymerase and 250ng 
genomic DNA in a total volume of 40μl. Reaction 2 contained primers for exons 2, 5 
and 6. Reaction conditions were 1x multiplex PCR buffer, 10% (v/v) DMSO, 20pmol 
exon 2 primers, 20pmol exon 5 primers, 10pmol exon 6 primers, 1mM (each) dNTPs, 4 
units ThermoPrime Taq DNA polymerase and 250ng genomic DNA in a total volume of 
30μl.  
For setup of PCR reactions, appropriate volume of PCR mastermix was prepared 
(containing all reagents except template DNA) and appropriate volume was dispensed 
into appropriate number of wells of an Abgene® PCR Plate (Thermo Scientific) on ice. 
An appropriate volume of 100ng/μl DNA was then added. Controls were also prepared 
using nuclease free dH2O in place of DNA, to ensure no contamination of reagents. 
Thermal cycles (identical for both reactions) were performed as follows: 
94°C 4.5 min 
94°C 30 s 
61°C 50 s 28 cycles 
68°C 60 s 
68°C 7 min 
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2.11.2.3. Analysis of PCR Products 
1.4% agarose gels were prepared by melting 1.4g of Ultrapure™ agarose in 100ml 
TBE buffer. Following cooling to ‘hand heat’, 10μl of 1mg/ml ethidium bromide 
solution was added (final concentration in gels, 0.1μg/ml). Gel solutions were mixed 
thoroughly, poured into large gel cassettes and allowed to set at room temperature. 
Gel cassettes were placed in Sub-Cell® GT Agarose Gel Electrophoresis Systems 
filled with TBE buffer. To allow estimation of the size of PCR products, 5μl of Quick-
Load® 100bp DNA Ladder was loaded in to the first well of each gel. For each reaction, 
10μl of PCR products was mixed with 2μl of Blue/Orange Loading Dye 6x (Promega UK, 
Southampton, UK) and loaded into the gel. Products from reaction 1 and 2 were 
loaded side by side for each mutant. Control reactions were loaded in the same way 
into the last wells of each gel. Electrophoresis was performed at 100V for an 
appropriate length of time, as indicated by the position of the dye front (approximately 
45 minutes).  
Gels were visualised and images captured for analysis according to Section 
2.9.3.3. Exon deletions were determined based on absence of bands of expected size 
(see Figure 6.4 for a representative gel image). 
2.11.3. Sequencing of HPRT cDNA for Detection of Point Mutations 
2.11.3.1. RNA Extraction and cDNA Preparation 
For each HPRT mutant which did not demonstrate exon deletion, the remaining 
cell pellet was used for total RNA extraction, quantitation and dilution to 200ng/μl 
according to Section 2.8.1. Reverse transcription to generate cDNA (at a concentration 
of 100ng/μl) from total mRNA was performed according to Section 2.8.2. 
2.11.3.2. Amplification and Sequencing of HPRT cDNA 
Sequences of PCR primers for amplification of HPRT cDNA were obtained from 
Meng et al., (2002) and were as follows: (Meng et al., 2002) 
Forward: CCTGAGCAGTCAGCCCGCGC 
Reverse: CAATAGGACTCCAGATGTTT 
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Primers were ordered from Sigma-Aldrich, reconstituted to 100pmol/μl using TE 
buffer upon receipt and stored at -20°C. Working stocks of primers at a concentration 
of 10pmol/μl were prepared using nuclease-free dH20 and stored at 4°C. 
PCR reaction conditions were 1x ReddyMix PCR buffer, 1.5mM MgCl2, 10pmol 
primers, 0.2mM (each) dNTPs, 0.5 units ThermoPrime Taq DNA polymerase and 100ng 
cDNA in a total volume of 20μl. For setup of PCR reactions, an appropriate volume of 
PCR mastermix was prepared and appropriate volume was dispensed into an 
appropriate number of wells of an Abgene® PCR Plate on ice. Appropriate volume of 
cDNA was added. Controls were also prepared using either a blank reverse 
transcription reaction or nuclease free dH2O in place of cDNA, to ensure no 
contamination of reagents. Thermal cycle was as follows: 
94°C 1 min 
94°C 30 s 
55°C 30 s  36 cycles 
72°C 45 s 
72°C 7 min 
To confirm successful amplification of HPRT cDNA, an aliquot of each reaction 
(7μl) was assessed using agarose gel electrophoresis according to Section 2.9.3. The 
remainder of PCR products were prepared and sent for sequencing to Source 
BioScience LifeSciences according to Section 2.9.4. Sequence analysis was performed 
according to Section 2.9.5. 
2.11.4. Amplification of HPRT Exons for Sequencing of Putative Splice Mutants 
Primers used for multiplex PCR amplification of HPRT exons (Table 2.7) are 
designed to also amplify sequences directly flanking exons, hence can be used to 
amplify individual HPRT fragments for sequencing of splice sites. Exons 7 and 8 and 
their associated splice sites were amplified and sequenced from genomic DNA in a 
number of HPRT mutants as follows: 
Reaction conditions for PCR amplification consisted of 1x ReddyMix PCR buffer, 
1.5mM MgCl2, 10pmol primers, 0.2mM (each) dNTPs, 0.5 units ThermoPrime Taq DNA 
polymerase and 100ng  genomic DNA in a total volume of 20μl. For setup of PCR 
reactions, appropriate volume of PCR mastermix was prepared and appropriate 
volume was dispensed into appropriate number of 0.2ml MicroAmp® Reaction Tubes 
on ice. Appropriate volume of genomic DNA was added. A control was also prepared 
 111 
 
using nuclease free dH2O in place of DNA, to ensure no contamination of reagents. 
Thermal cycle was as follows: 
94°C 2 min 
94°C 30 s 
56°C 30 s 36 cycles 
72°C 90 s 
72°C 7 min 
To confirm successful amplification, an aliquot of each reaction (7μl) was 
assessed using agarose gel electrophoresis according to Section 2.9.3. The remainder 
of PCR products were prepared and sent for sequencing to Source BioScience 
LifeSciences according to Section 2.9.4. Sequence analysis was performed according to 
Section 2.9.5. 
2.11.5. Calculation of Absolute and Ara-C-Induced Mutant Fractions 
Following characterisation, HPRT mutants were grouped into classes (point 
mutations (including splice site mutations), internal exon deletions, 3’ partial gene 
deletions, 5’ partial gene deletions or complete deletions) and the frequency of each 
class of mutation was used to estimate the fraction of total HPRT mutants represented 
by each class (i.e. the absolute mutant fraction). The following calculation was 
performed for each class of mutation for both the spontaneous and Ara-C-treated 
mutant populations: 
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑚𝑢𝑡𝑎𝑛𝑡 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 = % 𝑚𝑢𝑡𝑎𝑛𝑡𝑠 𝑖𝑛 𝑐𝑙𝑎𝑠𝑠 × 𝑚𝑒𝑎𝑛 𝑀𝐹§ 
From these results, the fraction of each class of mutation which was attributable 
to Ara-C (i.e. the Ara-C-induced mutant fraction) was estimated by subtraction of the 
spontaneous absolute mutant fractions from the Ara-C-treated absolute mutant 
fractions for each mutation class.  
Absolute mutant fractions (spontaneous and Ara-C-treated) and Ara-C-induced 
mutant fractions for each class of mutation were plotted on a stacked bar graph (using 
Microsoft Excel) in order to demonstrate the HPRT mutational spectra (see Figure 6.8). 
                                                     
§ Refers to the mean MF observed at 30nM Ara-C (or at 0nM Ara-C in the case of spontaneous 
mutants) (see Section 2.10.6).  
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2.11.6. Statistical Analysis 
A Chi-squared test was performed to determine if there was any significant 
difference between the overall spectra of Ara-C induced and spontaneously occurring 
HPRT mutants, as described in Section 6.2.3.4. Fisher’s exact testing was used to 
determine whether the frequencies of specific classes of mutant differed significantly 
between Ara-C induced and spontaneous mutants. A significance level of 0.05 was 
used in all cases. Bonferroni correction was applied in cases where multiple tests were 
performed on the same data. All statistical analyses were performed using Minitab 15 
statistical software package. 
2.12. Leukaemic Blast Quantitation and Enrichment from AML Patient Samples 
Matched presentation and relapsed material (cryopreserved mononuclear cells 
purified from peripheral blood) from a number of adult AML patients was received 
from the Newcastle Haematology Biobank (Newcastle University, REC reference 
07/H0906/109) for investigation of the clonal origins of relapsed AML via comparative 
SNP array analysis (Chapter 7). Prior to extraction and preparation of DNA for SNP 
array analysis (see Section 2.13 below), it was necessary to determine the percentage 
of leukaemic blasts in AML patient samples to ensure sufficient purity for array 
analysis. In cases where the percentage of leukaemic blasts was below the required 
threshold (85%), blasts were purified from the sample. The following processes were 
performed for AML patient samples at both presentation and relapse: 
2.12.1. Immunophenotyping 
Immunophenotyping is a technique used to identify and characterise cells 
according to lineage and stage of differentiation based on the expression of particular 
surface or intracellular markers. The process involves labelling of specific markers, 
commonly cluster of differentiation (CD) antigens, using fluorescence-conjugated 
monoclonal antibodies which can then be quantified by flow cytometry. Flow 
cytometry allows rapid analysis of fluorescently labelled markers, as well as other 
characteristics of single cells suspended in a stream of fluid as they pass through a 
beam of light (emitted by a laser). Emitted light signals are detected and digitised for 
computer analysis. 
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Immunophenotyping was used to quantitate the leukaemic blast population in 
each patient sample, based on the expression of CD33 and CD34 antigens (use of these 
particular antigens is described in Section 7.2.2) as follows:  
2.12.1.1. Antibody Labelling 
Fluorescence-conjugated monoclonal antibodies used for immunophenotyping 
are listed in Table 2.8. 
For antibody labelling of cells, cryopreserved mononuclear cells were rapidly 
thawed and transferred to 5ml pre-warmed RF10 culture medium. Cells were 
centrifuged at 230 x g for 5 min and resuspended in 5ml RF10 culture medium. Viable 
cells were counted using a haemocytometer and trypan blue dye (Section 2.3.2), 
following which 2 x 105 cells were dispensed into 2 BD Falcon™ capped polystyrene 
tubes (remaining cell suspension was incubated at 37°C/5% CO2).  
Cells were centrifuged at 450 x g for 4 min, supernatant was discarded and cells 
were resuspended in 100μl sterile PBS. To the first tube, 10μl each of CD34-FITC, CD33-
PE and CD45-PerCP antibodies were added. To the second tube, 10μl each of the 3 
isotype controls (see Table 2.8) were added in order to determine background levels of 
fluorescence and optimise flow cytometer settings, described below. Tubes were 
incubated in the dark at room temperature for 15 min. 
Following incubation, cells were washed by addition of excess PBSA [Dulbecco’s 
PBS (Invitrogen Life Technologies) containing 0.2% (w/v) BSA] and centrifuged at 450 x 
g for 4 min. Supernatant was discarded, wash step was repeated and cells were finally 
resuspended in 400μl PBSA. 
Antibody Clone Isotype Conjugatea Supplier Cat No.
CD45 2D1 Mouse IgG1 PerCP BD Biosciences 345809
CD33 AC104.3E3 Mouse IgG1 PE Miltenyi Biotec 130-091-732
CD34 AC136 Mouse IgG2a FITC Miltenyi Biotec 130-081-001
Mouse IgG1 isotype control X40 Mouse IgG1 PerCP BD Biosciences 345817
Mouse IgG1 isotype control IS5-21F5 Mouse IgG1 PE Miltenyi Biotec 130-092-212
Mouse IgG2a isotype control S43.10 Mouse IgG2a FITC Miltenyi Biotec 130-091-837
Table 2.8. Fluorescence-conguated antibodies used in flow cytometric assessment of blast immunophenotype.
a PerCP, peridinin chlorophyll protein; PE, phycoerythrin; FITC, fluorescein isothiocyanate.
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2.12.1.2. Flow Cytometry 
Flow cytometry was kindly performed by J. Irving (NICR) using a FACSCalibur flow 
cytometer with BD CellQuest Pro software. Prior to analysis of fluorescently-labelled 
cell surface markers, for each sample the isotype control mixture was used to optimise 
instrument settings (adjust voltages of fluorescence detectors to remove background 
fluorescence and adjust compensation settings for overlap of fluorescent spectra). 
Following optimisation, a total of 10,000 cells were assessed from the antibody-
labelled cell sample. 
For determination of blast percentage in the sample, cell debris and dead cells 
were first excluded based on forward and side scatter signals. Any residual red blood 
cells in the sample were then excluded based on lack of expression of CD45 (i.e. no 
detected PerCP fluorescence). Percentage of leukaemic blasts in the remaining cell 
population was determined based on positive expression of CD33 and/or CD34 (by 
detection of PE and FITC fluorescence, respectively). 
2.12.2. Magnetic-Activated Cell Sorting 
Magnetic Activated Cell Sorting (MACS®) is a method by which cells can be 
separated based on expression of specific cell surface markers. Cells are first labelled 
with magnetic MicroBeads specific for the marker of choice, following which cell 
suspension is loaded onto a MACS Column placed in the magnetic field of a MACS 
Separator. Magnetically labelled cells are retained on the column whilst unlabelled 
cells are washed through (the negative fraction). Removal of the column from the 
magnetic field allows elution of the labelled cells (the positive fraction). For this 
investigation, MACS was used for positive selection of CD33+ or CD34+ AML blasts 
from patient samples in which the blast percentage of the sample determined by 
immunophenotyping was less than the threshold required for SNP array analysis (85%). 
2.12.2.1. MicroBead Labelling  
CD33 and CD34 MicroBeads were purchased from Miltenyi Biotec (Bisley, UK) 
and stored at 4°C for use as required. For labelling of cells, cell populations were 
centrifuged at 300 x g for 10 min, supernatant was completely removed and cells were 
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resuspended in appropriate volume of MACS buffer [PBS pH 7.2, 0.5% (w/v) BSA, 2mM 
EDTA] according to manufacturer’s protocol. Appropriate volume of either CD33 or 
CD34 MicroBeads was added and suspensions were incubated at 4°C for 15 min. 
Following incubation, cells were washed by the addition of excess MACS buffer, 
centrifuged at 300 x g for 10 min and resuspended in 500μl MACS buffer.  
2.12.2.2. Cell Separation 
MACS MS Columns were purchased from Miltenyi Biotec. MACS Separators were 
kindly provided by H. McNeill (NICR). 
For separation of labelled cells, a MACS Column was placed into a MACS 
Separator and rinsed with 500μl MACS buffer. Cell suspension was then applied to the 
column and unlabelled cells which passed through were collected. Column was then 
washed 3 times using 500μl MACS buffer. Following washing, column was removed 
from the MACS separator, immediately placed on a sterile collection tube and 1ml 
MACS buffer was added in order to elute labelled cells. 
Due to the limited nature of patient material, separation efficiency could not be 
assessed on a case by case basis. It was deemed with confidence however, that 
separation efficiency would be high (> 98%) based on the results of a preliminary 
investigation in which a CD33+ cell line (KG-1) was efficiently separated from a mixture 
of CD33- cells (EoL-1) (data not shown). 
2.12.3. Storage of Cell Populations 
Remaining cell populations (either whole populations or separated fractions as 
appropriate) were divided equally between two sterile 1.5ml Eppendorf tubes and 
microfuged at 230 x g for 5 min. For one pellet, supernatant was completely removed 
and the pellet was stored at -80°C for future DNA extraction. For the other pellet, 
supernatant was removed and cells were resuspended in 350μl Buffer RLT (Qiagen) 
supplemented with 1% (v/v) β-mercaptoethanol for storage at -80°C (in order to 
preserve RNA integrity for possible future investigation of gene expression).  
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2.13. SNP Array Analysis 
SNP arrays were performed on matched presentation and relapsed AML samples 
in order to investigate clonal evolution of relapsed AML (Chapter 7). SNP arrays assess 
the expression of both SNPs and non-polymorphic sites distributed throughout the 
entire genome using probes hybridised to a chip. This data can be used to demonstrate 
copy number aberrations (CNAs) in individual patient samples, indicated by deletion or 
amplification of particular probes. It can also reveal regions of copy-neutral loss of 
heterozygosity (cn-LOH) (also referred to as acquired uniparental disomy (UPD)) by 
comparison of SNP genotype to those of either matched germline DNA (if available) or 
a pooled reference sample.  
SNP arrays were performed offsite by Almac Diagnostics Ltd (Craigavon, UK) 
using the Affymetrix SNP 6.0 platform. The SNP 6.0 array includes more than 906,600 
SNPs and 946,000 non-polymorphic probes, representing the highest level of detection 
of genetic variation currently available. 
2.13.1. Preparation of DNA for SNP Array 
Frozen cell pellets (see Section 2.12.3) were thawed and DNA was extracted 
using a QIAamp DNA Mini Kit (with DNA eluted in 50μl of buffer AE) and quantitated 
using a Nanodrop ND-1000 spectrophotometer as described in Section 2.9.1. For each 
sample a minimum of 10μl of DNA at a concentration above 100ng/μl was analysed 
(this required vacuum concentration of DNA samples in some cases using a Genevac 
SF50 Vacuum centrifuge (Genevac Ltd., Ipswich, UK)). 
2.13.2. Data Analysis 
Raw array-generated data in the form of .CEL files were received from Almac 
Diagnostics Ltd. Processing of raw data to identify CNAs and regions of cn-LOH in each 
sample was kindly performed by V. Rand (NICR) using Genotyping Console v4.0 
(Affymetrix, CA, USA).  
The workflow for data processing briefly involved initial generation of SNP 
genotype calls using the birdseed v2 algorithm (performed using all 14 samples in one 
batch to maximise efficiency of the clustering algorithm). This was followed by quantile 
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normalisation of data and copy number (CN) and LOH analyses (via Hidden Markov 
Model) using default software settings (with regional GC correction applied). 
HapMap270 data (SNP genotype calls for the 270 normal samples which comprise the 
International HapMap project) was used as a reference model for LOH analysis given 
that matched germline DNA was not available for the patients included in the study. 
Segment analysis of CN data was performed to identify regions of CNA (with detection 
thresholds set to exclude regions smaller than 100kb) and involving fewer than 5 
markers). Detected regions of CNA which mapped to regions of known (published) 
genetic variation were identified by the software (using annotations obtained from the 
Database of Genomic Variants [http://projects.tcag.ca/variation/]) and were excluded 
from further analysis.  
Remaining CNAs and regions of LOH were compared in matched presentation 
and relapsed samples from individual patients using Affymetrix Genotyping Console 
Browser (v1.0.12). This also allowed identification of genes within affected regions (of 
CNA or LOH) based on annotations taken from the NCBI RefSeq database. 
Quality control assessment of data was performed by determination of call rate 
at control SNPs (median 96.93%, range 94.34 – 99.21) and by measurement of 
concordance between presentation and relapse samples in individual patients (median 
99.23%, range 98.41 – 99.78). 
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Chapter 3. Loss of DNA MMR Components Mediates Response 
to Chemotherapeutic Nucleoside Analogues in vitro
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3.1. Introduction 
Ara-C is a nucleoside analogue used extensively in the treatment of AML. Its 
major mode of cytotoxicity involves incorporation of Ara-CTP into replicating DNA, 
leading to chain termination via inhibition of further polymerisation, as described in 
Section 1.5.2.1. Despite this, there is evidence from cell-free systems that chain 
termination is not 100% efficient and that chain extension can occur following Ara-CTP 
incorporation (Ohno et al., 1988). The presence of Ara-C residues at internucleotide 
linkage positions in leukaemic cells from treated patients and leukaemic cell lines 
treated in vitro (Major et al., 1981), provides further evidence of incorporation and 
extension.  
Certain antimetabolites which, like Ara-C, are metabolised to DNA precursors, 
are incorporated within DNA whereupon they represent substrates for DNA MMR 
components (MutSα) due to their miscoding properties. The most noted examples are 
the base analogues 6-TG and 5-FU, as described in Sections 1.2.1.2 and 1.2.2.1, 
respectively. Paradoxically, although DNA MMR mediates repair of accidental 
polymerase-mediated errors arising during normal DNA replication, in the case of 
drug-induced lesions, the MMR system initiates cell cycle arrest and apoptosis 
following their detection. Cells with dysfunctional DNA MMR, due to loss of key 
pathway components, lack the capacity to recognise or respond to lesions occurring 
due to the incorporation of 6-TG or 5-FU into DNA. Consequently cell cycle arrest and 
apoptosis are not initiated, leading to cell survival, but at the expense of an increased 
mutation rate due to tolerance of the lesions in the genome. 
Cellular resistance to cisplatin and IR, which are not themselves incorporated 
into DNA, but cause damage via the formation of crosslinks and/or strand breaks, can 
also be conferred by loss of certain DNA MMR components (see Sections 1.2.3.1 and 
1.2.4.1). The DNA MMR pathway cannot directly process these lesions however, 
illustrating that MMR components probably have roles in signalling DNA damage and 
initiating checkpoint responses unique from their roles in classical mismatch repair. 
Although originally proposed as a mechanism by which cells acquire resistance to 
DNA damaging drugs (Irving and Hall, 2001), emerging in vitro evidence suggests that 
loss of DNA MMR components may in fact also be able to confer increased sensitivity 
to the cytotoxic effects of certain chemotherapeutic agents. One such example is 
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methotrexate (MTX), the primary cytotoxic effect of which is through inhibition of 
folate metabolism (see Section 4.1 for further details). In addition to its major cytotoxic 
mechanism, MTX can also induce 8-oxo-G lesions in DNA (Martin et al., 2009). 
Persistence of these lesions in the DNA of MSH2-deficient cells increases cytotoxicity, 
presumably due to increased mutational load (Martin et al., 2009), which is consistent 
with the purported role of DNA MMR in 8-oxo-G repair (described in Section 1.2.4.2). 
Similarly curcumin, a dietary pigment showing promise in clinical trials for colorectal 
cancer (Chauhan, 2002), is also selectively cytotoxic to MSH2 (or MLH1) deficient cells 
through the induction of oxidative damage (Jiang et al., 2010). In this case, the 
purported mechanism involves loss of a DNA MMR-dependent checkpoint response 
following conversion of oxidative damage to DSBs, the result being extensive cell death 
due to mitotic catastrophe (Jiang et al., 2010).  
Gemcitabine (2’,2’-difluorodeoxycytidine)-induced cytotoxicity can also be 
modulated by cellular mismatch repair status. Like Ara-C, gemcitabine is a 2’-
deoxycytidine analogue which is active in a broad spectrum of solid tumours including 
pancreatic and bladder cancer (Burris et al., 1997; von der Maase, 2000). Gemcitabine 
is metabolised by the same cellular mechanisms as Ara-C, resulting in accumulation of 
its triphosphate (dFdCTP) which competes with dCTP for incorporation into DNA 
(Huang et al., 1991). Whereas Ara-C is primarily a chain terminating agent, treatment 
of human lymphoblastoid cell lines with gemcitabine demonstrates that greater than 
90% of dFdCTP is incorporated at internal positions in DNA (Huang et al., 1991). 
Furthermore, template assays reveal that DNA polymerases can extend from dFdCTP 
lesions with greater efficiency than is observed for Ara-C (Richardson et al., 2004), 
suggesting gemcitabine is a weaker chain terminator. One study has demonstrated 
that cells deficient in either MSH2 or MLH1 are hypersensitive to the cytotoxic effects 
of gemcitabine compared to MMR-proficient counterparts, although a mechanism has 
yet to be established (Takahashi et al., 2005). 
3.1.1. Aims of Chapter 3 
Despite the DNA damaging nature of Ara-C, there have been no published 
studies which have determined whether MMR components can interact with 
incorporated Ara-C nucleotides, or whether cellular DNA MMR status can mediate 
response to the drug either in vitro or in vivo. The objectives of the studies described in 
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this chapter were therefore to determine whether loss of key components of the DNA 
MMR pathway can affect in vitro response to the cytotoxic effects of Ara-C, similar to 
other antimetabolites. This was investigated using an established MMR proficient and 
deficient cell line pair, and cells in which DNA MMR components have been ‘knocked 
down’ using shRNA-mediated RNA interference.   
Specifically, the experimental aims of this chapter were as follows: 
• In the MMR-deficient cell line MT-1, determine the exact nature and 
extent of defects of the DNA MMR pathway at protein and gene 
expression levels. 
• Determine whether loss of MMR function in MT-1 affects response to 
treatment with Ara-C, and other therapeutic nucleoside analogues, using 
cytotoxicity assays. 
• Generate isogenic MMR-deficient cell lines using shRNA-mediated gene 
interference and determine whether loss of MMR function affects 
response to treatment with Ara-C, and other therapeutic nucleoside 
analogues. 
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3.2. Results 
3.2.1. Phenotypic Characterisation of the MMR-Defective Cell Line MT-1 
MT-1 is a subclone of the B-lymphoblastoid cell line TK6. It was generated in 
1986 by exposure of the parental cell line to the potent acridine mutagen, ICR-191, 
resulting in cells highly resistant to killing, but hypermutable by the methylating agent, 
MNNG (Goldmacher et al., 1986). This phenotype was later attributed to dysfunction 
of the DNA MMR pathway when it was found that MT-1 was unable to repair 
base:base mispairs (Kat et al., 1993). Subsequently, MT-1 was found to possess 2 
different missense mutations, one in each allele of the gene coding for the MutSα 
component, MSH6, accounting for the MMR-deficient phenotype (Papadopoulos et al., 
1995). 
3.2.1.1. Expression Levels of MMR Proteins Determined by Western Immunoblotting 
To further characterise the MMR-deficient phenotype of MT-1, western 
immunoblotting was performed to determine the levels of the MMR proteins, MSH2, 
MSH3 and MSH6, which form the heterodimeric MutSα and MutSβ damage 
recognition complexes (Figure 3.1A). MT-1 expressed almost negligible levels of MSH6 
compared to parental TK6 cells. This was accompanied by a slight reduction in MSH2 
but no difference in MSH3. MSH6 heterodimerises with MSH2 to form the MutSα 
complex; loss of MSH6 causes deficiency of the MutSα complex in the MT-1 cell line, 
resulting in a proportion of partnerless MSH2 which is likely susceptible to proteolysis, 
explaining the concomitant reduction in MSH2 levels. 
The MutLα complex is a heterodimer of MLH1 and PMS2. The levels of these 
proteins were also assessed in MT-1 via western immunoblotting, with no difference 
observed for either protein compared to parental TK6 cells (Figure 3.1B). 
MGMT is responsible for removal of methyl groups from O6-meG lesions which 
occur as a result of exposure to methylating agents (Margison and Santibanez-Koref, 
2002). Loss of MGMT expression correlates with increased sensitivity to the cytotoxic 
effects of methylating agents (Yarosh et al., 1983). Furthermore, reactivation of MGMT 
has been demonstrated as a mechanism by which cells can acquire resistance to these 
agents (Hampson et al., 1997). TK6 is deficient in MGMT due to hypermethylation of 
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the promoter region of the gene (Danam et al., 2005). Western immunoblotting 
confirmed lack of MGMT protein in TK6 and demonstrated that MT-1 also lacks the 
protein (Figure 3.1C). 
3.2.1.2. Expression Levels of MMR Genes Determined by Quantitative RT-PCR 
In addition to characterisation of MMR components at the protein level, 
quantitative RT-PCR was performed to assess gene expression in MT-1 relative to 
parental TK6 cells (Figure 3.2). Expression of MSH2, MSH3 and MSH6 was not 
significantly different in MT-1 cells relative to TK6. Bi-allelic MSH6 mutation in MT-1 
therefore does not affect transcription, and loss of expression is presumably due to an 
inability to produce functional MSH6 at the translational level. Similarly, reduction in 
MSH2 in MT-1 appears not to be due to down-regulated expression, suggesting that 
degradation of partnerless protein occurs as stated above. 
Relative expression of PMS2 was also unchanged in MT-1 cells, however an 
apparent reduction in the expression of MLH1 was observed (Figure 3.2). The 
significance of this finding remains unclear given that the levels of the MLH1 protein 
were not altered in MT-1 relative to the parental TK6 line (see Figure 3.1B). 
Quantitative RT-PCR of MGMT indicated a complete lack of expression in both 
TK6 and MT-1, presumably due to the methylation of the promoter which blocks 
transcription. 
3.2.1.3. Cytotoxicity in Response to MNU and 6-TG 
Tolerance to the cytotoxic effects of methylating agents and 6-TG is a hallmark of 
MMR deficiency (Karran, 2001). To confirm the MMR-deficient phenotype of MT-1, 
cytotoxicity in response to treatment with the methylating agent, MNU and 6-TG was 
compared in MT-1 and parental TK6 cells via 96-well clonogenic assay, as described in 
Section 2.6.2. MT-1 demonstrated increased tolerance to the cytotoxic effects of MNU 
(Figure 3.3A) and 6-TG (Figure 3.3B) relative to parental TK6 cells. This was consistent 
with previous reports of tolerance to these agents in MT-1 (Goldmacher et al., 1986; 
Kat et al., 1993) and the observed loss of MutSα activity. 
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Figure 3.1. MMR protein expression in TK6 and MT-1 cell lines.
Western immunoblotting was performed to determine protein expression of DNA
MMR components in the MMR-proficient cell line TK6 and its MMR-deficient
subclone MT-1 as follows: A. MutS components (MSH2, MSH3 and MSH6). B. MutLα
components (MLH1 and PMS2). C. MGMT. The MMR proficient HeLa cell line was
included as a positive control in each case. The MutS deficient LoVo cell line was
included as a negative control in the case of MSH2, MSH3 and MSH6. β-actin was
used as a loading control for all blots. Each blot is representative of three
independent experiments.
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Figure 3.2. Relative expression of DNA MMR components in MMR-deficient MT-1
cells.
RT-PCR was performed to determine changes in gene expression of the MutS (MSH2,
MSH3 and MSH6) and MutL (MLH1 and PMS2) components in MMR-defective MT-1
cells relative to parental MMR-proficient TK6 cells. Expression of each gene was
calculated relative to the parental cell line with the expression of β-actin used as
endogenous control. Values represent fold change in expression calculated from the
mean and standard error of three independent experiments.
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Figure 3.3. Cytotoxicity in response to MNU and 6-TG in TK6 and MT-1 cell lines.
Cell survival in response to MNU (A) and 6-TG (B) was compared in MMR-proficient
TK6 cells (black circles) and MMR-deficient MT-1 cells (grey circles) via clonogenic
assay. Data is presented as the number of viable colonies from dosed cell
suspensions as a percentage of the number of viable colonies from vehicle-only
treated cell suspensions. Data represents the mean and standard error of three
independent experiments.
Figure 3.4. Cytotoxicity in response to Ara-C in TK6 and MT-1 cell lines.
Cell survival in response to Ara-C was compared in MMR-proficient TK6 cells (black
circles) and MMR-deficient MT-1 cells (grey circles) via clonogenic assay. Data is
presented as described in the legend to Figure 3.3 above.
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3.2.2. Cytotoxicity in TK6 and MT-1 Cells Following Treatment with Ara-C 
Cytotoxicity in response to Ara-C was assessed in MT-1 relative to TK6 via 
clonogenic assay. Whereas MT-1 demonstrated tolerance to the cytotoxic effects of 
MNU and 6-TG, a different phenotype was observed in response to Ara-C. Specifically, 
MT-1 cells were significantly more sensitive to cell killing mediated by Ara-C than the 
MMR-proficient parental TK6 cells (Figure 3.4). These data are consistent with a role 
for the DNA MMR pathway in modulating cellular response to Ara-C, however the 
mechanism of interaction is likely different to that reported for methylating agents and 
6-TG given the differential drug response phenotypes observed following treatment 
with these agents and with Ara-C. 
3.2.3. Cytotoxicity in TK6 and MT-1 Cells Following Treatment with Fludarabine, 
Cladribine and Clofarabine 
In order to determine whether the increased sensitivity of MT-1 to Ara-C was 
also seen in response to other therapeutic nucleoside analogues, cytotoxicity in 
response to fludarabine, cladribine and clofarabine was assessed in MT-1 relative to 
TK6. 
Like Ara-C, the triphosphates of fludarabine, cladribine and clofarabine can be 
fraudulently incorporated into replicating DNA resulting primarily in chain termination 
(Hentosh et al., 1990; Huang et al., 1990; Parker et al., 1991), although there is also 
evidence for internucleotide incorporation (Hentosh et al., 1990; Xie and Plunkett, 
1995). In the case of clofarabine, at low concentrations, incorporation is mainly in 
internal positions within DNA, which has been reported to have inhibitory effects on 
DNA repair (Xie and Plunkett, 1995; Zhenchuk et al., 2009). 
MT-1 cells were hypersensitive to fludarabine (Figure 3.5A), cladribine (Figure 
3.5B) and clofarabine (Figure 3.5C) compared to parental TK6 cells, which was 
consistent with the phenotype observed in response to Ara-C. These data suggest that 
the role of DNA MMR as a modulator of cellular response to nucleoside analogues is 
not limited to Ara-C, but can also be extended to other arabinosyl nucleoside 
analogues. 
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Figure 3.5. Cytotoxicity in response to adenosine nucleoside analogues in TK6 and
MT-1 cell lines.
Cell survival in response to fludarabine (A), cladribine (B) and clofarabine (C) was
compared in MMR-proficient TK6 cells (black circles) and MMR-deficient MT-1 cells
(grey circles) via clonogenic assay. Data is presented as the number of viable colonies
from dosed cell suspensions as a percentage of the number of viable colonies from
vehicle-only treated cell suspensions. Data represents the mean and standard error
of three independent experiments.
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3.2.4. Assessment of RAS Mutation Status and Activity in TK6 and MT-1 Cells 
3.2.4.1. Sequencing of N-RAS and K-RAS Exons 
Activating mutations of RAS proto-oncogenes can sensitise cells to Ara-C in vitro 
(Koo et al., 1999; Meyer et al., 2009). Furthermore, patients with RAS mutations have 
been reported to benefit most from Ara-C therapy, particularly at high doses 
(Neubauer et al., 2008).  
Coding sequences of commonly mutated exons of N-RAS and K-RAS in MT-1 were 
wild-type (sequencing data not shown), indicating that mutation was not responsible 
for the Ara-C sensitivity observed in this cell line. 
3.2.4.2. Quantification of Activated ERK via Western Immunoblotting 
Activation of RAS is observed in a subset of AML patients in which detectable RAS 
mutations are not found, and this has also been correlated with improved CR rates 
following treatment with Ara-C, as well as improved overall survival (Illmer et al., 
2005). It is possible therefore, that RAS could be activated in MT-1 via a mechanism 
other than point mutation.  
ERK-2 is a downstream effector of RAS activation, and is phosphorylated to its 
active form, pERK-2, via a kinase signalling cascade (Meloche and Pouyssegur, 2007). 
Quantification of pERK-2 was performed in MT-1 cells relative to TK6 via western 
immunoblotting to determine if RAS activation had occurred despite there being no 
detectable N-RAS or K-RAS mutations. Parental TK6 cells did not demonstrate any 
phosphorylation of ERK-2 (Figure 3.6), consistent with absence of RAS activation in this 
cell line. A low level of pERK-2 was detectable in MT-1 cells (Figure 3.6), however it 
remains unknown whether this would be sufficient to confer hypersensitivity to Ara-C.  
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Figure 3.6. ERK-2 and pERK-2 protein levels in TK6 and MT-1 cell lines.
Western immunoblotting was performed to assess protein levels of ERK-2 (left) and
pERK-2 (right) in the MMR-deficient MT-1 cell line and its MMR-proficient parental
cell line TK6. PreB697 cells were included as a positive control. In both cases, the
major band corresponds to ERK-2 (42kDa). The minor band above corresponds to
ERK-1 (44kDa), an alternate ERK isoform. β-actin was used as a loading control.
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3.2.5.  Assessment of MMR Status in shRNA Knockdown Cell Lines 
Because MT-1 was generated from TK6 by exposure to a mutagenic compound, 
and has a mutator phenotype (Goldmacher et al., 1986; Kat et al., 1993), it is possible 
that MT-1 has acquired additional genomic mutations not present in the parental cell 
line. Consistent with this model, an investigation of methylating agent-induced 
transcriptome changes in TK6 and MT-1 revealed differences in the basal gene 
expression profile (di Pietro et al., 2003). TK6 and MT-1 therefore cannot be 
considered strictly isogenic, which highlighted a requirement for confirmation of the 
results described above in a truly isogenic system. To this end, cell lines were 
generated from TK6, and also from the myeloid leukaemic cell line, HL-60, in which 
MutS components (MSH2, MSH3 and MSH6) were stably knocked down using shRNA-
mediated RNA interference (see Section 2.4). These cell lines were then characterised 
for their DNA MMR status, following which cytotoxicity in response to nucleoside 
analogues was assessed relative to their respective parental cell lines as follows. 
3.2.5.1. Expression Levels of MutS Protein Components Determined by Western 
Immunoblotting 
Western immunoblotting was used to determine the protein levels of MSH2, 
MSH3 and MSH6 in each of the shRNA knockdown cell lines (Figure 3.7). Knockdown of 
MSH6 completely abolished MSH6 protein in TK6 MSH6i and HL-60 MSH6i, 
accompanied by a slight decrease in MSH2 but no difference in MSH3 relative to the 
respective parental cell lines. Knockdown of MSH2 resulted in complete loss of MSH2 
protein in both TK6 (TK6 MSH2i) and HL-60 (HL-60 MSH2i), accompanied by complete 
loss of both MSH3 and MSH6. Degradation of MSH3 and MSH6, due to instability in the 
absence of their binding partner (Drummond et al., 1997) is the probable explanation 
for this phenotype. MSH3 knockdown resulted in a reduction in MSH3 protein levels of 
approximately 95% in both cell lines (TK6 MSH3i and HL-60 MSH3i) but there was no 
observed effect on MSH2 or MSH6. In human cells, the ratio of MutSα to MutSβ is 
approximately 6:1 (Drummond et al., 1997), therefore loss of MSH3 would not be 
expected to have a significant impact on the stability of MSH2 because the majority is 
partnered with MSH6 in the MutSα complex. 
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Figure 3.7. MutS protein expression in MMR knockdown cell lines.
Western immunoblotting was performed to assess protein expression of MutS
components (MSH2, MSH3 and MSH6) as a result of shRNA-mediated knockdown of
MSH2, MSH3 or MSH6 in HL-60 and TK6 cell lines. Non-target shRNA was used to
control for effects of the transduction process on protein expression. β-actin was
used as a loading control.
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3.2.5.2. Cytotoxicity Following Treatment with MNU and 6-TG 
To determine the effects of knockdown of MutS components on DNA MMR 
status, cytotoxicity in response to MNU and 6-TG was assessed in knockdown cell lines 
relative to their MMR-proficient parental counterparts (Figure 3.8). TK6 MSH6i and HL-
60 MSH6i cells demonstrated tolerance to the cytotoxic effects of MNU and 6-TG 
compared to their respective parental cell lines, as did TK6 MSH2i and HL-60 MSH2i 
cells. This is consistent with the phenotype expected in MutSα defective cells when 
exposed to these agents, and confirms major perturbation of the DNA MMR pathway.  
MSH3 heterodimerises with MSH2 to form the MutSβ complex, which is 
responsible for detection of IDLs and extrahelical loops but is not thought to possess 
activity towards base:base mispairs (Palombo et al., 1996). Depletion of MSH3 protein 
alone in TK6 MSH3i and HL-60 MSH3i therefore results in deficiency of MutSβ, but this 
is not expected to affect MutSα. Consistently, TK6 MSH3i and HL-60 MSH3i 
demonstrated no difference in cytotoxicity in response to MNU or 6-TG compared to 
their respective parental cell lines (Figure 3.8). This demonstrates that MutSα function 
is not affected in these cell lines, and furthermore confirms that the MutSβ complex 
has no role in mediating cytotoxicity in response to MNU and 6-TG. 
3.2.6. Cytotoxicity in MMR Knockdown Cell Lines Following Treatment with 
Nucleoside Analogues 
Cytotoxicity in response to Ara-C, fludarabine and clofarabine was assessed in 
MMR knockdown cell lines relative to respective MMR-proficient parental cells (Figure 
3.9). Consistent with the results observed in the MT-1, TK6 MSH6i and HL-60 MSH6i 
cells demonstrated increased sensitivity to cytotoxicity induced by Ara-C, fludarabine 
and clofarabine compared to their parental counterparts. Additionally, TK6 MSH2i and 
HL-60 MSH2i also demonstrated increased cytotoxicity in response to these nucleoside 
analogues relative to their parental cells.  
Conversely, loss of MSH3 protein alone in TK6 MSH3i and HL-60 MSH3i cells 
conferred tolerance to the cytotoxic effects of Ara-C, fludarabine and clofarabine 
relative to parental cells (Figure 3.9). 
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Figure 3.8. Cytotoxicity in response to MNU and 6-TG in MMR knockdown cell lines.
A. Cytotoxicity in response to MNU (left) and 6-TG (right) was compared in TK6 and
its MMR knockdown subclones via clonogenic assay. Data is presented as the number
of viable colonies from dosed cell suspensions as a percentage of the number of
viable colonies from vehicle-only-treated cell suspensions. B. Cytotoxicity in response
to MNU and 6-TG was compared in HL-60 and its MMR knockdown subclones via
growth inhibition assay. Data are presented as the number of surviving cells from
dosed cell suspensions as a percentage of surviving cells from vehicle-only-treated
cell suspensions. In each case, data represents the mean and standard error of three
independent experiments. Cytotoxicity in TK6 and HL-60 cells transduced with non-
target shRNA was also assessed in response to MNU and 6-TG to confirm that the
transduction process itself did not affect drug response (data not shown).
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Figure 3.9. Cytotoxicity in
response to Ara-C,
fludarabine and clofarabine
in MMR knockdown cell
lines.
A. Cytotoxicity in response
to Ara-C (left), fludarabine
(centre) and clofarabine
(right) was compared in TK6
and its MMR knockdown
subclones via clonogenic
assay. Data is presented as
the number of viable
colonies from dosed cell
suspensions as a percentage
of the number of viable
colonies from vehicle-only-
treated cell suspensions.
B. Cytotoxicity in response
to Ara-C, fludarabine and
clofarabine was compared
in HL-60 and its MMR
knockdown subclones via
growth inhibition assay.
Data are presented as the
number of surviving cells
from dosed cell suspensions as a percentage of surviving cells from vehicle-only-treated cell suspensions. In each case, data represents the mean
and standard error of three independent experiments. Cytotoxicity in TK6 and HL-60 cells transduced with non-target shRNA was also assessed in
response to Ara-C, fludarabine and clofarabine to confirm that the transduction process itself did not affect drug response (data not shown).
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Taken together, these data further support a role for DNA MMR in mediating 
cellular response to Ara-C and other nucleoside analogues. Moreover it appears that 
the specific nature of MMR defects is important in influencing outcome, suggesting 
that MutSα and MutSβ components have different roles in modulating response to 
these agents. 
3.2.7. Cytotoxicity in MMR-Deficient Cell Lines Following Exposure to IR and UV 
Radiation 
 It has been reported that certain defects of the DNA MMR pathway can affect 
cytotoxicity following exposure to IR, although results are conflicting and the exact role 
of MMR in response to IR is unclear (see Section 1.2.4). To determine whether loss of 
MutS components in MT-1 or in MMR knockdown cells could affect response to IR, 
cytotoxicity following acute IR exposure was assessed in all lines relative to their 
parental counterparts. No differential cytotoxic response to IR was observed in any of 
the MMR-deficient cells relative to their respective MMR-proficient parental cells 
(Figure 3.10A). This is consistent with previous studies using strictly isogenic cell line 
pairs (Cejka et al., 2004) and suggests that neither MutSα nor MutSβ loss can 
significantly influence cytotoxicity in response to IR. It should be noted however, that 
cell cycle-related effects, for instance differences in activation of checkpoint proteins, 
cannot be excluded.  
It is possible that the difference in response to nucleoside analogues observed 
between MMR-proficient and MMR-deficient cell lines could be attributed to a defect 
affecting other DNA repair pathways, although this is unlikely given the isogenic nature 
of the cell line pairs. Nevertheless, to exclude this possibility, cytotoxicity in response 
to UV exposure was assessed, as UV radiation causes DNA lesions which are substrates 
for repair pathways acting independently of DNA MMR. There was no observable 
difference in cytotoxicity resulting from exposure to UV radiation in any of the MMR-
defective cells relative to parental lines (Figure 3.10B), therefore excluding a generic 
DNA repair defect. 
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Figure 3.10. Cytotoxicity in response to
IR and UV exposure in MMR-deficient
cell lines.
A. Cytotoxicity following exposure to IR
was compared in TK6 and MT-1 (left) and
in TK6 and its MMR knockdown
subclones (centre) via clonogenic assay.
Data is presented as the number of
viable colonies from exposed cell
suspensions as a percentage of the
number of viable colonies from
unexposed control cell suspensions.
Cytotoxicity following exposure to IR was
compared in HL-60 and its MMR
knockdown subclones (right) via growth
inhibition assay. Data are presented as
the number of surviving cells from
exposed cell suspensions as a
percentage of surviving cells from
unexposed control cell suspensions.
B. Cytotoxicity following exposure to UV
radiation was compared in TK6 and MT-1
(left), in TK6 and its MMR knockdown
subclones (centre) and in HL-60 and its
MMR knockdown subclones (right) as
described above. In all cases, data
represents the mean and standard error
of three independent experiments.
138
CELL
LINE
MMR PROTEIN EXPRESSIONa
MMR 
STATUS
DRUG RESPONSE PHENOTYPEb
MSH2 MSH3 MSH6 MLH1 PMS2 MGMT MNU 6-TG ARA-C FLUD CLAD CLOF IR/UV
MT-1 - NE -- NE NE --- MutSαdeficient Resistant Resistant Sensitive Sensitive Sensitive Sensitive ND
TK6 
MSH2i --- --- --- U U U
MutSα/β
deficient Resistant Resistant Sensitive Sensitive U Sensitive ND
HL-60
MSH2i --- --- --- U U U
MutSα/β
deficient Resistant Resistant Sensitive Sensitive U Sensitive ND
TK6 
MSH3i NE -- NE U U U
MutSβ
deficient ND ND Resistant Resistant U Resistant ND
HL-60 
MSH3i NE -- NE U U U
MutSβ
deficient ND ND Resistant Resistant U Resistant ND
TK6 
MSH6i - NE --- U U U
MutSα
deficient Resistant Resistant Sensitive Sensitive U Sensitive ND
HL-60 
MSH6i - NE --- U U U
MutSα
deficient Resistant Resistant Sensitive Sensitive U Sensitive ND
Table 3.1. Summary of MMR protein expression, MMR status and drug response phenotypes in MMR-deficient cells (relative to MMR-proficient 
parental cells).
a --- complete loss of protein expression   -- significantly reduced expression   - slight reduction in expression; NE, no effect; U, undetermined
b  ND, no difference in response; U, undetermined.
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3.2.8. Summary of Relative Cytotoxic Responses in MMR-Deficient Cell Lines 
Following Exposure to DNA Damaging Agents 
For ease of reference, a summary of the cellular defects, MMR status and drug 
response phenotypes observed in MT-1 and in each of the isogenic MMR knockdown 
cell lines is presented in Table 3.1. 
3.3. Discussion 
The requirement for functional DNA MMR in mediating response to methylating 
agents and the base analogue antimetabolite 6-TG is well established. In the case of 6-
TG, incorporation of the fraudulent nucleotide triphosphate (6-thio-dGTP) into DNA 
and subsequent in situ methylation and replication of the lesion results in mispairs 
which are a substrate for the damage recognition complex MutSα (Swann et al., 1996; 
Waters and Swann, 1997) (see Figure 1.4). Following damage recognition by MutSα, 
cells are arrested in G2 phase of the second cell cycle and apoptosis is initiated (Hawn 
et al., 1995). This may be due to repeated abortive repair attempts coordinated by 
MMR components which results in the formation of pro-cytotoxic strand breaks. 
Alternatively it could be due to an ability of MMR proteins to signal directly to cell 
cycle and/or apoptosis-mediating factors, implicating DNA MMR components as 
general DNA damage sensors, although this remains to be firmly established. Loss of 
key DNA MMR components (MutSα or MutLα) results in tolerance to 6-TG-induced 
DNA damage due to lack of MMR-mediated cell cycle arrest and/or apoptosis initiation 
(Aquilina et al., 1989; Aquilina et al., 1990). 
Using cell lines harbouring defined defects affecting specific MMR components, 
this study demonstrates a role for DNA MMR in mediating cytotoxicity in response to 
several therapeutic antimetabolite nucleoside analogues. Additionally, the data 
suggests that the mode of interaction of MMR components with nucleoside analogues 
differs from that with 6-TG. Furthermore, differences in the cytotoxic response to 
nucleoside analogues were observed when different MMR components were 
dysfunctional, demonstrating that the specific nature of MMR defects is important in 
influencing response to these agents. 
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Loss of the MutSα complex in MT-1 (through MSH6 mutation), and in TK6/HL-60 
MSH2i and TK6/HL-60 MSH6i (through gene knockdown) conferred tolerance to the 
cytotoxic effects of the methylating agent MNU and 6-TG as expected. Rather than 
being cross-tolerant to the cytosine nucleoside analogue Ara-C, MutSα-deficient cells 
were acutely sensitive. This initial finding was then extended to include other 
therapeutic nucleoside analogues, namely fludarabine, cladribine and clofarabine, 
which are each analogues of 2’-deoxyadenosine (see Section 1.5.4). These findings 
therefore add to a growing body of evidence that loss of DNA MMR components can 
confer sensitivity to specific DNA damaging agents. 
Despite differences in the metabolism, mechanism of action and clinical activity 
of the nucleoside analogues used in this study, the cytotoxic responses observed in 
MMR-deficient cells were consistent. This suggests a common mechanism (or 
mechanisms) by which DNA MMR interacts with the lesions caused by these agents. 
The following sub-sections outline a number of mechanisms which might account for 
the observations herein.  
 
S phase checkpoint abrogation 
Each of the nucleoside analogues used in this investigation causes stalling of the 
replication fork, eliciting activation of the S phase checkpoint (through ATR-Chk1-Cdk2 
signalling; see Figure 1.12), causing cells to accumulate in S phase (Ewald et al., 2008b). 
The involvement of DNA MMR components at the G2M checkpoint in response to 
methylating agents, 6-TG and IR is well characterised (see Sections 1.2.1.2 and 1.2.4.1 
respectively). Similarly, Brown et al. demonstrated that functional DNA MMR is 
required for S phase checkpoint activation in response to IR through an interaction 
between MSH2 and Chk2 (Brown et al., 2003). These findings led to the proposition 
that damage-enhanced association of checkpoint signalling molecules (such as Chk1 
and Chk2) with MMR complexes assembled at sites of DNA damage may be a key step 
in the activation of signalling cascades in response to genotoxic stress (Brown et al., 
2003; Wang and Qin, 2003). A possible explanation for these findings therefore (which 
could also extend to gemcitabine), is that such an MMR-mediated ‘molecular scaffold’ 
also forms at nucleoside analogue-induced stalled replication forks to mediate damage 
signalling, loss of which confers sensitivity to these agents. Abrogation of the S phase 
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checkpoint has previously been identified as a mechanism by which cells can be 
sensitised to nucleoside analogues via an increase in lethal DNA damage. This has been 
demonstrated in vitro in the case of Ara-C (Loegering et al., 2004; Cho et al., 2005; 
Karnitz et al., 2005; Mesa et al., 2005) as well as gemcitabine (Shi et al., 2001; Karnitz 
et al., 2005; Ewald et al., 2007). Furthermore, in response to IR exposure, cells 
deficient in MSH2 (or MLH1) demonstrate abrogation of the S phase checkpoint such 
that cells continue to replicate their DNA despite the presence of damage (Brown et 
al., 2003). This would presumably lead to mitotic catastrophe and increased cell death. 
Loss of MSH2 in MT-1, TK6/HL-60 MSH2i and TK6/HL-60 MSH6i in this study could 
similarly cause checkpoint failure, allowing cells to continue through the cell cycle 
despite the presence of nucleoside analogue-induced DNA damage and subsequently 
undergo increased cell death due to mitotic catastrophe. Further investigations to 
delineate the mode of nucleoside analogue-induced cytotoxicity in these cell lines, as 
well as the timing of cell death, are required to test these models. 
 
Deficiency in repair/removal of nucleoside analogues 
As well as initiating cell cycle arrest, activation of the ATR-Chk1-Cdk2 response 
also promotes replication fork stabilisation (Paulsen and Cimprich, 2007), likely 
allowing DNA repair mechanisms an opportunity to remove fraudulent nucleotides 
from DNA. Another possible explanation for the observations in this study is that DNA 
MMR components are involved in signalling to, or recruitment of, factors which 
facilitate removal of nucleoside analogues from stalled replication forks, for example 
unassociated 3’→5’ exonucleases, or BER and NER components. In particular, BER is 
capable of removing fludarabine nucleotides from DNA both in vitro and ex vivo, and 
inhibition of this response sensitises cells to the cytotoxic effects of fludarabine (Bulgar 
et al., 2010). It remains to be established whether DNA MMR components could 
directly or indirectly recruit BER components to stalled replication forks. Alternatively, 
it is possible that MMR components themselves might be involved in the removal of 
terminal nucleoside analogues hence permitting resumption of DNA replication, 
however this has yet to be investigated. In either case, dysfunction of DNA MMR 
would result in sensitisation of cells to nucleoside analogue-mediated cytotoxicity, 
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consistent with the observations herein and those previously reported with 
gemcitabine (Takahashi et al., 2005). 
 
Deregulation of HRR 
ATM kinase, the damage responsive histone γ-H2AX, and the MRN complex are 
also localised to sites of stalled replication forks in response to nucleoside analogues 
(Ewald et al., 2007; Ewald et al., 2008a). These molecules are classically associated 
with response to DSBs (Fernandez-Capetillo et al., 2004; Shiloh, 2006; Lamarche et al., 
2010); consistently, there is some evidence to suggest that DSBs form as a result of 
stalled replication forks which are not repaired (Arnaudeau et al., 2000; Arnaudeau et 
al., 2001). This appears to allow other repair pathways such as HRR an opportunity to 
rescue the replication fork (Arnaudeau et al., 2001; Lundin et al., 2002; Rothkamm et 
al., 2003). DNA MMR components have a role in HRR (described in Section 1.1.2.1), 
and deregulation of HRR has been demonstrated as a consequence of MMR-
dysfunction (Worrillow and Allan, 2006). Deregulation of HRR-mediated processing of 
nucleoside analogue-induced DSBs could therefore represent another potential 
explanation for increased sensitivity observed in MT-1, TK6/HL-60 MSH2i and TK6/HL-
60 MSH6i. Also consistent with this proposed theory, MSH2 deficiency sensitises cells 
to camptothecin (Pichierri et al., 2001), an agent which causes DSBs selectively at 
stalled replication forks, in this case through topoisomerase I inhibition (Hsiang et al., 
1989). 
There is some evidence to suggest that non-homologous end joining (NHEJ), an 
error-prone alternative DSB repair pathway, may also be involved in repair of DSBs at 
stalled replication forks, for example following exposure to fludarabine (de Campos-
Nebel et al., 2008). Additionally, a role for MSH2 (and MLH1) in regulation of NHEJ at a 
step involving pairing of terminal DNA tails has been suggested (Bannister et al., 2004; 
Smith et al., 2005). The observed sensitivity of MT-1, TK6/HL-60 MSH2i and TK6/HL-60 
MSH6i to fludarabine, and by extension other nucleoside analogues, could therefore 
also potentially be attributed to deregulation of NHEJ. This is speculative however, as 
deregulation of NHEJ as a consequence of DNA MMR-dysfunction has not been 
demonstrated. 
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Dysfunction of MutSβ-mediated damage signalling 
In contrast to the phenotype seen with loss of MSH2, loss of MSH3 (through 
MSH3 gene knockdown in TK6/HL-60 MSH3i) conferred increased tolerance to the 
cytotoxic effects of Ara-C and other nucleoside analogues. MSH3 loss however, did not 
affect response to MNU or 6-TG, presumably because MutSα function remains 
unaffected. Loss of MSH3 results in lack of functional MutSβ complex, demonstrating a 
potential role for this complex in response to nucleoside analogue-induced DNA 
damage. In turn, this would suggest that these agents can induce DNA lesions which 
are substrates for MutSβ. Consistent with this suggestion, in vitro cell-free translesion 
synthesis experiments demonstrate that replication of an oligonucleotide containing 
an internal Ara-C lesion can give rise to a daughter DNA product containing an 
extrahelical base (Figure 3.11, unpublished observations courtesy of J.M. Allan), 
generating a legitimate substrate for MutSβ. It is also conceivable that this could occur 
in vivo given that nucleoside analogues can become incorporated at internucleotide 
positions within DNA (Major et al., 1981; Ohno et al., 1988). Furthermore, there is 
evidence to suggest, at least in the case of Ara-C, that specialised translesion DNA 
polymerases can replicate across incorporated Ara-C nucleotides (Chen et al., 2006), 
although whether this occurs with low fidelity giving rise to extrahelical bases has yet 
to be determined.  
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3’ – CGGCTTAAAGATCTTAGCTTTCGAACGATCG – 5’
3’ – CGGCTTAAAGATCTTAG(Ara-C)TTTCGAACGATCG – 5’
3’ – CGGCTTAAAGATCTTA(6-TG)CTTTCGAACGATCG – 5’
1
2
3
5’ – GCCGAATTTCTA – 3’Primer
Substrate
17bp 19bp 31bp 33bp
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (A
rb
itr
ar
y 
U
ni
ts
)
B
Figure 3.11. Ara-C lesions induce replication slippage in cell-free assays.
(A) Single stranded 31-mer oligonucleotides were used as substrates in translesion
synthesis experiments (performed by JMA), and were either unmodified (1), or
contained a 6-TG lesion (2) or an Ara-C lesion (3). (B) Products generated following
replication of the individual substrates with Klenow fragment from E. coli. The large
arrow demonstrates the 31 base pair full length product generated in each reaction.
The smaller (red) arrowhead demonstrates the additional 32 base pair product
generated by replication of the Ara-C containing substrate (3). Similar results were
also obtained using DNA pol α (data not shown).
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Given that loss of MutSβ confers tolerance to nucleoside analogues, a model is 
proposed in which MutSβ-mediated detection of DNA lesions signals cell cycle arrest 
and apoptosis (either through futile repair cycles or direct signalling), analogous to the 
MutSα-mediated response to 6-TG (and other agents). The ‘futile cycling’ model 
requires the presence of the lesion in the parental strand following two rounds of 
replication. It remains possible that MutSβ can detect nucleoside analogues 
incorporated within the daughter DNA strand following a single round of DNA 
replication. It is expected however, that this would result in removal of the lesion, 
conferring sensitivity, rather than the observed resistance, with loss of DNA MMR. One 
possible approach to investigating this model is to perform cell cycle analysis in order 
to determine whether nucleoside analogue-mediated cytotoxicity in MSH3-deficient 
cells occurs in the first or second cycle following exposure. It would also be interesting 
to determine whether loss of MSH3 alone confers tolerance to gemcitabine given that 
this drug is primarily observed at internucleotide positions (Huang et al., 1991). 
The finding that MSH3 deficiency as a sole abnormality confers tolerance to the 
cytotoxic effects of nucleoside analogues is in contrast to recent evidence that MSH3 
loss (in a strictly isogenic system) can sensitise colorectal carcinoma cells to platinum 
drugs (Takahashi et al., 2011). It is thought that the sensitivity conferred by MSH3 loss 
is due to dysfunction of HRR, given that MSH3 loss in the same study was also found to 
sensitise cells to an inhibitor of poly(ADP-ribose) polymerase 1 (PARP-1), a phenotype 
characteristic of HRR-defective cells (Martin et al., 2008). This implicates the MutSβ 
complex in the regulation of HHR-mediated repair of platinum agent-induced DSBs, a 
role which has previously been suggested for other cross-linking agents (see Section 
1.2.3.2). This report is therefore consistent with the observations of nucleoside 
analogue sensitivity in TK6/HL-60 MSH2i, and suggests that the observed phenotype is 
due to deregulation of HRR as suggested above, but mediated through loss of MutSβ 
rather than MutSα. Deregulation of HRR though MutSβ loss however, would not 
explain the nucleoside analogue sensitivity in MT-1 or TK6/HL-60 MSH6i, given that 
this complex is apparently unaffected in these cell lines as demonstrated by western 
immunoblotting (Figure 3.1 and Figure 3.7). Rather, evidence suggests that MutSα loss 
is primarily responsible for nucleoside analogue sensitivity in MT-1, TK6/HL-60 MSH2i 
and TK6/HL-60 MSH6i. 
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In conclusion, DNA MMR components might have multiple roles in cellular 
response to nucleoside analogues (summarised in Figure 3.12), dysfunction of which 
could account for the data generated in these investigations. Importantly, it should be 
noted that such roles are not necessarily mutually exclusive. For instance, MutSβ might 
have a role in mediating cell cycle arrest and/or apoptosis in response to internal 
nucleoside analogue-induced lesions, however cellular phenotype could be 
determined by dysfunction of MutSα in S phase checkpoint signalling and/or HRR 
regulation at the stalled replication fork. Furthermore, the contrasting findings 
between Ara-C and other agents (such as platinum drugs) that may ultimately generate 
the same damage (i.e. DSBs), highlights the complexity of MMR-mediated responses to 
DNA damage, which appear to be agent specific.  
Although highly unlikely given the reproducibility of the observed drug response 
phenotypes in multiple cell lines, and that cytotoxicity in response to IR and UV 
radiation was unaffected, it cannot be completely excluded that factors independent 
of DNA MMR are responsible for the findings of this study. For instance, the mutator 
phenotype conferred by MMR dysfunction could permit mutation in a gene or genes 
which could subsequently affect response to nucleoside analogues. This possibility 
applies particularly to MT-1 given its mechanism of generation. Indeed, modest ERK2 
activation in MT-1 cells relative to TK6 might be a consequence of the mutator 
phenotype of this cell line. Although considered isogenic, it should also be noted that 
the MMR knockdown lines themselves will have acquired a mutator phenotype, 
however by using them at a very early passage, the risk of acquiring additional 
mutations is minimised. The most efficient way of confirming these findings would be 
to use a strictly isogenic model in which MMR status can be altered without the need 
for cell passage, for example the Tet-Off system. 
Despite not investigating specific mechanisms responsible for the observed 
phenotypic response to nucleoside analogues, these findings have clear implications 
for the use of nucleoside analogues in the treatment of AML, especially in those 
subtypes which are associated with DNA MMR dysfunction, such as relapsed and t-
AML. This will be discussed in Chapter 8.  
NUCLEOSIDE ANALOGUE 
INCORPORATION
CHAIN 
TERMINATION 
REPLICATION FORK 
STALLING
S-PHASE CHECKPOINT 
ACTIVATION
CELL CYCLE 
PROGRESSION
CHAIN 
ELONGATION
LOW FIDELITY REPLICATION 
(EXTRAHELICAL BASES)
G2M CHECKPOINT 
ACTIVATION
REPAIR/REMOVAL
(BER?, NER?, EXO?, MMR?)
CELL CYCLE ARREST/
APOPTOSIS
DSB-MEDIATED REPAIR
(HRR?, NHEJ?)
MutSβ
MSH2MMR
MSH2
MutSβ
Figure 3.12. Possible roles for DNA MMR components in cellular response to
nucleoside analogues.
Incorporation of nucleoside analogues into replicating DNA primarily results in chain
termination, in turn resulting in replication fork stalling, activation of the S-phase
checkpoint and subsequent cell cycle arrest and cell death via apoptosis (bold text,
solid arrows). Other processes which could occur (as described in the text) are
indicated by plain text/dashed arrows. DNA MMR components are highlighted in red,
alongside steps in which they are speculated to be involved.
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3.3.1. Summary of Chapter 
In summary, the studies described in this chapter demonstrate: 
• Deficiency of the DNA MMR pathway via loss of MutSα activity confers 
cellular sensitivity to the nucleoside analogues Ara-C, fludarabine, 
cladribine and clofarabine. 
• A number of mechanisms could be responsible for this phenotype 
including S phase checkpoint abrogation or deregulation of downstream 
repair pathways at the stalled replication fork, such as HRR. 
• Loss of MSH3 protein does not significantly perturb the function of the 
MMR pathway but is able to confer tolerance/resistance to the cytotoxic 
effects of the nucleoside analogues Ara-C, fludarabine and clofarabine. 
• Incorporation of nucleoside analogues into DNA may result in lesions that 
can act as substrates for the MutSβ complex, which mediates their 
cytotoxicity. This could explain the tolerance to these agents observed in 
MSH3-deficient cells. 
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Chapter 4. Overexpression of MSH3 Confers Resistance to 
Nucleoside Analogues in vitro
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4.1. Introduction 
Loss of MMR-mediated DNA damage signalling, through absence of functional 
gene products, results in the characteristic methylation (and 6-TG) tolerance 
phenotype of MMR-defective cells in vitro (Karran, 2001). Investigations described 
previously (Chapter 3) have extended these findings and demonstrated that loss of 
MMR components can also mediate response to chemotherapeutic nucleoside 
analogues. In particular, loss of MSH3 (through gene knockdown), and hence the 
MutSβ complex, confers tolerance to the cytotoxic effects of these agents (see Figure 
3.9). 
MMR dysfunction can arise not only through lack of a functional gene product, 
but also as a result of imbalance in the relative amounts of MMR proteins due to gene 
amplification. The best example of this phenomenon is provided by the cell line HL-
60R, an MMR-dysfunctional subclone of the myeloid leukaemic cell line HL-60. Relative 
to parental HL-60 cells, HL-60R demonstrates gross over-production of MSH3 protein, 
resulting in sequestration of virtually all cellular MSH2 protein into the MutSβ complex 
(Drummond et al., 1997). Lack of MSH6 (and hence the MutSα complex) is postulated 
to be due to proteasome-mediated degradation of the protein in the absence of any 
free MSH2 with which to heterodimerise (Drummond et al., 1995; Drummond et al., 
1997). Consequently, HL-60R cells are unable to repair mismatches as determined by in 
vitro assay (Drummond et al., 1997; Marra et al., 1998), and are hypermutable in 
comparison to parental HL-60 cells (Drummond et al., 1997). 
The overproduction of MSH3 protein in HL-60R is a direct result of 
overexpression of the MSH3 gene, located on chromosome 5q14.1. Interestingly, the 
promoter region of the MSH3 gene is shared with another gene, dihydrofolate 
reductase (DHFR), transcribed in the opposite direction (Figure 4.1). The protein 
product of the DHFR gene is an essential metabolic enzyme which catalyses reduction 
of dihydrofolate to tetrahydrofolate, essential for de novo synthesis of purines and 
certain amino acids (Schnell et al., 2004). The action of DHFR can be blocked by 
treatment with the antifolate drug MTX, leading to inhibition of cell growth and 
proliferation (Schweitzer et al., 1990), however resistance can develop via a number of 
mechanisms, including DHFR gene amplification (Banerjee et al., 2002). The HL-60R 
subclone was generated by treatment of HL-60 cells with prolonged, escalating doses 
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of MTX (up to 1μM). This considerable selective pressure caused gross amplification of 
the DHFR gene (leading to MTX resistance), which was accompanied by co-
amplification of MSH3 (Fujii and Shimada, 1989). Subsequently, MTX-resistant HL-60R 
cells were demonstrated to be cross-resistant to the cytotoxic effects of methylating 
agents and 6-TG (Pepponi et al., 2001) by virtue of the effects of MSH3 protein 
overproduction on assembly of DNA MMR damage recognition complexes as described 
above.  
Whereas defective DNA MMR caused by protein loss (either through mutation or 
promoter hypermethylation) has been observed in t-AML (Horiike et al., 1999; Zhu et 
al., 1999; Casorelli et al., 2003), as well as other cancers, MSH3 amplification leading to 
protein overproduction (or indeed amplification of other MMR genes) has yet to be 
documented in vivo.   
4.1.1. Aims of Chapter 4 
Loss of key DNA MMR components through either lack of gene expression or 
imbalances in cellular amounts of protein components is able to confer characteristic 
tolerance to the cytotoxic effects of methylating agents and 6-TG as described. The 
overall objective of this chapter was to determine whether amplification of MSH3 gives 
rise to concomitant MutS complex imbalance and whether this affects in vitro 
response to chemotherapeutic nucleoside analogues.  
Specifically, the experimental aims were as follows: 
• Using cell lines in which MSH3 is overexpressed to varying degrees (HL-
60R, TK6 MTXR and PreB697 MTXR), determine the effect on key DNA 
MMR components (and MutS complex formation) at protein and gene 
expression levels. 
• Determine whether overproduction of MSH3 protein affects response to 
Ara-C, clofarabine, fludarabine and cladribine using cytotoxicity assays. 
Chr 5
5q14.1
MSH3 (222Kb + strand)
DHFR (29Kb
- strand)
shared promoter (~89bp)
Figure 4.1. Structural organisation of human DHFR and MSH3 loci.
The human MHS3 gene is divergently transcribed from a promoter region shared with
the DHFR gene on chromosome 5q14.1. The relative orientation of the two loci is
shown, as well as the approximate total lengths of the genes (not drawn to scale).
Numbers above the chromosome 5 ideogram indicate cytogenetic bands.
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4.2. Results 
4.2.1. Phenotypic Characterisation of MSH3-Overexpressing Cell Lines 
HL-60R is a subclone of the myeloid leukaemic cell line, HL-60. As described 
above, it was generated by treating parental HL-60 with increasing concentrations of 
MTX over a period of several weeks, resulting in a 200-fold increase in DHFR and 
concomitant MSH3 copy number (Fujii and Shimada, 1989).  
TK6 MTXR and PreB697 MTXR are both subclones of the lymphoblastoid cell lines, 
TK6* and Preb697, respectively, also generated by treatment of the parental cells with 
escalating doses of MTX (Matheson et al., 2007). The doses used were much lower 
than those used to generate HL-60R and resulted in approximately 7-fold and 3-fold 
amplification of DHFR and MSH3 in TK6 MTXR and PreB697 MTXR, respectively 
(Matheson et al., 2007). 
4.2.1.1. Expression Levels of MMR Proteins Determined by Western Immunoblotting 
The relative amounts of MSH3 protein, as well as the other mismatch recognition 
proteins, MSH2 and MSH6, were compared in parental cells and their MTX-resistant 
subclones via western immunoblotting (Figure 4.2A). The HL-60R cell line 
demonstrated significantly higher levels of MSH3 protein relative to parental HL-60 
cells. This was accompanied by a slight increase in the levels of MSH2 protein and 
complete loss of MSH6 protein, consistent with previous studies which have assessed 
the levels of DNA MMR protein components in this cell line (Drummond et al., 1997; 
Marra et al., 1998). TK6 MTXR and PreB697 MTXR both demonstrated modest over-
production of MSH3 protein relative to their respective parental cells, consistent with 
previous investigations (Matheson et al., 2007). There was no effect however, on the 
levels of MSH2 or MSH6 protein in either cell line. 
In addition to the damage recognition proteins, relative levels of MLH1 and 
PMS2, which form the MutLα complex, were also assessed in MTX-resistant sublines, 
with no difference observed for either protein relative to respective parental 
counterparts (Figure 4.2B).  
                                                     
* Note that due to the paired nature of the cell lines used, the parental TK6 cell line described in 
this chapter is from a different source to the TK6 line used in all other investigations (see Section 2.2). 
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Figure 4.2. MMR protein expression in methotrexate-resistant cell lines.
Western immunoblotting to determine protein expression of DNA MMR components
in HL-60R, TK6 MTXR and PreB697 MTXR, relative to their respective parental
counterparts as follows: A. MutS components (MSH2, MSH3 and MSH6). B. MutLα
components (MLH1 and PMS2). The MMR proficient HeLa cell line was included as a
positive control in each case. The MutS deficient LoVo cell line was included as a
negative control for MSH2, MSH3 and MSH6 proteins. β-actin was used as a loading
control for all blots. Each blot is representative of three independent experiments.
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4.2.1.2. Expression Levels of MMR Genes Determined by Quantitative RT-PCR 
To determine whether the observed relative changes in MMR protein levels 
stemmed from changes at the transcriptional level, relative expression of MSH2, MSH3 
and MSH6 was determined in parental and corresponding MTX-resistant sublines 
(Figure 4.3). Consistent with previous reports (Fujii and Shimada, 1989; Matheson et 
al., 2007), approximate 200-fold, 5-fold and 2.5-fold increased MSH3 expression was 
observed in HL-60R, TK6 MTXR and PreB697 MTXR respectively. There was no change 
however, in expression of MSH2 or MSH6 in any of the MTX-resistant cell lines relative 
to their respective parental counterparts. These findings demonstrate that loss of 
MSH6 protein in HL-60R cells is due to post-translational regulation, probably 
proteasome-mediated degradation, as previously suggested (Drummond et al., 1995; 
Drummond et al., 1997). 
Relative expression of the MLH1 and PMS2 genes was also unchanged in MTX-
resistant subclones relative to parental cell lines (Figure 4.3). 
4.2.1.3. Cytotoxicity in Response to MNU and 6-TG 
To determine the MMR status of the MTX-resistant cell lines, response to 
treatment with MNU and 6-TG, was assessed, given that tolerance to the cytotoxic 
effects of these agents is indicative of a defective DNA MMR pathway.  
Previous studies have shown that HL-60R is tolerant to treatment with these 
agents, relative to parental HL-60 cells (Pepponi et al., 2001), and this was confirmed in 
the present study (Figure 4.4A). Conversely, neither TK6 MTXR nor PreB697 MTXR 
displayed differential sensitivity to MNU or 6-TG compared to their respective parental 
cells (Figure 4.4B-C), suggesting that MutSα-mediated DNA damage signalling is 
apparently unaffected in these cell lines.  
These data suggest that cellular DNA MMR status is dependent on the severity of 
the specific MMR defect. Whereas gross over-expression of MSH3 results in non-
functional DNA damage signalling via loss of the MutSα complex, as shown in HL-60R 
(Drummond et al., 1997; Marra et al., 1998), modest MSH3 over-production as 
observed in TK6 MTXR and PreB697 MTXR is not sufficient to perturb DNA damage 
signalling function and affect sensitivity to MNU and 6-TG. 
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Figure 4.3. Relative expression of DNA MMR components in
methotrexate-resistant cell lines.
RT-PCR to determine changes in gene expression of the MutS (MSH2,
MSH3 and MSH6) and MutL (MLH1 and PMS2) components in HL-
60R (A), TK6 MTXR (B) and PreB697 MTXR (C) cells relative to their
respective parental cell lines. Expression of each gene was calculated
relative to the parental cell line with the expression of β-actin used
as endogenous control. Values represent fold change in expression
calculated from the mean and standard error of three independent
experiments.
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Figure 4.4. Cytotoxicity in response to MNU and 6-TG in MSH3-overexpressing cell
lines.
Cytotoxicity in response to MNU (left) and 6-TG (right) was compared in HL-60 (A),
TK6 (B), PreB697 (C) and their respective MSH3-overexpressing subclones. For HL-60
and PreB697, cytotoxicity was assessed via growth inhibition assay, with data
presented as the number of surviving cells from dosed cell suspensions as a
percentage of surviving cells from vehicle-only-treated cell suspensions. For TK6 and
TK6 MTXR, cytotoxicity was assessed via clonogenic assay. Data is presented as the
number of viable colonies from dosed cell suspensions as a percentage of the
number of viable colonies from vehicle-only-treated cell suspensions. In each case,
data represents the mean and standard error of three independent experiments.
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4.2.2. Cytotoxicity in MSH3-Overexpressing Cells Following Treatment with 
Nucleoside Analogues 
Cytotoxicity assays were performed to assess response of the MTX-resistant 
subclones, relative to their respective parental cell lines, following treatment with the 
nucleoside analogues, Ara-C, clofarabine, fludarabine and cladribine (Figure 4.5).  
HL-60R was tolerant to the cytotoxic effects of each of the nucleoside analogues 
relative to parental HL-60 cells (Figure 4.5A). TK6 MTXR and PreB697 MTXR however, 
were not differentially sensitive to any of these agents, relative to their respective 
parental lines (Figure 4.5B-C). 
Taken together, these data demonstrate that overexpression of MSH3 can confer 
resistance to treatment with therapeutic nucleoside analogues, but only when MSH3 
amplification is substantial.  
4.2.3. Cytotoxicity in MSH3-Overexpressing Cells Following Exposure to IR and UV 
Radiation 
In addition to investigating the effect of MSH3 overexpression on response to 
nucleoside analogues, cytotoxicity in response to IR exposure was also assessed in 
MTX-resistant/MSH3 amplified cell lines, given that certain DNA MMR defects have 
been reported to affect response to IR. Neither HL-60R, TK6 MTXR nor PreB697 MTXR 
demonstrated differential sensitivity to IR relative to normal parental cell lines (Figure 
4.6A), which is consistent with the other cell lines tested (Section 3.2.7) and would 
argue against a role for DNA MMR in the cytotoxic response to IR. As previously stated 
however, defects in responses such as checkpoint activation cannot be excluded. 
Cytotoxicity following exposure to UV radiation was also assessed in order to 
control for generic DNA repair defects (see Section 3.2.7). No difference in sensitivity 
to UV radiation was observed in any of the MTX-resistant cell lines relative to their 
respective parental counterparts (Figure 4.6B). 
0.1
1
10
100
0 20 40 60 80
Su
rv
iv
al
 F
ra
ct
io
n 
(%
)
Ara-C (nM)
HL-60
HL-60R
0.1
1
10
100
0 20 40 60 80
Su
rv
iv
al
 F
ra
ct
io
n 
(%
)
Clofarabine (μM)
HL-60
HL-60R
0.1
1
10
100
0 20 40 60 80
Su
rv
iv
al
 F
ra
ct
io
n 
(%
)
Ara-C (nM)
TK6
TK6 MTXr
0.01
0.1
1
10
100
0.0 0.2 0.4 0.6 0.8
Su
rv
iv
al
 F
ra
ct
io
n 
(%
)
Clofarabine (μM)
TK6
TK6 MTXr
0.1
1
10
100
0 1 2 3 4 5
Su
rv
iv
al
 F
ra
ct
io
n 
(%
)
Fludarabine (μM)
HL-60
HL-60R
0.01
0.1
1
10
100
0 50 100 150 200
Su
rv
iv
al
 F
ra
ct
io
n 
(%
)
Cladribine (nM)
HL-60
HL-60R
0.01
0.1
1
10
100
0 1 2 3 4 5
Su
rv
iv
al
 F
ra
ct
io
n 
(%
)
Fludarabine (μM)
TK6
TK6 MTXr
0.01
0.1
1
10
100
0 40 80 120 160
Su
rv
iv
al
 F
ra
ct
io
n 
(%
)
Cladribine (nM)
TK6
TK6 MTXr
A
B
Figure 4.5. Cytotoxicity in response to nucleoside analogues in MSH3-overexpressing cell lines (continued on next page).
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Figure 4.5. Cytotoxicity in response to nucleoside analogues in MSH3-overexpressing cell lines (continued from previous page).
Cytotoxicity in response to Ara-C (far left), clofarabine (left), fludarabine (right) and cladribine (far right) was compared in HL-60 (A), TK6 (B),
PreB697 (C) and their respective MSH3-overexpressing subclones. For HL-60 and PreB697, cytotxicity was assessed via growth inhibition assay, with
data presented as the number of surviving cells from dosed cell suspensions as a percentage of surviving cells from vehicle-only-treated cell
suspensions. For TK6 and TK6 MTXR, cytotoxicity was assessed via clonogenic assay. Data is presented as the number of viable colonies from dosed
cell suspensions as a percentage of the number of viable colonies from vehicle-only-treated cell suspensions. In each case, data represents the mean
and standard error of three independent experiments.
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Figure 4.6. Cytotoxicity following
exposure to IR and UV in MSH3-
overexpressing cell lines.
A. Cytotoxicity following IR exposure
was compared in HL-60 (left), TK6
(centre), PreB697 (right) and their
respective MSH3-overexpressing
subclones. For HL-60 and PreB697,
cytotoxicity was assessed via growth
inhibition assay, with data presented
as the number of surviving cells from
dosed cell suspensions as a
percentage of surviving cells from
vehicle-only-treated cell suspensions.
For TK6 and TK6 MTXR, cytotoxicity
was assessed via clonogenic assay.
Data is presented as the number of
viable colonies from dosed cell
suspensions as a percentage of the
number of viable colonies from
vehicle-only-treated cell suspensions.
B. Cytotoxicity following exposure to
UV radiation was compared in HL-60,
TK6, PreB697 and their respective
MSH3-overexpressing cell lines as
described above. In all cases, data
represents the mean and standard
error of three independent
experiments.
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4.3. Discussion 
Prolonged exposure to MTX can cause amplification of the DHFR gene and co-
amplification of MSH3 due to its close proximity (Fujii and Shimada, 1989). 
Investigations using the myeloid cell line, HL-60R, confirm the findings of others and 
demonstrate that gross MSH3 protein overexpression, due to MSH3 amplification, 
results in loss of MutSα and consequently tolerance to methylating agents and 6-TG. 
This study, in addition, has extended these findings and demonstrates that extensive 
MSH3 overproduction can also confer tolerance to the cytotoxic effects of the 
nucleoside analogues Ara-C, clofarabine, fludarabine and cladribine. 
The observation that HL-60R demonstrates tolerance to the cytotoxic effects of 
nucleoside analogues is unexpected given that MSH3 knockdown also confers 
tolerance to these agents (as demonstrated by TK6/HL-60 MSH3i; see Figure 3.9). As 
such, amplification of MHS3 is expected to confer sensitivity, hence it is unclear how 
two seemingly opposing defects can result in a similar phenotype. Previous studies 
have demonstrated that the efficiency of repair of extrahelical loop substrates, 
mediated by the MutSβ complex, is reduced to approximately 40% in HL-60R cells, 
relative to parental HL-60 cells (Drummond et al., 1997). Single base extrahelical loops 
are proposed to occur following replication of Ara-C lesions (see Figure 3.11). It is 
possible therefore that dysfunctional MutSβ in HL-60R leads to diminished detection of 
and tolerance to nucleoside analogue-induced lesions as previously suggested (Section 
3.3). How the cellular ratios of MMR damage recognition proteins influence the 
efficiency of DNA repair remains to be fully understood. It is also important to note 
that the observations herein may reflect the inability of one or more DNA MMR 
components to participate in a damage response specific to nucleoside analogues, 
which is independent from routine DNA repair. This finding therefore exemplifies the 
previous suggestion that the involvement of DNA MMR in the response to nucleoside 
analogues, as well as to other DNA damaging agents, is complex and likely is only one 
factor in an interwoven network of pathways.  
The observed tolerance to nucleoside analogues in MSH3-amplified HL-60R adds 
to a small body of evidence that overexpression of a single DNA MMR component 
results in a phenotype that is traditionally assigned to MMR deficiency. For example, 
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forced over-expression of MLH1 in S. cerevisiae leads to compromised MMR function 
and a mutator phenotype (Shcherbakova and Kunkel, 1999). Similarly, over-expression 
of PMS2 in murine cells confers tolerance to MNU, as well as an increase in both 
spontaneous and MNU-induced mutation frequency (Gibson et al., 2006). Mechanisms 
are unclear but may involve formation of either MLH1 or PMS2 homodimers that 
inhibit formation of the MutLα complex (MLH1 + PMS2) (Shcherbakova and Kunkel, 
1999; Gibson et al., 2006). It would be interesting to determine whether 
overexpression of MutLα components could also confer tolerance to nucleoside 
analogues, or whether this response is restricted to dysfunction of damage recognition 
complexes. 
It is possible that the observed Ara-C-resistance (as well as resistance to other 
nucleoside analogues) in HL-60R is in fact not due to defective DNA MMR, but rather 
due to a common resistance mechanism that is shared with MTX. Resistance to MTX in 
HL-60R is due primarily to gross overexpression of DHFR, the target for the inhibitory 
effects of the drug (Fujii and Shimada, 1989). The intracellular metabolism of Ara-C, as 
well as the purine nucleoside analogues, does not involve DHFR, hence it is improbable 
that this would confer cross-resistance to these agents. It is also possible that other 
uncharacterised resistance mechanisms are operating in HL-60R, affecting drug 
transport or metabolism for instance. Again however, it is unlikely that this would 
affect response to Ara-C given that these drugs do not appear to share any intracellular 
pathways. It is remotely possible that other factors common to the metabolism of 
these drugs have yet to be discovered. 
Additionally, because of the selection method used to generate HL-60R, this line 
and HL-60 cannot be classed as an isogenic cell line pair. Furthermore, relative to HL-
60, HL-60R is a hypermutable cell line (Drummond et al., 1997) and could readily 
acquire mutations anywhere in its genome. It is possible that this cell line is mutated in 
a gene (unrelated to DNA MMR) which could confer resistance to nucleoside 
analogues, although this is unlikely in the absence of any selective pressures. 
Nevertheless, a strictly isogenic system in which MMR protein levels can be up-
regulated without the need for cell division would be useful to confirm whether these 
observations are directly attributable to defective DNA MMR.  
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In contrast to HL-60R, cell lines demonstrating a significantly lower level of MSH3 
amplification (~ 5-fold in TK6 MTXR and ~ 2.5-fold in PreB697 MTXR) were found to be 
proficient in DNA MMR by virtue of unaffected protein stoichiometry. Furthermore, 
these cell lines were not differentially sensitive to the cytotoxic effects of Ara-C and 
other therapeutic nucleoside analogues. The implications of these observations are 
two-fold: firstly they demonstrate that, in the case of over-expression of MMR genes, 
the extent of perturbation of DNA MMR components is important in determining 
whether the function of the pathway is significantly affected. It should be noted 
however, that although not sufficient to confer tolerance to the cytotoxic effects of 
methylating agents or 6-TG (or the nucleoside analogues), it is unknown whether the 
anticipated modest effects on the ratio of MutSα to MutSβ could affect MMR 
efficiency. Secondly, given that these cell lines did not differ in response to Ara-C 
relative to their parental counterparts, despite demonstrating resistance to MTX 
(Matheson et al., 2007), further weight is added to the model that Ara-C resistance is 
due to dysfunction of DNA MMR and is independent of MTX resistance. 
Despite being unable to delineate mechanisms at this point, these findings have 
clinical implications, particularly regarding the combined chemotherapeutic use of 
MTX and nucleoside analogues (or other drugs which are less effective in MMR-
defective cells). Additionally, it has also been suggested that overexpression of DNA 
MMR components may represent a mechanism by which cells become genetically 
unstable, contributing not only to drug resistance, but also to carcinogenesis (Gibson 
et al., 2006). These factors will be discussed in Chapter 8. 
4.3.1. Summary of Chapter 
In summary, the investigations described in this chapter have shown that: 
• Although significant overproduction of MSH3 protein can cause MutSα 
deficiency through protein imbalance, modest increases in the cellular 
amount of MSH3 protein do not significantly perturb DNA MMR-
mediated damage signalling, as demonstrated by lack of tolerance to the 
cytotoxic effects of MNU and 6-TG (in TK6 MTXR and PreB697 MTXR). 
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• Gross overproduction of MSH3 in HL-60R confers tolerance to the 
nucleoside analogues Ara-C, clofarabine, fludarabine and cladribine, 
possibly by affecting MutSβ function. 
• Modest MSH3 over-production in TK6 MTXR and PreB697 MTXR does not 
result in differential nucleoside analogue sensitivity relative to parental 
cell lines. 
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Chapter 5. Development of in vitro Cellular Model Systems of 
Therapy-Related Acute Myeloid Leukaemia 
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5.1. Introduction 
Many agents routinely used in cancer chemotherapy, despite being highly 
cytotoxic to malignant cells, are carcinogenic, mutagenic and toxic to other non-
malignant tissues. This can give rise to one of the most significant side effects 
associated with successful cancer therapy, which is development of a therapy-related 
malignancy (defined as a second primary malignancy pathologically independent from 
the first primary cancer, and which arises as a consequence of chemotherapy). 
Therapy-related malignancy can occur following treatment with a diverse range of 
chemotherapeutic agents, most notably methylating agents, topoisomerase inhibitors 
and thiopurine anti-metabolites, and can occur at almost all sites in the body. 
Compared to therapy-induced solid cancers, the relative risk of developing t-AML is 
considered highest due to the inherent sensitivity of the bone marrow to the toxic and 
mutagenic effects of several chemotherapeutic agents (Allan and Travis, 2005). For this 
reason extensive research efforts have been directed towards delineating the genetic 
and molecular mechanisms associated with development of t-AML. 
Methylating agents such as procarbazine, dacarbazine and temozolomide are 
used to treat numerous cancers, including HL and NHL. High incidence of t-AML (as 
well as other secondary malignancies) in survivors of HL and NHL (Armitage et al., 
2003; Josting et al., 2003; Schonfeld et al., 2006) is indicative of a causal link between 
the use of methylating agents in chemotherapy and the development of t-AML. A high 
incidence of t-AML is also observed in organ transplant patients who received the 
thiopurine anti-metabolite azathioprine as an immunosuppressive agent (Offman et 
al., 2004) (see Section 1.4.4). Additionally, t-AML has been identified as a potential 
complication of thiopurine therapy for ALL (Karran 2008). These findings suggest a 
causative association between the use of thiopurine anti-metabolites and t-AML 
development.  
The aetiology of t-AML following methylating agent chemotherapy, and by 
extension t-AML following the use of thiopurines, is particularly well defined and likely 
follows a ‘genomic instability’ pathway, whereby a mutator phenotype predisposes 
target cells to accumulate mutations in multiple genes that will eventually lead to 
leukaemic transformation, as described in Section 1.4.1.1. Because of the well 
established interaction between methylating agents (and 6-TG) and DNA MMR 
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components, coupled with the observation of high levels of MSI indicative of defective 
MMR in t-AML patients (see Figure 1.9), loss of activity of this pathway is postulated to 
be the causative event giving rise to genomic instability in methylating agent-related t-
AML carcinogenesis (Allan and Travis, 2005).  
Loss of DNA MMR activity in vitro provides a mechanism by which cells can 
tolerate the cytotoxic effects of methylating agents (Karran, 2001). It follows therefore, 
that dysfunction of DNA MMR in vivo would provide a selective advantage allowing 
cells to circumvent methylating agent-induced cell death, although this has not been 
firmly established. It is possible that this could occur due to methylating agents 
themselves inducing abrogation of DNA MMR activity, resulting in a sub-clone of 
MMR-defective cells in an otherwise MMR-proficient population. It is not clear 
however, why this would be selectively advantageous to haematopoietic cells within 
the bone marrow, given that they are non-malignant at the time chemotherapy is 
administered for the primary malignancy. It has been suggested that MMR-proficient 
cells which express low levels of MMR components may be particularly susceptible to 
methylating agent-induced mutations (Claij and Te Riele, 2002). An alternative 
possibility is that an MMR-defective sub-clone may already exist in an early myeloid 
progenitor population within the bone marrow, and methylating agent chemotherapy 
promotes expansion of this clone due to the survival advantage afforded by MMR loss. 
Evidence in support of this has been demonstrated in murine models using 
temozolomide (Reese et al., 2003), as well as in vivo following cisplatin chemotherapy 
(Fink et al., 1997; Samimi et al., 2000), as outlined in Section 1.4.1.1. In both cases, the 
highly proliferative nature of the bone marrow would mean MMR-defective cells 
would be rapidly expanded.  
There is some limited evidence to suggest that patients treated with 
chemotherapeutic nucleoside analogues are also at risk of developing t-AML. In 
particular, a number of studies have reported cases of t-AML with abnormalities of 
chromosome 7 following fludarabine therapy for CLL (Coso et al., 1999; Morrison et al., 
2002; McLaughlin et al., 2005; Carney et al., 2010). Similarly, a recent small study has 
reported 5 cases of t-AML with abnormalities of chromosome 7 arising in patients who 
received Ara-C during treatment for de novo AML (Arana-Yi et al., 2008). Mechanisms 
by which nucleoside analogues could contribute to t-AML development have yet to be 
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investigated but could involve MMR defects, given the evidence suggesting DNA MMR 
status can mediate response to these agents (Chapters 3 and 4). 
Therapy-related malignancies, by virtue of their aetiology, are generally difficult 
to treat and do not respond favourably to routine chemotherapeutic regimes. This is 
particularly exemplified in the case of t-AML in which the CR rate is as low as 28% 
(Larson, 2007). A direct link between DNA MMR loss and chemoresistance has yet to 
be firmly identified in t-AML, although the in vitro studies outlined in this work 
(Chapters 3 & 4) support a role for MMR-dysfunction in resistance to Ara-C and other 
nucleoside analogues routinely used in AML treatment. 
5.1.1. Aims of Chapter 5 
The purpose of these investigations was to determine whether treatment of 
myeloid cells with either a methylating agent, 6-TG or Ara-C in vitro could result in 
generation of DNA MMR-defective sub-clones, effectively re-capitulating early events 
in the postulated development of t-AML. Furthermore, to investigate whether drug-
resistant sub-clones demonstrate cross-resistance to chemotherapeutic agents 
routinely used in treatment of t-AML, hence providing a possible explanation for the 
typically chemoresistant nature of the disease. 
Specifically, the experimental aims were as follows: 
• Treat myeloid cell lines with escalating doses of MNU, 6-TG or Ara-C over 
an extended time period to determine if stable drug-resistant sub-
cultures could be generated. 
• Determine DNA MMR status of resulting drug-resistant sub-cultures via 
assessment of cytotoxicity in response to MNU and 6-TG, and via western 
immunoblotting for expression of DNA MMR proteins. 
• Assess cytotoxicity of drug-resistant sub-cultures in response to 
treatment with therapeutic nucleoside analogues (Ara-C, clofarabine and 
fludarabine). 
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5.2. Results 
5.2.1. Cell Lines 
The myeloid cell lines HL-60, EoL-1 and KG-1 were selected for use in these 
investigations because they are widely used, well characterised AML cell lines and 
most likely to represent the postulated in vivo target cell population. In addition, the 
lymphoblastoid cell line TK6 was selected as it had previously been used to generate 
drug-resistant sub-clones via escalating drug dosage (Matheson et al., 2007). 
5.2.2. Characterisation of Cell Lines Treated with MNU  
HL-60, EoL-1, KG-1 and TK6 were each treated with escalating doses of MNU as 
described in Section 2.5. For three of these cell lines (EoL-1, KG-1 and TK6) this 
resulted in establishment of cell cultures capable of survival in MNU concentrations 
10-fold, 20-fold and 50-fold greater than the initial MNU dose (cytotoxic to 70-80% of 
parental cells), respectively. These were termed EoL-1 MNUR, KG-1 MNUR and TK6 
MNUR. 
For HL-60, cells recovered from treatment with an MNU dose 10-fold greater 
than the initial dose (termed HL-60 MNUR). However treatment with higher doses 
consistently resulted in death of all cells. Assessment of MNU resistance in HL-60 
MNUR, relative to parental HL-60 cells, demonstrated no acquired MNU-resistance 
(data not shown), hence this sub-culture was excluded from further investigations. 
5.2.2.1. Confirmation of Stable MNU Resistance in TK6, KG-1 and EoL-1 
Cytotoxicity assays following passage in drug-free media demonstrated that EoL-
1 MNUR, KG-1 MNUR and TK6 MNUR retained resistance to MNU-induced cytotoxicity 
relative to their parental counterparts, indicating that the mechanisms of resistance 
were stable (Figure 5.1) and that cells did not require continuous exposure to MNU. 
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Figure 5.1. Stable acquired resistance to MNU in subcultures derived following
escalating MNU exposure.
Cytotoxicity assays were performed to confirm resistance to MNU in TK6 MNUR (A),
KG-1 MNUR (B) and EoL-1 MNUR (C) following serial passage in drug-free media. For
TK6 and its MNU-resistant subclone, cytotoxicity was compared via clonogenic assay.
Data is presented as the number of viable colonies from exposed cell suspensions as
a percentage of the number of viable colonies from unexposed control cell
suspensions. For KG-1, EoL-1 and their respective MNU-resistant subclones,
cytotoxicity was compared via growth inhibition assay. Data are presented as the
number of surviving cells from exposed cell suspensions as a percentage of surviving
cells from unexposed control cell suspensions. In all cases, data represents the mean
and standard error of three independent experiments.
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5.2.2.2. Cytotoxicity in MNU-Resistant Cell Lines Following Treatment with 6-TG 
To determine whether the observed MNU-resistance in the treated sub-cultures 
could be the result of a defect in DNA MMR, cellular response to 6-TG was assessed, 
given that cross-resistance to the cytotoxic effects of this agent is characteristic of 
MMR-defective cells (Aquilina et al., 1989; Aquilina et al., 1990; Hawn et al., 1995; Shin 
et al., 1998; Humbert et al., 1999). For TK6 MNUR (Figure 5.2A) and EoL-1 MNUR (Figure 
5.2C), no differential sensitivity to 6-TG was observed relative to respective parental 
cell lines. Unexpectedly, and inconsistent with defective DNA MMR, an increase in 
sensitivity to the cytotoxic effects of 6-TG was observed in KG-1 MNUR relative to 
parental KG-1 cells (Figure 5.2B). 
5.2.2.3. Expression Levels of MMR Proteins Determined by Western Immunoblotting 
Lack of cross-resistance to 6-TG suggests that the mechanism of MNU resistance 
does not involve significant dysfunction of the DNA MMR pathway in either KG-1 
MNUR, EoL-1 MNUR or TK6 MNUR. Nevertheless, western immunoblotting was 
performed to investigate expression of MutS components (MSH2, MSH3 and MSH6), 
MutLα components (MLH1 and PMS2) and MGMT in MNU-resistant cells and their 
normal parental counterparts (Figure 5.3). For TK6 MNUR, levels of MSH2, MSH3, 
MSH6, MLH1 and PMS2 were unaffected relative to parental TK6 cells, consistent with 
retention of functional DNA MMR. The western immunoblot for MGMT however, 
revealed that re-expression of the protein had occurred in TK6 MNUR (Figure 5.3). 
MGMT acts upstream of DNA MMR to remove MNU-induced methyl groups from DNA 
prior to replication. Re-expression of MGMT has previously been reported to be 
associated with acquired resistance to methylating agents (Hampson et al., 1997), 
therefore it is probable that this is the mechanism responsible for the MNU-resistance 
observed in this cell line. 
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Figure 5.2. Cytotoxicity following treatment with 6-TG in MNU-resistant cell lines.
Cytotoxicity assays were performed to assess resistance to 6-TG in TK6 MNUR (A), KG-
1 MNUR (B) and EoL-1 MNUR (C) relative to their respective parental cell lines. For
TK6 and its MNU-resistant subclone, cytotoxicity was compared via clonogenic assay.
Data is presented as the number of viable colonies from exposed cell suspensions as
a percentage of the number of viable colonies from unexposed control cell
suspensions. For KG-1, EoL-1 and their respective MNU-resistant subclones,
cytotoxicity was compared via growth inhibition assay. Data are presented as the
number of surviving cells from exposed cell suspensions as a percentage of surviving
cells from unexposed control cell suspensions. In all cases, data represents the mean
and standard error of three independent experiments.
174
Figure 5.3. MMR protein expression in MNU-resistant cell lines.
Western immunoblotting was performed to determine protein expression of DNA
MMR components (MSH2, MSH3, MSH6, MLH1, PMS2 and MGMT) in the MNU-
resistant cell lines TK6 MNUR, KG-1 MNUR and EoL-1 MNUR, relative to their
respective parental cell lines. The MMR proficient HeLa cell line was included as a
positive control. β-actin was used as a loading control. Each blot is representative of
three independent experiments.
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For KG-1 MNUR, an increase in the amount of MSH6 protein of approximately 
30% was observed, accompanied by an approximate 60% reduction in the amount of 
MSH3, whereas levels of MSH2, MLH1 and PMS2 were unchanged (Figure 5.3). It could 
be postulated that increased production of MSH6 protein results in sequestering of 
more MSH2 into the MutSα complex, leaving a proportion of partnerless MSH3 protein 
which is subsequently degraded. An increase in the activity of MutSα however, would 
be expected to confer increased sensitivity to treatment with methylating agents by 
virtue of an increase in cellular capacity for detection of mispairs. It is therefore 
unlikely that these observations account for the MNU resistance demonstrated by KG-
1 MNUR, although they could account for the observed increase in sensitivity to 6-TG. 
For EoL-1 MNUR, a slight reduction in MSH6 (approximately 10%) was evident, 
although this did not appear to affect MSH2 or MSH3 expression (Figure 5.3). Nor was 
expression of MLH1, PMS2 or MGMT affected relative to parental EoL-1 cells. It is 
unclear whether a reduction in MSH6 protein of this extent could be responsible for 
the MNU resistance observed, however this is unlikely given that cross-resistance to 6-
TG would also be observed, and it was not.  
5.2.2.4. Assessment of Thiopurine Methyltransferase Status in KG-1 MNUR via Western 
Immunoblotting 
Thiopurine methyltransferase (TPMT) mediates intracellular 6-TG concentration 
by methylating 6-TG and its derivative, 6-TG monophosphate, resulting in inactive 
metabolites (see Figure 1.3). Intracellular levels of TPMT vary between individuals due 
to constitutional genetic polymorphisms that affect gene expression. TPMT activity is 
correlated with sensitivity to thiopurine drugs in vivo (Coulthard and Hogarth, 2005), 
and in vitro studies have demonstrated that lower levels of TPMT are associated with 
increased sensitivity to 6-TG (Coulthard et al., 2002). To determine whether reduction 
in TPMT activity could provide an explanation for the 6-TG hypersensitivity observed in 
KG-1 MNUR, western immunoblotting was performed in KG-1 MNUR and parental KG-1 
cells to assess levels of TPMT protein. Both KG-1 and its MNU-resistant subclone, KG-1 
MNUR were found to express undetectable levels of TPMT protein (Figure 5.4), hence 
excluding reduction in activity as responsible for 6-TG hypersensitivity in KG-1 MNUR, 
relative to parental KG-1 cells. 
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Figure 5.4. TPMT protein expression in KG-1 and KG-1 MNUR.
Western immunoblotting to determine expression of TPMT protein in KG-1 and its
MNU-resistant subclone KG-1 MNUR and EoL-1 MNUR. Jurkat cell lysate was included
as a positive control. β-actin was used as a loading control. The blot is representative
of three independent experiments.
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5.2.2.5. Cytotoxicity in MNU-Resistant Cell Lines Following Treatment with Cytarabine 
Although it did not appear that MMR-mediated DNA damage signalling was 
affected in the MNU-resistant subclones, cytotoxicity in response to Ara-C treatment 
was assessed, given that relative proportions of certain MMR components was 
perturbed, as evidenced by western immunoblotting (Figure 5.3). For TK6 MNUR 
(Figure 5.5A) and EoL-1 MNUR (Figure 5.5C), there was no difference in response to 
Ara-C relative to parental cell lines. However, KG-1 MNUR, which has relative 
overexpression of MSH6 and underexpression of MSH3 (Figure 5.3), was resistant to 
cytotoxicity induced by Ara-C relative to parental KG-1 cells (Figure 5.5B). This is 
consistent with the studies using MMR knockdown cell lines in which MSH3 reduction 
resulted in resistance to Ara-C (see Figure 3.9), although other mechanisms of action 
cannot be excluded. 
5.2.2.6. Cytotoxicity in KG-1 MNUR Following Treatment with Clofarabine and 
Fludarabine 
Given that reduction of MSH3 protein in isogenic MMR knockdown cell lines 
conferred resistance to other therapeutic nucleoside analogues, cytotoxicity in 
response to clofarabine and fludarabine was also assessed in KG-1 MNUR. The MNU-
resistant subclone demonstrated increased resistance to the cytotoxic effects of both 
nucleoside analogues relative to the parental cell line (Figure 5.6). These data are 
therefore consistent with findings from isogenic MMR knockdown cell lines, and 
provide further evidence that reduction in MSH3 protein confers resistance to 
nucleoside analogue-induced cytotoxicity. 
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Figure 5.5. Cytotoxicity following treatment with Ara-C in MNU-resistant cell lines.
Cytotoxicity assays were performed to assess resistance to Ara-C in TK6 MNUR (A),
KG-1 MNUR (B) and EoL-1 MNUR (C) relative to their respective parental cell lines. For
TK6 and its MNU-resistant subclone, cytotoxicity was compared via clonogenic assay.
Data is presented as the number of viable colonies from exposed cell suspensions as
a percentage of the number of viable colonies from unexposed control cell
suspensions. For KG-1, EoL-1 and their respective MNU-resistant subclones,
cytotoxicity was compared via growth inhibition assay. Data are presented as the
number of surviving cells from exposed cell suspensions as a percentage of surviving
cells from unexposed control cell suspensions. In all cases, data represents the mean
and standard error of three independent experiments.
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Figure 5.6. Cytotoxicity in KG-1 MNUR following treatment with clofarabine and
fludarabine.
Growth inhibition assays to assess resistance to clofarabine (A), and fludarabine (B) in
KG-1 MNUR, relative to KG-1. Data are presented as the number of surviving cells
from exposed cell suspensions as a percentage of surviving cells from unexposed
control cell suspensions. Data represents the mean and standard error of three
independent experiments.
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5.2.3. Characterisation of Cell Lines Treated with 6-TG 
HL-60, EoL-1, KG-1 and TK6 were treated with escalating doses of 6-TG as 
described in Section 2.5. For both TK6 and HL-60, this resulted in establishment of cell 
cultures (termed TK6 6-TGR and HL-60 6-TGR) that retained viability in 6-TG 
concentrations 40-fold greater than the initial 6-TG dose. 
For EoL-1 and KG-1, cells recovered slowly from a 6-TG concentration which was 
cytotoxic to 70-80% of cells (0.1μM in both cases), however subsequent increases in 
dosage resulted in death of all cells and it was not possible to establish 6-TG-resistant 
sub-clones. 
5.2.3.1. Confirmation of 6-TG Resistance in HL-60 and TK6 
TK6 6-TGR and HL-60 6-TGR retained resistance to 6-TG-induced cytotoxicity 
relative to their parental counterparts following passage in drug-free media (Figure 
5.7). Furthermore, whereas the maximum dose of 6-TG these cells were exposed to 
during dose escalation was 20μM (see Table 2.2), a dose of 50μM 6-TG induced cell 
death in less than 50% of cells in both cases (Figure 5.7), demonstrating acquisition of a 
very high level of stable 6-TG resistance. 
5.2.3.2. Cytotoxicity in 6-TG-Resistant Cell Lines Following Treatment with MNU 
To determine if the mechanisms responsible for 6-TG resistance in TK6 6-TGR and 
HL-60 6-TGR could involve DNA MMR dysfunction, response of the cell lines to 
treatment with MNU was assessed via cytotoxicity assay. Neither TK6 6-TGR nor HL-60 
6-TGR demonstrated differential sensitivity to the cytotoxic effects of MNU relative to 
their respective parental counterparts (Figure 5.8), suggesting function of the DNA 
MMR pathway is unperturbed in these 6-TG-resistant subclones. 
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Figure 5.7. Stable acquired resistance to 6-TG following prolonged 6-TG exposure.
Cytotoxicity assays to confirm resistance to 6-TG in TK6 6-TGR (A) and HL-60 6-TGR (B)
following serial passage in drug-free media. For TK6 and its 6-TG-resistant subclone,
cytotoxicity was compared via clonogenic assay. Data is presented as the number of
viable colonies from exposed cell suspensions as a percentage of the number of
viable colonies from unexposed control cell suspensions. For HL-60 and its 6-TG-
resistant subclones, cytotoxicity was compared via growth inhibition assay. Data are
presented as the number of surviving cells from exposed cell suspensions as a
percentage of surviving cells from unexposed control cell suspensions. In all cases,
data represents the mean and standard error of three independent experiments.
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Figure 5.8. Cytotoxicity following treatment with MNU in 6-TG-resistant cell lines.
Cytotoxicity assays to assess resistance to MNU in TK6 6-TGR (A) and HL-60 6-TGR (B)
relative to their respective parental cell lines. For TK6 and its 6-TG-resistant subclone,
cytotoxicity was compared via clonogenic assay. Data is presented as the number of
viable colonies from exposed cell suspensions as a percentage of the number of
viable colonies from unexposed control cell suspensions. For HL-60 and its 6-TG-
resistant subclone, cytotoxicity was compared via growth inhibition assay. Data are
presented as the number of surviving cells from exposed cell suspensions as a
percentage of surviving cells from unexposed control cell suspensions. In each case,
data represents the mean and standard error of three independent experiments.
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5.2.3.3. Expression Levels of MMR Proteins Determined by Western Immunoblotting 
Western immunoblotting was performed to assess levels of DNA MMR proteins 
in TK6 6-TGR and HL-60 6-TGR, as described above. Neither cell line demonstrated any 
difference in the levels of DNA MMR components compared to their respective 
parental counterparts (Figure 5.9), confirming that escalating 6-TG dosage has had no 
apparent effect on the DNA MMR pathway.   
5.2.3.4. Assessment of HPRT Status in 6-TG-Resistant Cell Lines 
Loss of function of HPRT (an enzyme involved in intracellular metabolism of 6-TG; 
see Figure 1.3) through gene mutation represents one well established mechanism by 
which cells can acquire resistance to 6-TG, due to inability to form active thio-dGTP 
DNA precursors (van Diggelen et al., 1979). In order to determine whether HPRT 
mutation could be responsible for the high level of 6-TG resistance demonstrated by 
TK6 6-TGR and HL-60 6-TGR, HPRT mutational status was assessed in these sub-
cultures, as described in Section 2.11.  
Genomic multiplex PCR amplification of the HPRT locus revealed a deletion of 
exon 1 in HL-60 6-TGR and a wild type PCR profile for parental HL-60 cells (Figure 5.10). 
For TK6 6-TGR (and parental TK6 cells), a wild type PCR profile was also observed 
(Figure 5.10). Sequencing of HPRT cDNA amplified from TK6 6-TGR revealed a G:T 
transversion disrupting the start codon of the HPRT coding region (Figure 5.11). Both 
of these mutations are predicted to result in lack of HPRT protein expression, hence 
demonstrating the mechanism likely responsible for the high level of 6-TG resistance 
observed in these sub-cultures. 
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Figure 5.9. MMR protein expression in 6-TG-resistant cell lines.
Western immunoblotting to determine protein expression of DNA MMR components
(MSH2, MSH3, MSH6, MLH1 and PMS2) in the 6-TG-resistant cell lines TK6 6-TGR and
HL-60 6-TGR, relative to their respective parental cell lines. The MMR proficient HeLa
cell line was included as a positive control. β-actin was used as a loading control.
Each blot is representative of three independent experiments.
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Figure 5.10. Multiplex amplification of the HPRT locus in 6-TG-resistant cell lines.
All 9 exons of the human HPRT locus were amplified using 8 primer pairs in 2 multiplex PCR reactions. Mix 1 contains primers for exons 1, 3, 4, 7/8
(amplified on a single fragment due to close proximity of exons) and 9. Mix 2 contains primers for exons 2, 5 and 6. For each cell line, the results of
the 2 PCR reactions are shown side by side. TK6, TK6 6-TGR and HL-60 show the normal pattern of 8 bands. HL-60 6-TGR demonstrates loss of the
band corresponding to exon 1. The exons represented by each band, and the size of the amplicons are shown to the right of the gel. A 100 bp
marker ladder is shown to the left of the gel. The gel shown is a 1.5% agarose gel loaded with 15µl of the products from each multiplex PCR
reaction.
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Figure 5.11. Sequencing of the HPRT coding region in TK6 6-TGR.
Sequencing of cDNA from TK6 (upper trace) and its 6-TG-resistant subclone, TK6 6-
TGR (lower trace) revealed a G:T transversion at position 3 of the HPRT coding region
(highlighted in yellow). The entire HPRT coding region was sequenced for each cell
line, however only the portion of the positive strand (forward read) containing the
mutation is shown. The arrow above the traces shows the origin and direction of the
coding region, bases are numbered from the origin.
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5.2.4. Characterisation of Cell Lines Treated with Ara-C  
HL-60, EoL-1, KG-1 and TK6 were each treated with escalating doses of Ara-C as 
described in Section 2.5. For both TK6 and HL-60, this resulted in establishment of cell 
cultures that retained viability in Ara-C concentrations 50-fold and 100-fold greater 
than the initial Ara-C dose, respectively (termed TK6 Ara-CR and HL-60 Ara-CR). 
KG-1 cells recovered from exposure to Ara-C concentrations up to 5-fold greater 
than the initial dose (termed KG-1 Ara-CR), however treatment with higher doses 
consistently resulted in death of all cells. Assessment of resistance to Ara-C in KG-1 
Ara-CR, relative to parental KG-1 cells, demonstrated no acquired Ara-C-resistance 
(data not shown) and this sub-culture was excluded from further investigations. 
EoL-1 cells recovered from an initial dose of Ara-C (0.02μM) but consistently 
failed to recover from any further doses and were excluded from further investigation. 
5.2.4.1. Confirmation of Ara-C Resistance in HL-60 and TK6 
TK6 Ara-CR and HL-60 Ara-CR retained resistance to Ara-C relative to parental TK6 
and HL-60 cells following serial passage in drug-free media, indicating stable Ara-C 
resistance in these sub-cultures (Figure 5.12). 
5.2.4.2. Cytotoxicity in Ara-C-Resistant Cell Lines Following Treatment with MNU and 6-
TG 
Cytotoxicity in response to MNU and 6-TG was investigated in Ara-C-resistant 
sub-cultures and their respective parental counterparts. Sensitivity of TK6 Ara-CR 
(Figure 5.13A) and HL-60 Ara-CR (Figure 5.13B) to MNU or 6-TG was not significantly 
different to parental cells, suggesting that MMR function remains unaffected in these 
cell lines. 
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Figure 5.12. Stable acquired resistance to Ara-C following prolonged Ara-C
exposure.
Cytotoxicity assays were to confirm resistance to Ara-C in TK6 Ara-CR (A) and HL-60
Ara-CR (B) following serial passage in drug-free media. For TK6 and its Ara-C-resistant
subclone, cytotoxicity was compared via clonogenic assay. Data is presented as the
number of viable colonies from exposed cell suspensions as a percentage of the
number of viable colonies from unexposed control cell suspensions. For HL-60 and its
Ara-C-resistant subclones, cytotoxicity was compared via growth inhibition assay.
Data are presented as the number of surviving cells from exposed cell suspensions as
a percentage of surviving cells from unexposed control cell suspensions. In all cases,
data represents the mean and standard error of three independent experiments.
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Figure 5.13. Cytotoxicity following treatment with MNU and 6-TG in Ara-C-resistant
cell lines.
Cytotoxicity assays to assess response to MNU (left) and 6-TG (right) in TK6 Ara-CR (A)
and HL-60 Ara-CR (B) relative to their respective parental cell lines. For TK6 and its
Ara-C-resistant subclone, cytotoxicity was compared via clonogenic assay. Data is
presented as the number of viable colonies from exposed cell suspensions as a
percentage of the number of viable colonies from unexposed control cell
suspensions. For HL-60 and its Ara-C-resistant subclone, cytotoxicity was compared
via growth inhibition assay. Data are presented as the number of surviving cells from
exposed cell suspensions as a percentage of surviving cells from unexposed control
cell suspensions. In all cases, data represent the mean and standard error of three
independent experiments.
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5.2.4.3. Expression Levels of MMR Proteins Determined by Western Immunoblotting 
Western immunoblotting of DNA MMR proteins in TK6 Ara-CR and HL-60 Ara-CR 
demonstrated no changes in any of the proteins examined (Figure 5.14). Taken 
together with data demonstrating no differential sensitivity to either MNU or 6-TG in 
the Ara-C-resistant sub-cultures, there is no evidence that prolonged exposure to Ara-C 
induces defects in DNA MMR which could potentially contribute to the development of 
t-AML. 
5.2.4.4. Cytotoxicity in Ara-C-Resistant Cell Lines Following Treatment with Clofarabine 
and Fludarabine 
TK6 Ara-CR, HL-60 Ara-CR and their respective parental counterparts were treated 
with clofarabine and fludarabine in order to determine whether resistance to Ara-C-
induced cytotoxicity also extended to these agents. In the case of both Ara-C-resistant 
sub-cultures, no difference in cytotoxicity was observed following treatment with 
either agent, relative to normal parental cultures (Figure 5.15). Therefore, although the 
mechanism of Ara-C-resistance is undetermined in these sub-cultures, it does appear 
to be relatively specific to this analogue and it does not confer cross-resistance to 
other nucleoside analogues. 
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Figure 5.14. MMR protein expression in Ara-C-resistant cell lines.
Western immunoblotting to determine protein expression of DNA MMR components
(MSH2, MSH3, MSH6, MLH1 and PMS2) in the Ara-C-resistant cell lines TK6 Ara-CR
and HL-60 Ara-CR, relative to their respective parental cell lines. The MMR proficient
HeLa cell line was included as a positive control. β-actin was used as a loading
control. Each blot is representative of three independent experiments.
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Figure 5.15. Cytotoxicity following treatment with clofarabine and fludarabine in
Ara-C-resistant cell lines.
Cytotoxicity assays to assess response to clofarabine (left) and fludarabine (right) in
TK6 Ara-CR (A) and HL-60 Ara-CR (B) relative to their respective parental cell lines. For
TK6 and its Ara-C-resistant subclone, cytotoxicity was compared via clonogenic assay.
Data is presented as the number of viable colonies from exposed cell suspensions as
a percentage of the number of viable colonies from unexposed control cell
suspensions. For HL-60 and its Ara-C-resistant subclone, cytotoxicity was compared
via growth inhibition assay. Data are presented as the number of surviving cells from
exposed cell suspensions as a percentage of surviving cells from unexposed control
cell suspensions. In all cases, data represent the mean and standard error of three
independent experiments.
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5.3. Discussion 
The major focus of these investigations was to determine, using cell line models, 
whether prolonged exposure to a methylating agent, 6-TG or Ara-C could induce or 
select for cells defective in DNA MMR, and whether such defects affect cellular 
response to nucleoside analogues used routinely to treat AML.  
Using escalating doses of the methylating agent, MNU, three resistant subclones 
were generated (TK6 MNUR, KG-1 MNUR and EoL-1 MNUR). In TK6 MNUR, western 
immunoblotting demonstrated re-expression of MGMT which, in the absence of any 
apparent effects on DNA MMR components, represents the likely mechanism of MNU 
resistance. Using a similar experimental approach in which MGMT-deficient colorectal 
carcinoma cell lines were treated with MNU, Hampson and colleagues demonstrated 
that 3 out of 7 MNU-resistant sub-clones had re-expression of MGMT (Hampson et al., 
1997). Similarly, a single high dose of the methylating agent MNNG can also induce 
expression of MGMT in previously-deficient rat hepatoma cells (Fritz et al., 1991). The 
parental TK6 cells described in the current study exhibit silencing of MGMT through 
hypermethylation of CpG islands within the promoter region (Danam et al., 2005), and 
it seems probable that reactivation of the silenced gene due to demethylation is 
responsible for acquired MNU resistance. The mechanism by which this occurs is 
unknown but it could involve down-regulation of a DNA methyltransferase responsible 
for maintaining promoter methylation. In vivo, a correlation has been identified 
between extent of MGMT promoter methylation and response to temozolomide in 
glioma patients (Hegi et al., 2005). Patients with increased MGMT activity, due to a 
reduction in promoter methylation respond less well to temozolomide, leading to the 
suggestion that MGMT up-regulation could represent a mechanism associated with 
chemoresistance in cancers treated with methylating agents (Hegi et al., 2008). A study 
using human melanoma cells has suggested that increased expression of MGMT might 
also be associated with an increase in resistance to 6-TG (Gefen et al., 2010). In the 
current study however, re-expression of MGMT in TK6 MNUR resulted in resistance to 
MNU but not in cross-resistance to 6-TG, arguing against a role for MGMT in 6-TG 
resistance. Similarly, cross-resistance to Ara-C in TK6 MNUR was not observed, 
suggesting that if treatment-induced effects on MGMT expression were to occur in t-
AML, they likely would not impact therapeutic response.  
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In both EoL-1 MNUR and KG-1 MNUR, western immunoblotting revealed changes 
in the levels of DNA MMR proteins relative to respective parental counterparts. 
Despite this, neither of these MNU-resistant subclones demonstrated cross-resistance 
to 6-TG, suggesting that the function of the DNA MMR pathway (or at least of MutSα) 
was not significantly perturbed. A modest reduction (approximately 10%) in MSH6 
expression was observed in EoL-1 MNUR as a sole abnormality. Although reduction in 
MSH6 activity has previously been associated with MNU resistance (Hampson et al., 
1997), it is unlikely to be the mechanism responsible for MNU resistance in EoL-1 
MNUR, given that other DNA MMR components were unaffected and cross-resistance 
to 6-TG was not observed. It is possible that increased repair of MNU-induced lesions 
by a mechanism independent of MGMT could also account for the observed MNU 
resistance in EoL-1 MNUR, however this remains undetermined. Whatever the 
mechanism of MNU resistance may be, it did not confer cross-resistance to the 
nucleoside analogue, Ara-C. 
The mechanism of MNU resistance also remains undetermined in KG-1 MNUR. 
Western immunoblotting revealed significant over-expression of MSH6, a reduction in 
MSH3 expression, but no change in MSH2 relative to parental KG-1 cells. Based on the 
partnerless protein instability theory (Drummond et al., 1995; Drummond et al., 1997), 
over-production of MSH6 would result in sequestration of the majority of cellular 
MSH2 into the MutSα complex, leaving partnerless MSH3 subject to degradation. An 
increase in cellular levels of MutSα activity is expected to confer increased sensitivity 
to the cytotoxic effects of methylating agents and 6-TG, as has previously been 
demonstrated in the case of methylating agents (Dosch et al., 1998). Consistent with 
this model, KG-1 MNUR cells were hypersensitive to 6-TG relative to the parental KG-1 
cell line, suggesting an increase in MutSα-mediated detection of 6-TG-induced DNA 
damage. It is possible therefore, that MutSα-mediated recognition of O6-meG lesions is 
also elevated in KG-1 MNUR. If true however, the predicted increase in sensitivity to 
MNU is clearly masked by a different mechanism by which the cells have acquired 
resistance to MNU. Repair of a number of other cytotoxic MNU-induced methylated 
lesions, for instance methylation of the N3 atom of adenine, is mediated primarily by 
components of the BER pathway (Plosky et al., 2002). It is possible therefore that an 
increase in cellular capacity for BER may account for the observed MNU resistance in 
KG-1 MNUR. Indeed this model could equally apply to EoL-1 MNUR discussed above. 
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KG-1 MNUR demonstrated cross-resistance to the nucleoside analogues Ara-C, 
clofarabine and fludarabine relative to parental KG-1 cells. It is probable that this is 
due to reduction in cellular MSH3, and hence the MutSβ complex, as a consequence of 
increased MutSα activity. This model is consistent with the findings in MT-1 and 
isogenic MMR knockdown cell lines (described in Chapter 3), and adds weight to the 
suggestion that MutSβ is involved in mediating cellular response to nucleoside 
analogues. Furthermore, these data demonstrate that resistance to nucleoside 
analogues can be induced in myeloid cells in vitro by exposure to MNU and could 
confer chemoresistance in MMR-defective t-AML. 
Exposure of cells in vitro to escalating doses of 6-TG can induce 6-TG resistance 
by virtue of loss of DNA MMR function (Offman et al., 2004). Defects observed were 
limited to loss of MLH1, and hence MutLα activity, although not all drug resistant 
clones were characterised (Offman et al., 2004). In the current study, two sub-clones 
with a very high level of 6-TG resistance were generated (TK6 6-TGR and HL-60 6-TGR), 
however neither developed an apparent defect in DNA MMR as evidenced by western 
immunoblotting and lack of cross-resistance to MNU. Rather, both sub-clones were 
deficient in HPRT, a well characterised 6-TG resistance mechanism (which is exploited 
in mutation assays (see Chapter 6)). A possible explanation for the failure to generate 
MMR-defective sub-clones, aside from small study size, could be due to the 
concentration of 6-TG used. Offman and colleagues used a maximum 6-TG 
concentration of 6μM to generate DNA MMR-defective clones (Offman et al., 2004). In 
the current study however, a maximum 6-TG dose of 20μM was used. It is possible 
therefore that MMR-defective sub-clones were induced at lower concentrations of 6-
TG, however as the concentration was increased, these were unable to tolerate 
extensive DNA damage and were selected against. It cannot be ruled out therefore, 
that 6-TG exposure in vivo could result in generation of DNA MMR defective cell 
populations. 
Whilst trying to identify a possible mechanism accounting for 6-TG 
hypersensitivity in KG-1 MNUR, western immunoblotting revealed that neither KG-1 
MNUR nor parental KG-1 cells expressed detectable levels of TPMT protein. Although 
this could not account for the 6-TG hypersensitivity observed in the MNU-resistant 
subculture, it could provide a plausible explanation for the unsuccessful attempts to 
 197 
 
generate a 6-TG-resistant KG-1 sub-culture. Reduced levels of TPMT activity are 
associated with increased sensitivity to 6-TG in vitro, thought to be due to increased 6-
TG nucleotide incorporation into DNA (Coulthard et al., 2002). Lack of detectable TPMT 
protein in KG-1 cells would therefore presumably result in extensive 6-TG nucleotide 
incorporation and subsequent cytotoxicity, as observed. Similar failure to generate a 6-
TG-resistant subclone was also demonstrated in the case of EoL-1, hence it is possible 
that this cell line also expresses little or no TPMT protein, although this was not 
investigated. The generation of Ara-C-resistant EoL-1 and KG-1 sub-cultures was also 
not successful, although possible explanations were not investigated. 
Ara-C and fludarabine have both been implicated in development of t-AML (Coso 
et al., 1999; Morrison et al., 2002; McLaughlin et al., 2005; Arana-Yi et al., 2008; 
Carney et al., 2010), although these data are limited and mechanisms have not yet 
been investigated. In the current study, exposure to escalating doses of Ara-C resulted 
in the generation of two cell lines (HL-60 Ara-CR and TK6 Ara-CR) with a high level of 
resistance. DNA MMR components were unaffected in both HL-60 Ara-CR and TK6 Ara-
CR and neither line was cross-resistant to MNU, 6-TG or the purine nucleoside 
analogues clofarabine and fludarabine. These data therefore do not provide any 
evidence that prolonged Ara-C exposure can induce defects of the DNA MMR pathway. 
However this was a limited investigation using only a very small sample set, hence it 
cannot be completely excluded that such a mechanism could operate. Other 
mechanisms which could contribute to t-AML development have not been 
investigated. For instance, balanced translocations affecting haematopoietic genes, 
arising due to generation of DSBs, are purported to be key in t-AML aetiology following 
exposure to chemotherapeutic topoisomerase inhibitors (see Section 1.4.2). Ara-C and 
fludarabine could potentially contribute to t-AML development by a similar 
mechanism. Consistently, cases of t-AML with translocations affecting the MLL locus 
(11q23) have been reported following treatment of lymphoma patients with 
fludarabine (Martin-Salces et al., 2007). Furthermore, Ara-C is reported to affect the 
function of topoisomerase enzymes in vitro (Cline and Osheroff, 1999; Chrencik et al., 
2003). 
Further investigation of potential mechanisms responsible for Ara-C resistance in 
HL-60 Ara-CR and TK6 Ara-CR was not performed given that the primary focus of the 
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current study was DNA MMR. Mechanisms of resistance to Ara-C have been well 
characterised in vitro and in vivo (see Section 1.5.3) and any could feasibly be 
responsible for Ara-C resistance in HL-60 Ara-CR and TK6 Ara-CR. In both cases, the 
mechanism may be unique to Ara-C, as cross-resistance to clofarabine and fludarabine 
was not observed. It cannot be ruled out however, that resistance to other nucleoside 
analogues, for instance other deoxycytidine analogues, could occur. 
5.3.1. Summary of Chapter 
In conclusion, the current study has demonstrated the following: 
• Treatment of myeloid and lymphoid cell lines with escalating doses of 
MNU resulted in generation of MNU-resistant cell lines, although not as a 
result of dysfunction of the DNA MMR pathway. 
• Despite no apparent effects on MMR-mediated damage signalling, a 
reduction in the amount of MSH3 protein following MNU exposure (in 
KG-1 MNUR) conferred moderate resistance to the nucleoside analogues 
Ara-C, clofarabine and fludarabine (clinical implications will be discussed 
in Chapter 8). 
• No evidence was found that prolonged exposure to 6-TG or Ara-C could 
cause defects of the DNA MMR pathway. 
• Resistance to Ara-C (via undetermined mechanisms) did not confer cross-
resistance to other nucleoside analogues routinely used in AML 
treatment.  
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Chapter 6. In vitro Mutagenicity of Cytarabine in Mismatch 
Repair Proficient and Deficient Cell Lines 
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6.1. Introduction 
Any agent which can damage DNA either directly or indirectly has the potential 
to be mutagenic to DNA if the damage is not detected and repaired, or if apoptosis is 
not initiated when repair cannot successfully occur. Mutagenic agents are often 
carcinogenic due to their potential to cause and/or contribute to genomic instability, 
which is implicated in the aetiology of several malignancies, in particular therapy-
related cancer (see Section 1.4.1.1).  
The O6-meG lesion which forms in DNA as a result of exposure to methylating 
agents is highly pro-mutagenic. Studies using E. coli and mammalian cell lines 
demonstrate a high frequency of G:C to A:T transitions in particular (Horsfall et al., 
1990), which result due to mispairing of O6-meG with thymine by DNA polymerases 
during replication (Abbott and Saffhill, 1979; Toorchen and Topal, 1983; Snow et al., 
1984). The role of the DNA MMR pathway is to detect and repair polymerase-mediated 
base misinsertions before they can be converted to mutations. However, in the case of 
O6-meG mispairs (and certain other drug-induced mispairs), MMR-mediated detection 
does not result in repair, but rather initiation of apoptosis, as described in Section 
1.2.1.2. Consistently, the frequency of methylating agent-induced mutations is 
increased in cells defective in DNA MMR (Andrew et al., 1998). This is also observed in 
cells defective in MGMT (Yang et al., 1994), another important cellular line of defence 
against the cytotoxicity and mutagenicity of the O6-meG lesion.  
Nucleoside analogues such as Ara-C, which are routinely used in the treatment of 
AML and other leukaemias, exert their cytotoxic effects primarily by incorporation at 
the 3’-terminus of replicating DNA, leading to chain termination and subsequent 
replication fork stalling and collapse. Despite this, there is evidence to suggest that 
chain termination is not absolute, resulting in the incorporation of nucleoside 
analogues at internal positions within DNA (see Section 3.1). Such internucleotide 
lesions have the potential to be mutagenic if polymerase enzymes cannot efficiently 
replicate these lesions. Indeed, in vitro translesion synthesis experiments have 
demonstrated incorporation of an extra base in the daughter strand following 
replication of an oligonucleotide containing an internal Ara-C (see Figure 3.11), 
suggesting replicative polymerases fail to replicate past Ara-C lesions accurately.  
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Studies of the mutagenic potential of nucleoside analogues have focussed on a 
particular class of nucleoside analogues, termed nucleoside reverse transcriptase 
inhibitors (NRTIs), which are used in the treatment of viral infections such as HIV. 
NRTIs exert their effects mainly through incorporation into viral DNA by viral reverse 
transcriptase, although they can also be incorporated into host cell genomic DNA 
(Sussman et al., 1999; Meng et al., 2000). In vitro mutagenicity studies of clinically 
relevant NRTIs have demonstrated the mutagenic potency of several of these agents, 
leading them to be classified as carcinogens (Sussman et al., 1999; Meng et al., 2000; 
Meng et al., 2002; Carter et al., 2007). Despite similar mechanisms of action (i.e. the 
ability to be incorporated into genomic DNA), there have been no published studies to 
date investigating the mutagenic potential of chemotherapeutic nucleoside analogues 
such as Ara-C and fludarabine. Investigating the mutagenic potency of these agents 
might have clinical implications in terms of understanding mechanisms which could 
contribute to acquisition of drug resistance, or risks associated with development of 
therapy-related malignancy and/or relapsed disease, for example. 
The mutagenic potential of DNA damaging agents can be assessed by a number 
of in vitro and in vivo assays. The most commonly utilised in vitro mutation assay is the 
HPRT assay. The product of the X-linked HPRT gene is an enzyme involved in the purine 
salvage pathway. In addition to its role in purine metabolism, the HPRT enzyme is a 
necessary requirement for conversion of 6-TG to its active DNA precursor (see Figure 
1.3). Cells in which HPRT gene mutation causes loss of enzymatic function are viable, 
but resistant to the cytotoxic effects of 6-TG. The HPRT assay works by treating cells 
(commonly TK6 cells given that they possess only one X chromosome, and hence one 
functional HPRT allele) with the agent in question, following which cells are exposed to 
6-TG, allowing selection of mutants based on their acquired 6-TG resistance. The 
frequency of induced mutants, relative to control untreated cells, can be used as a 
measure of the mutagenicity of the agent under investigation. A second in vitro 
mutation assay, the TK assay, works on the same principles. Whereas the HPRT gene is 
X-linked, the TK locus is located on chromosome 17 in humans. Although the TK assay 
requires cells to be heterozygous for the TK gene (conveniently, TK6 cells are also TK 
heterozygotes), it has the advantage of being able to pick up larger mutations, such as 
multi-locus deletions, which would likely be lethal in the HPRT assay (Liber and Thilly, 
1982). In addition, for both the TK and HPRT genes, individual mutants can be 
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subjected to molecular analysis to determine the nature of the mutation type, 
enabling generation of an induced (or spontaneously-occurring) mutational spectrum. 
6.1.1. Aims of Chapter 6 
The main objective of this chapter was to investigate the mutagenicity of Ara-C, 
in terms of frequency and type of drug-induced mutations, using in vitro mutation 
assays. An additional aim was to determine whether Ara-C is more mutagenic to cells 
defective in DNA MMR in order to further investigate whether MMR components are 
involved in cellular response to Ara-C.   
Specifically, the experimental aims were as follows: 
• Perform TK and HPRT mutation assays to determine whether exposure to 
Ara-C is mutagenic at these loci, and whether mutation is increased in 
MMR-defective cells.  
• Determine the spectrum of mutations at the HPRT locus following 
exposure to Ara-C. 
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6.2. Results 
6.2.1. Effect of MNU Exposure on Mutation Frequency at TK and HPRT Loci in MMR-
Proficient TK6 and MMR-Deficient TK6 MSH2i Cells 
The methylating agent MNU is a potent DNA mutagen, and its mutagenicity is 
enhanced in cells lacking a functional DNA MMR pathway (Andrew et al., 1998). Initial 
investigations were performed using MNU to determine whether TK and HPRT 
mutation assays could be successfully performed in DNA MMR-defective cells, and 
whether this would result in an increase in the MNU-induced mutation frequency (MF) 
relative to the MMR-proficient TK6 cells. The TK6 MSH2i cell line, which is a subclone 
of TK6 generated using shRNA-mediated knockdown of the MSH2 gene (Section 2.4), 
was used as it lacks MutSα and MutSβ components and is deficient in DNA MMR-
mediated cell death signalling in response to MNU and 6-TG (see Section 3.2.5).  
TK6 and TK6 MSH2i were first purged of any pre-existing spontaneous TK or 
HPRT mutants by culture in CHAT (cytidine, hypoxanthine, aminopterin, thymidine) 
medium, as described in Section 2.10.1. Components in CHAT medium (aminopterin) 
result in cellular inhibition of purine nucleotide biosynthesis, forcing cells to rely on 
purine salvage pathways. This is therefore cytotoxic to TK and HPRT mutants because 
they lack key components of these pathways. Subsequently, TK6 and TK6 MSH2i cells 
were exposed to increasingly cytotoxic doses of MNU for 16 hours (each dose was 
performed in triplicate using three independent cell populations), following which MF 
was assessed at TK and HPRT loci as described in Section 2.10.6.  
Exposure of TK6 and TK6 MSH2i to MNU caused a significant dose-dependent 
increase in MF at both TK and HPRT loci (Table 6.1 and Figure 6.1), confirming the 
mutagenic potency of this agent. Furthermore, at both loci the MFs observed in MMR-
deficient TK6 MSH2i cells were higher than those observed in parental TK6 cells at 
each individual MNU concentration (Figure 6.1). This was also observed in the undosed 
control populations, demonstrating a higher spontaneous MF in MMR-deficient TK6 
MSH2i cells, relative to proficient TK6 cells. Two-way analysis of variance (ANOVA) 
testing demonstrated a significant interaction between drug dose and cell line on 
induced MF at both loci (Table 6.1), confirming that the enhanced mutability of MNU, 
presumably due to loss of DNA MMR function, is reflected at TK and HPRT loci.
Table 6.1. Effect of MNU exposure on mutation frequency at TK and HPRT loci.
a Figures represent the observed MF at each drug concentration. Data represents the
mean and standard error (in parentheses) of three independently treated cell
populations. These figures are displayed graphically in Figure 6.1.
b Figures represent the P value determined using a 1-way analysis of variance
(ANOVA) test for effect of dose on MF.
c Figures represent the P value determined using a 2-way ANOVA test for interaction
of dose and cell line on induced MF.
MNU (µM)
TK MF (x 10-6)a HPRT MF (x 10-6)a
TK6 TK6 MSH2i TK6 TK6 MSH2i
0 4.8 (0.2) 15.0 (0.9) 4.4 (0.3) 12.5 (0.7)
10 27.8 (6.0) 60.9 (9.5) 23.7 (1.4) 52.9 (4.7)
20 37.8 (6.1) 103.5 (9.2) 36.7 (6.8) 92.6 (10.4)
30 60.4 (6.4) 142.1 (23.0) 49.9 (4.1) 128.3 (16.1)
1-way ANOVAb <0.001 <0.001 <0.001 <0.001
2-way ANOVAc 0.004 <0.001
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Figure 6.1. Mutagenicity of MNU at TK and HPRT loci.
Mutation frequency (MF) at TK and HPRT loci was assessed in MMR-proficient TK6
cells (dark grey bars) and MMR-deficient TK6 MSH2i cells (pale grey bars) following
16 hour exposure to MNU. Data represents the mean and standard error of three
independently treated cell populations. Numbers above bars represent the induced
MF (x 10-6) at each dose, calculated by subtraction of the spontaneous MF (0μM
MNU). For cytotoxicity at each MNU concentration, see Figure 6.3B.
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6.2.2. Effect of Ara-C Exposure on Mutation Frequency at TK and HPRT Loci in MMR-
Proficient TK6 and MMR-Deficient TK6 MSH2i Cell Lines 
To assess the mutagenicity of Ara-C, cultures of MMR-proficient TK6 and its 
MMR-deficient derivative cell line, TK6 MSH2i were first purged of any pre-existing 
spontaneous mutants as described above, then exposed to increasingly cytotoxic doses 
of Ara-C for 16 hours. MF was subsequently determined at TK and HPRT loci.  
Exposure of TK6 and TK6 MSH2i to Ara-C caused a significant dose-dependent 
increase in MF at both TK and HPRT loci (Table 6.2 and Figure 6.2), the effect of which 
was more pronounced at the TK locus. Furthermore, similar to the response observed 
for MNU, TK and HPRT MF was higher in TK6 MSH2i cells compared to parental TK6 
cells at equivalent Ara-C concentrations (Figure 6.2). Two-way ANOVA analysis 
demonstrated a significant interaction between Ara-C dose and cell line on induced MF 
(Table 6.2). 
Although a strict statistical comparison was not possible between two different 
agents, a comparison of the drug-induced MFs at doses giving a near equivalent 
cytotoxicity was performed to give an indication of the mutagenic potency of Ara-C 
relative to MNU. At doses giving 70% cytotoxicity in MMR-proficient TK6, Ara-C was 
approximately 2.3-fold and 3.5-fold less mutagenic at TK and HPRT loci, respectively, 
compared to MNU (Figure 6.3). Furthermore, in MMR-deficient TK6 MSH2i cells, the 
difference increased to approximately 3.1-fold and 7.6-fold (Figure 6.3), demonstrating 
that loss of DNA MMR activity has a greater influence on the mutagenicity of MNU 
than Ara-C, particularly at the HPRT locus. This was similar at doses which result in 
approximately 95% cytotoxicity (data not shown). 
Taken together, these in vitro data provide evidence that exposure to Ara-C is 
weakly, but significantly, mutagenic to DNA, particularly at the TK locus. Furthermore, 
the mutagenic effect of Ara-C is enhanced in cells lacking a functional DNA MMR 
pathway. 
Ara-C (nM)
TK MF (x 10-6)a HPRT MF (x 10-6)a
TK6 TK6 MSH2i TK6 TK6 MSH2i
0.0 4.4 (0.3) 13.7 (0.9) 4.4 (0.6) 12.8 (1.0)
5 10.6 (0.5) 42.6 (3.4) 6.4 (0.4) 23.3 (4.7)
10 14.3 (1.4) 65.5 (1.4) 9.9 (0.4) 31.5 (2.6)
20 21.9 (1.4) 88.5 (10.8) 12.6 (1.4) 47.0 (3.0)
30 29.7 (0.5) 14.4 (1.5)
1-way ANOVAb <0.001 <0.001 <0.001 <0.001
2-way ANOVAc <0.001 0.001
Table 6.2. Effect of Ara-C exposure on mutation frequency at TK and HPRT loci.
a Figures represent the observed MF at each drug concentration. Data represents the
mean and standard error (in parentheses) of three independently treated cell
populations. These figures are displayed graphically in Figure 6.2.
b Figures represent the P value determined using a 1-way analysis of variance
(ANOVA) test for effect of dose on MF.
c Figures represent the P value determined using a 2-way ANOVA test for interaction
of dose and cell line on induced MF.
Note: No results were obtained for TK6 MSH2i at 30nM Ara-C due to insufficient cell
growth (attributed to the particular Ara-C hypersensitivity of this cell line).
207
020
40
60
80
100
120
0 5 10 20 30
M
ut
at
io
n 
fr
eq
ue
nc
y 
(x
 1
0-
6 )
Ara-C (nM)
HPRT locus
TK6
TK6 MSH2i
0
20
40
60
80
100
120
0 5 10 20 30
M
ut
at
io
n 
fr
eq
ue
nc
y 
(x
 1
0-
6 )
Ara-C (nM)
TK locus
TK6
TK6 MSH2i
6.2 9.9
17.5
28.9
51.8
74.8
Figure 6.2. Mutagenicity of Ara-C at TK and HPRT loci.
Mutation frequency (MF) at TK and HPRT loci was assessed in MMR-proficient TK6
cells (dark grey bars) and MMR-deficient TK6 MSH2i cells (pale grey bars) following
16 hour exposure to Ara-C. Data represents the mean and standard error of three
independently treated cell populations. Numbers above bars represent the induced
MF (x 10-6) at each dose, calculated by subtraction of the spontaneous MF (0nM Ara-
C). For cytotoxicity at each Ara-C concentration, see Figure 6.3B.
25.3
1.9 5.5
8.2
10.5
18.7
34.3
9.9
208
AB
Figure 6.3. Comparison of the mutagenicity of MNU and Ara-C at equivalent
cytotoxicity.
A. Induced mutation frequency (MF) at MNU (dark grey bars) and Ara-C (pale grey
bars) concentrations cytotoxic to approximately 70% of cells were compared in DNA
MMR-proficient TK6 cells and in MMR-deficient TK6 MSH2i cells at TK and HPRT loci.
Induced MFs (numbers shown above bars) were calculated by subtraction of the
spontaneous MFs (see Figures 6.1 and 6.2) and represent the mean and standard
error of three independently treated cell populations. B. Cytotoxicity of MNU (left)
and Ara-C (right). Data is presented as the the number of viable colonies from dosed
cell suspensions as a percentage of the number of viable colonies from vehicle-only
treated cell suspensions. The doses at which MFs were compared are highlighted in
red.
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6.2.3. Molecular Analysis of Mutations at the HPRT Locus in TK6 Cells 
To further investigate the mutagenicity of Ara-C, in terms of the types and 
frequencies of induced aberrations, a number of the individual mutants generated 
from the TK6 cell line were subject to molecular analysis in order to produce an Ara-C-
induced mutational spectrum. Of particular interest was whether an increase in 
mutation arising from potential DNA MMR substrates (single base substitutions and 
frameshift mutations) would be observed. Specific TK and HPRT mutants can be 
discerned using molecular analysis, however this is significantly more straight-forward 
for HPRT given the X-linked nature of the gene. As the focus of this investigation was 
on detection of point mutations it was deemed suitable to perform molecular analysis 
only on HPRT mutants given that they should be equally likely to occur at both loci. 
A total of 120 colonies (40 each from three independently treated cell 
populations) were selected at random from the TK6 HPRT mutants that arose following 
exposure to 30nM Ara-C. These single-cell cloned mutants were expanded in media 
containing the selective agent 6-TG as described in Section 2.11.1. During expansion, a 
plate containing 12 colonies had to be abandoned due to fungal infection. A further 4 
colonies were lost as they failed to grow in the selective media, giving a total of 104 
mutants for molecular analysis. Although the spectrum of mutations occurring 
spontaneously at the HPRT locus has been well characterised (Cariello and Skopek, 
1993; Giver et al., 1993), as a control, 60 mutant TK6 colonies (20 each from three 
independent cell populations) which had not been exposed to Ara-C were also 
randomly selected and expanded. A plate containing 12 colonies was also lost to 
further analysis, resulting in a total of 48 spontaneous mutants available for analysis. 
6.2.3.1. Analysis of large deletions 
The initial step in analysis of the HPRT mutants involved the use of genomic HRPT 
multiplex PCR to identify large deletions, as described in Section 2.11.2. Large 
deletions are operationally defined as deletions encompassing one or more HPRT 
exons, as evidenced by absence of the corresponding multiplex PCR fragment(s); 
Figure 6.4 shows representative multiplex PCR profiles observed in some of the HPRT 
mutants.
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Figure 6.4. Multiplex PCR amplification of the HPRT locus (continued on next page).
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Figure 6.4. Multiplex PCR amplification of the HPRT locus (continued from previous page).
The gels show examples of multiplex PCR profiles representing partial HPRT deletions which occured either spontaneously (A) or following exposure
to Ara-C (B). For each mutant, the results of the 2 multiplex PCR reactions are shown side by side, with the mutant identification number
(S, spontaneous; D, drug-exposed) and deleted region stated above. Mutants S5 and D1 both show the normal pattern of 8 bands. These mutants
contain point mutations which do not peturb the normal amplification pattern. The exons represented by each band, and the size of the amplicons
are shown to the right of the gels. A 100 bp marker ladder is shown to the left of each gel. The gels shown are 1.5% agarose gels loaded with 15µl of
the products from each PCR reaction.
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A total of 96 Ara-C-treated mutants, as well as 38 spontaneously-occurring 
mutants were found to harbour large deletions affecting the HPRT locus. After 
correction for identical mutations arising from the same original cell population, which 
possibly represent clonal expansion of a single mutant, a total of 13 independent large 
deletions were observed in Ara-C treated HPRT mutants, as well as 8 independent 
large deletions in the spontaneously-occurring mutants. Table 6.3 lists the specific 
deletions observed, and Figure 6.5 graphically illustrates the extent of the deleted 
regions. Interestingly, no common mutation was observed in both the Ara-C-treated 
and spontaneous mutant populations. Complete deletion of the HPRT locus was 
observed solely in the Ara-C-treated mutant population, as were 3’ partial gene 
deletions (affecting exons 2 – 9 or 6 – 9). 5’ partial gene deletions were observed in 
both spontaneous and Ara-C-treated mutant populations, although the extent of the 
deleted region differed (exons 1 – 3 or 1 – 7/8 in the spontaneous mutant population, 
exon 1 only in the Ara-C-treated population). Internal deletions of single exons were 
observed only in spontaneous HPRT mutants. A deletion of exons 2 – 3 was also 
observed solely in the spontaneous mutant cell population. A larger internal deletion 
encompassing exons 4 – 8 was observed in Ara-C-treated HPRT mutants. Together, this 
demonstrates that the spectrum of Ara-C-induced large HPRT deletions is clearly 
distinct from the spontaneously-occurring large deletion spectrum. 
Deleted Region  
Spontaneous Ara-C Treated
Number 
observeda
Number 
observeda
Complete gene deletion 2 (2)
5' partial gene deletions
1 3 (44)
1 – 3 2 (26)
1 – 7/8c 1 (1)
Total 3 (27) 3 (44)
3' partial gene deletions
2 – 9 3 (6)
6 – 9 3 (20)
Total 6 (26)
Internal exon deletions
4 1 (1)
5 1 (4)
7 1 (1)
2 – 3 1 (4)
4 – 8b 2 (24)
Total  4 (10) 2 (24)
Other            
1 and 7/8d 1 (1)
Total 1 (1)
Total 
Large Deletions 8 (38) 13 (96)
Table 6.3. Large deletions observed in spontaneous and Ara-C-treated HPRT
mutants.
a Figures represent the number of independent mutations after correction for
duplicate mutations which likely represent clonal expansions. Actual number
observed is shown in parentheses.
b For these mutants, deletion of exon 9 was observed on multiplex analysis, however
cDNA sequencing demonstrated an internal deletion of exons 4-8. The 3’ terminus of
the deletion must therefore lie within intron 8 and result in deletion of the forward
primer binding site for exon 9 amplification.
c As exons 7 and 8 are amplified on a single PCR fragment, and no cDNA was
generated for this mutant, it is not possible to determine the exact 3’ terminus of this
deletion.
d As exons 7 and 8 are amplified on a single PCR fragment, and no cDNA was
generated for this mutant, it is not possible to determine whether exon 7 or exon 8
or both are deleted.
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Figure 6.5. Extent of genomic deletions observed in spontaneous and Ara-C-treated HPRT mutants.
The HPRT locus is displayed to scale with exons shown in yellow. Blue bars demonstrate the deleted regions observed in HPRT mutants as determined
by multiplex PCR and analysis of HPRT cDNA. Those displayed above the gene were observed in spontaneously occurring mutants and those below
were in Ara-C-treated mutants. Note that deletions including terminal exons extend for undetermined distances outside of the locus (indicated by
arrowheads).
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6.2.3.2. Analysis of Point Mutations in HPRT Coding Region 
For mutants with a normal HPRT multiplex PCR result, reverse transcriptase-
mediated production of HPRT cDNA, PCR amplification, and cDNA sequencing were 
employed to identify small alterations, as described in Section 2.11.3. 
In total, 7 point mutations (3 independent) were observed in the spontaneous 
HPRT mutant population. All were base substitutions, comprising two transition 
mutations and one transversion mutation. In the Ara-C-treated mutant population, 7 
mutants were all found to have the same transversion mutation, which had occurred 
independently in all three of the treated cell populations. For each mutation, the 
target sequence and resulting amino acid change is shown in Table 6.4, and the 
distribution of the mutations within the HPRT coding sequence is shown in Figure 6.6.  
6.2.3.3. Analysis of Splice Site Mutations 
HPRT cDNA from 1 remaining Ara-C-treated HPRT mutant demonstrated a 
deletion of 77 base pairs corresponding to exon 8, although exon 8 appeared to be 
present based on multiplex PCR analysis. As this was potentially due to aberrant 
processing of the HPRT transcript, leading to exon skipping, genomic sequencing of the 
intronic regions flanking exon 8 was performed to identify possible mutations affecting 
splice donor and acceptor sites. This was achieved through sequencing of the PCR 
product amplified using the exon 7/8 primer pair from the multiplex (as the primer 
binding sites lie within intronic regions, meaning the exons and flanking sequences are 
amplified) as described in Section 2.11.4. Sequencing of the region distal to exon 8 
revealed a G:A transversion within the donor splice site (Figure 6.7A). The exon 8 5’ 
donor splice site is susceptible to mutation at each position, with all reported 
mutations (including the G:A mutation detected herein) causing loss of exon 8, without 
the use of a cryptic donor splice site (O'Neill et al., 1998). 
51 93 86 72 4
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ARA-C TREATED
Figure 6.6. Distribution of point mutations within the HPRT coding region.
HPRT exons are drawn to scale relative to each other. The rectangles represent point
mutations, all of which were single base substitutions, observed within the HPRT
coding region. Spontaneously occurring mutations are shown above the transcript,
those observed in Ara-C-treated mutants are shown below. Transitions are shown in
yellow, transversions are shown in red. Sites at which multiple independent mutations
were observed are indicated as stacked symbols.
Positiona
cDNA 
Alteration
Amino Acid 
Change
Target 
Sequenceb
Spontaneous Ara-C Treated
Number 
Observedc
Number 
Observedc
Transitions
E5:395 T:C Ile > Thr TTGATTGTG 1 (2)
E2:118 G:A Gly > Arg TCATGGACT 1 (1)
Transversions
E6:409 A:T Ile > Phe TATAATTGA 1 (4)
E6:412 G:T Asp > Tyr AATTGACAC 3 (7)
Total Point Mutations 3 (7) 3 (7)
Table 6.4. Point mutations observed in spontaneous and Ara-C-treated HPRT
mutants.
a Mutated position is identified by the exon in which it occurs and numbered according
to the cDNA position.
b Within the target sequence, the affected base is shown in bold.
c Figures represent the number of independent mutations after correction for
duplicate mutations which likely represent clonal expansions. Actual number observed
(ie. uncorrected) is shown in parentheses.
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gtaagt...                          …atgattctttttag TTGTTGGATTTGAAATTCCAGACAAGTTTGTTGTAGGATATGCCCTTGACTATAATGAATACTTCAGGGATTTGAAT gtaagt…                             …atttttttttatag
INTRON 7 INTRON 8EXON 8 E 9E 7
gtaagt...                          …atgattctttttag TTGTTGGATTTGAAATTCCAGACAAGTTTGTTGTAGGATATGCCCTTGACTATAATGAATACTTCAGGGATTTGAAT gtaaat…                             …atttttttttatag
INTRON 7 INTRON 8EXON 8 E 9E 7
gtaagt...                          …atgattctttttaa TTGTTGGATTTGAAATTCCAGACAAGTTTGTTGTAGGATATGCCCTTGACTATAATGAATACTTCAGGGATTTGAAT  gtaagt…                             …atttttttttatag
INTRON 7 INTRON 8EXON 8 E 9E 7
Wild type
g40032 a
g40114 a
A
B
Ara-C-treated
Spontaneous
Figure 6.7. Splice site mutations in the HPRT gene, causing splicing of exon 8.
The wild type splicing pattern of introns 7 and 8 of the HPRT gene is displayed in the top image. Sequences of the intronic splice sites are shown in
lower case (intervening intronic sequence is not shown), exon 8 sequence is shown in uppercase. Spliced regions are indicated by dashed lines. Note
that exons and introns are not displayed to scale. A. Point mutation of the 5’ splice donor sequence in intron 8 resulted in exon 8 skipping in one
Ara-C-treated HPRT mutant. B. In one independent spontaneously-occurring mutation event, point mutation of the 3’ splice acceptor sequence in
intron 7 resulted in splicing of the first 21 bases of exon 8 due to the use of a cryptic splice acceptor site (shown in bold type). Mutated sites (shown
in red type) are numbered according to their position in genomic DNA.
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Similarly, 3 (2 independent) spontaneously-occurring mutants which 
demonstrated a normal multiplex PCR profile were found to have a 21 base pair 
deletion corresponding to the beginning of exon 8. Sequencing of the flanking intronic 
regions, as described above, revealed a G:A transversion within the acceptor splice site 
in all three mutants (Figure 6.7B). This mutation has also been previously reported and 
causes loss of the first 21 bases of exon 8 due to the use of a cryptic acceptor splice 
site within exon 8 (Figure 6.7B) (O'Neill et al., 1998). 
6.2.3.4. Comparison of Spontaneous and Ara-C-Induced HPRT Mutational Spectra 
A summary of the mutations observed in spontaneous and Ara-C-treated HPRT 
mutant populations, after correction for duplicate mutations that represent 
presumptive clonal expansions, is shown in Table 6.5. Although large deletions 
affecting the HPRT locus are classified as complete gene deletion, partial gene 
deletions (3’ or 5’) or internal exon deletions, given that these deletions would be 
expected to arise by the same mechanism (discussed below), these deletions were 
combined for the purposes of statistical analysis of mutational spectra. A Chi-squared 
test of the homogeneity of spontaneous and Ara-C treated mutant populations (in 
terms of large deletions and point mutations) demonstrated that the change in the 
spectrum of mutations due to Ara-C was not significant (P = 0.44).  
Despite this, the frequency of each class of mutation was used to estimate the 
Ara-C-specific mutational burden at the HPRT locus (Table 6.5 and Figure 6.8), as 
described in Section 2.11.5. The drug-induced HPRT mutation spectrum (Figure 6.8) 
demonstrates that Ara-C induces all classes of mutation. Furthermore the increase in 
mutation frequency over background can be mostly accounted for by large deletions 
affecting the HPRT locus, in particular 3’ partial deletions. Consistently, a Fisher’s exact 
test demonstrated the occurrence of 3’ partial gene deletions in the Ara-C mutant 
population to be significantly increased over background (P = 0.02). Similar testing 
performed for other classes of mutation did not reach statistical significance (data not 
shown). 
Table 6.5. Summary of spontaneous and Ara-C-treated HPRT mutants.
a Figures represent the number of independent mutations after correction for
duplicate mutations which might represent clonal expansions. Actual numbers
observed (i.e. uncorrected) are shown in parentheses.
b Calculated by multiplying the mean mutation frequency (from Table 6.2) by the
percentage of total mutants represented by each class of mutation.
c Calculated by subtraction of the spontaneous (absolute) mutant fraction from the
Ara-C-treated (absolute) mutant fraction.
d The single mutant with deletion of exon 1 and exon 7/8 is included here.
e Includes base substitutions within coding regions and those affecting splice sites.
Mutation Type
Spontaneous Ara-C Treated
Number 
Observeda
% Total 
Mutants 
(independent)
Absolute 
Mutant 
Fractionb
(x 10-6)
Number 
Observeda
% Total 
Mutants 
(independent)
Absolute 
Mutant 
Fractionb
(x 10-6)
Induced 
Mutant 
Fractionc
(x 10-6)
Complete gene 
deletion 0 2 (2) 11.76 1.69 1.69
5’ partial gene 
deletion 4 (28)
d 30.77 1.37 3 (44) 17.65 2.53 1.17
3’ partial gene 
deletion 0 6 (26) 35.29 5.06 5.06
Internal exon
deletions 4 (10) 30.77 1.37 2 (24) 11.76 1.69 0.32
Point mutationse 5 (10) 38.46 1.71 4 (8) 23.53 3.38 1.67
Total 13 (48) 100.00 4.44 17 (104) 100.00 14.35 9.91
Figure 6.8. Spectra of spontaneous and Ara-C-induced HPRT mutations in TK6 cells.
Coloured bars demonstrate the estimated fraction of the total HPRT mutants
represented by each type of mutation, determined as described in Section 2.11.5.
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6.3. Discussion 
Despite widespread use in the treatment of AML, as well as other malignancies, 
there is a paucity of data investigating the mutagenicity of anti-leukaemic nucleoside 
analogues. The initial aim of this study therefore, was to determine whether the 
nucleoside analogue Ara-C is mutagenic using in vitro mutation assays. In two well 
established independent mutation assays, a statistically significant dose-dependent 
increase in MF was observed following 16 hour exposure to the drug, suggesting that 
Ara-C is capable of acting as a DNA mutagen at the doses investigated. Relative to the 
potent mutagen MNU, the mutagenic effect of Ara-C in both assays was appreciably 
weak, however this is expected given the difference in the major mechanistic actions 
of these agents and the expectation that the majority of Ara-C lesions in DNA would 
result in chain termination hence would inhibit further rounds of DNA replication 
required for mutation fixation.  
TK6 cells are heterozygous at the TK locus and hemizygous at the HPRT locus. 
Many mutagenic mechanisms that involve homologous interaction, such as gene 
conversion, therefore cannot occur at the X-linked HPRT locus. In addition, large multi-
locus deletions are likely to be lethal in the HPRT assay, because gross deletions may 
span adjacent genes essential for cell survival. Therefore, if the primary mechanism of 
mutation induction by a particular agent implicates either homologous interaction or 
large deletion, the mutagenicity of that agent will be significantly underestimated by 
the HPRT mutation assay. In this investigation, Ara-C-induced MF at the TK locus was 
greater than that induced at the HPRT locus, suggesting that the primary mechanism of 
Ara-C-induced mutation is through one (or both) of these mechanisms. Nucleoside 
analogue-induced chain termination gives rise to stalled replication forks, which can in 
turn be converted to DSBs (Arnaudeau et al., 2000; Arnaudeau et al., 2001). Two DSBs 
in relatively close proximity could therefore give rise to loss of the intervening 
sequence, resulting in a large deletion. In addition, evidence suggests that HRR is the 
primary mechanism recruited to repair DSBs at stalled replication forks (Arnaudeau et 
al., 2001; Lundin et al., 2002; Rothkamm et al., 2003), hence it is possible Ara-C could 
also induce gene conversion type mutations. Indeed, chain termination could give rise 
to LOH-type mutations, which can occur by either gene conversion or large deletion 
events, among others, which would be consistent with a higher Ara-C-induced TK MF 
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relative to HPRT MF. Also consistent with these data, studies of the mutagenicity of 
Zidovudine (3’-Azido-2’,3’-dideoxythymidine), an NRTI which can cause DNA chain 
termination, have demonstrated a greater increase (2.2 fold) in MF at the TK locus 
than at the HPRT locus (Sussman et al., 1999; Meng et al., 2000). 
MMR-deficient TK6 MSH2i cells (generated from TK6 using shRNA-mediated 
gene knockdown, see Section 2.4) were used to investigate whether the mutagenic 
potency of Ara-C could be further affected by loss of DNA MMR. As expected, Ara-C 
was more mutagenic to TK6 MSH2i than to parental MMR-proficient TK6 cells, 
although the influence of DNA MMR loss was relatively modest in comparison to its 
effect on the mutagenicity of MNU. The mutator phenotype is a hallmark of cells 
lacking functional DNA MMR (Karran, 2001), consistently, the spontaneous mutation 
frequencies observed at TK and HPRT loci were around 3-fold and 4-fold higher 
respectively in TK6 MSH2i cells than parental TK6 cells (see Figure 6.1 and Figure 6.2). 
The increase in Ara-C-induced mutation frequency observed in TK6 MSH2i is therefore 
likely due, in part, to the hypermutability of this cell line. Two-way ANOVA testing 
however, demonstrated a statistically significant influence of both Ara-C concentration 
and cell line on TK and HPRT mutation frequency, suggesting an interaction between 
DNA MMR and Ara-C. In other words, these findings suggest that Ara-C-induced 
mutation is suppressed by DNA MMR, providing further weight to the evidence that 
this pathway is somehow implicated in cellular response to Ara-C. 
The influence of DNA MMR dysfunction on Ara-C mutagenicity appeared to be 
greater at the TK locus than the HPRT locus (Figure 6.2) (although this was not 
assessed statistically), which would indicate a greater increase  in structural mutations 
better detected at this locus, including those arising via multi-locus deletion or gene 
conversion. Given the purported role of DNA MMR components in suppression of 
recombination between imperfectly matched sequences (see Section 1.1.2), as well as 
evidence that gene conversion type mutations occur in cells lacking MSH2 (Elliott and 
Jasin, 2001; Villemure et al., 2003; Smith et al., 2007), it is feasible that MMR 
dysfunction in TK6 MSH2i would give rise to an increase in this class of mutation at the 
TK locus. A role for DNA MMR dysfunction in induction of large deletions is harder to 
envisage, but nevertheless may occur due to loss of an as yet uncharacterised function 
of DNA MMR components at the replication fork. 
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As far as can be determined, this work represents one of a limited number of 
reports of the use of in vitro TK and HPRT mutation assays in DNA MMR-compromised 
cell lines. Given the consistent results observed with MNU, well characterised as 
hypermutable in DNA MMR-deficient cells (Andrew et al., 1998), these data 
demonstrate that in vitro mutation assays can be routinely performed in MMR-
compromised cells and may represent a useful resource for investigating the influence 
of DNA MMR status on the mutagenicity of particular agents, as this study has 
demonstrated for Ara-C. 
The Ara-C mutational spectrum is predominated by mutants originating from 
DNA strand breakage events (i.e. Large deletions; 76%), consistent with chain 
termination as a major mechanism of this agent. Additionally, the inhibitory effects of 
Ara-C on topoisomerase enzymes (Cline and Osheroff, 1999; Chrencik et al., 2003) 
could also feasibly give rise to this class of mutation. Although a greater number of 
large deletions were observed in the Ara-C mutant population compared to the 
spontaneous population (see Table 6.5), after correction for presumptive clonal 
expansions, this was not statistically significant. It is probable however that some of 
the identical deletion events detected within the same dosed cell population were in 
fact true independent mutation events and not clonal siblings, given that certain 
deletions (for instance Ara-C induced deletion of HPRT exons 2-9) occurred in 
independently dosed cell populations. Also it is important to note that some 
apparently identical deletion events may have different breakpoints, although this was 
not investigated experimentally. Given that the majority of Ara-C-induced mutants are 
partial gene deletions which extend for undetermined distances outside of the HPRT 
coding sequence it was not possible to sequence breakpoints. The corrected 
frequencies of each class of mutation are therefore likely to be an underestimation of 
the true frequencies due to an inability to reliably determine which mutation events 
arising in the same cell population are independent and which represent clonal 
siblings. This highlights a caveat of this particular investigation in that only 3 
independent Ara-C-dosed cell populations were investigated at each dose. It was not 
anticipated that such a degree of apparent clonal expansion would be observed, which 
could potentially be masking independent mutation events. It is therefore planned to 
extend this investigation to generate a greater number of independently-dosed HPRT 
mutants for molecular analysis. 
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Although it is likely that each class of large deletion would arise by the same 
mechanism, there was a statistically significant increase in the occurrence of 3’ partial 
HPRT gene deletions in the Ara-C mutant population (P = 0.02). Furthermore, this was 
estimated to account for a large proportion of the Ara-C-induced HPRT mutation 
frequency (Figure 6.8), which could reflect the possible existence of a site (or sites) in 
the 3’ region of the HPRT gene at which Ara-C-mediated chain termination is more 
likely to be converted to a strand break. Similarly, prior to correction for possible clonal 
siblings, a large proportion of Ara-C-induced mutants were deletions of exon 1 which 
extend for undetermined lengths 5’ of the HPRT gene (see Table 6.3), suggesting the 
possible existence of preferential sites of Ara-C-induced breakage also in this region. In 
both cases however, it cannot be determined whether all of these mutants share the 
same breakpoints or whether they represent individual mutational events. 
One of the assumptions prior to molecular analysis of Ara-C-induced HPRT 
mutants was that mutations arising from fixation of potential DNA MMR substrates, 
such as base substitutions and frameshift mutations, would be increased relative to 
the spontaneously-occurring mutant population. On the contrary, a lower number of 
independent point mutations was observed in the Ara-C-treated mutant population 
relative to the spontaneous population. Furthermore, all point mutations observed 
were single base substitutions, with no frameshift-type mutations observed in either 
HPRT mutant population. Single base substitutions (including those affecting mRNA 
splicing) are reported to account for around 31% of spontaneously-occurring HPRT 
mutations (Giver et al., 1993), which is consistent with the percentage of independent 
point mutations analysed in this investigation (38%). The slightly lower number of this 
class of mutation detected in the Ara-C-induced HPRT mutant population (24%) 
suggests that Ara-C does not readily induce point mutations in DNA (although 
estimation of the proportion of total HPRT mutants represented by point mutations 
argues that Ara-C is a weak point mutagen (see Figure 6.8)). It cannot be ruled out that 
these mutations do occur more readily as a result of base misincorporation (or 
polymerase slippage in the case of frameshift mutations) but the cells possess an 
efficient mechanism for their reversal prior to fixation to mutation, for instance the 
DNA MMR pathway. Consistently, the mutagenic potency of Ara-C is significantly 
increased in MMR-deficient TK6 MSH2i cells, which could reflect a reduction in cellular 
capacity for repair of Ara-C-induced lesions prior to mutation fixation. It is important to 
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note however, that the mutagenicity of MNU is also significantly increased in MMR-
defective cells, although this is not due to a lack of MMR-mediated repair, but rather a 
failure to initiate death in cells carrying pro-mutagenic mispairs. In this circumstance 
cells persist and mispairs become fixed as mutation. Insight into whether the DNA 
MMR pathway is capable of detection and/or repair of Ara-C-induced lesions could be 
provided by an analysis of the Ara-C-induced mutational spectrum in MMR-deficient 
TK6 MSH2i cells. For instance, if Ara-C can induce base insertion mutations, as 
suggested by translesion synthesis experiments (see Figure 3.11), which could 
represent a potential substrate for DNA MMR components, an increase of this class of 
mutation would be expected in MMR-defective cells.  
An analysis of the Ara-C-induced mutation spectrum in TK6 MSH2i cells is one of 
the anticipated follow-up investigations to this work. It may also be interesting to 
determine the spectrum of Ara-C-induced mutations in TK6 MSH3i cells. As these cells 
are apparently solely dysfunctional in the MutSβ complex (see Section 3.2.5), such an 
investigation may be helpful in further delineating the influence of this complex on 
cellular response to Ara-C. Given the possibility that DNA MMR status may influence 
the induction of LOH-type mutations, such as gene conversion (or possibly multi-locus 
deletion) as suggested above, it may be more pertinent to perform analysis of Ara-C-
induced mutations occurring at the TK locus, although this type of analysis is 
significantly more labour intensive. 
With the exception of a single mutant which was mutated in the exon 8 donor 
splice site (see Figure 6.7A), all Ara-C-induced point mutants demonstrated the same 
transversion mutation (E6:412 G:T; see Table 6.4). The mutability of any particular 
base pair is affected by several parameters including initial lesion incorporation, ability 
to remove/repair the lesion and the efficiency of insertion of an incorrect base 
opposite the lesion by a DNA polymerase. Although speculative, the most likely 
scenario which would give rise to this particular mutation is that an Ara-C nucleotide 
was incorporated in place of dCTP in the non-transcribed strand of the HPRT gene, and 
dTTP was misincorporated (instead of dGTP) opposite the lesion at the next round of 
DNA replication. Given that this mutation occurred independently in all 3 dosed cell 
populations suggests that this site represents a ‘hotspot’ for Ara-C-induced point 
mutation, although this would require extensive further investigation. Why 
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incorporation of Ara-C would be favoured at this particular site, and also why the 
mispair appears able to escape repair, is unknown. Such a finding, if substantiated, 
could have potential implications for the therapeutic use of Ara-C if preferential sites 
of incorporation at risk of mutation were identified in genes associated with drug 
resistance, for example. Although observed in independently exposed populations, 
strongly suggesting independent Ara-C-induced mutational events, the possibility that 
these mutants originated from a single spontaneous mutant clone cannot be 
completely excluded. For instance, a mutation could arise subsequent to elimination of 
pre-existing HPRT mutants but prior to drug exposure and hence would be present in 
independent cell populations, although this seems unlikely.  
In conclusion, in vitro evidence suggests that Ara-C is mutagenic to DNA, 
although a more extensive molecular analysis of independent mutants is required to 
fully delineate the types of mutation this agent can induce, and to further investigate 
whether mutability is influenced by DNA MMR status. At the time these investigations 
were underway, another member of the laboratory performed a TK assay in TK6 cells 
to assess the mutagenicity of the nucleoside analogue fludarabine. A similar result to 
that described here in response to Ara-C was observed, specifically fludarabine was 
able to induce a dose-responsive increase in MF at the TK locus (V. Forster, 
unpublished data), adding further weight to the evidence that nucleoside analogues 
have the potential to be mutagenic to DNA. Given the widespread chemotherapeutic 
use of these agents, often in patients which may exhibit compromised DNA MMR, in 
vivo investigation of the mutability of these agents would seem warranted (see 
Chapter 8). 
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6.3.1. Summary of Chapter 
In summary, these investigations have demonstrated that: 
• Exposure to Ara-C results in a dose-dependent increase in mutation 
frequency at both TK and HPRT loci in TK6 cells, suggesting Ara-C is 
mutagenic to DNA in vitro. 
• Ara-C-induced MF is significantly increased in DNA MMR dysfunctional 
cells at both loci, suggesting MMR components have a role in suppression 
of Ara-C-induced mutation. 
• Large deletions account for the majority of Ara-C-induced mutations, 
consistent with the chain terminating nature of the drug. 
• Ara-C can induce point mutations in DNA (although not statistically 
significantly). Such mutations arise via fixation of mispairs in DNA, which 
could potentially represent substrates for DNA MMR. 
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Chapter 7. The Clonal Origins of Relapse in Acute Myeloid 
Leukaemia
 229 
 
7.1. Introduction  
Despite the ability of standard chemotherapeutic regimes to induce remission in 
50 – 85% of de novo AML patients, the majority of patients will relapse within 2 years 
of achieving remission (Larson, 2007; Shipley and Butera, 2009). Furthermore, relapsed 
AML, in patients who are unsuitable for bone marrow transplant, is almost always fatal 
(Shipley and Butera, 2009), regardless of whether patients are treated with standard 
re-induction chemotherapy or alternative regimes using different chemotherapeutic 
agents. A similarly poor outcome is also observed in patients treated for t-AML that 
develops following therapy for a previous unrelated malignancy (Larson, 2007).  
Important genetic differences have been identified between de novo and 
relapsed AML, including the acquisition of new chromosomal abnormalities (Estey et 
al., 1995; Kern et al., 2002), gene mutations (Kottaridis et al., 2002) and UPD 
(Raghavan et al., 2008). Additionally, MSI is observed in some patients with relapsed 
AML (see Figure 1.9). This, combined with the similarly poor treatment response 
observed in t-AML patients, suggests that at least some of the mechanisms by which 
relapsed AML and t-AML evolve are likely to be similar. However, many uncertainties 
still remain about the molecular abnormalities responsible for relapse in AML, as well 
as the cellular and genetic relationship between presentation and relapsed disease in 
individual patients. 
The clonal evolution of de novo leukaemia, as well as the majority of cancers, is 
now well characterised (Figure 7.1). Furthermore, in the case of ALL, a recent genome 
wide SNP analysis in matched samples at diagnosis and relapse from individual 
patients has provided valuable insights into the clonal origins of relapsed disease 
(Mullighan et al., 2008). This study demonstrated that, rather than being identical to or 
evolved from the major clone present at initial disease presentation, the majority of 
relapsed ALL cases represent clonal evolution from ancestral, pre-diagnosis leukaemic 
clones (Figure 7.1). Additionally, in a small subset of cases, the clone identified at 
relapse was genetically distinct from the clone at initial presentation, suggesting the 
occurrence of either a second de novo leukaemia, or possibly a therapy-related 
malignancy which was misinterpreted as relapsed disease. 
Similar studies aimed to delineate the clonal nature of relapsed AML are clearly 
warranted, but have yet to be published. Understanding the origins of relapsed AML, 
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as well as t-AML, will prove crucial to the development of novel therapeutic 
approaches which are targeted towards minimising the risk of their occurrence. 
7.1.1. Aims of Chapter 7 
The objective of this work was to perform a small pilot study to compare 
molecular lesions present at initial AML diagnosis to those present at relapse in 
individual patients in order to investigate the clonal origins of relapsed AML. 
Specifically, the experimental aims were to: 
• Isolate leukeamic blasts from matched presentation and relapsed AML 
samples, and prepare DNA for array analysis using the Affymetrix SNP 6.0 
platform. 
• Use genotyping software to identify CNAs and cn-LOH in the presentation 
and relapsed AML samples. 
• Compare abnormalities detected at presentation and relapse in order to 
map the clonal evolution of relapsed disease in each patient. 
• Determine if any genes involved in DNA MMR, or other DNA repair 
pathways, are affected by CNA or cn-LOH in each patient. 
 
INITIATION                        PROGRESSION                           PRESENTATION       REMISSION          RELAPSE
CT
STEM/PROGENITOR 
CELLS
mutation
ANCESTRAL CLONES
Same clone as at 
presentation
Clonal evolution from 
presentation clone
Clonal evolution from 
ancestral clones
Genetically distinct 
leukaemia (therapy-
related?)
or
or
or
Fig 7.1. Clonal evolution of leukaemia.
Leukaemia, like all cancers, occurs due to the sequential accumulation of genetic abnormalities (termed clonal evolution) which eventually results in
transformation to overt leukaemia (presentation). Chemotherapy (CT) can induce remission in the majority of cases, however relapse is likely.
Relapsed leukaemia may occur due to re-population of the dominant presentation clone (green), or as a result of subsequent clonal evolution from
either the presentation clone (yellow) or from an ancestral clone (dark blue/red). An alternative possibility is that the leukaemic clone observed at
relapse is entirely genetically distinct from the original disease (purple), and may represent a second de novo leukaemia or a therapy-related
leukaemia. Note that at disease presentation, only the dominant clone is depicted, although other minor clones might be present. Similar clonal
heterogeneity probably also exists at relapse (see Section 7.3).
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7.2. Results 
7.2.1. Patients 
Matched presentation and relapsed material (mononuclear cells purified from 
peripheral blood) from 6 adult AML patients was obtained from the Newcastle 
Haematology Biobank (Newcastle University) (Table 7.1). Median age at initial 
diagnosis (where information was available) was 37 years (range 32 – 44). Median 
latency period (from date of initial diagnosis to date of diagnosis of relapsed disease) 
was 335 days (range 235 – 719). In the case of patient 3, a second relapse occurred a 
further 1761 days (4.8 years) after the initial relapse, subsequent to bone marrow 
transplant. Karyotypes, where available, are also included in Table 7.1. In the case of 
patients 1, 3 and 6, there was evidence of a cytogenetically abnormal clone at 
presentation. For patient 3, the abnormal clone was not detected at first relapse, and 
at second relapse, karyotype was not determined (relapse karyotype was also not 
determined in the case of patient 1). Similarly in patient 6, the abnormal clone was not 
detected at relapse. All patients were alive at the point of last follow up, with the 
exception of patient 6, although cause of death is unknown. 
7.2.2. Immunophenotypes of Leukaemic Blasts  
In order to estimate the percentage of leukaemic blasts in each mononuclear cell 
sample, flow cytometry was performed to assess expression of CD33 and CD34 (and 
CD45 for exclusion of any residual red blood cells present in the samples) as described 
in Section 2.12.1. Blast cells expressing these surface markers are detected in the 
blood of approximately 90% and 75% of AML patients, respectively (Scolnik et al., 
2002; Linenberger, 2005), but are significantly rarer in normal peripheral blood (see 
Figure 7.2). 
Blast immunophenotypes and blast percentages of the samples are included in 
Table 7.1. All samples consisted of blasts which were positive for CD33 expression. 
With the exception of patient 3 (described below) all blasts were negative for CD34. 
For samples where the blast percentage was lower than 85%, blasts were isolated 
using CD33 MACS® microbeads as described in Section 2.12.2, to ensure sufficient 
purity of leukaemic blast cells for SNP array analysis. 
Patient ID Statusa Date of Diagnosis
Age at 
Diagnosis
Latency 
(days) Karyotype
b Blast Immunophenotype Blast %c
1
P 21/07/93 46,XY,+21c/46,XYd CD33+ CD34- 83.2
R 10/07/95 719 ND CD33+ CD34- 95.0
2
P 22/10/93 46,XX CD33+ CD34- 93.3
R 30/08/94 312 ND CD33+ CD34- 91.8
3
P 08/04/94 32 46,XX,del(7)(q33q36),del(16)(q22q22) CD33+ CD34+ / CD33+ CD34- 26.1 / 39.1
R 09/01/95 33 276 46,XX CD33+ CD34- 38.0
2nd R 05/11/99 38 2037 ND CD33+ CD34+ 41.5
4
P 09/06/94 46,XX CD33+ CD34- 89.5
R 01/06/95 357 ND CD33+ CD34- 94.2
5
P 09/04/98 37 46,XY[20] CD33+ CD34- 96.5
R 10/12/99 38 610 46,XY[20] CD33+ CD34- 91.8
6
P 17/01/94 44 46,XX,del(3)(p1?p2?)/46,XX CD33+ CD34- 98.3
R 09/09/94 45 235 46,XX CD33+ CD34- 50.6
Table 7.1. Selected features of matched presentation and relapsed AML patient samples included in this study.
a P, Initial disease presentation; R, relapsed disease.
b ND, not determined.
c Expressed as a percentage of viable cells, determined by flow cytometry.
d +21c in the karyotype of this patient refers to constitutional trisomy 21 (Down syndrome).
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Figure 7.2. Immunophenotyping of leukaemic blasts in peripheral blood at
presentation and relapse in AML patient 3.
In each case, 10,000 cells were assessed for expression of CD33, CD34 and CD45 via
flow cytometry. Viable cells were identified based on forward scatter and side scatter
properties (left plots; R1 gate). Negative CD45 expression (centre plots) was used to
identify any contaminating red blood cells (red). Normal blood leukocytes were
positive for CD45 expression but negative for both CD33 and CD34 (pink). Leukaemic
blasts were identified based on positive expression of CD33 and/or CD34 (right plots).
Blast percentages are shown in Table 7.1 and described in the text. Dashed lines
indicate cutoff for positive expression of each marker, determined based on analysis
of fluorochrome-conjugated isotype controls (data not shown).
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Two apparent blast populations were identified at presentation in patient 3 
(Figure 7.2) and SNP array analysis was performed independently on each cell 
population. CD33+CD34+ blast cells were isolated initially using CD34 microbeads, 
following which the CD33+CD34- cells were isolated from the remaining population 
using CD33 microbeads. At first relapse, all blasts were CD33+CD34-, whereas at 
second relapse, all blasts were CD33+CD34+ (Figure 7.2), providing preliminary 
evidence that the two observed relapses in this patient were due to emergence of 
different cell clones. In both cases, initial blast percentages were below 85% (see Table 
7.1) and so were subsequently isolated using CD33 microbeads. 
7.2.3. Copy Number Abnormalities 
After exclusion of changes in copy number which likely represent constitutional 
genetic variation (see Section 2.13.2), a small number of apparently somatic CNAs 
were detected in 4 of the 6 AML patients (Table 7.2). The majority of CNAs were 
trisomies of the detected region (copy number 3), ranging in size from 103.1kb 
(13q32.1; patient 1) and affecting a single gene, to 74.5Mb, representing the majority 
of a whole chromosome and affecting approximately 430 genes (Chr14; patient 3). The 
remainder, with the exception of a complex abnormality of chromosome 17p in 
patient 3 (see below), were monosomies of the detected region (copy number 1), and 
ranged in size from 1.1Mb (16q22.1, containing 48 genes; patient 3) to 15.5Mb 
(3p14.1-p12.1, 15 genes; patient 6). Several alterations were common to both 
presentation and matched relapse, although there were also examples of alterations 
unique to presentation or relapse (Table 7.2). 
In the case of patient 1, the CNA affecting chromosome 21 (copy number 3) 
correlated with the reported karyotype (constitutional trisomy 21). The same CNA was 
detected in the relapse sample, consistent with constitutional trisomy 21 in this 
patient, although karyotype had not been formally determined. All other CNAs 
detected in this patient using SNP arrays were too small to be detected cytogenetically 
(also the case for the CNA detected at presentation in patient 2). 
Patient ID Chromosome
PRESENTATION RELAPSE
Band Copy Number
Length
(Mb)
No. 
Genesa Band
Copy 
Number
Length
(Mb)
No. 
Genesa
1
6 NDb q25.3 3 0.3 0c
12 q13.3 3 0.1 6 As presentation
13 q32.1 3 0.1 1 As presentation
21 pter-qter 3 46.9 ~220 As presentation
2 15 q25.3 3 0.4 3 As presentation
3
7 q33 – q36.1d 1 14.9 139 ND
14 ND q12 – q32.33e 3 74.5 ~430
16 q22.1d 1 1.1 48 q22.1f 1 1.1 48
17 ND pter – p13.1e 1 8.1 196
17 ND p13.1e 4 1.1 15
17 ND p13.1 – p12e 3 3.0 19
6 3 p14.1 – p12.1 1 15.5 15 As presentation
Table 7.2. Regions of detected copy number abnormality in AML patients at presentation and relapse.
a Estimated based on current RefSeq collection.
b ND, not detected.
c This region was also searched for known micro RNA genes and was found not to contain any.
d Detected in both blast populations at presentation.
e Detected at second relapse only.
f This CNA was detected at 2nd relapse (but not 1st relapse), however reported breakpoints were slightly different to those at presentation,
suggesting it might be an independent CNA (see text).
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COPY NUMBER: 1 234
PRESENTATION
(CD33+CD34-)
PRESENTATION
(CD33+CD34+)
1ST RELAPSE
2ND RELAPSE
Figure 7.3. Complex copy number abnormality of chromosome 17 (pter – p12) at second relapse in AML patient 3.
Shown is a screen print taken from Genotyping Console software, demonstrating copy number analysis of chromosome 17p in presentation and
relapse samples from AML patient 3. Displayed is the copy number profile of chromosome 17p (see ideogram at top of screen print) for each sample
in the form of log2 ratio at each marker. This is calculated by the software for every marker (SNP or copy number probe) as log2 of the signal
intensity in the sample divided by the mean signal intensity of all normal samples at that particular marker. Regions of copy number variation are
determined from the log2 ratios using segmentation algorithms. Regions of copy number abnormality reported at second relapse are represented by
the annotation below the screen print.
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CNA of chromosome 3 at presentation and relapse in patient 6 correlated with 
the reported karyotype at AML presentation (del(3)(p1?p2?)), although at relapse, a 
normal karyotype was reported. In the case of the relapse sample, the blast 
percentage determined by immunophenotyping was 50.6% (see Table 7.1), 
furthermore the blast population at relapse might have been heterogeneous (as 
reported at presentation), suggesting that cells with the deletion could have been 
missed during karyotypic analysis which only analyses 20 cells. 
For patient 3, CNA of chromosome 7q (copy number 1) detected at presentation 
was consistent with the reported karyotype (del(7)(q33q36)). Additionally, a region of 
monosomy was detected at 16q22.1 in both blast populations at presentation 
(consistent with karyotype, del(16)(q22q22)) and also at second relapse (karyotype not 
determined). In both presentation clones, the breakpoints discerned for this region 
were identical, however at second relapse the breakpoints differed slightly from those 
at presentation, resulting in a shorter reported region (approximately 28kb shorter). It 
is possible therefore, that the 16q22.1 abnormality at second relapse is distinct from 
that detected at presentation, as discussed below. The complex 17p abnormality 
detected in patient 3 at second relapse involved a region of monosomy, as well as 
regions of trisomy and tetrasomy (copy number 4) (Figure 7.3). It is likely that this is 
the result of a complex chromosomal rearrangement, although this could not be 
confirmed without the karyotype. Alternatively this may also represent clonal 
heterogeneity within the blast population, as suggested above. Copy number gain was 
also reported for the majority of chromosome 14 at second relapse, suggesting a 
cytogenetically-detectable abnormality of this chromosome was also present.  
Although the primary focus of this pilot study was investigation of clonal 
evolution, a brief search of the genes in regions affected by CNA was performed in 
order to identify any potential candidate genes involved in AML pathogenesis. Of 
particular interest given the focus of this research project was whether any DNA MMR 
genes were affected by CNA or cn-LOH. However, no DNA MMR genes, nor any genes 
which have been previously associated with AML were identified in regions of CNA at 
either presentation or relapse, with the exception of heterozygous loss affecting the 
TP53 gene (17p13.1) in patient 3 at second relapse. Interestingly, a number of genes 
involved in other DNA repair pathways were also found within CNA regions in patient 3 
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at second relapse. These were heterozygous gain affecting ATXN3 (nucleotide excision 
repair), RAD51L1 and XRCC3 (both DSB repair), and heterozygous loss affecting RPA1 
(involved in several DNA repair pathways). It is possible therefore, that defects in DNA 
repair which could affect response to DNA-damaging cytotoxic therapies may have 
contributed to the development of the second relapse in this patient. 
Abnormalities affecting genes involved in drug transport and/or metabolism may 
represent one factor contributing to the development of relapsed AML through 
acquisition of chemoresistance. Therefore, regions of CNA were also interrogated for 
genes implicated in drug resistance (genes encoding multidrug transporters and drug 
metabolising enzymes) as well as those specifically associated with intracellular 
metabolism of Ara-C (see Section 1.5.3 for details of these pathways), but none were 
found in any of the patients studied.   
7.2.3.1. Putative Focal CNAs 
In addition to the abnormalities listed in Table 7.2, which were identified 
automatically using Affymetrix Genotyping Console software, a more detailed manual 
interrogation of the raw data was performed to identify any CNAs which might affect 
key genes involved in either leukaemogenesis or drug resistance. A small number of 
putative focal abnormalities were observed; the most significant in terms of this 
project being a region of monosomy incorporating the MSH3 gene (5q14.1) at relapse 
in patient 6. This region was approximately 9.5kb in length and spanned exons 2 and 3 
of MSH3. In addition, a small (0.3kb) region of tetrasomy was detected within exon 6 
of the BRCA1 gene (17q21.2) at second relapse in patient 3, again potentially 
implicating defective DNA repair in development of the late relapse in this patient. It is 
important to note in both cases that these abnormalities affected only a small number 
of markers and therefore escape detection by the algorithms used by the Genotyping 
Console software. Confirmation of their presence in individual patients by another 
method, such as fluorescence in situ hybridisation (FISH), is therefore required. 
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7.2.4. Copy-Neutral Loss of Heterozygosity 
In addition to defining CNAs, an analysis of regions of cn-LOH was also performed 
by comparison of the SNP genotypes of individual samples to pooled reference 
samples from the International HapMap project. Using this method of analysis, regions 
of cn-LOH were frequently observed in AML patients, with a mean of 71.1 and 70.7 cn-
LOH regions detected throughout the genome at presentation and relapse, 
respectively. Given that LOH analysis was performed using pooled reference samples 
as opposed to matched reference material from the individual patients, it was not 
possible to confidently determine which of the detected regions were constitutional 
and which were specific to the leukaemic blasts. For this reason, only regions of cn-
LOH which were unique to either the presentation or relapse samples were further 
analysed. 
Regions of cn-LOH which were unique to either the presentation or relapse 
sample in individual patients are listed in Table 7.3. Size of detected cn-LOH regions 
ranged from 0.1Mb to 95.3Mb (median 1Mb); the largest region representing cn-LOH 
of the majority of chromosome 13. In combination with the detected regions of CNA, 
these regions can be used to estimate the possible clonal origins of relapse in each 
patient. In addition, regions of cn-LOH acquired at relapse might contain mutated 
duplicated genes or unmask recessive mutations that could contribute to the 
development of relapsed AML. For instance, acquisition of cn-LOH of chromosome 13, 
which was observed in 2 patients in this study, has previously been associated with the 
generation of homozygous FLT3 (13q12) mutations via recombination-mediated gene 
duplication of a single copy (Raghavan et al., 2008). Candidate genes in regions of 
acquired cn-LOH which may warrant further investigation for mutational status include 
FLT3 (patients 2 and 4), and the DNA repair genes BRCA2 (13q12.3; patients 2 and 4), 
ERCC5 (13q33.1; patients 2 and 4) and LIG4 (13q33.3; patients 2 and 4). 
Patient 
ID Chromosome
PRESENTATION RELAPSE
Band Length (Mb)
No. 
Genesa Band
Length 
(Mb)
No. 
Genesa
1
1 p35.2 - p35.1 1 22 NDb
1 p34.3 0.6 11 ND
1 p12 0.2 3 ND
2 q22.3 1.5 6 ND
3 q11.2 0.7 1 ND
3 ND q13.13 1 1
4 q12 1 0 ND
4 ND q13.2 0.3 5
4 q13.2 0.7 5 ND
4 q26 1.1 3 ND
4 q31.21 1.6 7 ND
5 p15.1 1.2 2 ND
5 q13.3 1 5 ND
6 p21.33 0.9 31 ND
6 q12 1.2 1 ND
6 ND q12 1.2 2
6 q22.31 1.2 5 ND
7 ND q22.1 1 20
8 ND q24.3 0.1 6
10 ND q22.3 1 9
12 q21.31 1.1 0 ND
13 q21.1 1.1 0 ND
16 ND p12.2 1 8
16 ND p11.2 1.1 0
17 ND q25.1 1 33
18 q11.2 1.2 6 ND
2 13 ND q12.11 - qter 9.4 ~280
17 q21.2 1.3 62 ND
3
1 ND q43f 1 3
2 ND p12g 1 0
2 ND p12h 1 0
2 ND q11.2g 0.3 8
5 ND p14.2g 1.2 1
6 ND q13g 1.2 7
7 ND q11.23f 1.9 19
7 q34c 1.4 13 ND
8 p11.21d 0.4 5 ND
8 q21.2e 1 9 ND
10 ND q11.22f 1.6 8
12 ND q12f 1 5
14 ND q32.33h 0.4 8
16 ND p12.2g 1 8
19 ND p12g 2 9
X ND p11.3f 1 12
X ND p11.23g 1.2 42
X ND q13.1g 2.1 11
Table 7.3. Regions of detected copy-neutral LOH in AML patients at presentation
and relapse (continued on next page).
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Patient 
ID Chromosome
PRESENTATION RELAPSE
Band Length (Mb)
No. 
Genes Band
Length 
(Mb)
No. 
Genes
4
1 p12 0.1 1 ND
2 p15 0.8 4 ND
7 p11.2 1 11 ND
7 ND q11.23 0.9 15
13 ND q12.11-qter 95.2 ~300
15 ND pter-q11.2 20.3 6
X p21.1 1.1 7 ND
5
1 ND q25.3 1.1 5
2 ND q33.1 1.1 9
6
10 ND q11.23 1 11
16 ND p11.2 0.1 0
Table 7.3. Regions of detected copy-neutral LOH in AML patients at presentation
and relapse (continued from previous page).
a Estimated based on current RefSeq collection
b ND, not detected.
c Detected only in CD33+CD34+ blast population at presentation
d Detected in both blast populations at presentation
e Detected only in CD33+CD34- blast population at presentation
f Detected at both first and second relapse
g Detected at first relapse only
h Detected at second relapse only
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7.3. Discussion 
Despite being of limited size, this study demonstrates that the pattern of clonal 
evolution of relapsed AML likely shares some similarities with ALL, with respect to the 
origins of clones responsible for relapsed disease. In all patients studied there was 
clear evidence of a relationship between the presentation and relapse AML samples. In 
two cases (patients 5 and 6), relapse appeared to represent clonal evolution of the 
major presentation leukaemic clone. This is illustrated in the case of patient 6 (Figure 
7.4A) in which all abnormalities detected at presentation were also present at relapse, 
but were accompanied by the acquisition of further regions of cn-LOH unique to the 
relapse clone.  
In three cases (patients 1, 2 and 4), the presence of abnormalities at diagnosis 
but not at relapse suggests that, rather than evolving directly from the major 
presentation clone, the relapse clone was derived from an ancestral, pre-leukaemic 
clone which also gave rise to the major clone at presentation. This is illustrated in the 
case of patient 1 in Figure 7.4B. In this case, the acquisition of a large number of 
regions of cn-LOH unique to the relapse clone (as well as a unique region of CNA; see 
Table 7.3 and Table 7.2, respectively) could suggest evolution from a particularly early 
ancestral clone. Alternatively, it is possible that relapse evolved from a minor 
leukaemic clone at presentation that was not detected using SNP arrays, which are 
limited in their scope to identify such low frequency clones. 
For the remaining patient (patient 3), in which first relapse was followed 4.8 
years later by a second relapse, the available evidence suggests that at least one of the 
relapses is in fact independent from the initial presentation disease. Based on 
immunophenotypic and cytogenetic data (Table 7.1) in combination with detected 
CNAs (Table 7.2), it appears that the second relapse in this patient was derived from an 
ancestral clone which also gave rise to both presentation clones (Figure 7.4C i). Given 
that the clone detected at first relapse does not demonstrate any cytogenetic or CN 
abnormalities, this suggests it to be an independent AML (or it could be derived from a 
very early clone prior to acquisition of any numerical abnormalities). Addition of the 
cn-LOH data (Table 7.3) however suggests a different model. The observation of a 
number of regions of cn-LOH which are common to both relapses, but not observed in 
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either presentation clone, suggests that both relapse clones in fact share a common 
ancestor and are both semi-independent of the initial presentation AML (Figure 7.4C 
ii). In this case, the 16q CNA detected at second relapse must have occurred 
completely independently in initial presentation disease and second relapse. 
Consistently, independent acquisition of the same abnormality in two or more clones 
has been demonstrated in ALL (Anderson et al., 2011). Also consistent with this model, 
the breakpoints of the 16q CNA at second relapse in patient 3 were slightly different to 
those reported at presentation (which were identical in both presentation clones), 
suggesting it to be derived from an independent event. Sequencing of the breakpoints 
is required to confirm whether the presentation and relapse 16q CNAs are in fact 
unique. 
It is not clear from this analysis whether the abnormalities specific to relapse in 
these patients were already present in a minor clone at AML presentation and selected 
for at relapse, or whether they were acquired as new genomic alterations subsequent 
to initial therapy. This again highlights a caveat of the use of SNP arrays in the study of 
CNAs in that the results reflect predominant cell populations and fail to detect 
alterations in minor, less abundant clones, as suggested above. Approaches designed 
to detect alterations at low frequency, or even in single cells, could be used to further 
determine the temporal acquisition of specific lesions, and whether they developed as 
a consequence of cytotoxic therapy. In the aforementioned study performed in ALL 
(Mullighan et al., 2008), lesion-specific PCR assays provided evidence for the existence 
of the relapse clone at diagnosis in the majority of samples, suggesting presence of this 
clone as a minor subpopulation at initial disease presentation. Further extension of this 
work, in which the presence of multiple CNAs was investigated in single cells (using 
FISH), demonstrated considerable genetic heterogeneity of clones at ALL presentation 
(Anderson et al., 2011), therefore providing a rich, genetically diverse population from 
which disease can progress. It is possible that a similar scenario exists in AML, although 
currently this is more difficult to establish given that relatively few CNAs are identified 
in AML (Radtke et al., 2009; Walter et al., 2009). Clonal heterogeneity, if confirmed in 
AML, will likely have therapeutic implications, in particular in the use of targeted 
therapies, as will be described in Chapter 8. 
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Figure 7.4. Clonal evolution of relapse in AML patients (continued on next page).
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Figure 7.4. Clonal evolution of relapse in AML patients (continued from previous
page).
A. Evolution from the major clone detected at presentation (patient 6).
B. Evolution from an ancestral clone not detectable at disease presentation (patient 1).
C. Evolution from an independent clone (patient 3). Pathways are described in the text.
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Delineating the clonal origins of relapsed AML only represents one part of the 
complete picture of how and why relapse occurs. Understanding mechanisms which 
promote clonal expansion is an equally important goal. For example, mutagenic 
therapy can initiate leukaemogenesis leading to t-AML (see Section 1.4.1.1), but also 
probably plays a role in promoting relapse following treatment for de novo disease. For 
some malignancies, relapse can be attributed in large part to the acquisition of 
generalised drug resistance mechanisms, such as overexpression of membrane efflux 
pumps (drug transporters) resulting in reduced intracellular levels of multiple 
chemotherapeutic agents (Choi, 2005). Likewise, in AML, reduced intracellular levels of 
Ara-CTP are associated with clinical resistance to Ara-C (Galmarini et al., 2002; Cros et 
al., 2004), demonstrating that the Ara-C metabolic pathway is closely related to Ara-C 
resistance. Furthermore, in freshly isolated blast samples from AML patients, a low 
cellular content of membrane-bound nucleoside transporters is correlated with Ara-C 
resistance (Gati et al., 1997). Taken together, these data suggest that AML relapse 
could be due, at least for some patients, to acquired resistance to Ara-C through 
genetic aberrations affecting genes associated with intracellular transport and/or 
metabolism. Larger studies will be required to identify all mechanisms responsible for 
promoting disease relapse. Furthermore, it is also important to consider that 
aberrations detected in this study (CNAs) represent only one type of genetic alteration; 
genome sequencing analysis (see below) coupled with analysis of gene expression and 
epigenetic changes will also be important requirements for understanding mechanisms 
contributing to development of relapsed as well as therapy-related AML. 
Although only a small number of patients were analysed in the current study, the 
findings suggest that the occurrence of CNAs is not a prominent feature of AML. This is 
in agreement with previous studies in which CNAs were identified in only 50-60% of 
patients at presentation, with a mean of 2.3 CNAs per genome (Radtke et al., 2009; 
Walter et al., 2009). The observation of MSI in a subset of relapsed AML patients 
(Ohyashiki et al., 1996; Tasaka et al., 1997) suggests that acquisition of a genomic 
instability phenotype, possibly induced by the effects of chemotherapy (similar to 
methylating agent-related t-AML), could be one of the mechanisms promoting clonal 
expansion leading to relapsed disease. If this was the case, AML clones at relapse 
might be expected to demonstrate an increase in CNAs relative to genomically stable 
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clones at presentation. In this study, a similar number of CNAs were observed at 
relapse relative to initial disease presentation, which would argue against this form of 
genomic instability as a major contributing mechanism. Furthermore, no confirmed 
abnormalities affecting DNA MMR genes were identified in these patients, which 
would confer a mutator phenotype. However, it should be noted that the SNP array 
approach cannot detect copy-neutral DNA mutations which may also affect gene 
function, such as base substitutions, hence a mutator phenotype cannot be excluded 
in these patients. Indeed, base substitution and gene silencing are the primary 
mechanisms of DNA mismatch repair gene inactivation. It remains possible that MSI+ 
relapsed AML are incorrectly classified as relapsed disease, and are in fact cases of t-
AML arising from a completely independent cell of origin, similar to the scenario 
suggested in ALL (Mullighan et al., 2008). Further interrogation of the clonal origins of 
apparent MSI+ relapsed AML would provide valuable clues as to whether such cases 
are bona fide relapse, and whether genomic instability represents a mechanism 
contributing to relapse in AML.  
Data from this pilot study suggest that larger and more extensive investigations 
of the clonal origins of relapse in AML are warranted. Indeed, it is now planned to 
extend this study to include more patients and to perform ‘ultra deep’ exomic 
sequencing using high-throughput pyrosequencing to further delineate the clonal 
relationships of presentation and relapse in AML.  This so-called ‘next generation’ 
approach will be employed to sequence the entire exome of the leukaemic blast 
population at presentation and relapse in each patient, enabling detection of DNA 
point mutations and small insertions/deletions acquired at relapse. However, rather 
than sequencing pools of DNA templates, as is the case in conventional sequencing 
approaches, ‘ultra deep’ sequencing allows simultaneous sequencing of individual 
molecules of DNA (termed massively parallel sequencing), meaning abnormalities 
present at very low levels (in as few as 1% of cells, depending on level of coverage 
achieved) can be detected. The proof of principle of this approach has been 
demonstrated by the publication of the sequences of two AML genomes at 
presentation, which enabled identification of novel mutations which might contribute 
to AML pathogenesis (Ley et al., 2008; Mardis et al., 2009). The planned exomic 
sequencing of matched presentation and relapsed AML samples will permit extension 
of these findings, enabling identification of mutations potentially responsible for 
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development of relapse in individual patients. Additionally, this approach will allow 
investigation of the genetic heterogeneity of AML at both presentation and relapse 
(which is not possible using SNP array, as discussed above), providing further insights 
into the origins of relapse-initiating clones. 
7.3.1. Summary of Chapter 
In conclusion, this pilot study has demonstrated the following: 
• Clonal evolution leading to relapse in AML shares similarities with ALL in 
that, for the majority of cases, relapse represents evolution from 
ancestral pre-diagnosis clones, and does not often evolve directly from 
the dominant clone at disease presentation. 
• Although yet to be formally confirmed, the presence of low numbers of 
relapse-initiating clones at initial presentation has implications for the use 
of targeted therapeutic approaches in AML. 
• Larger studies and alternative approaches (e.g. deep sequencing) are 
required to fully delineate the heterogeneity of AML and disease 
evolution from diagnosis to relapse. 
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Chapter 8. Concluding Discussion
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8.1. DNA MMR Dysfunction and Chemoresistance in t-AML 
The poor survival of patients with t-AML is a function of multiple competing risks, 
including persistence of the primary malignancy, organ dysfunction from prior 
therapies, prolonged immunocompromised status, patient age, and lack of uniform 
treatment (Smith et al., 2003; Godley and Larson, 2008). Chemoresistance is also likely 
to be a significant contributing factor, particularly in the case of methylating agent-
related t-AML, given the probable origin of the condition, in many cases, from a 
population of DNA MMR-defective, genomically unstable cells selected (or initiated) 
due to tolerance to cytotoxic therapy (see Section 1.4.1.1). Furthermore, associations 
between DNA MMR dysfunction and adverse treatment response have been 
highlighted in other malignancies in which MMR defects are commonplace. For 
instance, defective DNA MMR has been associated with poor response to 5-FU therapy 
in colorectal cancer patients (Ribic et al., 2003; Carethers et al., 2004; Jover et al., 
2006), although the contribution of other repair pathways is not clear. Despite the 
possibility that DNA MMR-mediated chemoresistance may be operating in t-AML, 
there have yet to be any in vitro or in vivo investigations aimed at elucidating an 
association between DNA MMR status and response to routine chemotherapeutic 
regimes used in t-AML treatment, of which nucleoside analogues form the backbone. 
Through the use of MMR-proficient and MMR-dysfunctional cell line models 
(widely available, extensively studied cell line pairs, as well as others generated 
specifically for use in this project using gene knockdown), this study has provided the 
first evidence that DNA MMR status affects response to nucleoside analogues in 
routine use for the treatment of t-AML, including Ara-C, clofarabine and fludarabine. 
Notably, the investigations herein (Chapters 3 and 4) demonstrate that apparent 
defects of MSH3, and hence the MutSβ complex, confer tolerance to the cytotoxic 
effects of these nucleoside analogues, suggesting that chemoresistance due to MSH3 
defects could represent a potential factor contributing to poor outcome in t-AML 
patients. 
The detailed mechanisms underlying the observed phenotypes remain to be fully 
elucidated, and the postulated roles for DNA MMR components in cellular response to 
nucleoside analogues (described in Section 3.3) should be formally investigated. One 
thing which remains particularly unclear is how two apparently opposing defects in 
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MMR (i.e. loss of MSH3 due to gene knockdown, or overproduction of MSH3 due to 
genetic amplification; Sections 3.2.6 and 4.2.2 respectively) give rise to the same drug 
tolerant phenotype, but only when the function of the MutSα complex is unperturbed 
(see below). This particular finding suggests multiple roles for DNA MMR components 
in mediating response to chemotherapy-induced DNA damage, and possible effects on 
other cellular functions, including other DNA repair activities. Further work will be 
required to delineate these mechanisms. 
8.2. Exploitation of DNA MMR Dysfunction to Improve Therapeutic Outcome 
Given the identification of DNA MMR defects as a possible causative factor in an 
increasing repertoire of malignancies, an important goal is the identification of current 
chemotherapeutic agents (or indeed the development of novel agents) which are 
selectively toxic to MMR-defective cells. Some examples have already been 
highlighted, of particular note the cytidine nucleoside analogue gemcitabine, which is 
differentially cytotoxic to MSH2 or MLH1-deficient colorectal carcinoma cells relative 
to wild type counterparts in vitro (Takahashi et al., 2005).  
In the present study, defects of the MutSα complex resulted in a moderate 
increase in sensitivity to nucleoside analogues, relative to MMR-proficient parental 
counterparts (Chapter 3). Furthermore, this response appeared to override any effects 
of MutSβ dysfunction in cells in which the formation of both MutSα and MutSβ 
complexes were perturbed. A number of nucleoside analogues are currently being 
trialled in AML treatment, many with favourable results in t-AML patients and other 
historically poor prognosis patient groups (see Section 1.3.2.2). The findings herein 
could help to explain the favourable responses observed in these patients. Notably, 
clofarabine is being used successfully in the treatment of elderly AML, a subgroup also 
associated with increased incidence of MSI and putative DNA MMR dysfunction (Das-
Gupta et al., 2001). This investigation suggests the generally favourable response 
observed in these patients might be due, in part, to DNA MMR status, although 
increased tolerance of the drug due to its favourable toxicity profile is also likely a 
contributory factor (see Section 1.5.4).  
Defects in DNA MMR components could also impact on other cellular functions 
and other DNA repair pathways, some of which could be exploited for patient benefit. 
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For example, DNA MMR dysfunction can affect HRR (Worrillow and Allan, 2006), 
although the precise role of specific MMR components has yet to be fully determined. 
Defects in DNA repair function suggests the possibility of using a so-called ‘synthetic 
lethality’ approach in treatment of MMR deficient t-AML patients, in which inhibitors 
of other DNA repair pathways are used to potentiate the effects of DNA damaging 
agents. This approach has already been used successfully in the treatment of solid 
cancers, such as breast cancer (Calvert and Azzariti, 2011). PARP-1 is an enzyme 
involved in the BER pathway, the activity of which can be blocked using various small 
molecule inhibitors. Inhibition of PARP-1 in vitro has previously been shown to be 
selectively toxic to MMR deficient cells when used in combination with the 
chemotherapeutic methylating agent, temozolomide (Curtin et al., 2004). In MMR 
proficient AML patients, the possibility exists of developing small molecule inhibitors of 
DNA MMR components which could be used in combination with inhibitors of other 
DNA repair components, such as PARP-1, to increase the efficacy of established 
genotoxic DNA damaging chemotherapeutic agents. Therapeutic approaches aimed at 
disrupting DNA MMR components however, will need to be used with caution due to 
their potential to increase mutation frequency. Such an effect in either leukaemic or 
non-leukaemic cells could promote the development of relapsed or t-AML, 
respectively, particularly if mutagenic nucleoside analogues are also included in 
treatment (see Section 8.4, below). Evidence suggests that exposure to agents that 
interact with DNA MMR (notably methylating agents and 6-TG), although highly 
effective at eradicating malignant cells, can promote emergence of genomically 
unstable DNA MMR defective sub-clones with a mutator phenotype (described in 
Section 1.4.1.1). The use of agents which specifically disrupt DNA MMR function could 
have a similar effect and should therefore be used with caution.  
8.3. Detection of DNA MMR Defects in t-AML Patients 
Given the potential for DNA MMR defects to influence outcome and/or direct 
therapeutic choice, retrospective or prospective studies aimed at detection of specific 
DNA MMR defects and their potential association with treatment response in t-AML 
patients are warranted. A small number of studies have previously demonstrated 
mutations in MSH2 in t-AML patients (Horiike et al., 1999; Zhu et al., 1999). Similarly 
there have been some reports of aberrations affecting MLH1 expression (Casorelli et 
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al., 2003). A putative deletion within the MSH3 gene was observed at AML relapse in 
this study (Chapter 7), although whether aberrations affecting other MMR 
components, in particular MSH3, occur in t-AML remains to be determined. 
Importantly, such studies would also determine whether specific DNA MMR 
abnormalities affect leukaemic blast cell response to clinically relevant concentrations 
of nucleoside analogues in vivo, as suggested by the in vitro findings herein. 
Translation of these findings into routine clinical practice would require an 
appropriate method for screening MMR defects at disease presentation. Observation 
of MSI at certain microsatellite markers is used as a biomarker of defective MMR in 
HNPCC (Umar et al., 2004), however the results herein suggest this would not be 
suitable in AML patients, given that it does not discriminate between different 
abnormalities which might be associated with different treatment responses. Gene 
expression profiling of DNA MMR genes is a second possibility, although this will fail to 
identify mutations which affect translation or protein function, but not gene 
expression. For example, bi-allelic mutation of MSH6 in MT-1 results in lack of MSH6 
protein, but this is not detected using quantitative RT-PCR, as gene expression is 
unaffected (see Figure 3.2). Techniques which assess cellular levels of DNA MMR 
proteins, such as western immunoblotting, are also a possibility, although this 
approach is rarely used clinically given that a large amount of cellular material is 
required. Immunohistochemical staining has been demonstrated as a straight-forward 
and cost effective method of assessment of DNA MMR protein expression in colorectal 
cancer (Newton and Hill, 2010). A similar approach could be used for t-AML, especially 
since suitable material (bone marrow or peripheral blood smears) is already routinely 
prepared for assessment of cellular morphology at disease presentation. In the case of 
both techniques however, mutations which produce a non-functional protein might 
still be missed. Furthermore, protein expression levels may vary between individuals, 
requiring appropriate controls to be established. Next generation targeted DNA 
sequencing is currently being assessed in myeloid leukaemia patients as a means of 
mutation detection (Grossmann et al., 2011b; Grossmann et al., 2011a). Although this 
approach is in its infancy, it is possible that DNA MMR genes could form part of a panel 
of prognostically relevant genes routinely sequenced for mutations at disease 
presentation (if of course, recurrent mutations associated with treatment response are 
identified). 
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8.4. Chemotherapy Involving Nucleoside Analogues and Risk of t-AML Development 
Several lines of evidence provided in this study suggest that nucleoside 
analogues used either alone, or in combination with agents known to interact with 
DNA MMR components, could result in risk of therapy-associated complications such 
as adverse treatment response and risk of relapse or t-AML development. 
Data reported herein provide the first evidence that exposure to Ara-C is 
mutagenic to DNA (Chapter 6), demonstrating the potential genotoxicity of this agent 
and implicating Ara-C itself as a risk factor for the development of t-AML. A similar 
conclusion can also be drawn regarding fludarabine (see Section 6.3), which might 
partly explain why risk of developing t-AML is increasingly being associated with prior 
use of this drug (Coso et al., 1999; Morrison et al., 2002; McLaughlin et al., 2005; 
Carney et al., 2010). In vivo, if Ara-C-induced mutation occurred in a gene involved in 
haematopoietic regulation, it could contribute to the development of t-AML. Similarly, 
if a mutation occurred in a gene implicated in Ara-C resistance, such as one involved in 
cellular uptake or metabolism of the drug, this could increase the likelihood of relapse 
or development of treatment-refractory disease. Such a mutation might be responsible 
for the Ara-C-resistant cell lines generated in this project (Chapter 5), although this was 
not determined. Given the in vitro mutagenicity of Ara-C demonstrated in this study, 
an in vivo investigation into the genetic consequences of Ara-C chemotherapy is 
warranted and would provide important insight into the potential involvement of this 
and other nucleoside analogues in development of t-AML, as well as relapsed and/or 
refractory disease. Human T-cells containing mutations at the HPRT locus can be 
cloned directly from peripheral blood and investigations have demonstrated the HPRT 
locus as an efficient biomarker reflective of genome-wide somatic mutational events 
occurring in non-malignant cells (Albertini et al., 1993). Indeed, this approach has been 
used to investigate the in vivo mutagenicity of chemotherapeutic regimes for the 
treatment of ALL (Finette et al., 2000; Kendall et al., 2006), and could easily be 
recapitulated in AML patients receiving Ara-C chemotherapy. 
As a result of treating myeloid cells with escalating doses of a methylating agent 
(Chapter 5), a cell line with reduced expression of MSH3 protein (and over-expression 
of MSH6) was generated, which demonstrated moderate tolerance to the cytotoxic 
effects of nucleoside analogues. Furthermore, in vitro mutation assay (Chapter 6) 
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demonstrated that mutability of Ara-C was enhanced in cells with defective DNA MMR. 
If a similar mechanism were operating in vivo, the therapeutic combination of a 
methylating agent with a nucleoside analogue could potentially result in an adverse 
treatment response and increased risk of relapse or t-AML development due to 
increased mutability. A similar phenotype might be expected in the case of 
simultaneous use of a thiopurine and a nucleoside analogue, given that these agents 
can also select for DNA MMR defects (Offman et al., 2004), although in the 
investigation herein, this was not observed. 6-Mercaptopurine, a 6-TG analogue with 
similar cytotoxic mechanisms, is used in combination with Ara-C in the treatment of 
children with ALL (Pui et al., 2011). Reports suggest that t-AML is a significant risk in 
survivors of ALL (Barnard and Woods, 2005), which might be a consequence of the 
combined use of a mutagenic agent with another agent that contributes strongly to 
genomic instability. Consistently, HPRT mutations are observed at an increased level in 
ALL patients (Kendall et al., 2006), although which particular agent(s) are responsible is 
presently unclear.  
The use of agents which do not directly interact with DNA MMR components, 
but which could affect MMR function through a coincidental mechanism should also 
be used with caution if combined with agents that do specifically interact with the 
MMR pathway. A notable example of this is MTX, where exposure can lead to co-
amplification of DHFR and MSH3 loci (as described in Section 4.1). Children with ALL 
are routinely treated with MTX, in combination with 6-mercaptopurine and Ara-C, 
during the maintenance phase of chemotherapy (Pui et al., 2011). Concerns have 
previously been raised about using MTX and thiopurines in combination 
chemotherapy, given that co-resistance to both agents could be acquired due to gene 
amplification. The observation herein that MSH3 overexpression (in HL-60R; Chapter 4) 
confers tolerance to the cytotoxic effects of Ara-C in vitro, suggests that Ara-C 
resistance in vivo should be considered as a potential risk of using this nucleoside 
analogue in combination with MTX in ALL treatment. However, the observation that 
TK6 MTXR and PreB697 MTXR, which were generated using clinically relevant 
concentrations of MTX (Matheson et al., 2007), were not differentially sensitive to Ara-
C, relative to respective parental cell lines, argues against this being a significant 
clinical risk. Nevertheless, it is possible that additional selective pressure during long-
term drug exposure could result in further amplification of these loci to an extent 
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where DNA MMR function is perturbed. Ara-C and MTX are also used in combination in 
the treatment of primary central nervous system lymphomas (Ferreri et al., 2009), and 
co-resistance to these agents through acquired gene amplification should also be 
considered a risk in this malignancy. 
Genetic susceptibility determined by polymorphic variation can also affect risk of 
adverse therapeutic responses, and/or the risk of developing relapsed or therapy 
related malignancy. Of particular relevance to this work are studies which have 
identified polymorphisms in DNA MMR genes which may confer increased risk of t-
AML development (described in Section 1.4.6). Susceptible individuals, at diagnosis of 
a primary malignancy, are particularly unlikely to be suitable for treatment with agents 
known to be mutagenic to DNA, including Ara-C. This highlights the importance of 
developing evidence-based personalised medicine, the goal of which is to 
prospectively identify patients more or less likely to respond favourably to particular 
therapies, in order to tailor therapeutic regimes appropriately. The aim of such an 
approach is to both improve initial treatment outcome, as well as minimise risk of 
therapy-related complications. Screening for common DNA MMR polymorphisms 
associated with increased risk of t-AML development may be warranted at diagnosis of 
a de novo malignancy, particularly in cases where frontline treatment involves the use 
of agents known to interact with the DNA MMR pathway. 
8.5. Clonal Evolution and Clonal Heterogeneity in AML 
A key recent investigation performed by Anderson et al., (2011) demonstrated 
for the first time that genetically distinct populations of leukaemia propagating cells 
are present at low levels at the time of leukaemia diagnosis that can survive 
chemotherapy and provide a reservoir for clonal expansion leading to relapse. The 
pilot study performed during this project (Chapter 7) provides evidence that similar 
clonal heterogeneity exists in the case of AML. Furthermore, these data also shed light 
on the evolution of relapsed AML, implicating transformation of an ancestral pre-
leukaemic clone not part of the major clone at diagnosis. The planned extension of this 
study (as described in Section 7.3) will provide more detailed evidence for the clonal 
origins of these malignant complications. The demonstration of clonal heterogeneity of 
leukaemia, with the potential existence of relapse-initiating cell clones at disease 
presentation, could represent a significant roadblock to effective chemotherapy. For 
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instance, the use of an agent targeted towards a mutation present in a dominant clone 
could allow enrichment of minor (ancestral) clones which lack the mutation, and 
subsequently acquire further mutation leading to relapse. Advances in technology 
which allow cost effective and rapid whole genome analysis at the single cell level will 
be required to identify the full complexity of AML in individual patients at diagnosis in 
order to enable selection of the appropriate therapeutic agents to induce complete 
remission with minimal risk of subsequent relapse or therapy-related complications. 
8.6. Summary of Findings 
In summary, this project has demonstrated that cellular DNA MMR status 
mediates response to therapeutic nucleoside analogues routinely used in treatment of 
t-AML. Ex vivo studies are now warranted to investigate the occurrence of particular 
MMR defects in t-AML patients and whether they are associated with treatment 
response. For instance, in the case of t-AML, patients demonstrating loss of MSH2 in 
the leukaemic clone would be expected to respond favourably to therapeutic regimes 
containing nucleoside analogues. Similar treatment of patients with defects of MSH3 
however could potentially result in an adverse treatment response. This will potentially 
assist development of personalised medicine, with the aim of improving treatment 
response in patient subgroups which currently do not respond favourably to 
conventional therapies. Additionally, the potential genotoxicity of Ara-C has been 
demonstrated, which highlights the possibility of an association with t-AML 
development, suggesting use of this agent in combination with other drugs known to 
select for DNA MMR dysfunction should be avoided. Finally, the likely clonal 
heterogeneity of AML at diagnosis, as well as clonal evolution of relapsed disease has 
been demonstrated. This not only has implications for selection and success of 
chemotherapy, but also suggests another factor which might contribute to poor 
therapeutic response in certain AML subgroups.  
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8.7. Future Directions 
A number of further investigations are anticipated subsequent to the completion 
of this project: 
8.7.1. MSH3 overexpression and tolerance to nucleoside analogues 
The investigations detailed in Chapter 4 demonstrate that gross overexpression 
of MSH3 in the HL-60R cell line confers tolerance to the cytotoxic effects of Ara-C and 
other therapeutic nucleoside analogues. As a follow up to this work, a further 
investigation is planned in which MSH3-stably overexpressing cells will be generated 
(from both HL-60 and TK6 cell lines) using a commercially available expression vector 
system. Cytotoxic response to nucleoside analogues will then be assessed relative to 
isogenic parental cells. It is predicted that this will recapitulate the Ara-C-tolerant 
phenotype of HL-60R cells and hence provide evidence that this response is a direct 
consequence of MSH3 over-expression. 
8.7.2. Ara-C-induced mutation spectrum in TK6 (MMR proficient) and TK6 MSH2i 
(MMR deficient) cell lines 
Mutation screening in TK6 cells revealed that Ara-C can induce a spectrum of 
HPRT mutations which are unique compared to the spontaneous background mutation 
spectrum (see Chapter 6). Due to small numbers of independent mutations remaining 
after correction for possible clonal expansion, it is planned to generate a much larger 
number (n=50) of independently induced Ara-C mutants for inclusion in the drug-
induced mutation spectrum. Additionally, it is anticipated that a similar investigation 
will be performed using the MMR-deficient TK6 MSH2i (or TK6 MSH3i) cell line 
generated herein, in order to determine whether DNA MMR status can influence the 
mutagenicity of Ara-C in terms of types of mutations induced.  
8.7.3. Clonal evolution in relapsed and therapy-related AML 
Chapter 7 describes the results of a pilot study in which patterns of clonal 
evolution were investigated (via SNP array analysis) in matched presentation and 
relapsed samples from a small number of AML patients. Based on the results of this 
study, it is now planned to extend the study and perform similar SNP 6.0 arrays on 
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further matched presentation and relapsed samples (14 patients in total). In addition 
to SNP array analysis, another study is planned in which high-throughput 
pyrosequencing will be performed on the matched samples, as well as on some t-AML 
patient samples which have been collected. Sequencing of the entire exome of the 
leukaemic blasts will enable identification of mutations potentially responsible for 
development of relapse (or t-AML) in individual patients. Additionally, this approach 
will allow investigation of the genetic heterogeneity of AML at both presentation and 
relapse, providing further insights into the origins of relapse-initiating clones. 
8.7.4. Effect of varying levels of knockdown of DNA MMR components on drug 
response 
Knockdown of DNA MMR components using shRNA was performed as part of the 
studies described in Chapter 3. In these studies, cell clones in which 95-100% 
knockdown of the target gene (MSH2, MSH3 or MSH6) was achieved were used in 
cytotoxicity assays to assess effect of loss of key MMR components on drug response. 
Although not described herein, cell clones in which different levels of knockdown (20-
80%) of the target genes were also generated from TK6 and HL-60 cells. Another 
possible line of investigation therefore may involve assessment of whether different 
levels of reduction of MMR components can affect response to therapeutic nucleoside 
analogues.  
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